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Long INterspersed Element-1 (LINE-1 or L1) is the only autonomously active 
transposable element in the human genome. The vast majority of L1s are inactive, but a 
small number (~80-100 per human genome) retain the ability to mobilize by a ‘copy and 
paste’ mechanism called retrotransposition. L1 encodes two proteins (ORF1p and 
ORF2p) required for retrotransposition. ORF2p is a 150kDa protein that has 
endonuclease (EN) and reverse transcriptase (RT) activities that are responsible for 
initiating L1 integration by a mechanism termed target-site primed reverse transcription 
(TPRT). During canonical TPRT, the L1 EN makes a single-strand endonucleolytic nick 
at a double-stranded genomic DNA target sequence (typically 5’-TTTT/A-3’ and variants 
of that sequence), to expose a 3’-hydroxyl group that is used as a primer by the L1 RT 
to reverse transcribe L1 messenger RNA.  
Different types of transposable elements (TEs) have evolved convergent strategies 
to target genomic ‘safe havens,’ where TE insertions are predicted to have relatively 
minimal effects on host fitness and gene expression. Whether L1 integrates into specific 
genomic regions requires elucidation. In this thesis, I have examined L1 integration 
preferences in four human cell lines that are proxies for in vivo cell types known to 
accommodate endogenous de novo L1 retrotransposition events. By combining cultured 
cell, molecular biological, the Pacific Bioscience sequencing platform, and 
computational approaches, I characterized 65,079 de novo engineered human L1 
integration sites. I compared our L1 insertion dataset to a weighted random model, 
which assumes that L1 integration preferences are mediated solely by the presence of a 
degenerate L1 EN consensus cleavage site in the human genome. The data suggest 
that gene content, transcriptional activity, strand bias, epigenetic environment, and DNA
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replication status have minimal effects on L1 integration. Thus, L1 EN is the principal 
determinant of L1 integration. 
In contrast to canonical EN-dependent L1 retrotransposition, previous studies 
indicated that L1s could also integrate at sites of DNA damage, including dysfunctional 
telomeres, by an endonuclease-independent (ENi) mechanism in certain cultured cell 
lines that contain mutations in genes that render the non-homologous end-joining 
(NHEJ) pathway of DNA repair and p53 inactive. Here, we explored whether the 
disruption of other DNA repair pathways influence ENi L1 integration. We observed ENi 
retrotransposition in certain tissue culture cell lines containing defects in the Fanconi 
anemia (FA) DNA repair pathway. Since defects in the FA pathway can lead to the 
accumulation of inter-strand DNA crosslinks that, if left unrepaired, can interfere with 
DNA replication, we hypothesized that lesions arising at stalled DNA replication forks 
may provide substrates for enhanced ENi retrotransposition. Indeed, the examination of 
L1 EN mutant integration sites in FANCD2-deficient cells, suggests that a 3’-hydroxyl 
group present at Okazaki fragments and/or double-strand DNA breaks generated at 
collapsed DNA replication forks might be used as a primer to initiate ENi L1 
retrotransposition.  
In sum, our results suggest that ENi L1 retrotransposition may represent an 
ancestral mobilization mechanism used by LINE-like retrotransposons prior to the 
acquisition of an endonuclease domain. Under this scenario, LINE-like elements were 
reliant upon genomic features (e.g., sites of genomic DNA damage, replication forks, 
and, less frequently, dysfunctional telomeres) to initiate TPRT in the absence of an 
endonuclease. Indeed, we posit that the acquisition of an endonuclease domain allowed 
L1 to autonomously insert throughout the genome and, as originally implied by its name, 




Transposable Elements Mobilize in Genomes 
Overview 
 This thesis aims to determine if LINE-1 displays preferential integration sites in 
the human genome. Chapter one provides a general overview of transposable elements 
and their means of mobilization in genomes. I then primarily focus on LINE-1 and 
previously published methods to characterize endogenous LINE-1 integration events in 
the human genome. Finally, I explore the integration preferences of several 
transposable elements and discuss what is known about LINE-1 integration preference. 
Chapter two provides the bulk of my thesis work and describes the generation, capture, 
and analysis of thousands of engineered LINE-1 integration events.  In Chapter 2, I also 
describe the creation of a weighted model data set, which we used in our analysis to 
determine the influence of the LINE-1 endonuclease on integration preference in the 
human genome with respect to several examined genomic features. In Chapter 3, I 
explore the influence of DNA repair proteins on LINE-1 integration preference. Chapter 
4 provides a summary of my findings, conclusions, and discusses areas for future study. 
Abstract 
Eukaryotic genomes are littered with the remnants of parasitic mobile pieces of 
DNA known as transposable elements (TEs). For the most part, transposable elements 
exist in a delicate balance with their host genome – promoting their own replication 
while minimizing detrimental mutations that can damage their host. TEs are mutagenic, 
and their insertion can disrupt normal gene expression, create genomic structural 
variation, and alter epigenetic marks within the genome, which can lead to intra-species, 
intra-individual, and inter-individual genetic diversity. From a teleological standpoint, it is
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imperative that TEs do not become too ‘greedy,’ as their relentless mobility may 
adversely affect genome integrity. As such, it is not surprising that many TEs have 
evolved strategies to insert into specific genomic regions, thereby minimizing damage to 
their respective host genomes.  
In this chapter, I provide a brief background about general TE biology, and then 
delve further into the biology of the only autonomously active retrotransposable element 
in the human genome, Long INterspersed Element-1 (LINE-1 or L1). I then discuss 
previous studies, which highlight methods used to discover polymorphic germline and 
somatic human TE insertions within early developmental precursor cells, cancers, and 
neurons. Finally, I discuss different integration mechanisms and known insertion site 
preferences of several TEs, and then provide additional information about LINE-1 to 
address the over-arching question in this dissertation: Do LINE-1 retrotransposition 
events display integration preferences within the human genome?   
A Plethora of Repetitive Elements 
The completion of the human genome working draft sequence (HGWD) led to the 
realization that protein-coding exons only comprise ~1.5% of the human genome 
(Consortium, 2012; Lander et al., 2001). We now know that sequences outside of 
exonic and intronic sequences, such as promoters and enhancers, are also critical 
genomic components that are needed to ensure proper gene expression (Khoury and 
Gruss, 1983; Smale and Kadonaga, 2003). However, these sequences only compose 
between 8 and 15% of our genome (Kellis et al., 2014; Ponting and Hardison, 2011; 
Rands et al., 2014).  
In 1968, Britten and Kohne performed DNA hybridization experiments (i.e., C0t 
analyses) to determine the relative proportions of repetitive DNA sequence in several 
mammalian genomes (Britten and Kohne, 1968; Waring and Britten, 1966). Surprisingly, 
at least 50% of the human genome can be classified as repetitive DNA (Lander et al., 
2001). These repetitive sequences can be divided into four categories: (1) interspersed 
repeats, also known as transposable element (TE) derived repeats; (2) short k-mer 
nucleotide repeats, such as microsatellite and minisatellite DNAs; (3) segmental 
	 3	
duplications, which generally range in size from 10-300 kb; and (4) tandem repeat 
sequences, such as the α-satellite DNA present at many centromeres.  
Transposable element derived repeats comprise ~45% of the human genome 
(Lander et al., 2001) and can be subdivided into 2 groups: DNA transposons and 
retrotransposons (Figure 1.1). DNA transposons comprise 3% of the human genome, 
while retrotransposons comprise the remaining 42% of our genome (Lander et al., 
2001). Elements in both groups can be further subdivided into autonomous and non-
autonomous elements. Autonomous elements encode proteins required for their 
mobility, whereas non-autonomous elements rely upon the proteins of the autonomous 
elements to mobilize throughout the genome (Craig, 2014; Richardson et al., 2015). 
Since the cells in our body must expend energy during DNA replication to create 
new cells to maintain the life of the organism, the following questions arise: (1) why 
would our genome retain all this extra sequence if it is not ‘required’ for survival; and (2) 
why does an organism ‘keep’ this extra ‘baggage’ [i.e., commonly referred to as ‘junk’ 
DNA (Ohno, 1972)] if it requires more effort to maintain? 
DNA Transposons 
In the 1940’s, almost two decades prior to the completion of the seminal 
experiments of Britten and Kohne, Barbara McClinktock discovered that DNA 
transposable element activity is responsible for the variegated corn kernel color 
phenotypes observed in certain strains of Zea mays (McClintock, 1950). Subsequent 
work uncovered two DNA transposable elements responsible for this phenomenon: the 
autonomous Activator (Ac) DNA transposon, and its non-autonomous partner, 
Dissociation (Ds) (Fedoroff et al., 1983). Activator encodes an enzyme that makes a 
double-strand break (i.e., transposase). When Activator creates double-strand breaks at 
a specific locus harboring Dissociation, it leads to genomic instability that effects the 
expression of a pigmentation gene. Thus, the phenotypic variation leading to kernel 
color variegation was due to TE activity during different stages of kernel development. 
These data provided the first evidence suggesting that genomes are unstable entities, 
and that mobile DNA sequences can lead to genomic instability resulting in phenotypic 
	 4	
variation. In recognition of this discovery, Barbara McClintock won the Nobel Prize in 
Physiology or Medicine in 1983 (McClintock, 1950). 
DNA transposons typically consist of a pair of terminal inverted repeat sequences 
(TIRs) that surround a transposon-encoded open reading frame (ORF) that encodes an 
enzyme named transposase (Figure 1.1). Transposase is a member of the DD35E 
superfamily of integrase proteins. In eukaryotes, transposase binds the transposon TIRs 
within the nucleus, ‘cuts’ the element from its existing genomic location, and ‘pastes’ the 
excised DNA into a new genomic location. Transposition leads to the generation of 
signature length, short 4-6 bp target-site-duplications (TSDs) that flank the TIRs in 
genomic DNA (Feschotte and Pritham, 2007; Munoz-Lopez and Garcia-Perez, 2010). 
As a consequence of this non-replicative ‘cut and paste’ transposition mechanism, the 
copy number of DNA transposons within a genome remains relatively constant—the 
DNA transposon sequence is simply ‘cut’ out of one genomic location and moved (or 
‘pasted’) into a new genomic location (Kleckner, 1990). While DNA transposons thrive in 
bacteria and simple eukaryotes, they appear to be extinct in most mammalian, including 
human, genomes (Lander et al., 2001).  
The maize Activator  (Ac), Drosophila melanogaster hobo, and Antirrhinum majus 
(a flowering plant) Tam3 DNA transposons are members of the hobo-Ac-Tam3 (hAT) 
superfamily of eukaryotic DNA transposons (Calvi et al., 1991; Feldmar and Kunze, 
1991). The hAT transposons are the most abundant DNA transposons found in 
humans; however, they have been inactivated by mutational processes and were 
rendered immobile approximately 40 million years ago (Pace and Feschotte, 2007) 
(Figure 1.1). Interestingly, while DNA transposons are extinct in most mammalian 
genomes, recent studies suggest that some hAT DNA transposons remain active in the 
little brown bat, Myotis lucifigus (Ray et al., 2008; Ray et al., 2007), indicating that 
transposable elements follow different evolutionary trajectories in different mammalian 
lineages. Additional examples of active DNA transposons are the Drosophila 
Melanogaster P-element (Kidwell, 1992), the bacterial Tn7 transposon (Craig, 1996), 
and insect piggyBac transposons (Cary et al., 1989).  
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HUH DNA transposons (where H represents a histidine and U represents a 
hydrophobic residue) are DNA transposons found in all domains of life. HUH 
transposons can be distinguished from other classes of mobile elements because they 
mobilize by a replicative process that employs a single-strand DNA (ssDNA) 
intermediate (Lam and Roth, 1983). Indeed, many HUH elements preferentially 
integrate into the lagging strand during DNA replication, leading to a copy of the 
transposon at the initial donor site and newly inserted copy in genomic DNA. HUH DNA 
transposons elements also carry sub-terminal palindromic structures, instead of TIRs, at 
their termini and insert 3’ to specific AT-rich tetra- or penta- nucleotides without 
duplicating nucleotides at the genomic DNA target site (Figure 1.2). Examples of HUH 
DNA transposons include: IS608, originally discovered in the pathogen Helicobacter 
pylori (Kersulyte et al., 2002) and ISDra2 from Deinococcus radiodurans (Ton-Hoang et 
al., 2010). Integration of IS608 always occurs immediately downstream of a tetra- 
nucleotide sequence (5’-TTAC) (Kersulyte et al., 2002), whereas the target sequence of 
ISDra2 is a penta- nucleotide sequence (5’-TTGAT) (Islam et al., 2003).  
Retrotransposons 
The second category of TEs, retrotransposons, mobilize by a replicative ‘copy 
and paste’ mechanism in which the progenitor retrotransposon sequence is first 
transcribed into RNA, ‘copied’ into complementary DNA (cDNA) by a reverse 
transcriptase (RT), and then ‘pasted’ into a new genomic location (Cost et al., 2002; 
Mager and Stoye, 2015). Thus, the progenitor element is left unaltered and a reverse 
transcribed copy is inserted into a new genomic location. This replicative mechanism 
bestows retrotransposons with the potential to undergo exponential amplification in the 
genome.  
Phylogenetic analyses led to the identification of two distinct groups of RT-
containing retrotransposons (Malik et al., 1999; Xiong and Eickbush, 1988). The first 
group consists of retroviruses, certain DNA viruses, and long terminal repeat (LTR) 
retrotransposons. The second group consists of RT-containing sequences of fungal 
mitochondrial introns and non-LTR retrotransposons. Indeed, mobile group II introns in 
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bacterial and organellar genomes are proposed predecessors of non-LTR 
retrotransposons (Lambowitz and Zimmerly, 2004). 
Retrotransposons can be further subdivided into two distinct classes: LTR 
retrotransposons and non-LTR retrotransposons. LTR retrotransposons are structurally 
similar to simple retroviruses, but since most contain a non-functional envelope (env) 
gene, they are confined to replicate within the cell (Bannert and Kurth, 2006). Non-LTR 
elements move by a fundamentally different mechanism termed target-site primed 
reverse transcription (TPRT), which is discussed in greater detail below. 
Long Terminal Repeat Retrotransposons: Intracellular Retroviral-like Mobilization 
LTR retrotransposons structurally resemble simple retroviruses and consist of 
direct sequence repeats (i.e., LTRs) that flank an internal coding region. The LTRs 
consist of U3 (unique to the 3’ end); R (repeated); and U5 (unique to the 5’ end) 
sequences. Transcription of the LTR initiates in the 5’ LTR at the U3/R junction and 
terminates in the 3’ LTR at the R/U5 junction (Craig, 2014; Mager and Stoye, 2015). 
Thus, RNA polymerase II generates a full-length LTR-retrotransposon RNA that 
contains the following structure: 5’-R-U5-internal coding regions-U3-R-3’.  
The internal coding region of LTR retrotransposons contain at least two open 
reading frames (ORFs), which encode structural and enzymatic proteins. The first ORF 
encodes gag, a structural protein that plays a key role in the formation of cytoplasmic 
virus-like particles (VLPs). The second ORF encodes pol, a protein with four, distinct 
enzymatic activities (protease, reverse transcriptase, integrase, and RNase H) (Craig, 
2014). Like DNA transposons, LTR retrotransposon integrase proteins generally are 
members of the DD35E superfamily of proteins. The third open reading frame, if present, 
encodes envelope (env), a protein crucial for retroviral packaging and cellular export. 
Since env is either absent or not functional in most LTR retrotransposons, LTR 
retrotransposons are generally relegated to intracellular replication (Bannert and Kurth, 
2006). 
   The mechanism of LTR retrotransposition involves packaging the element 
encoded RNA and additional host factors [e.g., a specific transfer RNA (tRNA)] into 
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VLPs (Craig, 2014). Within cytoplasmic VLPs, a specific host encoded tRNA binds to a 
complementary sequence located downstream of the R/U5 junction, creating a 
tRNA/RNA hybrid. The 3’ hydroxyl group at the end of the tRNA is then used as a 
primer by the reverse transcriptase activity encoded by pol to convert the 
retrotransposon RNA into a double-stranded cDNA. Integrase then binds to the LTR 
sequences at the end of the resultant double-stranded cDNA, transports it to the nuclear 
DNA, and integrates the cDNA at a new site in genomic DNA. Integration occurs by a 
mechanism similar to that employed by DNA transposons and leads to the generation of 
short, signature length, TSDs (usually 4-6 bp in size) that flank the LTRs in genomic 
DNA (Telesnitsky and Goff, 1997).  
Unlike DNA transposons, LTR retrotransposons are quite prevalent in 
eukaryotes. For example, the mouse genome contains multiple active LTR-
retrotransposon families.  Indeed, it is estimated that approximately 10-12% of sporadic 
mutations in the mouse are due to the retrotransposition of autonomous and non-
autonomous LTR retrotransposons (Maksakova et al., 2006; Kazazian and Moran, 
1998). Human-specific endogenous retroviruses (HERVs) comprise ~8% of human 
genomic DNA, have been rendered inactive by mutations, and are no longer active 
within our genomes (Lander et al., 2001). However, certain members of the HERV-K 
family (where the K designates a lysine tRNA that is critical for priming first-strand 
HERV-K cDNA synthesis) are polymorphic with respect to presence/absence in the 
human population (Belshaw et al., 2005; Moyes et al., 2007). These findings suggest 
that endogenous retroviruses (ERVs) have been active since the divergence of humans 
and chimpanzees, but that HERV activity has since decreased in the human lineage. 
Other examples of autonomous LTR retrotransposons include: Saccharomyces 
cerevisiae Transposon yeast 1 (Ty1), Ty2, Ty3, and Ty5 (Boeke et al., 1985), 
Schizosaccharomyces pombe Tf1 (Esnault and Levin, 2015), and autonomously active 




Non-Long Terminal Repeat (non-LTR) Retrotransposons: Target-site Primed Reverse 
Transcription 
 Non-LTR retrotransposons lack LTR sequences, but like LTR retrotransposons, 
require an RT-containing protein to mediate their retrotransposition (Gilbert et al., 2005; 
Lander et al., 2001; Luan et al., 1993; Moran et al., 1996). Non-LTR retrotransposons 
also encode an endonuclease (EN) activity that is required for integration. While the 
reverse transcriptase domain is shared among different non-LTR elements, the 
endonuclease domain varies between elements. In some cases, this nuclease has a 
profound effect on non-LTR retrotransposon target-site integration preference (see 
below).  
Non-LTR elements are able to ‘copy and paste’ themselves into a new genomic 
location by a process termed target-site primed reverse transcription (TPRT). TPRT 
requires both endonuclease and reverse transcriptase activities (Luan et al., 1993). In 
its simplest form, TPRT involves cleavage of one strand of target site genomic DNA, 
exposing a free 3’ hydroxyl (OH) group that can be used as a primer for reverse 
transcription of the element-encoded RNA. Second-strand DNA cleavage typically 
occurs downstream of the initial single-strand endonucleolytic nick, exposing a 3’-OH 
group that is presumably used by the element-encoded RT to mediate second-strand 
DNA synthesis (Christensen and Eickbush, 2015). The completion of integration 
generally leads to the generation of variably sized TSDs flanking the newly inserted 
element, which for human L1s range in size from ~7-20bp (Gilbert et al., 2005; Lander 
et al., 2001).  
Types of non-LTR Retrotransposons 
Penelope-like Elements 
 Penelope-like elements (PLE) are a widespread class of retroelements named 
after Penelope, a transposable element originally isolated from Drosophila virilis 
(Evgen'ev et al., 1997). PLEs contain a single open reading frame (ORF) that encodes a 
reverse transcriptase (RT) and GIY-YIG endonuclease (EN) domain, which is also 
found in the proteins encoded by certain bacterial group I introns (Arkhipova et al., 
	 9	
2003; Belfort and Perlman, 1995; Evgen'ev and Arkhipova, 2005). Interestingly, several 
PLE members encode spliceosomal introns, which is unusual for an element that is 
believed to move through an RNA intermediate (Figure 1.2C). The ends of PLEs usually 
contain several hundred base pair long direct repeats that encode a self-splicing 
hammerhead ribozyme, which is believed to mediate the excision of the Penelope RNA 
from a larger, precursor pre-mRNA transcript (Cervera and De la Pena, 2014).  
Through the process of TPRT, the EN activity of PLE creates a single-strand 
endonucleolytic cleavage at a double-strand DNA target, resulting in the generation of a 
free 3’-OH group, which can be used as a primer by the element-encoded RT to initiate 
reverse transcription of Penelope mRNA (Pyatkov et al., 2004). The EN exhibits some 
sequence preference, preferring AT-rich targets in genomic DNA, but otherwise 
contains no other pronounced sequence specificity (Evgen'ev and Arkhipova, 2005; 
Pyatkov et al., 2004). The examination of Penelope integration sites in several 
geographical strains of D. virilis reveals an integration preference for euchromatic 
chromosome arms; Penelope elements are rarely found in heterochromatic regions of 
chromatin (Evgen'ev et al., 2000; Evgen'ev and Arkhipova, 2005; Zelentsova et al., 
1999). Interestingly, 45% of the Penelope integration sites found in multiple D. virilis 
strains, termed ‘hot spots’, coincide or lie in close vicinity of inversion breakpoints 
(Evgen'ev and Arkhipova, 2005). PLEs have also been discovered in crustaceans, 
echinoderms, fish, amphibians, flatworms, roundworms, and rotifers (Dalle Nogare et 
al., 2002; Lozovskaya et al., 1990; Lyozin et al., 2001; Volff et al., 2001).   
Phylogenetic analysis of the PLE reverse transcriptase reveals that it forms a 
sister clade with telomerase reverse transcriptase (TERT), which is distinct from the 
non-LTR and LTR clades of retrotransposons (Gladyshev and Arkhipova, 2007). These 
data have fueled speculation that the RTs of PLEs are the progenitor of telomerase 
(Curcio and Belfort, 2007; Gladyshev and Arkhipova, 2007). Notably, TERTs are not 
TEs and lack a recognizable endonuclease domain. Instead, they are specialized 
ribonucleoprotein (RNP) enzymes that maintain telomeres by reiteratively copying a 
short segment of an unlinked template RNA (commonly called TERC) onto the 3’-OH 
group present at the end of a linear chromosome (Greider and Blackburn, 2004).  
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Mobile Group II Introns: A Proposed Ancestor of Non-Long Terminal Repeat 
Retrotransposons  
 Mobile group II introns are catalytic self-splicing RNAs that are found in bacterial, 
eukaryotic organelle, and certain archaebacteria genomes (Novikova and Belfort, 2017). 
Mobile group II introns are thought to be the evolutionary precursors of splicesomal 
introns (Lambowitz and Zimmerly, 2004). They typically encode a single ORF, which 
encodes a protein that is critical for splicing (i.e., a maturase activity) and/or intron 
mobility (i.e., reverse transcriptase and DNA endonuclease activities)  (Figure 1.2C) 
(Gorbalenya, 1994; Kennell et al., 1993; Michel and Lang, 1985; Moran et al., 1994). 
Notably, some group II introns (e.g. aI1 and aI2 in the yeast mitochondrial coxI gene 
and LI.LtrB in the bacteria Lactococcus lactis) are mobile genetic elements (Moran et 
al., 1995; Cousineau et al., 1998). Group II intron mobilization can occur by two distinct 
mechanisms: retrohoming and retrotransposition (Ichiyanagi et al., 2002; Lambowitz 
and Zimmerly, 2004).  
Retrohoming enables group II introns to insert into an intronless allele of their 
cognate gene. During the first step of retrohoming, a ribonucleoprotein complex, which 
consists of the intron encoded protein (IEP) and spliced intron lariat RNA, uses both 
RNA-DNA base pairing and IEP-DNA interactions to reverse splice into the sense 
strand of a double-strand DNA target present in the intronless allele of its cognate gene 
(Lambowitz and Zimmerly, 2004). By a process similar to TPRT, the IEP endonuclease 
then cleaves the opposite strand of DNA, exposing a 3’ hydroxyl group that is used by 
the IEP RT to reverse transcribe the reverse spliced intron RNA (Zimmerly et al., 1995). 
Bacterial group II introns most likely rely upon cellular RNase H to digest the RNA 
template and host DNA polymerase to complete second-strand synthesis (Cousineau et 
al., 1998). Additional host factors (e.g., DNA ligase) likely act to complete retrohoming.  
Retrotransposition allows group II introns to insert into new genomic locations, 
allowing intron dispersal. Retrotransposition does not require EN activity, but instead 
occurs when group II introns insert into an ectopic site (generally ssDNA or ssRNA) that 
resembles the normal retrohoming substrate (Ichiyanagi et al., 2002).  Like retrohoming, 
the first step of retrotransposition involves reverse splicing of the group II intron RNA 
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into an ectopic target site. The integrated intron RNA is then reverse transcribed by the 
IEP RT, but integration is completed by recombination repair, using the original donor 
intron as a repair substrate. 
Autonomous Non-LTR Retrotransposons 
Autonomous non-LTR retrotransposons consist of one or two open reading 
frames (ORFs) that encode endonuclease (EN) and reverse transcriptase (RT) activities 
critical for retrotransposition. Some non-LTR retrotransposons (e.g., mammalian LINE-
1s) end in a poly(A) tract, whereas others (e.g., the African clawed frog Tx1L element, 
Drosophila I-factor, and zebrafish LINE-2 elements) end in a series of simple repeated 
DNA sequence.   
Autonomous non-LTR retrotransposons replicate by TPRT (Cost et al., 2002; 
Feng et al., 1996; Luan et al., 1993; Moran et al., 1996). During TPRT, the element-
encoded endonuclease makes a single-strand  endonucleolytic nick in target site DNA 
to expose a 3’ hydroxyl group that is used by the element encoded RT as a primer to 
reverse transcribe the transposable element mRNA.  
Although they share an evolutionary conserved RT domain, different autonomous 
non-LTR retrotransposons encode for different endonucleases. For example, some site-
specific non-LTR retrotransposons (e.g., insect R2 elements) contain a type-II restriction 
endonuclease (RE)-type domain, whereas others (e.g., mammalian LINE-1s, insect R1, 
Waldo, and MinoAg1, silkworm SART1 and TRAS1, frog Tx1L, and green algae DRE 
retrotransposons) encode apurinic/apyrimidinic-like endonucleases (APEs) (Figure 1.3) 
(Zingler et al., 2005). The different endonuclease activities likely mediate the different 
integration preferences for each type of retrotransposon (see later in Chapter). 
Non-autonomous Non-LTR Retrotransposons: Alu, SVA, and Some Cellular RNAs 
 Non-autonomous non-LTR retrotransposons, such as Short INterspersed 
Elements (SINEs), include Alu and SINE-R/VNTR/Alu-like (SVA) elements comprise 
~11% human genomic DNA (Figure 1.1) (Lander et al., 2001).  Alu is named after the 
AluI restriction site within the element (Houck et al., 1979). Full-length Alus are ~280bp 
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in length and consist of two related monomers that are derived from 7SL RNA (Rubin et 
al., 1980; Ullu and Tschudi, 1984). The left monomer contains an internal RNA 
polymerase III promoter and is followed by an A-rich linker sequence, which separates it 
from the right monomer (Ullu and Weiner, 1985). Likes L1s, Alus typically end in a 
poly(A) tract. However, the poly(A) tract is encoded by genomic DNA and may be 
extended during TPRT by a template switching mechanism (Roy-Engel et al., 2002); it 
is not added to Alu RNA during post-transcriptional processing. 
 SVA elements comprise ~0.2% of human genomic DNA (Richardson et al., 
2015). A typical SVA element is ~2kb in length, appears to be transcribed by RNA 
polymerase II, and has a composite structure that consists of:  (1) a hexameric 
CCCTCT repeat; (2) an inverted Alu-like element repeat; (3) a set of GC-rich variable 
nucleotide tandem repeats (VNTRs); (4) a SINE-R sequence derived from HERV-K10, 
an inactive retrotransposon; (5) a canonical RNA polymerase II cleavage 
polyadenylation specificity factor binding site that is followed by a poly(A) tract 
(Richardson et al., 2015).  
Non-autonomous non-LTR retrotransposon elements do not encode proteins. 
Instead, they must rely upon the endonuclease and reverse transcriptase activities 
encoded by autonomous non-LTR retrotransposons, such as L1 for Alu and SVA, to 
mediate their retrotransposition (Dewannieux et al., 2003; Hancks et al., 2011; Raiz et 
al., 2012). Since these elements are mobilized via TPRT, they are typically flanked by 
variable-length target-site duplications (Grimaldi and Singer, 1982; Rubin et al., 1980).  
The LINE-1 encoded proteins have been implicated in the mobilization of other 
cellular RNAs. For example, ORF1p and ORF2p can occasionally act in trans to 
mobilize mature cellular mRNAs to new genomic locations, resulting in processed 
pseudogene formation (Esnault et al., 2000; Vanin, 1985; Wei et al., 2001; Weiner et al., 
1986). Similarly, ORF1p and/or ORF2p can mobilize non-coding RNAs such as U6 
uracil-rich small nuclear RNAs (U6 snRNA) and small nucleolar RNAs (snoRNAs) (i.e., 
U3 snoRNA) to new locations within the genome (Buzdin et al., 2003; Buzdin et al., 
2002; Garcia-Perez et al., 2007; Gilbert et al., 2005). Unlike the mechanism of 
processed pseudogene formation, the structures of chimeric U6/L1 pseudogenes 
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suggest that U6 snRNA is conjoined to a 5’ truncated LINE-1 cDNA during the process 
of LINE-1 integration (Buzdin et al., 2002; Garcia-Perez et al., 2007). U6/LINE-1 
chimeras have been discovered in several primate genomes (Hasnaoui et al., 2009) 
and in cultured cell retrotransposition assays (Garcia-Perez et al., 2007; Gilbert et al., 
2005), suggesting their formation is ongoing in the human population. 
LINE-1 in the Human Genome  
 L1s are responsible for ~17% of human genomic DNA and are the only known 
autonomously active retrotransposons in the human genome (Lander et al., 2001). The 
majority of L1s have been rendered inactive by mutational processes [i.e., 5’ truncations 
(Grimaldi and Singer, 1983), internal rearrangements (Ostertag et al., 2001), and/or 
point mutations that disrupt the activities of the L1-encoded proteins (ORF1p and 
ORF2p)]. However, experiments in cultured cells indicate that ~80-100 L1s per 
individual retain the ability to retrotranspose (Brouha et al., 2003; Moran et al., 1996; 
Sassaman et al., 1997). 
A Brief History of L1 Evolution 
L1s have been replicating in mammalian genomes since the marsupial/placental 
divergence, which occurred ~170 MYA (Burton et al., 1986; Smit et al., 1995; Yang et 
al., 2014). The vast majority of L1s present in the human genome amplified since the 
divergence of the ancestral mouse and human lineages ~65 to 75 MYA. Sequence 
comparisons of primate-specific L1s identified sixteen subfamilies (termed PA1 to 
PA16) (Khan et al., 2006; Smit et al., 1995). These L1 subfamilies have a monophyletic 
origin and have undergone an amplification process known as subfamily succession, 
where one L1 subfamily is replaced over evolutionary time by an emergent L1 
subfamily. This evolutionary trajectory is a signature of an ‘arms race’ and suggests that 
the emergent L1 subfamily replicates more efficiently than its predecessor, perhaps 
because it evades the effects of host factors that repress retrotransposition (Jacobs et 
al., 2014). As a result of subfamily succession, only one L1 subfamily preferentially 
amplifies in the human genome at any given time. 
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 The youngest L1 subfamily (termed PA1 or L1Hs) has amplified since the 
divergence of humans and chimpanzees, which occurred ~6 MYA (Goodman et al., 
1998). The majority of active L1Hs elements belong to a small subset termed 
transcribed-active L1s (the Ta-subset) (Skowronski et al., 1988), which arose  ~4 MYA 
(Beck et al., 2011; Brouha et al., 2003; Moran et al., 1996; Sassaman et al., 1997). Ta-
subset L1s contain a defining 5-‘ACA’ trinucleotide sequence and G nucleotide in their 
3’ UTR (at positions 5930-5932 and 6015, respectively based on the sequence L1.2, an 
active L1: GenBank accession number M80343) (Dombroski et al., 1991). These 
nucleotides allow one to distinguish Ta-subset L1s from chimpanzee and older L1s in 
the human genome using BLAT or BLAST searches (Altschul et al., 1997; Kent, 2002) 
and PCR-based molecular biological approaches. Together, these approaches have 
been used to identify human-specific, polymorphic, and de novo L1 insertions in human 
genomes (Beck et al., 2010; Beck et al., 2011) (see below). 
The Ta-subset can be further sub-divided into two subgroups, the older Ta-0 and 
newer Ta-1 L1s (Boissinot et al., 2000). Approximately 80% of Ta-0 elements inserted 
into the human genome over ~1.6 MYA (Boissinot et al., 2000). The newer Ta-1 subset 
appears to have arisen about 2.5 MYA, and most (~75%) of the Ta-1 L1s having been 
generated during the last ~1.6 million years (Boissinot et al., 2000). While Ta-0 contains 
some active elements, Ta-1 contains the greatest number of active LINE-1s (Beck et al., 
2010). It is believed that ~69% of a small number of Ta-1-containing loci are 
polymorphic with respect to presence/absence in the genome (Boissinot et al., 2000). 
Examination of the human genome reference reveals that approximately 30% to 35% 
Ta-subset L1s are full-length, while 65% to 70% contain 5’ truncations. Notably, 
approximately 25% of 5’ truncated L1s contain internal rearrangements known as 
inversion/deletions (Boissinot et al., 2000; Lander et al., 2001; Myers et al., 2002; 
Ostertag and Kazazian, 2001).  
LINE-1: Structure of a Full-length Element 
 A full-length human L1 sequence is approximately 6 kb in length (Dombroski et 
al., 1991; Scott et al., 1987). Full-length L1s contain a 5’ untranslated region (UTR), two 
ORFs, and a 3’ UTR that is typically ends in a poly(A) tract (Figure 1.1).  The 5’UTR 
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contains cis-acting DNA binding sites for multiple transcription factors (e.g., YY1, Sp1, 
RUNX3, and SRY-like) that are important for L1 transcription (Athanikar et al., 2004; 
Becker et al., 1993; Kuwabara et al., 2009; Minakami et al., 1992; Swergold, 1990; 
Tchenio et al., 2000; Yang et al., 2003). The human L1 5’UTR also contains both a 
sense and an antisense RNA polymerase II promoter. Transcription from the sense 
strand promoter can generate full-length L1 RNAs (Swergold, 1990). Transcription from 
the L1 antisense promoter (ASP) can influence the expression of genes residing 
upstream of a full-length L1 (Macia et al., 2011; Speek, 2001). The ASP also encodes 
an open reading frame (ORF-0) (Denli et al., 2015); however, whether ORF-0 plays any 
role in L1 retrotransposition requires further elucidation.  
Two open reading frames (ORF1 and ORF2) that are separated by a 63bp inter-
ORF spacer (Dombroski et al., 1991) follow the L1 5’UTR. Human ORF1 encodes a 
~40kDa RNA binding protein (ORF1p) that contains an amino-terminal protein-protein 
interaction domain, a centrally located RNA recognition motif (RRM) (Khazina et al., 
2011; Khazina and Weichenrieder, 2009), and a carboxyl-terminal basic domain (Moran 
et al., 1996). Biochemical studies indicate that ORF1p forms a trimer (Khazina et al., 
2011) that can bind ~50 base pairs of unstructured single-strand RNA and DNA 
substrates in a sequence independent manner (Callahan et al., 2012; Khazina and 
Weichenrieder, 2009; Martin and Bushman, 2001; Martin et al., 2005). Interactions 
between the ORF1p RRM and carboxyl-terminal basic domain mediate nucleic acid 
binding (Hohjoh and Singer, 1996, 1997; Holmes et al., 1992; Januszyk et al., 2007; 
Khazina et al., 2011; Khazina and Weichenrieder, 2009; Martin, 1991). ORF1p also 
contains nucleic acid chaperone activity that may play an important role in the initial 
steps of TPRT (Khazina and Weichenrieder, 2009; Martin and Bushman, 2001). ORF1p 
is required for retrotransposition in cultured human cells (Holmes et al.,1992; Leibold, et 
al., 1990;Moran et al., 1996 ). 
Human ORF2 is translated from a bicistronic L1 RNA by an unconventional 
termination/reinitiation mechanism, leading to the production of a ~150kDa protein 
(ORF2p) (Alisch et al., 2006; Doucet et al., 2010; Ergun et al., 2004). ORF2p contains 
endonuclease (EN) (Feng et al., 1996) and reverse transcriptase (RT) activities (Hattori 
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et al., 1986; Mathias et al., 1991). ORF2p also contains a carboxyl-terminal cysteine-
rich (C) domain of unknown function (Fanning and Singer, 1987; Feng et al., 1996; 
Moran et al., 1996). Mutational analyses demonstrate that the ORF2p EN, RT, and C-
domains are required for L1 retrotransposition in cultured cells (Moran et al., 1996; Wei 
et al., 2001). 
The L1 3’UTR is ~206bp in length and contains a conserved polypurine tract that 
is predicted to form a G-quadruplex structure (Usdin and Furano, 1989). While this 
polypurine tract is evolutionary conserved amongst mammalian L1s (Howell and Usdin, 
1997; Usdin and Furano, 1989), it is dispensable for L1 retrotransposition in cultured 
cells (Moran et al., 1996). Thus, how the polypurine tract functions in L1 biology 
requires elucidation. The L1 3’UTR also contains a functional RNA polymerase II 
polyadenylation signal. This poly(A) signal is relatively weak and is often bypassed in 
favor of adjacent downstream poly(A) signals present in 3’ flanking genomic DNA 
sequences (Moran et al., 1999). The use of these genomic polyadenylation sequences 
can lead to addition of 3’ genomic sequences to the L1 RNA; the retrotransposition of 
the resultant RNAs can lead to L1-mediated 3’ sequence transductions [(Holmes et al., 
1994; Moran et al., 1996; Moran et al., 1994) (also, see below)].  
Mobilization of L1 in the Human Genome 
The L1 retrotransposition cycle begins with transcription of a full-length genomic 
L1 from the internal RNA polymerase II sense strand promoter located within its 5’UTR 
(Figure 1.4). The L1 mRNA is then exported from the nucleus to the cytoplasm, where 
its translation results in the production of ORF1p and ORF2p. Within the cytoplasm, 
ORF1p and ORF2p bind to their encoding mRNA by a process termed cis-preference 
(Esnault et al., 2000; Wei et al., 2001). The ORF1p/ORF2p/mRNA complex forms a 
ribonucleoprotein particle (RNP), which is necessary for L1 retrotransposition (Esnault 
et al., 2000; Hohjoh and Singer, 1996; Kulpa and Moran, 2005, 2006; Martin, 1991; Wei 
et al., 2001). 
The resultant L1 RNP gains access to the nucleus, by a mechanism that does 
not strictly require nuclear envelope breakdown (Kubo et al., 2006), where TPRT 
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occurs. During TPRT, the ORF2p L1 EN activity makes a single-strand endonculeolytic 
nick at a double-stranded DNA target sequence in genomic DNA (Cost and Boeke, 
1998; Cost et al., 2001; Feng et al., 1996). This endonucleolytic nick is typically made at 
an L1 EN degenerate consensus cleavage site [(5’-TTTT/A-3’, where ‘/’ represents the 
location of the scissile phosphate)] (Gilbert et al., 2002; Morrish et al., 2002; Symer et 
al., 2002; Szak et al., 2002). The L1 EN endonucleolytic nick exposes a free 3’ hydroxyl 
group that can be used as a primer by the ORF2p L1 RT activity to reverse transcribe 
the associated L1 RNA (Cost et al., 2002; Feng et al., 1996; Kulpa and Moran, 2006; 
Luan et al., 1993). Through a mechanism that is still incompletely understood, second-
strand DNA cleavage typically occurs downstream of the initial single-strand 
endonucleolytic nick, exposing a 3’-OH group that is likely used as a primer by the L1 
RT DNA-dependent DNA polymerase activity to synthesize second-strand L1 cDNA 
(Christensen and Eickbush, 2005). The completion of L1 integration, which likely 
requires host factors (e.g., DNA ligase), leads to a newly inserted L1 that is generally 
flanked by variable-length TSDs (~7-20 bp) or, on fewer occasions, small target site 
deletions (Gilbert et al., 2005; Gilbert et al., 2002; Symer et al., 2002). If the new L1 
insertion is full-length, it can continue to amplify, thereby increasing the repertoire of 
active L1 copies in the genome. 
LINE-1 TPRT Associated Rearrangements 
 LINE-1 mediated retrotransposition events are occasionally accompanied by 
intra-L1 rearrangements (e.g., 5’ truncations and 5’ truncations associated with 
inversions/deletion events) or larger genomic structural rearrangements. In an 
anthropomorphic sense, L1 would ‘desire’ to generate full-length copies that can 
undergo subsequent rounds of retrotransposition. Consistent with this idea, in vitro 
studies suggest that the L1 reverse transcriptase (Piskareva and Schmatchenko, 2006), 
as well as the reverse transcriptase encoded by the Bombyx mori R2 retrotransposon 
(Bibillo and Eickbush, 2002), are efficient enzymes that are more processive than those 
encoded by retroviruses. Thus, it would be reasonable to hypothesize that the host 
would evolve pathways to ‘restrict’ unabated L1 retrotransposition. An extension of this 
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logic suggests the host may have evolved factors that recognize DNA structures 
generated during TPRT to combat retrotransposition.  
It is hypothesized that DNA structures associated with TPRT intermediates (e.g., 
a single-strand nick, a 3’ flap structure, and/or a double-strand break) are recognized as 
substrates by host DNA repair proteins. For example, 5’ truncated L1s are proposed to 
occur via a process termed abortive retrotransposition (Gilbert et al., 2005), where the 
L1 RT becomes dissociated from the L1 cDNA during TPRT. How this dissociation 
occurs requires further study; however, it is notable that the over-expression of proteins 
involved in the nucleotide excision repair (e.g., ERCC1/XPF) inhibits the 
retrotransposition of engineered L1s in cultured human cells (Gasior et al., 2008; 
Servant et al., 2017). Similarly, the APOBEC3A protein can deaminate cytidine 
residues, which converts them to uracil residues, in transiently exposed single-strand L1 
cDNAs that arise during TPRT (Richardson et al., 2014); repair processes that remove 
the uracil residues from single-strand DNA and the completion of L1 integration may 
lead to 5’ truncation. Finally, the ataxia telangiectasia mutated (ATM) protein is 
hypothesized to recognize lesions (perhaps double-strand DNA breaks) generated 
during TPRT to inhibit L1 retrotransposition (Coufal et al., 2011). Given this data, it is 
intriguing to speculate that other DNA damage sensing pathways, such as damage 
recognized by the ataxia telangiectasia mutated-related (ATR) protein also play a role in 
the inhibition of L1 integration in the genome. Indeed, the initial steps in L1 integration 
likely represent a battleground between L1 and its host to limit retrotransposition. 
A variation of TPRT, termed “twin-priming,” can lead to the formation of L1 
inversion/deletion structures (Ostertag and Kazazian, 2001). During twin priming, it is 
proposed that sequences in the L1 poly(A) tail and an internal segment of L1 RNA 
anneal to short (~4-6 bp) single-strand sequences in target site DNA, leading to the 
formation of a double-strand break. The 3’-OH groups present at the 3’ termini of the of 
the resultant RNA/DNA hybrids then serves as primers for the L1 RT RNA-dependent 
DNA polymerase activity to mediate the convergent synthesis of two L1 cDNAs from 
different regions of the L1 RNA template (presumably through a template switching 
mechanism). The resolution of the convergent L1 cDNAs can occur through two distinct 
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mechanisms. Most often, microhomology-mediated annealing between the cDNAs, 
followed by the completion of second-strand synthesis by either a L1 RT DNA-
dependent DNA polymerase activity or a host-encoded DNA polymerase then leads to 
the formation of inversion/deletion structures. Less frequently, one of the L1 cDNAs can 
use non-allelic L1 copies located on the same chromosome as repair templates, by a 
process termed synthesis dependent strand annealing (SDSA), to generate more 
complex genomic rearrangements (Beck et al., 2011; Gilbert et al., 2005). 
 TPRT can also lead to small or larger structural rearrangements in genomic 
DNA. For example, if second-strand cleavage is directly opposed to the initial 
endonucleolytic nick, TPRT can lead to a ‘blunt’ insertion that does not contain target 
site alterations. By comparison, if second-strand cleavage occurs upstream of the initial 
endonucleolytic break, the completion of TPRT can lead to the generation of small 
deletions at the target site (Gilbert et al., 2002).  
TPRT can also occasionally lead to large genomic deletions. In one model, large 
(> 10 kb) deletions can be generated if the L1 cDNA invades a double-strand break 
upstream of the initial integration site (Gilbert et al., 2005; Gilbert et al., 2002). In a 
second model, termed single-strand annealing, the newly synthesized first-strand L1 
cDNA can undergo non-allelic homologous recombination (NEHJ) with an L1 located 
upstream of the insertion site. The resolution of TPRT intermediates can result in the 
generation of a ‘chimeric’ L1 and the concomitant deletion of DNA (typically on the order 
of hundreds of base pairs to ~3.1 kb) that resides between the newly integrated L1 
cDNA and the genomic L1. Finally, although far less frequent, newly integrated L1 
cDNAs may be able to undergo inter-chromosomal recombination events, leading to the 
formation of translocations (Gilbert et al., 2005). Thus, structural variants generated 
during TPRT can lead to the formation of large structural variants in the genome. 
Genomic deletions generated during TPRT can lead to various human diseases.  For 
example, a 46 kb L1 insertion/deletion event into the PHDX gene has resulted in a case 
of pyruvate dehydrogenase deficiency (Mine et al., 2007), and several L1 
insertion/deletion deletions into NF1, have led to sporadic cases of neurofibromatosis 
(Kazazian and Moran, 2017; Vogt et al., 2014). 
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L1-Mediated Transductions 
On occasion, L1s are able to mobilize genomic DNA sequences flanking their 3’, 
and 5’ ends to new genomic locations by a process termed L1-mediated transduction. 
L1-mediated 3’ transductions occur when RNA polymerase II bypasses the ‘weak’ L1 
polyadenylation site present in the L1 3’UTR, and instead uses a ‘stronger’ 
polyadenylation site in flanking genomic DNA to generate a full-length L1 mRNA 
(Holmes et al., 1994; Moran et al., 1999; Moran et al., 1996). Retrotransposition of the 
resultant mRNA can lead to the mobilization of 3’ flanking genomic sequence, resulting 
in 3’ transductions (Goodier et al., 2000; Pickeral et al., 2000). Approximately 20% of 
human-specific L1s harbor 3’ transduction events, and these sequences have been 
used to infer progenitor offspring relationships among L1Hs subfamily members (Beck 
et al., 2010; Goodier et al., 2000; Holmes et al., 1994; Kidd et al., 2010; Macfarlane et 
al., 2013; Pickeral et al., 2000; Tubio et al., 2014a).  
L1-mediated 5’ transductions occur when RNA polymerase II initiates 
transcription from genomic sequences that reside upstream of the L1 5’UTR. 
Retrotransposition of the resultant RNA can then lead to a full-length L1 copy, which 
contains additional genomic sequence at its 5’ end. Although L1-mediated 5’ 
transductions are quite rare, they have been identified in the HGWD (Lander et al., 
2001), cultured cells (Symer et al., 2002; Wei et al., 2001), a mutagenic mouse L1 
insertion (Chen et al., 2006), and a somatic L1 insertion in the human brain (Evrony et 
al., 2012).  
Endonuclease Independent LINE-1 Retrotransposition 
While endonuclease activity is generally required for L1 retrotransposition, under 
certain cellular environments L1s lacking endonuclease activity are capable of 
mobilizing throughout the genome by an alternative integration pathway termed 
endonuclease-independent (ENi) L1 retrotransposition. Engineered L1s containing 
missense mutations in the L1 EN domain can undergo ENi retrotransposition in Chinese 
hamster ovary (CHO) cells that are deficient in components of the non-homologous 
end-joining (NHEJ) pathway of DNA double-stranded break repair (Morrish et al., 2007; 
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Morrish et al., 2002). ENi retrotransposition events are distinct from canonical TPRT-
mediated L1 insertions in that they are frequently both 5’ and 3’ truncated, do not occur 
in typical L1 endonuclease cleavage sites, generally lack TSDs, and often are 
associated with genomic deletions at the integration site (Morrish et al., 2002). 
Additionally, some ENi retrotransposition events contain the addition of short cDNA 
fragments at their L1/genomic DNA junctions, which appear to be derived from the 
reverse transcription of cellular mRNAs (Morrish et al., 2007; Morrish et al., 2002). 
Indeed, in DNA protein kinase catalytic subunit-deficient (DNA-PKcs) CHO cells, ENi 
retrotransposition events can occur at dysfunctional telomeres (Morrish et al., 2007). In 
this cellular environment, chromosome ends likely provide the free 3’ OH required for 
initiating priming of reverse transcription. Thus, endonuclease-deficient L1s can use 
genomic lesions to initiate TPRT (Morrish et al., 2002). 
Although the vast majority of L1 retrotransposition proceeds via TPRT, putative 
ENi retrotransposition events have been identified in the human genome (Sen et al., 
2007; Srikanta et al., 2009). Moreover, an ENi retrotransposition event into EYA1, which 
is accompanied by a ~17kb genomic DNA deletion, is responsible for a sporadic case of 
human oto-renal syndrome (Morisada et al., 2010). It remains to be determined whether 
mutations in double-strand break repair pathways other than NHEJ may also provide 
permissible means for ENi retrotransposition.   
Post-integration Genomic Rearrangements 
Non-allelic homologous recombination (NAHR) events between genomic L1s can 
also lead to genomic structural variation. NAHR between genomic L1s, as well as 
between genomic Alus has been observed in several sporadic cases of disease and 
has been shown to play a role in the generation of CNVs in the genome (Burwinkel and 
Kilimann, 1998; Kazazian and Moran, 2017; Lehrman et al., 1985; Segal et al., 1999; 
Startek et al., 2015; Temtamy et al., 2008). For example, NAHR between genomic L1s 
has led to sporadic cases of phosphorylase kinase deficiency, Alport syndrome, and 
Ellis-van Creveld syndrome (Burwinkel and Kilimann, 1998; Segal et al., 1999; 
Temtamy et al., 2008).  
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L1 as a Mutagen 
The first notion that L1 is still actively moving within the human genome was 
highlighted by the discovery of two independent mutagenic L1 insertions found within 
exon 14 of the Factor VIII gene, which caused hemophilia A in two unrelated males 
(Kazazian et al., 1988). A few years later, an L1 insertion within the Dystrophin gene 
was found to be the cause of a case of muscular dystrophy (Holmes et al., 1994).  Since 
that time, ~130 mutagenic L1-mediated retrotransposition events (which include L1, Alu, 
SVA, and to a lesser extent processed pseudogenes insertions) have been reported in 
various diseases (Hancks and Kazazian, 2016; Kazazian and Moran, 2017). Indeed, a 
comprehensive study characterizing mutations in the NF1 gene suggested that L1-
mediated retrotransposition events are responsible for approximately 1 in 250 disease-
producing mutations in humans (Wimmer et al., 2011). 
L1-mediated retrotransposition events are estimated to occur, at a minimum, in 1 
of 20 meioses for Alu, 1 of 20 to 200 meioses for LINE-1, and 1 of 900 meioses for SVA 
(Cordaux and Batzer, 2009; Kazazian and Moran, 2017). L1-mediated retrotransposition 
events can cause mutations by a variety of mechanisms. For example, insertions into 
exons can disrupt the coding potential of a gene, whereas insertions into introns can 
result in exon skipping or mis-splicing, leading to the generation of hypomorphic or null 
expression alleles (Awano et al., 2010; Holmes et al., 1994; Kagawa et al., 2015; 
Kazazian and Moran, 1998; Kondo-Iida et al., 1999; Musova et al., 2006; Narita et al., 
1993; Rodriguez-Martin et al., 2016). The L1 antisense promoter also can generate 
transcripts that can affect gene expression (Speek, 2001). Similarly, in vitro experiments 
indicate that full-length L1 retrotransposition events into introns can either introduce 
premature polyadenylation sites or RNA polymerase II transcriptional pause sites into 
genes, thereby disrupting gene expression (Han et al., 2004; Perepelitsa-Belancio and 
Deininger, 2003).  
Overview: Polymorphic and Somatic L1 Insertions 
Comparative genomic analyses between the human genome reference 
sequence and the draft chimpanzee genome led to the identification of ~11,000 
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species-specific transposable elements, including 5,530 Alu, 1,174 L1 and 864 SVA 
elements specific to humans (Mills et al., 2006). Several sequencing studies have 
focused on capturing L1Hs specific integration events (e.g., Sheen et al., 2000; Badge 
et al. 2003; Beck et al., 2010). In sum, these studies have identified L1s that are 
polymorphic with respect to presence/absence in the human population. Indeed, the 
genomes of any two unrelated individuals contain ~300 polymorphic L1s (Ewing and 
Kazazian, 2010). Thus, an individual genome only provides a ‘snapshot’ of L1 diversity 
in the population, leading to an under-representation of polymorphic, and active, L1Hs 
sequences in the current human genome draft sequence (Beck et al., 2010) (Table 1.2). 
Notably, recent studies have also found, as originally predicted by Barbara McClintock’s 
studies, that active L1s retrotranspose during early development and in a subset of 
somatic cells, leading to the presence of L1 insertions that are present in some somatic 
lineages, but not others  (i.e., creating somatic mosaicism) (Table 1.3). In this section, I 
focus on methods to discover polymorphic and somatic L1 integration events and then 
discuss the developmental timing of such L1 retrotransposition events.  
Approaches to Identify Polymorphic and Somatic LINE-1 Insertions 
The diagnostic ‘ACA’ tri-nucleotide and downstream ‘G’ in the 3’UTR L1Hs 
sequences (Badge et al., 2003; Ewing and Kazazian, 2010; Huang et al., 2010; Iskow et 
al., 2010; Ovchinnikov et al., 2001; Rodic et al., 2015; Sheen et al., 2000; Solyom et al., 
2012) have been exploited using PCR-based approaches to identify polymorphic L1Hs 
sequences. For example, Sheen et al. used targeted PCR approaches to identify six 
L1Hs elements, which were polymorphic with respect to presence/absence in the 
human population. Similarly, a derivation of classical transposon-based display methods 
[amplification typing of L1 active subfamilies (ATLAS)], which involves the generation of 
libraries containing short sequences of genomic DNA (typically 100-1,000 bp in length) 
containing artificial DNA linkers at their termini in conjunction with suppression PCR 
methodology, led to the isolation of eight full-length polymorphic L1Hs sequences. 
Three of these  (3 out of 8) were highly active in cultured cell retrotransposition assays 
(Badge et al., 2003). Thus, ATLAS provided a means to capture active, polymorphic 
L1Hs sequences that were absent from the human genome draft sequence.  
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Variations of the general PCR-based approach used in ATLAS, which use the 
targeted capture of L1Hs sequences (Baillie et al., 2011; Shukla et al., 2013), 
microarray based approaches to identify L1Hs sequences (Cardelli et al., 2012; Huang 
et al., 2010) and the identification of size differences in individual fosmid DNA libraries 
(Beck et al., 2010; Kidd et al., 2008; Tuzun et al., 2005), have been used in conjunction 
with high-throughput sequencing and sophisticated bioinformatics analysis pipelines to 
capture both polymorphic germline and somatic L1 integration events. Indeed, the ever-
increasing availability of individual human DNA sequences (e.g., such as those from the 
1000 Genomes Project) has also allowed the identification of polymorphic and somatic 
L1Hs sequences using post-sequencing bioinformatics tools that allow the identification 
of L1-mediated insertions in short-read whole-genome sequencing data (Figures 1.5 
and 1.6) (Genomes Project et al., 2015; Helman et al., 2014; Lee, 2012; Stewart et al., 
2011; Tubio et al., 2014a). An extensive list of techniques used to identify polymorphic 
and somatic L1Hs integration events is presented in Tables 1.2, 1.3, and 1.4. 
Advantages and disadvantages exist for targeted capture/PCR-based and whole 
genome-based approaches. In general, PCR-based capture approaches allow the 
identification and ‘calling’ of L1Hs integration sites from relatively small amounts of 
genomic DNA input. However, chimeric artifacts arising during the PCR process can 
lead to a high false discovery rate, complicating downstream bioinformatics analysis. 
Moreover, short-read DNA sequencing technologies can complicate efforts of mapping 
genomic DNA that flank L1Hs sequences to unique regions of the human genome, 
especially in areas of the genome replete with repetitive DNA sequences. Similarly, 
microarray chip-based approaches are limited by probe design/coverage and often have 
difficulty in identifying L1Hs sequences in repetitive areas of the genome. Finally, 
fosmid-based approaches, while representing the ‘gold standard,’ are costly and effort 
intensive, which limits throughput, and are unable to detect severely 5’ truncated L1 
integration events. By comparison, whole-genome approaches offer the advantage of 
leveraging the plethora of DNA sequence data available to the scientific community.  
However, low sequence coverage, combined with the abovementioned difficulty in 
assembling short read DNA sequences containing repetitive DNA are notable technical 
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hurdles that hamper the identification of polymorphic (and somatic) L1Hs sequences in 
the genome. 
The advent of whole genome single-cell DNA amplification (WGA) followed by 
targeted capture/and high-throughput DNA sequencing offers promise to detect both 
low frequency and/or ‘private’ L1Hs germline polymorphism and somatic L1Hs 
insertions within individual cells. Indeed, these approaches have been used to confirm 
that L1Hs elements can retrotranspose in somatic cells (Erwin et al., 2016; Evrony et 
al., 2012; Evrony et al., 2015; Upton et al., 2015). However, WGA is still in its infancy; 
different WGA approaches lead to different efficiencies in genome amplification, and 
often result in uneven genomic DNA amplification and allelic drop-out in repetitive 
regions of the genome. This can further lead to chimeric artifacts that complicate 
downstream analyses, and may not faithfully amplify and/or map genomic regions rich 
in repetitive DNA, as they are often filtered out in downstream bioinformatics pipelines. 
The advantages and disadvantages aside, a combination of the above methodologies, 
as well as classical genetic and molecular biological approaches, have led to important 
insights about when and where L1s retrotranspose during development.   
Endogenous LINE-1 Retrotransposition 
Evidence for L1 Mobilization in Germline and During Early Embryogenesis 
The first evidence that retrotransposition can occur during early human 
embryonic development involved the discovery of a 5’ truncated L1 containing a 3’ 
transduction in exon 4 of the X-linked CYBB gene of a male chronic granulomatous 
disease patient (Brouha et al., 2002). The L1 3’ transduction allowed the identification of 
the progenitor source element, LRE3, on chromosome 2q24.1. Interestingly, these data 
suggested that RNA derived from the maternal LRE3 allele retrotransposed into the 
CYBB gene in a primary oocyte prior to the onset of maternal meiosis II, and that 
independent assortment during meiosis II resulted in the inheritance of the de novo 
insertion, but not the progenitor LRE3 allele, in the patient.    
Initial studies in transgenic mice further indicated that L1 can retrotranspose 
during gamete generation. Evidence from a male transgenic mouse containing an 
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engineered human L1 containing an acrosin signal peptide/EGFP retrotransposition 
indicator cassette whose expression was driven by a pre-proacrosin promoter indicated 
that de novo L1 retrotransposition events were present in 2 of 135 offspring. Thus, 
these events likely occurred in the male germline prior to the onset of meiosis II at a low 
frequency (Athanikar et al., 2002; Ostertag et al., 2002).  
An emerging body of evidence suggests that L1s may also retrotranspose in the 
female germline. For example, genetic and molecular biological experiments revealed 
that mutagenic de novo L1 retrotransposition that led to hemophilia A in a male patient 
likely occurred in his mother’s germline (Kazazian and Moran, 1998; Richardson et al., 
2017). Similarly, studies using engineered human L1s suggest that L1 can 
retrotranspose in female oocytes (Georgiou et al., 2009), whereas L1 expression and or 
retrotransposition may lead to oocyte attrition in mice (Malki et al., 2014). Finally, whole-
genome DNA sequencing of representative mice in two and three generation pedigrees 
uncovered eleven de novo full-length L1 insertions (Richardson et al., 2017). 
Subsequent PCR-based validation experiments from parental mice and their offspring 
on genomic DNA derived from reproductive organs, as well as tissues representing the 
three distinct primary germ layers, revealed that the de novo L1 insertions occurred in 
primordial germ cells, later in germline development, and in the early embryo 
(Richardson et al., 2017). Thus, it is clear that L1 can retrotranspose in both the male 
and female germlines.  
Post-zygotic Insertions  
In addition to the Richardson et al. (2017) study mentioned above, it is now 
apparent that L1 retrotransposition events can occur after fertilization during early 
zygotic development. For example, the characterization of a full-length L1 insertion into 
the CHM gene, which led to the X-linked recessive disorder choroideremia in a male 
patient, provided the initial evidence that L1 retrotransposition could occur during early 
embryogenesis (van den Hurk et al., 2007). This mutagenic insertion contained two 3’-
transductions events, which allowed the identification of the progenitor L1 in the 
patient’s mother. Intriguingly, the patient and his sisters shared the same X-
chromosome haplotype, but only one sister inherited the mutagenic L1 insertion, 
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indicating that the mother was a germline mosaic. Subsequent experiments, using the 
mother’s lymphoblast DNA, revealed that she also was a somatic mosaic with respect to 
this mutagenic L1 insertion. Thus, this mutagenic L1 insertion must have occurred early 
during embryogenesis in the mother, prior to the segregation of the germline and 
somatic lineages.  
Additional support for L1 retrotransposition in the early embryo comes from cell 
culture studies in human embryonic stem cells (hESCs), a model of early human 
embryonic development. Approximately 20% of expressed L1Hs elements in cultured 
hESCs are retrotransposition competent and both ORF1p and endogenous L1 
ribonucleoprotein particles are highly expressed in hESCs (Garcia-Perez et al., 2007; 
Macia et al., 2011). Moreover, engineered L1 constructs tagged with a 
retrotransposition indicator cassette can mobilize in cultured hESCs, although at lower 
levels when compare to L1 mobilization in HeLa cells (Garcia-Perez et al., 2007; Moran 
et al., 1996; Wei et al., 2000). Thus, these data provide orthogonal pieces of 
experimental evidence to support the hypothesis that heritable retrotransposition events 
can occur in the early embryo. 
Somatic L1 Retrotransposition Events: Cancers 
Early studies revealed that cell lines derived from epithelial tumors exhibited 
higher levels of L1 RNA and ORF1p expression than primary cell types. Moreover, the 
increase in L1 expression correlated with the methylation status of the L1 5’UTR—CpG 
residues within the L1 5’UTR tended to exhibit more hypomethylation in tumor cell lines 
than primary cells (Alves et al., 1996; Doucet-O'Hare et al., 2016; Hata and Sakaki, 
1997; Nur et al., 1988; Thayer et al., 1993; Woodcock et al., 1996; Yoder et al., 1997). 
The realization that L1 retrotransposition events may play a role in tumor 
initiation and/or progression was realized upon the discovery of a mutagenic L1 
insertion that disrupted the APC tumor suppressor gene in a colon tumor (Miki, 1992). 
Notably, the mutagenic insertion was not present in the surrounding normal colonic 
tissue, suggesting that it may have been a ‘driver’ mutation responsible for the initiation 
of tumorigenesis. Indeed, a recent study identified a 5’ truncated somatic L1 insertion 
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located 388bp upstream of the aforementioned L1 insertion in the APC gene (Scott et 
al., 2016). This mutagenic L1 insertion disrupted the open reading frame of the APC 
tumor suppressor gene (Miki, 1992; Scott et al., 2016). The other APC allele contained 
a stop codon, which most likely led to its inactivation (Scott et al., 2016). Thus, these 
mutations likely represent two ‘driver’ mutations required for APC inactivation and 
initiation of tumorigenesis. 
During the past 17 years, a number of PCR-based targeted capture sequencing 
and whole-genome sequencing approaches have identified somatic L1 insertions in 
several epithelial tumor cancer types (Baillie et al., 2011; Ewing and Kazazian, 2010; 
Helman et al., 2014; Iskow et al., 2010; Lee, 2012; Rodic et al., 2015; Tubio et al., 
2014a), and have been reviewed in Scott et al. (2017). A number of emerging themes 
have resulted from these studies, which are summarized below.  
First, it is clear that some L1 insertions occur into exons of known tumor 
suppressor genes (e.g., PTEN) (Helman et al., 2014) or into the untranslated regions of 
candidate genes that have been implicated as putative tumor suppressor genes in 
cancers (e.g., ROBO2, CDH12, and CDH11) (Lee, 2012; Solyom et al., 2012). Second, 
a proof-of-principle experiment revealed that a mutagenic L1 insertion disrupted a 
transcriptional repressor site in the ST18 gene (Shukla et al., 2013). Since ST18 is 
frequently amplified in hepatocellular carcinomas, these data suggest that the L1 
insertion may result in ST18 over-expression and oncogenic activation. Thus, it is 
possible that some L1 insertions may serve as driver mutations in cancers. 
Second, the rate of L1 retrotransposition seems to vary greatly between these 
different tumor types (Doucet-O'Hare et al., 2015; Lee, 2012; Rodic et al., 2015; Tubio 
et al., 2014a). For example, individuals with Barrett’s esophagus contain on average 
five L1 insertions per person, while individuals with esophageal adenocarcinoma 
observe a rate almost five times that of 23.5 L1 insertions per person (Doucet-O'Hare et 
al., 2015). Indeed, one study identified 102 candidate L1 insertions in a colorectal tumor 
(Lee, 2012). However, no somatic insertions have been discovered to date within brain 
(Carreira et al., 2016; Helman et al., 2014; Iskow et al., 2010) or blood (Helman et al., 
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2014; Lee et al., 2012) based tumors. Thus, it seems that the L1 mutagenic load varies 
within and between cancers. 
Third, and consistent with what has been learned from germline L1 insertions 
(Beck et al., 2010; Holmes et al., 1994; Kidd et al., 2008; Moran et al., 1999; Moran et 
al., 1996), approximately 24% of somatic retrotransposition events in tumors contain 3’ 
transductions, and these transduced sequences have been used to identify highly active 
progenitor L1s in cancers (Macfarlane et al., 2013; Tubio et al., 2014a). For example, a 
comprehensive study found that two highly active L1Hs elements account for more than 
a third of all somatic transductions identified in several tumor sample types, and that 
95% of all the identified 3’ transductions could be attributed to 72 germline L1Hs loci 
(Tubio et al., 2014b). Since that time, elegant methods have been developed to exploit 
DNA sequences between L1Hs elements, instead of transductions, to infer 
progenitor/progeny L1 relationships and to map RNA-seq reads to individual L1 loci 
(Scott et al., 2016). Clearly, L1 retrotransposition occurs in several cancers, and on 
occasion, can result in ‘driver’ mutations that affect cell growth. However, given the 
evidence at hand, it seems likely that the bulk of the resultant insertions represent 
‘passenger’ mutations that have little contribution to the tumor phenotype (Kazazian and 
Moran, 2017; Tang et al., 2017).  
The Role of Transposable Elements During Neurogenesis  
Epithelial tumor cells are not the only cells harboring somatic L1 
retrotransposition events. Indeed, recent studies have demonstrated that L1s can 
undergo somatic retrotransposition in neuronal progenitor cells, and leads to somatic 
mosaicism in the brain that contributes to intra-individual genetic variation. Since 
neurons are among the longest-lived cells in the body, it has been hypothesized that 
somatic L1 retrotransposition events may contribute to individual phenotypic differences 
and disease susceptibilities. Below, I highlight some of the seminal findings in this area 




Discovery of L1 Retrotransposition in Neurons 
In 2005, Muotri et al. discovered that an engineered human L1 containing an 
EGFP retrotransposition indicator cassette could retrotranspose in adult rat neural 
progenitor cells (NPCs) in vitro and in the brains of transgenic mice in vivo, leading to 
EGFP-positive cells within the brain. Notably, EGFP-positive cells co-localized with 
neuronal marker proteins, but not oligodendrocyte or astrocyte markers, indicating that 
L1 retrotransposition occurred in neuronal progenitor cells (NPCs) rather than in a 
common precursor cell early during early embryogenesis. The characterized L1 
integration events revealed that 5/17 (29%) integrated within neuronally-expressed 
genes. Intriguingly, one antisense L1 insertion within the 5’UTR of Psd-93 (also referred 
to as DLG2), led to its overexpression, which promoted the differentiation of precursor 
cells to neuronal fates. In agreement with previous studies, EGFP-positive cells were 
also detected in germ cells (ovary and testes) of transgenic mice (Ostertag et al., 2002). 
Taken together, these data indicate that a engineered human L1 can retrotranspose in 
the mouse brain and, at least in one case, the insertion could influence the expression 
of the resultant gene, leading to a measurable cell-based phenotype. 
Subsequent studies revealed that engineered L1s can retrotranspose at low 
levels in human fetal brain stem cells, at high levels (e.g., in up to 20% of cells) in 
human embryonic stem cell (hESC)-derived NPCs when compared to fetal NPCs 
(Coufal et al., 2009), and at similarly high levels in a human embryonic carcinoma cell 
line, PA-1, which shares attributes with NPCs (Garcia-Perez et al., 2010). Thus, human 
NPCs also can accommodate engineered L1 retrotransposition in vitro—sometimes at 
surprisingly high levels. 
Similar to studies in cancer cells, bisulfite conversion analyses on human adult 
genomic DNA revealed that the L1 5’UTR exhibits significantly less methylation in brain 
samples when compared to matched skin samples (Coufal et al., 2009). Moreover, 
sensitive quantitative PCR assays revealed that L1 DNA content is reproducibly 
elevated in certain regions of the brain (containing ~80 additional copies of ORF2 DNA 
per cell) when compared to heart and liver DNA from the same individuals. These data 
suggested that endogenous L1s could possibly contribute to intra-neuronal genetic 
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diversity; however, it remained possible that other cellular processes, besides 
retrotransposition, were responsible for the increase in ORF2 copy number (Coufal et 
al., 2009). 
Discovery of Somatic Retrotransposition Events in the Brain 
Bulk Tissue Experiments 
A targeted-capture PCR-based approach performed in conjunction with next 
generation DNA sequencing [i.e., retrotransposon capture sequencing (RC-seq)] led to 
the identification of 7,743 putative somatic L1 insertions, 13,692 somatic Alu insertions, 
and 1,350 SVA insertions that were present in bulk DNA samples derived from the 
hippocampus and caudate nucleus of three donors, which were absent from their blood 
DNA (Baillie et al., 2011). The characterization of 14 L1 integration events revealed 
typical L1 structural hallmarks, suggesting that at least some represent bona fide 
instances of de novo endogenous L1 retrotransposition. The authors further claimed 
that ~3.4% of insertions were within coding exons, whereas ~43.3% were within the 
introns of annotated genes. Gene ontology analyses further suggested an enrichment of 
L1 retrotransposition events within genes involved in neurogenesis in synaptic function. 
Although a groundbreaking study that established L1-mediated retrotransposition 
events could occur within the brain, some have suggested that many (or perhaps the 
majority) of the calls represent false-positives. If so, the conclusions of many 
downstream analyses (e.g., understanding the proportion of insertion into genes, etc.) 
may require refinements. 
Single Cell Experiments 
 A number of laboratories have utilized whole genome amplification (WGA) 
approaches to amplify DNA from single neurons. The WGA products are then subject to 
targeted capture and/or whole genome sequencing to detect somatic L1 
retrotransposition events in neurons. For example, Evrony et al., isolated single neurons 
from postmortem and surgically resected human brains and used WGA to analyze 300 
single neurons from the cerebral cortex and caudate nucleus of three neurologically 
normal individuals (Evrony et al., 2012). L1Hs sequences were then identified in the 
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WGA samples using L1 insertion profiling (L1-IP), an approach previously used by 
Ewing and Kazazian to identify polymorphic L1Hs sequences in 15 individual genomes. 
Intriguingly, the authors identified a full-length somatic insertion within intron 4 of ICQH. 
This insertion was identified in two cortical neurons, but not single caudate neurons, and 
was present at a low level in an unsorted 50,000 nuclei, as well as in bulk brain DNA. 
The observed low-level mosaicism of this somatic insertion, and its detection only in 
cortical neurons suggests the insertion occurred during cortical development.  
Subsequent studies, which used droplet digital PCR to analyze DNA samples 
from 32 different brain regions for two of the somatic L1 retrotransposition events 
identified above, revealed that one L1 insertion most likely occurred in a neocortical 
progenitor of the left middle frontal gyrus, giving rise to mostly neurons (Evrony et al., 
2015). The second L1 insertion seems to have mobilized considerably earlier during 
nervous system development in a progenitor for both neurons and glia. Taken together, 
the above studies confirmed that L1 retrotransposition occurs, albeit at a low level 
(~0.04-0.6 unique somatic L1 insertions occur per neuron), in the human brain, and 
indicated that L1 retrotransposition may occur during different times of brain 
development. 
Faulkner and colleagues have also adapted RC-seq to identify somatic L1 
insertions in single hippocampal and cortical neurons and glial cells (Upton et al., 2015). 
In contrast to the above studies, they identified over 2,000 putative somatic L1Hs 
insertions in at least one hippocampal neuron, resulting in a predicted rate of 13.7 
somatic L1 insertions per hippocampal neuron. Four of these insertions were identified 
in both neurons and glial cells, suggesting that L1 retrotransposition events can arise in 
proliferating neural stem cells prior to glial or neuronal commitment, but that glia cells 
generally support less L1 retrotransposition than neurons. Intriguingly, once again, 
Faulkner and colleagues found that 1.2% of L1 insertions were within exons, whereas  
~36.8% were within introns. They also reported an 1.8-fold enrichment for L1 insertions 
into highly transcribed neuronal genes and active enhancer elements in neuronal stem 
cells. However, some have criticized this study, claiming that chimeric artifacts arising 
during WGA have led to large number of false-positive calls (Evrony et al, 2016).  
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Finally, Gage and colleagues used a targeted single-cell sequencing approach 
and machine learning-based analysis to identify somatic L1-associated variants 
(SLAVs) on single nuclei derived from the frontal cortex and hippocampus of three 
healthy individuals (Erwin et al., 2016). A SLAV is defined as a somatic L1Hs insertion, 
or a deletion (as large as 792kb) in the genome believed to be due to a post-integration 
recombination or homology-mediated event. The authors identified 46 putative SLAVs. 
Interestingly, an endogenous SLAV was discovered in DLG2, in hippocampal progenitor 
cells. This was the same gene in which an engineered human L1 retrotransposition 
event was discovered in rat NPCs previously (Muotri et al., 2005). As above, SLAVs are 
generated during a variety of neural development stages, including in an early 
progenitor cell that contributes to the development of both the hippocampus and frontal 
cortex. Together, these data led the authors to suggest that SLAVs occur at a rate of 
~0.58 to 1 events per neuron and/or glial cell and are predicted to affect ~44% to 63% 
of cells in the healthy brain.  
Discrepancies in Rate of L1 Integration in the Brain 
In general, the field now agrees that somatic L1-mediated retrotransposition 
events within the brain contribute to intra-individual genetic variation. However, the 
discrepancies among the above studies have sparked a spirited debate regarding the 
‘true’ rate of somatic L1 retrotransposition in the brain. Indeed, it is unlikely that one 
group is fully correct, while another is completely wrong. Thus, how can one account for 
these observed differences in values?  
Some of the discrepancies could be attributed to the difference in cell types 
examined in the above studies (hippocampal versus cortical neurons).  It remains 
possible that different types of neurons accommodate L1 retrotransposition at different 
efficiencies. Moreover, the stringency used in bioinformatics calling pipelines could 
contribute to variability. For example, while Faulkner and colleagues have been 
criticized for having a high-false positive rate in their putative call sets, it also is possible 
that high false-negative rates, which are harder to detect, contribute to the lower 
estimates in the Evrony and Erwin studies. Finally, technical issues that arise using 
different WGA methodologies in single cell-based studies likely lead to differences in 
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genome coverage and allelic dropout (which are generally assessed using single copy 
sequences), which would confound downstream analyses. Moreover, time will tell 
whether WGA actually provides an accurate depiction of the repetitive DNA content of 
the genome—a significant problem that has not satisfactorily been addressed in the 
literature. Indeed, given the above caveats, the field should critically assess whether 
WGA single cell-based methods provide a suitable means to make quantitative 
conclusions about L1, and repetitive DNA content, in the human genome. Finally, given 
these controversies, the field should be wary about downstream claims regarding the 
integration preferences of L1s in cells. Indeed, a high false positive rate (as well as 
exaggerated claims made on ‘call sets’ containing a small number of events) could 
confound, and perhaps skew, results of downstream analyses. 
Integration Preferences of Transposable Elements   
Transposable element (TE) insertions are mutagenic. From a teleological 
standpoint, the unabated mobility may adversely affect genome integrity, thereby 
harming the host. As such, it is not surprising that many TEs have evolved strategies to 
insert into specific genomic regions, thereby minimizing damage to their respective host 
genomes. Below, I describe convergent evolutionary strategies used by different TEs to 
‘minimize’ damage to their host genomes. Sultana et al. (2017) recently published a 
similar review on integration site selection by eukaryotic retroviruses and transposable 
elements, while Levin and Moran (2011) also addressed several of the topics presented 
here. I then briefly describe what is known about L1 integration preferences and 
address the main question in this dissertation: Do L1 retrotransposition events display 
integration preferences within the human genome?   
Integration into Ribosomal DNA 
Work on the Bombyx mori R2 non-LTR retrotransposon has been instrumental in 
generating the TPRT model of retrotransposition. The R2 protein, like L1 ORF2p, has 
both EN and RT activities, but the EN belongs to the type-II RE family of proteins (Yang 
et al., 1999). The R2 EN cleaves a specific sequence within the 28S ribosomal RNA 
(rRNA) gene to mediate its integration (Eickbush, 2002). Interestingly, insect R1 
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retrotransposons encode an APE-type EN that also cleaves a specific sequence within 
the 28S rRNA gene, which is located 74 bp downstream of the R2 cleavage site, to 
mediate their integration (Xiong and Eickbush, 1988). These findings demonstrate non-
LTR retrotransposons possessing different types of EN domains can integrate into 
similar genomic compartments. Indeed, the redundant nature of rDNA genes in an 
organism may provide a safe haven for retrotransposon insertions (i.e., knocking out a 
small number of rDNA genes may not have a dramatic effect on rRNA synthesis). 
Consistent with these thoughts, it is notable that R1 and R2 occupy anywhere from a 
few percent to over half of the rDNA units of most insects (Jakubczak et al., 1991). 
Integration into transfer RNAs 
The examination of whole genome sequences and subsequent experimental 
work indicates that some Saccharomyces cerevisiae LTR-retrotransposons (i.e., Ty1 
and Ty3) preferentially integrate upstream of RNA polymerase III-transcribed genes, 
such as tRNAs, which are generally located in gene-poor environments (Bushman, 
2003; Devine and Boeke, 1996; Lesage and Todeschini, 2005; Sandmeyer, 2003). For 
example, Ty3 integration occurs in a position-specific manner inserting in either 
orientation 16 to 19 nucleotides upstream of tRNA genes (Chalker and Sandmeyer, 
1990). Interactions between Ty3 integration complexes and components of the RNA III 
polymerase complex mediate precise integration at the tRNA transcription start site 
(Sandmeyer et al., 2015). By comparison, Ty1 integration occurs within a nucleosome 
bound ~700 bp window upstream of tRNA and other RNA polymerase III genes at a 
periodicity of ~80 bp (Devine and Boeke, 1996). Indeed, the finding that highly 
transcribed tRNAs are preferential targets suggest that interactions between the Ty1 
integration complex and RNA polymerase III, which appear to differ from those used by 
Ty3, are important components that influence Ty1 target site specificity.  
Transfer RNA genes are also targeted by non-LTR retrotransposons. For 
example, Dictyostelium repeat element (DRE or TRE5-A), an APE-type non-LTR 
retrotransposon found in Dictyostelium discoideum (a soil-living amoeba), occurs ~48 
nucleotides upstream and in the opposite orientation of tRNA genes (Marschalek et al., 
1992; Spaller et al., 2017). The stable tRNA gene transcription complex, TFIIIB, is 
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postulated to play a role in the position-specific integration of DRE upstream of various 
tRNA genes (Chung et al., 2007; Marschalek et al., 1992). By comparison, a related 
element, Tdd-3, appears to integrate in a position-dependent manner downstream ~100 
bp downstream from tRNA genes (Szafranski et al., 1999). Thus, different types of 
retrotransposons (LTR and non-LTR) have developed convergent mechanisms to target 
integration near tRNA genes. 
Telomeres as Favorable Substrates for Integration 
 Terminal repeat sequences at chromosomal ends, referred to as telomeres, 
shorten with each cell division, since lagging strand DNA synthesis cannot fully copy the 
end of a chromosome (Fujiwara et al., 2005; Greider and Blackburn, 2004). Most 
eukaryotic telomeres consist of short, five to six base pairs, repeated nucleotides 
sequences called telomeric repeats. The lengths of telomeric repeats are maintained by 
a specialized RNP, termed telomerase, which uses a reverse transcriptase activity to 
reiteratively copy a small sequence in its associated template RNA onto chromosome 
ends after the completion of DNA replication, thereby maintaining chromosomal stability 
(Blackburn, 1991; Lundblad and Wright, 1996). When telomeric repeat lengths become 
shorter than a critical threshold, cells can cease to undergo cellular division. 
  Intriguingly, a variety of retrotransposons either target telomeres or have been 
co-opted by the host for telomere maintenance. For example, Drosophila melanogaster 
does encode telomerase and their chromosome ends do not contain canonical 
telomeric repeats. Instead, Drosophila relies upon the following three non-LTR 
retrotransposons to maintain telomeres: the non-autonomous HeT-A element, and the 
autonomous TART, and TAHRE (Telomere-associated and HeT-A-related element) 
elements. These elements are primarily found in an array at Drosophila telomeres. 
TART and TAHRE encode a reverse transcriptase that uses the retrotransposon RNAs 
as templates to mediate end replication at chromosome ends (Biessmann et al., 1990; 
Traverse and Pardue, 1988). TART and TAHRE also contain an AP-like EN domain; 
however, how or if this activity functions in telomere maintenance requires elucidation 
(Arkhipova, I.R. et al., 2017. 
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Similar to Drosophila, the silkworm Bombyx mori has two telomere-specific APE-
type non-LTR retrotransposons, telomeric-repeat-associated sequence 1 (TRAS1) and 
SART1, which is ‘TRAS’ inverted, as it is transcribed and found inserted in a reverse 
orientation relative to TRAS1 (Takahashi, et al., 1997; Takahashi and Fujiwara, 1999). 
However, unlike the situation observed for Drosophila, the ends of Bombyx mori 
chromosomes contain a telomeric repeat sequence of (TTAGG)n. Thus, it appears that 
TRAS1 and SART1 preferentially integrate into a 6-8 kb stretch of the (TTAGG)n 
telomeric repeats.  
Although telomerase activity has not been observed at any developmental stage 
of B. mori somatic (fat bodies, silk glands) or germ-line cells (testes), a putative 
telomerase reverse transcriptase (TERT) has been identified within its genome, termed 
BmoTERT (Fujiwara et al., 2005). BmoTERT contains various structural differences 
when compared to conventional eukaryotic TERT genes (e.g. it lacks introns, has lost 
an N-terminal domain, and contains five putative AUG codons in its 5’ UTR), which is 
thought to result in the repression of BmoTERT expression and enzymatic activity. By 
comparison, genomic copies of both TRAS1 and SART1 appear to be conserved 
among telomere regions in a wide variety of Lepidopteran insects (butterflies and 
moths), are generally full-length, and undergo abundant transcription (Kubo et al., 2001; 
Mandrioli, 2002; Mita et al., 2004; Okazaki et al., 1995; Takahashi and Fujiwara, 1999; 
Takahashi et al., 1997). Thus, TRAS1 and SART1 may play an important role in 
telomere maintenance. 
The green algae Chlorella genome harbors multiple copies of an 8.9kb full-length 
non-LTR retrotransposon, Zepp (Higashiyama et al., 1997). Although the majority of 
Zepp retrotransposons are distributed at non-telomeric regions of different 
chromosomes, two chromosomes contain a cluster of Zepp sequences near or at the 
telomere region. These finding suggest that Zepp elements may either target 
subtelomeric regions for integration and/or possibly play a role in telomere protection 
(Higashiyama et al., 1997). 
Some Penelope-like (PLE) retrotransposons encode a reverse transcriptase 
domain, but lack an overt endonuclease domain. Interestingly, a subset of PLEs 
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comprise telomeric ends in bdelloid rotifers, basidiomycete fungi, stramenopiles, and 
plants (Gladyshev and Arkhipova, 2007). Since most PLEs also carry short stretches of 
telomeric repeats at or near their 3’ ends, they appear to use a 3’OH group at G-rich 
telomeric termini to reverse transcribe their RNA onto chromosome ends (Gladyshev 
and Arkhipova, 2011). This mechanism is akin to endonuclease-independent 
retrotransposition of L1 EN mutants which can use dysfunctional telomeres as 
integration substrates (Curcio and Belfort, 2007; Morrish et al., 2007).  
Telomeric targeting is not unique to non-LTR retrotransposons. For example, 
approximately 90% of the Saccharomyces cerevisiae Ty5 LTR-retrotransposon are 
preferentially located within silent heterochromatic—68% of Ty5 elements are found in 
sub-telomere regions, whereas 22% are found in the silent mating type loci (Zou et al., 
1996). Ty5 integration specificity has been mapped to a nine amino acid targeting 
domain that binds to Sir4, a structural component of heterochromatin, to target 
integration (Levin and Moran, 2011). Intriguingly, under conditions of stress, such as 
nitrogen deprivation, the failure to phosphorylate an amino acid (Ser1095) within the Ty5 
integrase protein, allows Ty5 to integrate into expressed, gene-rich genomic regions 
(Dai et al., 2007). Thus, the integration preferences of certain transposable elements 
are not static and may be altered by environmental stress—a result that harkens back to 
McClintock’s ‘genome shock’ hypothesis (McClintock 1950). 
Replication Targeted for Integration 
Other TEs appear to take advantage of components involved in DNA replication 
to target integration. For example, original studies suggested that Drosophila P 
elements preferentially insert near a gene promoter; however more recent studies 
revealed that they preferentially integrate into origin recognition complex protein-binding 
sites (ORCs) (Spradling et al., 2011). Indeed, promoters associated with ORC binding 
sites exhibit 29-fold enriched for P element insertions than those lacking ORC binding 
sites (16-fold enrichment for P elements). Thus, P elements may be able to effectively 
increase their copy number in Drosophila by inserting into ORC binding sites prior to 
DNA replication (Spradling et al., 2011). 
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IS608 and ISDra2 (types of HUH DNA transposons) exhibit a strong bias for 
integration into the lagging-strand template (Ton-Hoang et al., 2010).  Moreover, other 
genomic features, such as stalled DNA replication forks containing lagging-strand 
templates, are a ‘hot spot’ for IS608 integration, raising the possibility that access to 
lagging-strand templates may increase when replication forks stall.  
The targeting protein, TnsE, encoded by the E.coli DNA transposon Tn7 
recognizes and targets components found on the lagging strand template during 
replication. The preferred binding substrate of TnsE is a structure that contains a 3’ 
recessed end (Peters and Craig, 2001), a structure that is abundant during DNA 
replication. Subsequent investigations revealed that the sliding-clamp processivity factor 
is required for TnsE-mediated transposition (Parks et al., 2009). Sliding-clamp proteins 
are deployed with each new priming cycle on the lagging strand template, and residual 
sliding clamps are believed to be important for recruiting proteins involved in maturation 
of the lagging strand template, including RNA primer removal, ligation of Okazaki 
fragments, and mismatch repair (Lopez de Saro and O'Donnell, 2001; Pluciennik et al., 
2009). Interestingly, biochemical and genetic studies uncovered a putative clamp-
interacting motif within TnsE that was important for interactions with the sliding clamp. 
Mutations in TnsE that disrupted the TnsE-sliding clamp interaction eliminated or 
severely reduced transposition. Intriguingly, TnsE appears to specifically target Tn7 
transposition into lagging strands, where DNA replication forks tend to stall (Peters and 
Craig, 2000, 2001). Another possibility is that Tn7 targets the double-strand break repair 
intermediates created by DNA repair proteins working to resolve stalled replication forks 
(Peters and Craig, 2000; Shi et al., 2008). 
Certain retrotransposons also appear to target DNA replication intermediates as 
integration substrates. For example, blocking the endonuclease activity of the L1.LtrB 
group II intron still allowed ENi retrohoming into leading strand templates of DNA 
replication forks, suggesting 3’OH groups present at the nascent leading DNA strand 
can serve as a primer for reverse transcription of the reverse spliced intron RNA. 
Likewise, the mobilization of L1.LtrB via the EN-independent mechanism of 
retrotransposition exhibit an integration preference into DNA replication forks, 
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specifically into the lagging strand templates (Ichiyanagi et al., 2003; Ichiyanagi et al., 
2002). These findings suggest a mechanism in which the intron reverse splices into 
single-stranded DNA at a replication fork, followed by priming from a nascent lagging 
DNA strand with a free 3-’OH to mediate cDNA synthesis of the reverse spliced RNA. 
Finally, the RmInt1 group II intron, which encodes an IEP lacking an EN domain also 
shows the same integration preference into the lagging strand template (Martinez-
Abarca et al., 2004). 
Integration Preference into RNA polymerase II Transcribed Genes 
Some transposable elements preferentially target RNA polymerase II transcribed 
genes for integration. For example, the Schizosaccharomyces pombe Tf1 LTR 
retrotransposon preferentially integrates into the promoters of RNA polymerase 
transcribed genes (Chatterjee et al., 2009; Guo and Levin, 2010; Leem et al., 2008; 
Majumdar et al., 2011). Approximately 95% of Tf1 integration sites generated in vitro 
occur upstream of ORFs and some of the most frequently targeted promoters are 
associated with stress responsive genes (Guo and Levin, 2010). Furthermore, other 
studies suggest that Tf1 targeting requires Switch Activating Protein 1 (Sap1), a protein 
that is involved in DNA replication (de Lahondes et al., 2003) that is enriched at 
nucleosome-free regions (Tsankov et al., 2011), and the presence of an active 
replication fork barrier (Jacobs et al., 2015).  
Several retroviruses also display integration preferences for RNA polymerase II 
transcribed genes. For example, human immunodeficiency virus-1 (HIV-1) and other 
lentiviruses display strong preferences for transcription units with a distinct bias towards 
highly expressed and intron-rich genes (Lesbats et al., 2016). Moloney murine leukemia 
virus (MLV) preferentially integrates near the start of transcriptional units (Wu et al., 
2003), as well as at strong enhancers and active promoters (LaFave et al., 2014). This 
integration preference appears to benefit the retrovirus as it inserts itself into an area of 




Targeted Integration into Microsatellite Repeats 
 Certain APE-type non-LTR retrotransposons can integrate within multi-copy 
microsatellite repeats. For example, Waldo has been shown to integrate near 5’-AC-3’ 
repeats in Drosophila melanogaster (Busseau et al., 2001), whereas Waldo elements in 
A. gambiae (mosquito) and F. scudderi (earwig) specifically integrate into 5’-ACAY-3’ 
(where Y can be a C or T) repeats (Kojima and Fujiwara, 2003). In addition, the A. 
gambiae APE-type non-LTR retrotransposon, MinoAg1, preferentially integrates into 5’-
AC-3’repeats (Kojima and Fujiwara, 2003). 
L1 Integration Preference 
While it is clear that several DNA transposons and retrotransposons 
preferentially target certain areas of the genome for integration, it remains unclear 
whether L1s specifically integrate into certain regions of the genome.  Below I briefly 
summarize what is known about L1 integration preferences. 
Known L1 Accumulation Preferences  
 The release of the human genome reference sequence revealed that L1s are 
predominantly found in AT-rich genomic regions (Lander et al., 2001). Curiously, while 
Alus rely upon L1 ORF2p for retrotransposition (Dewannieux et al., 2003), older Alu 
subfamilies show a strong bias towards GC-rich DNA. In contrast, Alu elements from 
younger subfamilies (e.g., Ya5 and Yb8) are found in AT-rich regions of the genome 
(Lander et al., 2001). Thus, it appears that post-integrative selection process played an 
important role in shaping L1 and Alu distributions in the human genome. As such, 
simply looking at where L1s and Alus accumulate in the genome over evolutionary time 
may not accurately reflect their initial insertion preferences. 
L1s are also dramatically overrepresented on the X-chromosome (Lander et al., 
2001; Smit, 1999). Whether this overrepresentation is due to the preferential targeting of 
L1s to the X-chromosome or suggests a function for L1s in X-chromosome biology 
remains a spirited debate. The most significant increase of L1s is on Xq13, which 
contains the X-inactivation center (Bailey et al., 2000). Interestingly, genomic loci that 
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escape X-chromosome inactivation are reduced in L1 content when compared with loci 
that are subject to X-inactivation. This data has led to the hypothesis that L1 sequences 
may function as cis-acting elements that propagate X-inactivation along the X 
chromosome (Bailey et al., 2000; Gartler and Riggs, 1983; Lyon, 1998; Riggs, 1990). 
However, others have suggested that the accumulation of L1s on the X-chromosome is 
primarily due to the fact that unlike autosomes, the X chromosome is incapable 
undergoing recombination with its homolog in male meiosis (Langley et al., 1988; 
Wichman et al., 1992). 
L1s tend to be more prevalent in intergenic regions of the genome, though many 
occur within the introns of genes. As expected from purifying selections, L1 insertions 
are highly underrepresented in protein coding exons and generally do not occur near 
intron/exon boundaries (Medstrand et al., 2002; Zhang et al., 2011). Finally, the L1s that 
reside within genes exhibit a strong tendency to be oriented in the opposite 
transcriptional orientation of the resident gene (Smit, 1999; Zhang et al., 2011).  
Regions of the Human Genome that Lack TEs 
There are a number of ‘transposon-free regions’ that do not accumulate TE 
insertions in the human genome (Simons et al., 2006). In general, these regions are at 
least 5kb in length, are conserved between the human and mouse genomes, lack 
recognizable transposable element sequences, and are composed of non-protein 
coding DNAs that may have functions in gene regulation. Moreover, several 
‘transposon-free regions’ overlap with ultra-conserved regions of the genome, which 
contain 100% sequence identity between human, mouse and rat genomes over a 
minimum of 200bp (Bejerano et al., 2004). Some of these ‘transposon free regions’ are 
clearly important for development. For example, homeobox gene clusters (i.e., HOX 
genes) completely lack TE sequences (Lander et al., 2001). Whether ‘transposon-free 
regions’ are inaccessible for transposon integration or whether TE integration within 
these regions is catastrophic to the host and are therefore subject to strong negative 
selection remains an open question. I will further explore these possibilities in Chapter 
2. 
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Evidence for Nonrandom Integration in the Human Genome 
Anecdotal evidence from disease producing L1-mediated retrotransposition 
events has led to the idea that L1-mediated retrotransposition events might target 
particular genes. For example, two unrelated hemophilia B patients contained 
mutagenic Alu insertions at adjacent nucleotides in the Factor IX gene (Vidaud et al., 
1993; Wulff et al., 2000). Similarly, two unrelated families with X-linked 
agammaglobulinemia contained an Alu or SVA retrotransposon insertions at the same 
nucleotide within a coding exon of the BTK gene (Conley, 2005). Finally, a 
comprehensive analysis of 18 L1 mediated de novo mutations within the NF1 gene 
revealed that 12 occurred at unique positions in the gene (Wimmer et al. 2011). 
However, three sites within the gene contained two independent insertions. Thus, 
although ascertainment biases must be considered in the studies, it is possible that 
there are ‘hot spots’ for L1-mediated insertions in the genome. 
Closing Remarks and Overview of Thesis 
Whether L1 integrates into preferential sequences within the human genome 
requires elucidation. It is not unreasonable to assume that L1 displays integration 
preference since several non-LTR retrotransposons, which also contain an APE-type 
EN like L1, display sequence-specific integration preference. Thus, the following 
questions come to mind: (1) Does L1 integration preferentially occur into expressed 
genes or those open and accessible regions of the genome? (2) Does L1 target multi-
copy sequences in the genome so as to minimize damage to the host? (3) Are there 
cellular mechanisms that L1 may target to aid in the process of retrotransposition?  
These are just a few of the questions I will address in the following chapters of my 
thesis.  
In this thesis, I focus on examining several thousands of de novo engineered 
human L1 integration events, under several different conditions, to determine if L1 
preferentially integrates within the human genome. The data presented in Chapter 2 
suggests that the L1 EN is the primary determinant of L1 integration site preference in 
the human genome, allowing L1 to disperse throughout the genome. In Chapter 3, I 
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examine how disruption of two different DNA repair processes in the cell may influence 
L1 integration preference, and discuss how and when these DNA repair proteins may 
act during L1 retrotransposition. In Chapter 4, I discuss the results presented in 
Chapters 2 and 3, discuss remaining questions, and provide suggestions for future 
experimental directions. Appendices present slight modifications made to our capture 
technique to isolate de novo engineered Zebrafish L2 integration events (Appendix A), 




Figure 1.1: Types of mobile elements in the human genome.  
Types of transposable elements (TEs) in the human genome and an example structure 
of each is shown. DNA transposons mobilize by a DNA intermediate in a ‘cut and paste’ 
mechanism utilizing their coded enzymatic transposase activity. Transposons are 
flanked by inverted terminal repeats. Autonomous retrotransposons, which encode their 
own proteins, mobilize in a ‘copy and paste’ fashion utilizing an RNA intermediate. Long 
Terminal Repeat (LTR) retrotransposons, such as the human endogenous retrovirus 
(ERV), contain a protein with group-specific antigen (GAG), protease (Pro), and 
polymerase (Pol) activities and an envelope protein (Env). The most abundant, and 
currently active autonomous non-LTR retrotransposon in our genome is Long 
INterspersed Element-1 (LINE-1). LINE-1 contains an internal promoter within it’s 5’ 
untranslated region (UTR) and encodes and ORF1p with RNA binding properties and 
ORF2p with both endonuclease (EN) and reverse transcriptase (RT) activities. The 
element ends with a 3’UTR, followed by a poly (A) tail and is typically flanked by 
variable sized target sized duplications (TSDs). Non-autonomous retrotransposons 
must rely upon the L1 encoded proteins for mobilization. An example of a Short 
INterspersed Element (SINE), still active within our genome to date, is Alu. Alu is 
roughly 280bp containing an RNA polymerase III promoter with A and B components, 
followed by two 7SL monomers separated by an adenosine-rich (AR) segment. Alus 
and processed pseudogenes are also followed by a poly(A) tail and flanked by TSDs as 













































































Figure 1.2: Specific types of transposable elements.  
A) HUH Transposons: HUH Transposons contain two ORFs, tpnA and tpnB.  TpnA is 
required for mobilization as it contains the Histidine-hydrophobic-hystidine (HUH) 
transposase.  The element is flanked by two subterminal palindromes; one on the left 
end (LE) and one on the right end (RE).  
B) Retroviral-like Retrotransposons: The main difference between Ty1 versus Ty3 and 
Tf1 is the order of the integrase (IN), reverse transcriptase (RT), and RNaseH (RH) 
domains in the polymerase (pol) domain.  The Ty5 element’s group-specific antigen 
(gag) and pol domains are fused. There is an additional RNA-binding domain (RB) as 
well.  
C) Additional TPRT Elements: Penelope-like elements (PLE) utilize TPRT for 
mobilization and contain flanking LTR-like sequences. Occasionally some PLEs contain 
an intron within the 5’ LTR. PLEs encode a reverse transcriptase (RT) and a GIY-YIG 
endonuclease (EN). The mobile group II intron, L1.LtrB, is flanked by a 5’ and 3’ exon 
(E1 and E2, respectively) disrupted by intron RNA sequence. L1.LtrB encodes an 
intron-encoded protein (IEP) that contains RNA maturase that facilitates splicing, as well 
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Figure 1.3: Specific types of non-LTR retrotransposons.   
In total there are 11 clades of non-LTR retrotransposons phylogenetically divided by RT 
domain (CRE, R2, R4, L1, RTE, Tad1, R1, LOA, Jockey, CR1, and I). For brevity, 
examples of 4 of the 11 clades are shown, many of which have known target-site or 
position-specific integration preference. The R2 clade contains elements which encode 
a single ORF containing a site-specific restriction endonuclease-like (REL) domain that 
is located after the reverse transcriptase domain.  All elements of the L1 clade contain 
two ORFs, where ORF2 encodes a apurinic/apyrimidinic (AP)-type endonuclease (APE) 
domain before the RT domain. The human specific L1 sequence is followed by a 
poly(A) tail. The TX1L element is flanked by terminal inverted repeat sequences and 
two types of tandem internal repeats (PTR-1 and PTR-2). DRE is flanked by non-
symmetric LTRs containing a combination of three specific repeat sequences (A,B, and 
C) and is followed by a poly(A) tail. Members of the R1 clade differ by the presence or 
absence of a poly(A) tail. TRAS1 has acquired an additional RNaseH domain. The 
Jockey clade contains elements that have LTR-like domains similar to the gag and pol 
domains. HeT-A is a non-autonomous retrotransposon and lacks reverse transcriptase 
activity and thus must rely upon TART or TAHRE for mobilization in the genome. 
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Figure 1.3: Specific types of non-LTR retrotransposons. 
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Figure 1.4: LINE-1 retrotransposition cycle. 
 Within the nucleus of the cell a full length LINE-1 sequence is transcribed. This mRNA 
is then exported to the cytoplasm where ORF1p and ORF2p are translated and bind 
back to their encoded transcript in ‘cis-preference’, forming a ribonucleoprotein particle 
(RNP).  The RNP then returns to the nucleus where the EN activity of ORF2p creates a 
single-strand endonucleolytic nick at a double-stranded site in the human genome (5’-
TTTT/A).  This cut creates a free 3’-OH which can then be used as a primer for reverse 
transcription of the L1 mRNA in a process termed target-site primed reverse 
transcription (TPRT).  After cDNA synthesis, second-strand cleavage and second-
strand synthesis, now at a new chromosomal location (green ellipses) there is a new 
integration site in the genome.  This new integration site contains TPRT characteristics; 
5’ truncated, contains a poly(A) tail, and flanked by target site duplications (green 






Figure 1.5: A general outline of L1Hs capture techniques.  
L1Hs capture techniques involve (1) collection of gDNA from at least a blood source as 
a control, and then depending upon the study, from a tumor sample, brain sample, heart 
and or liver sample. (2) Genomic DNA is then randomly sheared by mechanical means 
or digested with restriction enzymes to smaller fragment sizes. (3)  Known adapter 
sequences of varying designs are then ligated on to processed DNA ends. (4)  L1Hs 
specific sequences are amplified with at least one L1Hs specific sequence containing 
the ‘ACA’ trinucleotide in the 3’UTR sequence, and a primer specific to the ligated 
adapter sequence in order to successfully amplify the 3’ end of L1Hs sequences and 
their 3’ flanking gDNA. A second round of PCR utilizing primers specific to the ‘G’ in the 
L1Hs 3’UTR may also be performed.  (5) Amplified 3’ L1Hs/3’ flanking gDNA products 









Figure 1.6: Paired-end sequencing reads analysis to identify L1Hs insertions.   
This image is adapted and modified from Lee et al. 2015. This figure displays the basic 
rationale of whole genome sequencing algorithms identifying de novo L1Hs polymorphic 
or somatic insertions not present in the Reference Genome. Paired-end sequencing 
reads (long arrows pointing towards each other) in which one read aligns to the genome 
(Genomic Anchoring Reads in black) and the other read aligns to L1Hs sequences 
(Reads Mapped to L1Hs Sequence in grey) help identify the location of the de novo 
L1Hs sequence in the genome.  Junction reads (reads containing grey and green and/or 
black) are those reads that contain part of the L1Hs sequence and the exact ‘junction’ 
sequence where the L1 sequence ends and the genomic flanking sequence begins. 
Junction reads can be used to determine L1Hs integration sites to single nucleotide 























Junction Reads Junction Reads
Figure 1.6 . Paired-end Sequencing Reads of Interest in Identification of L1-mediated Insertions
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Table 1.1: Retrotransposable elements and their preferential integration sites. 
 
Column 1: Transposable element clade. Column 2: Specific example and name of 
transposable element in designated clade in column 1.  Column 3: The species in which 
the transposable element is found in the genome. Column 4: Description of the 
preferential target site of the given transposable element. Column 5: If applicable, the 
known specific targeted sequence in the genome. If not applicable an ‘X’ is shown.  












45% of ‘hot spots’ within 
or near breakpoints
of inversion
A + T rich Evgen’ev, MB et al. 2005 






Lewis, RW et al. 1993 
Biessmann, H 1992 






47- 53 bp 
upstream of 
tRNA genes







Garrett, J et al. 1986 














Takahashi, H et al. 1997
5’-CCTAACCTAACCTAA
3’-GGATTGGATTGGATT
Okazaki, S et al. 1993
Okazaki, S et al. 1995
non-LTR,





Xiong, Y et al. 1998
non-LTR,
R1 clade
MinoAg1 Anopheles gambiae (AC)n
5’-ACACACACACACACAC
3’-TGTGTGTGTGTGTGTG








Kojima, KK and Fujiwara H 
2003
Table 1. Retrotransposable Elements and their Preferential Integration Sites
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Table 1.2. L1-mediated capture techniques identifying polymorphic insertions. 
Column 1: The published name of the technique. Column 2: Experimental details of the 
technique. Column 3: The number of polymorphic insertions identified by the given 
technique. Column 4: References (Note: Number of polymorphic insertions identified in 
this table reflect de novo reported polymorphic sites that are not found in dbRIP or by 
other documented studies at the time). 
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Table 1.2. L1-mediated capture techniques identifying polymorphic insertions. 
 
 
















2 PCRs: 1. L1Hs specific ‘ACA’ and 
10bp arbitrary primer
2. L1Hs nested 3’UTR primer ‘G’ and 
same 10bp primer; Products are 
Southern blotted
 6 L1Hs in 6 males
 53 L1Hs in 91 
individuals
Sheen, FM 




of L1 Active 
Subfamilies (ATLAS)
Restriction digested gDNA;
Suppression PCR with L1Hs specific 
primer and linker primer; Linear PCR 
with radiolabeled L1Hs specific 







Assymetric PCR with L1Hs specific 
‘ACA’; Hemi-specific PCR with L1Hs 
specific ‘ACA’ and 5-mer degenerate 
primer; L1Hs nested 3’UTR primer ‘G’;
paired-end Illumina sequencing




TranspoSeq Paired-end whole genome and exome 
sequencing bioinformatics tool
 2704 L1Hs,  Alu, SVA
from 200 matched samples  in 
lung squamous, head and neck, 








Hybridization to custom tiling array 
probes or liquid-phase sequence 
capture probes targeting 5’ and 3’ 
of active retrotransposons; 
paired-end Illumina sequencing
7644 L1Hs, Alu, SVA, and 
LTR-flanked
 in 19 individuals
Baillie, JK 
et al.  2011






blotting; Sequencing to identify 
full-length L1Hs




Ligation of partially double-stranded 
linkers with 3’ ammine;  L1Hs or Alu 
specific amplification followed by nested 
PCR; ABI capillary sequencing or
pyrosequencing







Restriction digested gDNA 
ligated to vectorettes; PCR 
amplification by L1 or Alu 
specific primers; Amplicons are 
hybridized to microarray
125 L1Hs on X 
chromosome in 75 males
4 Alus in 10 individuals
Huang, CR
 et al. 2010
Cardelli, M 
et al.2012




Bioniformatics tool to analyze 
paired-end whole genome 
sequencing data
3521 polymorphic 






Table 1.3: L1-mediated capture techniques identifying somatic insertions in 
epithelial cancers. 
Column 1: The name of the technique. Column 2: Experimental details of the technique. 
Column 3: The number of somatic insertions and in which tumor sample type identified 
by the technique. Column 4: References. 
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Technique Details #  Insertions Reference
L1-seq
Assymetric PCR with L1Hs specific 
‘ACA’; Hemi-specific PCR with L1Hs 
specific ‘ACA’ and 5-mer degenerate 
primer; L1Hs nested 3’UTR primer ‘G’;
Paired-end Illumina Seq




 802 L1Hs, 7 Alu,1 SVA
from 200 matched samples  in 
lung squamous, head and neck, 
colorectal, and endometrial 
carcinomas 
TranspoSeq Paired-end whole genome and 








Hybridization to custom tiling array 
probes or liquid-phase sequence 
capture probes targeting 5’ and 3’ 
of active retrotransposons; 
paired-end Illumina sequencing
12 L1Hs, 1SVA, and Alu 
events in 5 individuals with 
hepatocellular carcinoma 
Baillie, JK 
et al.  2011
Shukla, R  
et al. 2013
Tranposome Finder in 
Cancer 
(TraFic)
Whole genome sequence pipeline 
identifying L1 events and 
transductions
2756 L1Hs and 93 Alu
(24% of which are 3’ transductions) 
from 290 samples containing 11 
tumor types (Lung, head and neck, 
colon, prostate, breast, bone, 
bladder, glioma, melanoma, 
pancreas, renal)
Tubio, JM  
et al. 2014
Transposon insertion 
Profiling by Sequencing 
(TIP-seq)
Restriction digested gDNA;
ligation to vectorette oligonucleotides;
One sided PCR with L1Hs ‘ACA’ specific 
primer amplification;
PCR amplicons are sheared and 
paired-end sequenced







Ligation of partially double-stranded 
linkers with 3’ ammine;  L1Hs or Alu 
specific amplification followed by 
nested PCR; ABI capillary sequencing or
pyrosequencing
9 L1Hs in 6 lung tumors
Iskow, RC 
et al.2010




Bioinformatics tool to analyze 
paired-end whole genome 
sequencing data
194 somatic insertions (183 
L1Hs, 10 Alu, 1 ERV) in 
epithelial cancers (colorectal, 
prostate, ovarian) in 43 samples
Lee, E 
et al. 2012
118 L1Hs in 10 individuals 
with Barrett’s esophagus or 
esophageal adenocarcinoma
Doucet-O’Hare, 
TT et al. 2015
36 L1 insertions in 7 type 
II ovarian carcinomas
Tang, Z
 et al. 2017





Table 1.4: L1-mediated capture techniques identifying somatic insertions in 
neurons. 
Column 1: The name of the technique. Column 2: Experimental details of the technique. 
Column 3: The number of somatic events identified in the specified neuronal cells.  
Column 4: References. 
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Technique Details #  Insertions Reference




Targeted MDA amplified single-cell 
ligation-mediated PCR with 
biotinylated L1Hs oligo;
Illumina paired-end split-read 
identification of the 3’ end of L1Hs 
and flanking gDNA;data-driven, 
machine-learning-based prediction
47 SLAVs; 89 single nuclei 
and bulk samples from 
frontal cortex and 







Hybridization to custom tiling array 
probes or liquid-phase sequence 
capture probes targeting 5’ and 3’ of 
active retrotransposons; paired-end 
Illumina sequencing
7,743 L1, 13,692 Alu, 
1,350 SVA
from bulk hippocampus and 
caudate nucleus of 
3 individuals
Baillie, JK 
et al.  2011
L1Hs Insertion Profiling
(L1-IP)
Whole genome amplify genomes of 
single neurons (MDA); 
PCR amplification with L1Hs 
specific-oligos (’ACA’ and ‘G’); 
Amplify 3’ of L1Hs and 3’ flanking 
gDNA
5 L1Hs identified in
50 single neurons from 
cerebral cortex and 50 from 








Analysis of whole genome amplified 
single neurons (MDA) with modified 
version of Tea with high sensitivy and 
specificity to identify AluY, L1Hs, and 
SVA elements
2 L1Hs from 16 
single-neuron genomes of 
neurologically normal 
individual (1 L1Hs limited to 
left middle frontal gyrus, 1 







Whole genome amplify genomes of 
single neurons (MALBAC);
Illumina library preparation;
Hybridization capture of 5’ and 3’ 
ends of L1Hs with locked nucleic 
acid probes; paired-end sequencing
2,782 somatic L1Hs 
insertions from glia, and 
hippocampal and cortical 
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The LINE-1 Endonuclease is the Principal Determinant of  
LINE-1 Integration Preference in the Human Genome 
 
This chapter represents a working draft of a manuscript in preparation. Dr. 
Ángela Macia and Ms. Laura Sanchez, while in the laboratory of Dr. José L. García-
Pérez, performed retrotransposition assays in hESCs and NPCs. Bru-seq was 
performed on PA-1 cells by Michelle Paulsen and the resultant data were compiled in Dr. 
Mats Ljungman’s laboratory. PacBio sequencing was performed at the University of 
Michigan Sequencing Core. I performed all retrotransposition assays in HeLa and PA-1 
cells, the targeted LINE-1 sequencing, and final data analyses. 
Abstract 
Long INterspersed Element-1 (LINE-1 or L1) encodes two proteins (ORF1p and 
ORF2p) required for its mobilization (i.e., retrotransposition) in the human genome. 
Human ORF2p, a 150kDa protein, has endonuclease (EN) and reverse transcriptase 
(RT) activities. L1 EN is classified as an apurinic/apyrimidinic-like endonuclease (APE) 
and is responsible for initiating target-site primed reverse transcription (TPRT) during 
the L1 retrotransposition cycle. During canonical TPRT, the L1 EN activity makes a 
single-strand endonucleolytic nick at a double-strand DNA target sequence in genomic 
DNA. The endonucleolytic nick is typically made at an L1 EN degenerate consensus 
cleavage sequence (5’-TTTT/A-3’), exposing a free 3’ hydroxyl group that can be used 
as a primer by the ORF2p L1 RT activity to reverse transcribe the associated L1 RNA. 
Here, we characterized greater than 65,000 de novo engineered L1 retrotransposition 
events in four different cultured human cell lines to determine if L1 exhibits overt 
integration preferences in the human genome. To determine if L1 EN is the prominent 
determinant of L1 integration preference, we compared our insertion data
	 85	
sets to a weighted random model that accounts for the ability of L1 EN to direct 
integration to degenerate L1 EN consensus sequences in genomic DNA. Our data 
suggest that L1 EN drives L1 integration into ~100 base pair AT-rich regions of the 
genome and is the principal determinant in directing L1 integration. Furthermore, we 
found that L1 integration is not targeted to transcribed regions of the genome and 
exhibits a slight integration bias toward lagging strand DNA templates. Importantly, 
engineered L1s readily integrate into protein coding exons and ‘transposon free’ regions 
of the genome; thus, no region of the genome appears to be ‘off limits’ for L1 integration. 
Thus, we conclude that L1 has earned the title of “interspersed element,” as engineered 
L1 insertions are generally dispersed throughout the genome. 
Introduction 
Long INterspersed Element-1 (LINE-1 or L1) is the only known human 
autonomous non-Long Terminal Repeat (non-LTR) retrotransposon, and L1-derived 
sequences account for ~17% of human genomic DNA (Lander et al., 2001). In addition 
to moving itself throughout the human genome by a ‘copy and paste’ mechanism 
termed retrotransposition (Boeke et al., 1985), the L1-encoded proteins can mobilize 
Short INterspersed Element (SINE) RNAs (e.g. Alu and SINE-R/VNTR/Alu-like (SVA) 
elements) (Dewannieux et al., 2003; Hancks et al., 2011; Raiz et al., 2012), non-coding 
RNAs (e.g., U6 snRNA) (Buzdin et al., 2003; Buzdin et al., 2002; Garcia-Perez et al., 
2007; Gilbert et al., 2005), and messenger RNAs to new genomic locations (Esnault et 
al., 2000; Wei et al., 2001); the latter process results in the formation of processed 
pseudogenes. Collectively, the movement of other cellular RNAs by the L1-encoded 
proteins is termed L1-mediated retrotransposition. L1-mediated retrotransposition 
events are responsible for greater than 130 documented cases of human disease 
(Hancks and Kazazian, 2016; Kazazian and Moran, 2017). 
   A full-length L1 element is 6kb in length and contains a 5’ untranslated region 
(UTR) with a sense and antisense promoter, two open reading frames (ORF1 and 
ORF2), and a 3’UTR that is typically followed by a poly(A) tract (Dombroski et al., 1991; 
Scott et al., 1987; Speek, 2001; Swergold, 1990). Human L1 ORF1 encodes a ~40kDa 
RNA binding protein (ORF1p) that contains nucleic acid binding and nucleic acid 
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chaperone activities (Basame et al., 2006; Hohjoh and Singer, 1996; Januszyk et al., 
2007; Khazina and Weichenrieder, 2009; Kolosha and Martin, 1997; Martin and 
Bushman, 2001; Moran et al., 1996). Human L1 ORF2 encodes a 150kDa protein 
(ORF2p) (Doucet et al., 2010; Ergun et al., 2004) that has endonuclease (EN) (Feng et 
al., 1996) and reverse transcriptase (RT) activities (Mathias et al., 1991). Activities 
associated with both ORF1p and ORF2p are required for L1 retrotransposition (Feng et 
al., 1996; Moran et al., 1996). 
The amino terminus of ORF2p contains an apurinic/apyrimidinic (AP) 
endonuclease (APE)-like domain (Feng et al, 1996; Martin et al, 1995). L1 EN initiates 
the process of L1 integration by creating a single-strand endonucleolytic cleavage at a 
double-strand L1 EN degenerate target sequence in genomic DNA (5’-TTTT/A-3’ and 
variants of that sequence, with the ‘/’ indicating the scissile phosphate bond where 
cleavage occurs) (Cost and Boeke, 1998; Cost et al., 2001; Feng et al., 1996; Gilbert et 
al., 2002; Jurka, 1997; Morrish et al., 2002; Symer et al., 2002; Szak et al., 2002). This 
endonucleolytic nick liberates a free 3’ hydroxyl group that acts as a primer for the 
ORF2p RT activity to copy its associated L1 mRNA template (Cost et al., 2002; Feng et 
al., 1996) by a process termed target-site primed reverse transcription (TPRT) (Cost et 
al., 2002; Feng et al., 1996; Kulpa and Moran, 2006; Luan et al., 1993). How L1 
integration is completed requires elucidation; however, it is proposed that L1 EN 
generally cleaves the ‘top’ strand of genomic DNA downstream of the single-strand 
endonucleolytic nick, and that the resultant 3’-OH group is used as a primer by an 
ORF2p DNA-dependent polymerase activity to copy L1 (-) strand cDNA. Host proteins 
(e.g., DNA ligase) are then thought to ligate the L1 cDNA to genomic DNA. TPRT 
generally leads to the generation of variable-length target site duplications (TSDs) in 
genomic DNA that flank the newly inserted L1 (Christense and Eickbush, 2005; Gilbert 
et al., 2005; Gilbert et al., 2002; Maita et al., 2004; Symer et al., 2002). 
L1s can retrotranspose in the germline (Brouha et al., 2002; Ostertag et al., 
2002; Richardson et al., 2017), during early development (Garcia-Perez et al., 2007; 
Richardson et al., 2017; van den Hurk et al., 2007), and in select somatic cells, such as 
epithelial tumors (Doucet-O'Hare et al., 2015; Ewing et al., 2015; Helman et al., 2014; 
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Iskow et al., 2010; Lee, 2012; Miki, 1992; Rodic et al., 2015; Scott et al., 2016; Tubio et 
al., 2014) and neuronal progenitor cells (Baillie et al., 2011; Coufal et al., 2009; Evrony 
et al., 2012; Evrony et al., 2015; Upton et al., 2015).  
Different types of transposable elements (TEs) have evolved elegant convergent 
strategies to target genomic ‘safe havens’, where TE insertions are predicted to have 
relatively minimal effects on host fitness and gene expression (Levin and Moran, 2011; 
Sultana et al., 2017) (see Chapter 1). However, whether L1 integrates into specific 
genomic regions requires elucidation. 
Previous studies have revealed that L1 EN targets integration into local, ~100 bp 
A-T rich regions of the genome (Gasior et al., 2007). However, it is clear that selective 
forces act over evolutionary time to skew the initial distribution of L1-mediated 
retrotransposition events to different genomic regions (Lander et al., 2001). For example, 
while L1s accumulate in A-T rich genomic regions, ‘older’ Alu elements, which require 
ORF2p to retrotranspose (Bennett et al., 2008; Dewannieux et al., 2003), accumulate in 
G-C rich genomic regions (Lander et al., 2001). As such, simply analyzing the resident 
L1s and Alus present in genomic DNA, many of which are tens of millions of years old, 
may not give an accurate picture of the initial insertion preferences of these 
retrotransposons.  
The analysis of disease producing L1-mediated retrotransposition events has led 
to the suggestion that certain regions within genes could be integration ‘hot-spots.’ For 
example, recent data demonstrates that mutagenic L1-mediated retrotransposition 
events can occur either at the same nucleotide or within a small size window within the 
Factor IX (Li et al., 2001; Vidaud et al., 1993; Wulff et al., 2000), BTK (Conley, 2005), 
NF1 (Wimmer et al., 2011), and APC tumor suppressor genes (Miki, 1992; Scott et al., 
2016). However, the number of disease cases are limited and whether these findings 
represent a general rule for L1 insertions or whether ascertainment biases account for 
these data (i.e., the insertion sites within genes likely are L1 EN substrates and must 
result in gene activation to produce disease) requires further study. 
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Here, we asked whether L1 preferentially integrates into specific regions of the 
human genome by generating a relatively unbiased dataset of engineered L1 integration 
events in human cultured cells that serve as a proxy for cellular environments known to 
support endogenous L1 retrotransposition (Moran et al., 1996). We then used Pacific 
Bioscience (PacBio) sequencing-based strategies to capture the 3’ ends of >65,000 
engineered L1 insertions and their respective 3’ flanking genomic DNA sequences and 
mapped the genomic DNA to the human genome reference sequences. The integration 
preferences of the engineered L1s were then compared to a weighted random model, 
which assumes that L1 integration preferences are mediated solely by the presence of a 
degenerate L1 EN consensus cleavage site in the human genome. Remarkably, the 
genomic features analyzed (e.g., gene content, transcriptional activity, strand bias, 
epigenetic environment, and DNA replication status) have minimal effects on L1 
integration. Thus, we conclude that L1 has earned the title of ‘interspersed’ and that L1 
EN is the principal determinant predicting L1 integration. 
Results 
Generation of Libraries of Engineered Human L1 Retrotransposition Events 
We utilized a cultured cell L1 retrotransposition assay (Moran et al., 1996) to 
generate over 65,000 de novo engineered L1 retrotransposition events in the following 
four biologically relevant female-derived cell lines: HeLa, an embryonic carcinoma cell 
line PA-1 (Garcia-Perez et al., 2010), human embryonic stem cells (hESCs), and hESC-
derived neuronal progenitor cells (NPCs). We choose these four cell lines because L1 
can retrotranspose in vivo during early development (hESCs) (Brouha et al., 2002; 
Garcia-Perez et al., 2007; Richardson et al., 2017; van den Hurk et al., 2007), in cancer 
cells (HeLa) (Iskow et al., 2010; and reviewed in Scott and Devine, 2017), and in 
neuronal progenitor cells (PA-1 and NPCs) (Baillie et al., 2011; Coufal et al., 2009; 
Evrony et al., 2012; Evrony et al., 2015; Garcia-Perez et al., 2010; Muotri et al., 2010; 
Upton et al., 2015) (Figure 2.1B). We reasoned that the use of engineered L1 insertions 
would allow us to generate a relatively unbiased dataset of L1 insertions that would be 
minimally affected by selective pressures that influence L1 accumulation preferences in 
the genome over evolutionary time. 
	 89	
Briefly, a subset of HeLa cells were transfected with a retrotransposition-
competent engineered human L1 sequence (pJM101/L1.3) (Sassaman et al., 1997) 
containing a retrotransposition indicator cassette (mneoI) in its 3’UTR (Freeman et al., 
1994; Moran et al., 1996). The use of the retrotransposition indicator cassette ensures 
that we are characterizing cells (in this case, G418-resistant cells) that contain de novo 
L1 retrotransposition events. Similar assays were conducted in hESCs [using a modified 
human engineered L1 (pKUB102/L1.3-sv+) (Wissing et al., 2012) containing an mneoI 
retrotransposition indicator cassette], in PA-1 and a subset of HeLa cells [using a 
retrotransposition-competent L1 containing an EGFP retrotransposition indicator 
cassette (Ostertag et al., 2000) in its 3’UTR (pCEP4/LRE3-mEGFPI), which leads to 
EGFP-positive cells upon a successful L1 retrotransposition event (Brouha et al., 2002; 
Garcia-Perez et al., 2010)], and in H9 hESC-derived NPCs [using a retrotransposition-
competent L1 containing a modified EGFP retrotransposition indicator cassette in its 
3’UTR (pCEP99/UB-LRE3-mEGFPI) (Coufal et al., 2009)] (Figure 2.1A and 2.8). 
We next developed an approach to specifically capture the 3’ ends of L1 
integration events and their associated 3’ flanking genomic DNA sequence. Briefly, 
genomic DNA was isolated from cells containing engineered L1 retrotransposition 
events. The resultant DNAs were then randomly sheared to ~3kb, the ends were 
repaired, a dA nucleotide was added to the DNA, and adapters were ligated onto the 
repaired ends (Figure 2.1C). The adapter sequences are similar to those previously 
used by Iskow et al. 2010. They contain a partially double-stranded DNA sequence 
containing a 5’ overhang; the 3’-OH group is blocked by an amine group to prevent it 
from being used as a primer in subsequent PCR reactions. 
  Aliquots of the resultant DNA library were used as substrates to capture the 
engineered L1 retrotransposition events. First, a linear extension reaction was 
conducted with a dual biotinylated primer complementary to a sequence specific to the 
engineered L1 construct [i.e., termed the LEAP sequence (Kulpa and Moran, 2006) 
(Figure 2.1C)]. The resultant products were then captured on magnetic streptavidin 
beads, washed to remove un-biotinylated products, and used as input DNA templates 
for subsequent PCR reactions using a primer specific to the SV40-polyA start signal of 
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the engineered L1 and with a primer specific to the ligated adapter sequence (Figure 
2.1D). The resultant PCR products were then processed to add PacBio ‘dumbbell’ linker 
sequences to their ends and were sequenced on a PacBio instrument at the University 
of Michigan Sequencing Core Facility using the single molecule real-time (SMRT) 
circular consensus sequence (CCS) sequencing mode.  
We chose PacBio CCS Sequencing because: (1) the generation of CCS reads 
should minimize DNA sequencing errors that arise during PacBio sequencing; and (2) 
the longer reads of PacBio sequencing should improve our ability to map L1 sequence 
reads to repetitive regions of the human genome. On average, we obtained ~600 bp 
PacBio CCS reads from our various samples. (Figure 2.7D). Moreover, as an additional 
control, all sample library preparations were performed in parallel with a clonal cell line, 
PC39, which contains three engineered L1 insertions (Garcia-Perez et al., 2010) (Figure 
2.10). 
Sequence Identification of L1 Integration Events 
We developed a computational pipeline to identify PacBio CCS containing de 
novo engineered L1 integration events. Briefly, the PacBio (CCS) reads were first 
consistently oriented to ensure that the 5’ ends of a read began with the SV40-polyA-
start primer sequence. To “call” a PacBio CCS as an L1 integration sites required: (1) 
The presence of the SV40-polyA-start primer sequence at its 5’ end, followed by 3’ 
flanking genomic DNA and the 3’ adapter primer sequence. (2) The presence of a >14 
bp poly(A) tract following the SV40-polyA-start primer. The SV40-polyA-start primer 
ends in seven adenosine residues; thus, an additional eight adenosines, which were 
added during the post-transcriptional processing of L1 RNA in vivo, were required to 
ensure we were analyzing bona fide de novo engineered L1 retrotransposition events. 
The hard-clipped reads with removed flanking primer sequences aligned to ‘unique’ 
regions in both the GRCh37/hg19 and GRCh38/hg38 (http://genome.ucsc.edu; Kent et 
al. 2002) versions of the human genome reference sequence (Lander et al., 2001) using 
Bowtie2 (Langmead and Salzberg, 2012) (Figures 2.7A, 2.7B,  and 2.7C).  
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The poly(A) tract in sequence reads can disrupt alignment to the genome to 
base-pair resolution; thus, we devised an approach to address this issue. When defining 
an L1 insertion site to base-pair resolution, we used an ‘A-sliding’ approach, where we 
always assigned a poly(A) tract to the genome (Figure 2.7A). Reads were further 
refined to base-pair resolution using the Smith-Waterman algorithm. The genomic 
sequence of the mapped position predicted by Bowtie2 was then realigned to the 
corresponding CCS read under the Smith-Waterman algorithm. The alignment resulting 
in the highest score was chosen as the base-pair location of the genomic insertion. We 
then re-verified the presence of a poly(A) tract of at least 15bp in size that was not 
attributable to the corresponding mapped 3’ flanking genomic sequence. The proportion 
of filtered PacBio CCS reads that led to identification of an L1 insertion site call set is 
shown in Figure 2.7B.  
We tested the accuracy of mapping sequences containing a poly(A) tract to the 
genome by randomly selecting 100,000 positions in the human genome and capturing 
genomic sequence lengths that mimicked the distribution of reads lengths in our 
empirical insertion dataset (Figure 2.7D). We also added poly(A) tracts of similar lengths 
observed in our insertion dataset to these randomly picked genomic sequence reads 
(Figures 2.1G and 2.7F). These randomly selected sequences were mapped to the 
genome reference (GRCh37/hg19) with the same Bowtie2 settings used to map our 
empirical insertion dataset, and we applied the same algorithms and criteria mentioned 
above to ‘call’ the insertions. Only 2.13% of these 100,000 reads could not be uniquely 
mapped to one genomic location; 0.12% represent incorrect calls that mapped to 
another genomic location. Thus, 97.75% of the simulated reads were called correctly, 
giving us confidence that our calling algorithms are accurate and efficient (Figure 2.20).  
Engineered L1 Insertions Display Known L1 Integration Characteristics 
Two or more independent CCS sequencing reads were identified for many of our 
engineered L1 insertions [4.7% of HeLa insertions; 20.1% in PA-1 insertions; 8.9% of 
NPC; 60.6% of hESC (Figure 2.1F and Figure 2.7E)], indicating that we sequenced at 
least two independent DNA molecules containing the same L1 insertion. The 5’ end of 
the sequences are required to map to the L1 poly(A) tract/3’ genomic sequence junction 
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site in the genome; thus, sequences are considered as independent CCS reads for the 
same insertion site if the 3’ adapter ligated to different regions of 3’ flanking genomic 
DNA. As expected, the numbers of insertions represented by two or more sequencing 
reads reflects the numbers of independent engineered L1 retrotransposition events in 
our initial population of cells (i.e., hESCs had the fewest number of insertions but 
displays the largest proportion of independent CCS reads). Fewer total engineered 
insertions were identified in hESCs because as observed previously (Garcia-Perez et al., 
2007), L1 retrotransposition efficiently in hESCs is at least an order of magnitude lower 
than in transformed cell lines. 
We next sought to verify that our method results in identification of authentic L1 
retrotransposition events. The de novo insertions exhibit poly(A) tail lengths longer than 
those typically observed in endogenous L1 insertions, due to the strong SV40 
polyadenylation signal present at the 3’ end of the engineered L1 constructs (Figure 
2.1G and Figure 2.7F). Furthermore, examination of 25bp upstream and downstream of 
integration events revealed that the L1s integrated into a previously defined L1 EN 
degenerate consensus cleavage site (5’-TTTT/A-3’) (Feng et al., 1996; Gilbert et al., 
2002; Morrish et al., 2002; Symer et al., 2002; Szak et al., 2002) (Figure 2.12A). Indeed, 
logo plots suggest that L1 actually recognizes a 7mer, (5’-TTTTT/AA-3’), as opposed to 
the previously published 5mer (Figure 2.1I, Figure 2.7G, Figure 2.11B, and Figure 
2.12A). Since the L1 insertions are, in some cases, represented by independent CCS 
reads, contain a 3’ poly(A) tail, and integrate into a L1 EN consensus sequence 
cleavage site, we are quite confident that our dataset contains a population of authentic 
de novo L1 integration events. 
The above efforts resulted in the identification of 65,079 independent L1 insertion 
sites (Figure 2.1E and Tables 2.1-2.4). Examination of the sequence upstream and 
downstream of these L1 integration events demonstrates that the sequence directly 
surrounding L1 integration sites (up to a 100bp window span) is adenosine, and 
particularly thymidine-rich (Figures 2.1H,, 2.11, and 2.11B). Resident endogenous 
genomic L1Hs sequences (the human-specific L1 subfamily that contains ‘active’ L1s) 
also display this strong AT-rich preference (Figure 2.15A). By comparison, this AT-rich 
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bias appears to be less pronounced for evolutionary ‘older’ L1 subfamilies (Figure 
2.15A). Thus, the engineered L1 insertions mimic the features of the human-specific, 
but not ‘older’ L1s. These data suggest that mutational processes have eroded the 
original AT-rich integration environment of sequences flanking ‘older’ L1s (Lander et al., 
2001). These findings further serve as an orthogonal piece of evidence that that we 
have captured bona fide de novo engineered L1 integration events from cultured cells.  
A Weighted Random Model of L1 Insertions Built on the EN Cleavage Site 
To determine whether the L1 endonuclease cleavage site is the sole factor 
influencing L1 integration, we created a weighted random model based upon the 
frequencies of 7mer L1 EN cleavage sites observed in our empirical L1 insertion dataset. 
Since the L1s in each of the four cell types examined in our study contain nearly 
identical distributions of observed L1 EN integration site variants (Figures 2.2A and 
2.12C), we created a simulated L1 insertion model based upon the total insertion 
dataset [(as opposed to creating an independent model for each specific cell type) 
(Figure 2.2A and 2.12C)].  
To generate our model, we first asked whether each base pair in the 7mer EN 
consensus cleavage sequence are an independent variable or whether certain positions 
in the 7mer were co-dependent. For the 7bp EN consensus cleavage site (5’-
TTTTT/AA), we refer to the base-pairs from 5’ to 3’ as positions 1 through 7, with 
position 1 referring to the first 5’ most T, and position 7 referring to the 3’ most A. Our 
large dataset allowed us to subset (e.g. EN sites with a C present in position 5) and 
observe specific L1 EN consensus cleavage sites and resulting logo plots.  
We compared the initial variability of the EN consensus cleavage site (Figure 
2.1I) to the variability observed in ‘conditional’ EN sites that lack a T or contain a C at 
position 5 (Figure 2.2B). We observed a slight shift in nucleotide probabilities at position 
1 on the conditional logo plots (Figure 2.2B). Under these same conditions, we observe 
no change in nucleotide probabilities in positions 6 and 7 on the logo plot. However, the 
nucleotide probabilities at positions 2 through 5 changes, favoring a higher preference 
for T, when we require a C residue at either position 3 or position 5. Moreover, when we 
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required a T at position 3, we observe a higher probability of observing a C in the 
remaining 3 bps of positions 2 through 5 (Figure 2.2B). Over three-quarters of the L1 
insertions display a 7mer EN consensus cleavage site in which positions 2 through 5 
contains all Ts or three Ts and one C (Figure 2.2C). Thus, as previously described, L1 
insertions are found within a degenerate L1 EN consensus cleavage site.   
Based on the above analyses, we concluded that positions 2 through 5 of the L1 
cleavage site are co-dependent, whereas the nucleotide residing at position 1 is 
independent of the sequence at positions 2 through 5 (Figure 2.2B). Likewise, positions 
6 and 7 are independent of the sequence within the first five positions of the L1 
cleavage site. Thus, instead of creating a model that treats every base pair in the EN 
consensus as an independent variable, we created a 1-4-2 model (where position 1 
represents a 1bp unit at position 1, positions 2 through 5 represent a 4bp unit, and 
positions 6 and 7 represent a 2bp unit).  
We determined the frequency of each 12,288 possible 7mer L1 EN consensus 
cleavage site variants observed in our empirical insertion dataset. Notably, since our 
mapping methods always favors a genomic poly(A) sequence to map L1s, position 6 
cannot be a T residue, making the 7mer sequence 5’-NNNNN/VN-3’ (where N is any 
nucleotide and V represents an A, C, or G, nucleotide). To calculate the predicted L1 
EN cleavage site frequencies, we counted the frequency of observing an A, C, G, or T 
base present at position 1 in our L1 insertion dataset. For positions 2-5, we counted the 
frequency of the 256 possible 4mers. For positions 6-7, we counted the frequency of the 
12 possible 2mers. The modeled L1 EN insertion frequencies are then calculated as the 
products of the position probability matrix (Figure 2.2E). 
 We next sought to identify an appropriate insertion count threshold for when we 
should use predicted L1 integration frequencies vs. the empirical data L1 integration 
frequencies. The frequencies of each L1 integration sequence was then normalized to 
the most commonly observed L1 EN consensus cleavage site, 5’-TTTTT/AA-3’ (Table 
2.5; uncorrected model). After comparing weights calculated from the predicted model 
frequencies to our observed frequencies (Figure 2.2D), we determined the modeled and 
empirical data begin to converge when the same L1 EN site is observed in three or 
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more independent insertions (Figure 2.2D; 97% of our modeled data utilizes observed 
L1 insertion frequencies; the gray line represents 1:1 ratio between calculated and 
observed weights). For L1 EN sites observed in fewer than three independent insertions 
(~3% of cases), the modeled data tends to provide lower weight values than the weight 
values observed in the actual data. On the other hand, L1 EN site variants in which we 
observed no engineered L1 integration sites will undoubtedly be modeled higher.  
We next used the weighted random model to create a simulated dataset of L1 
insertions in the human genome. For every base pair in the genome (excluding gapped 
regions, and certain highly repetitive sequence regions), we determined the L1 EN 
cleavage 7mer if an insertion occurred at that nucleotide position, and assigned the 
corresponding 7mer weight. If the calculated position resulted in a T at the 6th position of 
the L1 EN site, we ‘slid’ the cleavage site to the next base pair position in which a T is 
absent from the 6th position. This procedure was done in the same manner used to call 
our mapped empirical L1 insertions to base pair nucleotide resolution (Figure 2.7A).  
We simulated L1 integration sites by randomly selecting sites in the human 
genome based upon the weighted probabilities calculated above. Our simulated 
datasets contained the same numbers of L1 integration events (65,079) as those 
observed in our empirical dataset. We then repeated the process of generating 
weighted random simulation datasets for 10,000 iterations. As expected, L1 EN 
consensus sequences from our simulated integration sites generated using the 
weighted random model were very similar to those observed in our empirical L1 
insertion dataset (Figure 2.12D and Figure 2.2F). For experiments where we limited our 
analyses to individual cell types, our weighted random simulated datasets contained the 
same numbers of insertions obtained from an individual cell line (i.e., we compared 
10,000 iterations of 27,777 simulated vs. 27,777 actual L1 EN sites in PA-1 
experiments). 
We also created a ‘corrected’ weighted random model that calculated 7mer site 
frequencies as described above, but these frequencies are divided by the frequency of 
the same 7mer found in the human genome reference (GRCh37/hg19) sequence. This 
‘corrected’ model thus adjusts 7mer frequencies with respect to how often they occur in 
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the genome. Since the 5’-TTTTT/AA-3’ 7mer occurs most frequently in the genome, 
when we ‘correct’ the observed frequencies and apply the weighting scheme, this 7mer 
becomes the 21st highest weighted 7mer (Table 2.5). This ‘corrected’ weighted random 
model was applied in transcription and replication data analyses and appears as ‘PWM 
Corrected’ in plots. Otherwise the uncorrected model was used in data comparisons 
(box plots) and is also listed as ‘Simulated Insertions’ in plots.  
Insertion Preference Observed on X Chromosome 
We next examined where our engineered L1 insertions integrate within the 
genome. We plotted the chromosomal location of each empirical L1 and compared 
those data to the same numbers of simulated insertions generated from 10,000 
iterations of our weighted random model. L1 insertions are located throughout the 
genome and do not appear to integrate at distinct ‘hot spots’ (Figures 2.3B and 2.14). 
L1 insertion counts are positively correlated with chromosome size, with larger 
chromosomes containing more insertions than smaller chromosomes [(Spearman’s rho 
ranges from 0.927 to 0.948) (Figure 2.3A and 2.13A)]. HeLa cells display a distinct 
increase of insertions on chromosomes 1 and 5, which can be explained by previous 
SKY-FISH experiments, which revealed more than 2 copies of each of these 
chromosomes (data not shown). Intriguingly, the X-chromosome contains more L1 
insertions than predicted from our weighted random model in PA-1s, hESCs, and NPCs, 
but not HeLa cells. Since PA-1 cells have been shown to have attributes similar to 
neurons (Garcia-Perez et al., 2010), and NPCs are derived from the hESCs, we 
hypothesize that these somewhat related cell types may have similar cell type-specific 
mechanisms that allow for an increased number of L1 insertions on the X-chromosome, 
which are absent in HeLa cells. 
LINE-1 EN Consensus Sequence Influences Antisense Integration in Genes  
  Previous somatic studies in the brain have suggested that L1 preferentially 
integrates into expressed genes (Baillie et al., 2011; Coufal et al., 2009; Upton et al., 
2015). Thus, we explored whether genes represent preferential L1 integration sites. In 
agreement with previous studies (Beck et al., 2010; Gilbert et al., 2005; Gilbert et al., 
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2002; Moran et al., 1999; Symer et al., 2002), we observed that engineered L1s can 
readily integrate into the introns and exons of genes; however, genes are not 
preferentially targets for L1 integration (Figure 2.3C and 2.3D). Indeed, in PA-1 cells we 
observe significantly fewer genic L1 insertions than predicted by our random model; 
instead, we observe an increase of L1 integration events into intragenic regions of the 
genome (χ2 test p-value for exons: 5.782 x 10-8; χ2 test p-value for introns: <2.2 x 10-16). 
Interestingly, in all the cell types examined, except hESCs, we observe fewer insertions 
into introns than is expected by our weighted random model (χ2 test p-value for HeLa: 
1.48 x 10-9; χ2 test p-value for NPC: <2.2 x 10-16). Furthermore, we did not observe a 
significant enrichment of NPC L1 insertions within neuronal genes via DAVID analysis 
(Table 2.15). 
Previous studies demonstrated that polymorphic L1Hs insertions display a 
preference for accumulating in the antisense transcriptional orientation of the genes in 
which they reside (Beck et al., 2010; Ewing and Kazazian, 2010; Huang et al., 2010; 
Smit, 1999; Zhang et al., 2011). Thus, we explored whether we observe this same 
antisense preference in our datasets of L1 insertions. We first identified L1 insertions 
within genes and then calculated the antisense to sense ratio by calculating the 
numbers of insertions that integrated into the antisense transcriptional orientation of a 
gene divided by the numbers of insertions that integrated into the sense transcriptional 
orientation of a gene (Figures 2.3E and 2.3F). Unexpectedly, the middle line of the 
boxplots, which represents the median observation from 10,000 iterations of the 
weighted random model, is greater than 1.0, suggesting that L1 EN consensus 
cleavage sites are slightly enriched on the coding strand of a gene, which would lead to 
a greater number of antisense L1 insertions. L1 insertions in hESCs exhibit a 
pronounced preference for antisense integration (χ2 test p-value: 0.00272). 
Expressed Genes are not L1 Preferential Integration Sites 
We next performed RNA-seq on two biological replicates of each of our cell types 
to test if L1 preferentially targets expressed genes. We found that L1 integration is 
generally depleted in expressed regions of the genome (Figure 2.13B). Insertions from 
HeLa, PA-1s, and NPCs are significantly overrepresented in unexpressed regions of the 
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genome, and the rate of expression also has no influence on integration (χ2 test p-
values: 1.776 x 10-12, < 2.2 x 10-16, < 2.2 x 1016 respectively) (Figure 2.13C). PA-1 and 
NPC insertions contain significantly more L1 insertions in low-level expressed regions of 
the genome (Figure 2.13C). Furthermore, PA-1s have a significant depletion of L1 
insertions in highly expressed regions of the genome. These data suggest that L1 
integration is actually depleted in highly expressed regions of the genome. Human 
embryonic stem cells are the only cell type that does not contain a significant reduction 
in L1 insertions in expressed regions of the genome when compared to the weighted 
random dataset. Thus, our data suggest that L1 insertions: (1) do not preferentially 
target genes for integration; (2) display an antisense insertion preference into genes 
due to a bias of the L1 EN cleavage site on the coding strand; (3) do not preferentially 
target expressed genes for integration.  
L1 Does Not Preferentially Insert within Transcribed Regions of the Genome 
  While the UCSC genome browser, RefSeq database, and many other databases 
have predicted notations and boundaries for genes, we know that transcription of a 
gene can actually initiate before, terminate beyond, or occur completely outside of these 
annotated genomic regions (Paulsen et al., 2013). Thus, we asked whether  
transcription influences L1 integration preferences in the human genome.  Since 
transcribed regions of the genome often contain open chromatin, we hypothesized that 
LINE-1 may take advantage of and target open chromatin that arises during RNA 
transcription. More specifically, we hypothesized that the ORF2p L1 EN activity may 
specifically target the accessible coding strand during the process of transcription, as 
RNA polymerase is engaged with the noncoding strand (Figure 2.4A). If so, we would 
expect to observe an antisense bias of insertions into transcribed genes.   
While RNA-seq is a sensitive approach to measure gene expression, it only 
provides a steady state snapshot of RNA abundance in a cell. RNAs that either undergo 
rapid degradation or are transcribed in very low quantities may be missed in RNA-seq 
experiments. Thus, we performed Bru-seq, a method that assesses nascent RNA 
synthesis, on two biological replicates of our PA-1 cell line, and analyzed two previously 
generated Bru-seq datasets from two biological replicates of HeLa cell lines (Paulsen et 
	 99	
al., 2014; Paulsen et al., 2013). The two independent HeLa Bru-seq samples are highly 
correlated with each other (Spearman’s rho of 0.8536), as are the two PA-1 samples 
(Spearman’s rho of 0.935). Thus, we performed subsequent comparisons with both 
HeLa Bru-seq sample datasets; since the observed trends were the same using both 
datasets, only one was used in comparisons to our empirical L1 insertion database. 
Similarly, since the PA-1 datasets were highly correlated, only one dataset was used in 
comparisons to our empirical L1 insertion database. 
As observed in Figures 2.4B and 2.4C, transcribed regions of the genome 
contain fewer L1 insertions (χ2 Test: HeLa p-value: 6.795 x 10-6; PA-1 p-value: < 2.2 x 
10-16) than expected when compared to our weighted random dataset (32.6% of HeLa 
insertions, and 19.4% of PA-1 insertions reside within transcribed regions of the 
genome). Thus, contrary to our original hypothesis, L1s do not preferentially integrate 
into transcribed regions of the genome. Notably, this effect is not due to a lack of L1 EN 
degenerate consensus sites in transcribed regions (Figures 2.4B and 2.4C). We next 
analyzed insertions that reside within transcribed regions of the genome to determine 
whether the rate of transcription influences L1 integration (Figures 2.4C and 2.16A). 
Consistent with the RNA-seq data, highly transcribed genes are not preferential L1 
integration sites; indeed there are fewer L1 insertions in highly expressed genes than 
predicted from our weighted random dataset (Kolmogorov-Smirnov bootstrap test p-
value < 1 x 10-6 for PA-1 and HeLa).  
Finally, because our insertion data is stranded, we asked whether the L1 EN 
preferentially cleaves the predominant coding or noncoding strand in the genome during 
transcription. We calculated transcription bias as the absolute value of the difference in 
RPKM expression values between the top and bottom strand expression of a 
transcribed region and divided that number by total RPKM expression value (by adding 
the combined top and bottom strand expression values). A transcription bias of 0 
indicates that both strands are transcribed at the same level, while a value of 1.0 means 
only one strand (either the top or the bottom) is transcribed (Figure 2.16B). We 
subdivided the transcribed genome into eleven bins of transcription bias values from 0 
to 1.0 based upon the transcription bias of the region in the genome, and plotted the 
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observed fraction of insertions in which the L1 EN cleaved the predominant coding 
strand in the genome for integration in each transcription bias ratio bin and compared 
these values to data obtained from 10,000 iterations of our weighted random dataset 
(Figure 2.4D). While HeLa insertions display a slight L1 EN cleavage preference on the 
coding strand regardless of the magnitude of transcription bias, we did not observe a 
strong L1 EN cleavage preference on the predominant coding strand in the genome 
(Figures 2.16C and 2.16D).  This slight coding strand cleavage preference is even 
harder to distinguish in PA-1 insertions (Figures 2.4D and 2.16D). Together, the 
available data lead us to conclude that L1 does not specifically target transcribed 
regions of the genome for integration. That being stated, L1 insertions found within 
transcribed regions do exhibit slight L1 EN cleavage preference on the coding strand. 
This preference for cleavage on the coding strand is small and only exerts a minimal 
effect on L1 integration preferences (Figure 2.16D Kolmogorov Smirnov bootstrap test 
HeLa Top and Bottom: pvalue < 0.05; PA-1 Top: p-value < 0.01).  
Transposon Free Regions Accommodate L1 Integration 
Several genic and intergenic regions of the genome overlap with ultraconserved 
regions of the genome. Ultraconserved regions are at least 200bp in size contain 100% 
sequence identity between the human genome and other mammalian genomes (i.e., 
mouse, rat and dog) (Bejerano et al., 2004; McCole et al., 2014). Several 
ultraconserved regions are associated with essential genes that play critical roles during 
early development, such as the SOX, HOX, and FOX gene families. Additionally, 
several of these ultraconserved regions overlap with regions of the genome that lack 
transposon sequences, which are termed ‘transposon free regions’ (Simons et al., 
2006). Since several transposon free regions coincide with ultra conserved regions of 
the human genome, we sought to discriminate whether these regions are transposon 
free because they are inaccessible for transposable element integration or whether 
transposable elements insertions into these regions result in catastrophic mutations, 
that are subject to strong negative selection (e.g., they cause early embryonic lethality).  
To address the above possibilities, we examined our insertion dataset to 
determine if any L1 insertions reside within ultraconserved regions, ultraconserved non-
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coding regions, or ‘transposon free’ genomic regions (Bejerano et al., 2004; Dimitrieva 
and Bucher, 2013; McCole et al., 2014; Simons et al., 2006). We discovered anywhere 
from one to four insertions per cell type within ultra-conserved regions of the genome 
(Table 2.6), which is in stark comparison to the complete absence of RepBase L1Hs 
sequences within these same genomic regions. Of all the LINE-1 sequences in the 
human genome, only one severely 5’ truncated element overlaps with an ultra-
conserved noncoding region. Since our L1 insertion dataset contains de novo 
engineered insertions within these ultraconserved regions, the data suggest that there is 
not an active mechanism that prevents L1 integration into these regions.  
Likewise, as expected, young L1Hs reference sequences do not reside within 
transposon free genomic regions (Table 2.6). However, we observed 1,282 of our total 
engineered L1 integration events into transposon free regions. Thus, transposon free 
regions can accommodate L1 integration events at a cellular level, but as above, these 
events are likely subject to strong negative selection, which effectively removes the L1 
containing alleles from the population.    
L1 Integration is Interspersed Throughout the Genome 
Our RNA-seq and Bru-seq analyses suggest that L1 EN is not preferentially 
targeting open chromatin regions in the genome. Thus, we sought to determine if closed 
regions of the genome are preferential integration sites. We compared our L1 insertion 
datasets to hidden Markov modeled 15 and 18 chromatin state data generated as part 
of the Roadmap Epigenomics Project (Roadmap Epigenomics et al., 2015). In general, 
L1 insertions were not enriched in any of the examined chromatin states (Figure 2.5 and 
Figure 2.18). HeLa and hESC insertions show a small (less than 2-fold) enrichment in 
some enhancer states. This enrichment is minimal in comparison to the enrichment 
MLV insertions observed in transcriptional start sites, strong enhancers, and active 
promoters of the genome (Figure 2.5) (LaFave et al., 2014). We also discovered 
minimal (less than 2.5-fold) enrichment of HeLa and hESC insertions in super 
enhancers and typical enhancers (Figure 2.23A). We compared the chromatic states 
with their respective GC content to ensure that any observed enrichments are not due 
to the presence of confounding AT-rich sequences; these regions are not overly AT-rich 
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(Figures 2.22 and 2.23B). As with our Bru-seq analyses, we once again observed a 
depletion of insertions in transcribed regions of the genome, as defined by this 
chromatin state analysis (Figures 2.4B and 2.5).  
To verify that the enrichment we observed in the MLV dataset is not simply due 
to presence of over 300,000 events (almost 10x as many events as we observe in PA-
1s), we next downsized the MLV insertion dataset, so that it contained the same 
numbers of insertions observed in our PA-1 dataset, and reanalyzed the data. As above, 
we still observe enrichment of MLV integration events in transcriptional start sites, 
promoters, and enhancer regions (Figure 2.17A).  
Finally, we examined our HeLa and hESC L1 insertion datasets to look for 
overlaps with ENCODE DNaseI hypersensitive sites, which serve as a proxy for 
accessible chromatin structures in the genome. While we observed an enrichment of L1 
insertions into DNaseI hypersensitive regions of the genome when compared to the 
weighted random dataset, L1s are not preferentially targeting DNaseI hypersensitive 
sites for integration (minimally 1-4% of total insertions are found in DNaseI 
hypersensitive sites; Table 2.7). Thus, we conclude that L1 integration is generally 
interspersed throughout the genome and that L1 does not preferentially target open or 
closed states of the genome, or other repetitive element sequences for integration 
(Table 2.14).  
Lagging Strand Template Preferentially Cleaved by L1 Endonuclease for Integration 
To determine whether DNA replication influences L1 integration preferences, we 
compared our L1 integration sites to the previously published HeLa cell and GM06990 
lymphoblastoid cell line Okazaki fragment sequencing data (Petryk et al., 2016). Briefly, 
OK-seq allows the capture, sequencing, and mapping of Okazaki fragments that arise 
during DNA replication. Analyses of the resultant data then allow a means to determine 
replication fork initiation, replication fork termination, and replication fork directionality 
throughout the genome (Petryk et al., 2016). 
We compared our L1 insertion datasets to both the HeLa and lymphoblastoid 
GM06990 OK-seq datasets and observed similar trends in all sample set comparisons. 
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As defined by Petryk et al. (2016), Replication Fork Direction (RFD) is a value that 
ranges from -1 to 1 and is determined by the difference of Okazaki fragments that map 
to the Crick strand from Okazaki fragments that map to the Watson strand, divided by 
the total of Okazaki fragments for a given genomic region. We partitioned the genome 
into eleven bins with RFD values from zero to 1, based on the absolute value of the 
RFD value of a region in the genome. Thus, an RFD of 0 means that there is no 
replication direction bias, as replication is occurring equally from both directions in the 
genome. An RFD of 1 means that replication is only occurring in one direction. Since 
Petryk et al. (2016) performed OK-seq on a population of cells, most areas of the 
genome undergo bidirectional replication. As described by Petryk et al. (2016), only a 
small portion of the genome (2.4% in HeLa and 5.6% in GM06990) is replicated in only 
one distinct direction.  
The published data by Petryk et al. (2016) allowed us to determine which strand 
in a replication fork is the leading strand template and which is the lagging strand 
template in areas of the genome in which there is a replication forks directional bias 
(Figure 2.6A). We plotted our L1 insertion data based upon the absolute value of the 
RFD of a given genomic segment harboring the L1 insertion. For each of the eleven 
RFD bins, we then counted the proportion of the L1 insertions where L1 EN cleaved the 
lagging strand template. Each of the cell types examined displayed a small 
(Kolmogorov-Smirnov boot strap test P-values: HeLa bottom strand cleavage: < 1x10-6; 
HeLa top strand cleavage: < 0.05; PA-1 bottom and top strand cleavage: < 1x10-6; NPC 
bottom and top strand cleavage: < 0.001; hESC bottom strand cleavage: < 0.05), but 
similar trend, suggesting that L1 EN has slight preference for cleaving lagging strand 
template (Figure 2.6B). This preference could be due to accessibility of the lagging 
strand template, as the leading strand template is actively replicated by the passing 
polymerase. We also observe no enrichment of insertions in sites of replication fork 
initiation or termination (Figure 2.19D).  
Discussion 
We have developed a large-scale approach to characterize greater than 65,000 
bona fide de novo engineered human L1 integration sites and their associated 3’ 
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flanking genomic DNA sequence from several different human cell lines. This technique 
has led to the capture, sequencing, and identification of >100-fold more L1 integration 
sites than previous approaches (Gilbert et al., 2005; Gilbert et al., 2002). We utilized the 
longer read sequences provide by the PacBio single molecule real time (SMRT) circular 
consensus sequencing mode to improve our ability to map insertions to repetitive areas 
of the genome (Table 2.14).  Since we observed L1 insertions with long poly(A) tails, it 
indicates that the PacBio sequencing platform can successfully sequence long 
polynucleotide stretches of DNA, which frequently prove to be problematic using 
Illumina-based sequencing approaches (Figures 2.1G and 2.7F). We are quite confident 
that our insertion dataset represents authentic L1 insertions, as the L1 insertions have 
long poly(A) tails (Figures 2.1G and 2.7F) and integrate into an L1 EN consensus 
cleavage site (Figures 2.1I and 2.7G). Moreover, in many cases, more than one 
independent CCS sequencing read was used to call the L1 integration event (Figures 
2.1F and 2.7E).  
 We designed a weighted random model using the L1 EN consensus cleavage 
site as the principal determinant of L1 integration. To generate our weighted random 
model, we dissected the L1 EN consensus cleavage site. We discovered that several of 
the nucleotides within the 7bp L1 EN degenerate consensus cleavage site (5’-
TTTTT/AA-3’) are co-dependent variables (Figure 2.2B).  Interestingly, we found that 
nucleotide positions 2 through 5 of the 7bp L1 EN cleavage site are dependent upon 
each other, and quite frequently contain a string of Ts with a single C nucleotide 
interspersed (Figure 2.2C). The last two nucleotides of the L1 EN site are also 
dependent upon each other. We created a model that considered these nucleotide 
dependencies. 
We found that our weighted random model mimics our observed engineered L1 
integration sites. The weighted random model involves picking random L1 insertion 
locations throughout the genome, taking into account the likelihood of whether the 7mer 
provides a favorable L1 EN degenerate consensus cleavage site to accommodate L1 
integration. Our weighted random model mimics the same degenerate L1 EN 
consensus cleavage site observed in our empirical L1 insertion dataset (Figure 2.2F) 
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and recapitulates the finding that L1 EN drives insertions towards genomic regions that 
contain a ~100 bp AT-rich content (Figure 2.12D).  In sum, our weighted random model 
assumes that L1 EN is the principal determinant that dictates L1 integration preferences 
in the human genome.  
We next compared our empirical L1 insertion dataset against the weighted 
random model simulated L1 integrations to determine if other genomic features 
influence L1 integration preferences. In general, we find that L1 integration sites are 
interspersed throughout the genome (Figures 2.3B and 2.14), and the human genome 
lacks preferential hotspots for integration. As observed previously, we report that L1 
insertion counts correlate with chromosome size; however, somewhat unexpectedly, we 
observed an over-representation of L1 insertions on the X-chromosome in PA-1, NPCs, 
and hESCs, but not HeLa cells (Figure 2.3A and Figure 2.13A) (Lander et al., 2001; 
Smit, 1999). The genomic and/or cellular feature(s) responsible for the increase of L1 
insertions on the X-chromosome, and whether this is a female-specific phenomenon 
requires elucidation. However, it is notable, that previous studies have suggested a role 
for increased L1 content in propagating X-inactivation (Bailey et al., 2000; Gartler and 
Riggs, 1983; Lyon, 1998; Riggs, 1990). 
Unlike previous studies that reported an enrichment of somatic neuronal L1 
insertions within neuronal stem cell enhancers and neuronal genes (Baillie et al., 2011; 
Upton et al., 2015), we did not observe an enrichment of engineered L1 insertions within 
neuronal genes (Table 2.15). This discrepancy could be due to differences between 
neurons isolated from the brain and hESC-derived NPCs that are cultured in vitro. 
However, it also is possible that many of the previously characterized L1 insertions are 
actually false positives (Baillie et al., 2011), and/or result from the amplification of 
chimeric artifacts generated during WGA in single cell-based experiments (Evrony et al., 
2016; Upton et al., 2015). Indeed, a high false positive call rate would complicate 
downstream analysis pipelines, as these analyses assumed that the L1 somatic 
insertions represented bona fide de novo somatic L1 retrotransposition events. The 
large size of our empirical L1 database, coupled with the high stringency we used to call 
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engineered L1 retrotransposition events gives us confidence that we have 
unprecedented statistical power to analyze L1 insertion preferences in cells.  
Engineered L1s can integrate into exons and introns of a number of different 
genes (Figures 2.3C an 2.3D). However, genes are not preferential targets for L1 
integration. Indeed, we observed fewer insertions into exons (in PA-1 cells) and introns 
(in HeLa, PA-1, and NPCs), given the number of favorable EN consensus cleavage 
sites in these areas of the genome predicted by our weighted random model. 
Furthermore, we found that L1 integration sites are less likely to occur into expressed 
regions of the genome (Figure 2.13B).  This result, while counterintuitive at face value, 
may be indicative of host factors at work, carefully protecting the vulnerable, open, 
accessible genome from L1 integration during the process of transcription.  
L1 insertions within genes (exons or introns) display an antisense integration 
preference (Figure 2.3F). The L1 EN consensus cleavage site drives this antisense 
preference, as our weighted random model indicates that the L1 EN consensus 
cleavage site is not evenly distributed across the genome, but instead, is slightly 
enriched on the sense strand of genes. Utilization of a sense strand L1 EN cleavage 
site to initiate TPRT would result in an antisense L1 insertion. The L1 EN consensus 
cleavage site bias found on the sense strand of genes accounts for the antisense genic 
integration preference observed. 
The significant antisense L1 integration preference observed in hESCs may 
reflect a higher degree of negative selection acting within these cells. For example, L1 
insertions in the same transcriptional orientation of a gene that disrupt the expression of 
genes required for pluripotency or, less frequently, cellular viability, could lead to 
differentiation or cell death. Under this scenario, the loss of detrimental L1 insertions in 
the sense transcriptional orientation could explain the strong antisense bias in hESCs. 
Notably, the antisense orientation preference observed in hESCs is still well below the 
1.8 antisense to sense ratio value of resident human genome LINE-1 events (Smit, 
1999). Thus, older L1s also appear to be under strong negative selective forces in the 
genome, driving this antisense preference even higher. Indeed, experimental studies 
have suggested that L1 insertions in the same transcriptional orientation of a gene are 
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more detrimental than those in the opposite transcriptional orientation of a gene (Han et 
al., 2004). 
We also asked whether the L1 EN is more accessible for cleavage on the coding 
strand of an actively transcribed gene. Although we found a depletion of L1 integration 
events within transcribed regions of the genome (Figures 2.4B and 2.4C), the insertions 
into transcribed regions show a significant deviation from the weighted random model 
suggesting a slight preference for L1 EN cleavage on the coding strand (Figures 2.4D 
and 2.16D). However, once again, these findings could simply reflect the fact that L1 EN 
target sequences are slightly enriched on the coding strand of genes.   
We utilized previously published Okazaki sequencing data to determine if L1 EN 
cleavage is favored on the leading or lagging strand template during DNA replication 
(Petryk et al., 2016). We observe a slight preference for L1 EN cleavage on the lagging 
strand template, the strand that is most likely to be accessible for cleavage as it is not 
near the active replicating polymerase (Figure 2.6). We did not find any preference for 
L1 EN cleavage in DNA replication fork initiation sites or termination sites (Figure 2.19B). 
Since we utilized several human cell lines in our studies, we were able to 
observe differences in L1 integration preferences among different cell lines (e.g., 
enrichment of X-chromosome insertions in PA-1s, NPCs, and hESCs vs. HeLa.). 
However, some cell types (e.g., NPCs, and PA-1s) have similar neuronal-type 
characteristics and exhibit similar L1 integration preferences. Notwithstanding these 
differences, we did not observe a high degree of variability in L1 integration preferences 
among cell lines, suggesting that L1 integration generally is interspersed throughout the 
genome.  
Our study is not without caveats and potential limitations. For example, some 
may criticize the use of engineered L1 vectors used to generate our L1 insertion dataset 
because, in most cases, the identification of bona fide de novo L1 retrotransposition 
events required expression of an indicator gene and the isolation of G418-resistant or 
EGFP-positive cells. Thus, we could miss L1 integration events that occur into non-
transcribed or heterochromatic regions of the genome. Such a scenario would be 
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predicted to lead to an enrichment of engineered L1s in expressed parts of the genome. 
However, counter to these predictions, we found that engineered L1s do not 
preferentially integrate into actively transcribed genes, and actually show a slight 
preference for non-expressed regions of the genome. Moreover, we did not observe a 
strong preference for engineered L1 insertions into chromatin states associated with 
expressed genes or open chromatin. As such, our findings would actually over-estimate 
the frequency of L1 integration events into expressed genes. Simply stated, our data 
differs from those in previous studies that claimed L1 preferentially targets actively 
expressed genes and promoters for integration. 
The use of PacBio sequencing to characterize our L1 insertion dataset is another 
area that could be criticized in our studies. For example, many of our L1 insertion calls 
are only supported by one DNA sequence read. However, in hESCs, which support 
lower levels of engineered L1 retrotransposition (Garcia-Perez et al., 2007), ~60% of 
our L1 insertion calls are supported by two or more reads. Moreover, our stringent 
filtering algorithm, coupled with the fact that our L1 insertion calls have long poly(A) tails 
and integrate into a degenerate L1 EN consensus cleavage site are in agreement with 
smaller scale functional studies of L1 biology. Indeed, we generated a dataset of bona 
fide de novo engineered L1 retrotransposition events and our validation efforts indicate 
that this large dataset has afforded us an unprecedented opportunity to characterize L1 
integration preferences in a statistically robust manner.  
Conclusion 
In sum, we conclude that L1 EN is the principal determinant in driving L1 
integrations sites into degenerate, AT-rich, L1 EN consensus cleavage sites in the 
human genome. While it remains possible that other genomic features affect L1 
integration preferences, our random weighted model indicates that any such features 
would only have minor effects on L1 integration. In an anthropomorphic sense, these 
findings suggest that L1 is not fickle and opportunistically uses any accessible L1 EN 
consensus cleavage site to integrate into the genome. Indeed, we posit that the 
acquisition of the L1 EN domain allowed L1 to live up to its name as an interspersed 
element. 
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Materials and Methods 
Plasmids 
All plasmids were grown in DH5α (F-φ80lacZΔM15Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk+) phoA supE44 λ- thi-1 gyrA96 relA1) competent E.coli (Invitrogen; 
Carlsbad, CA). Prepared in house as described in (Inoue et al., 1990). Plasmids were 
prepared using the Qiagen Plasmid Midi Kit (Qiagen; Hilden, Germany, #12125) 
according to the manufacturer’s protocol.  
 
pCEP4/GFP: has been described previously (Alisch et al., 2006). It consists of a pCEP4 
backbone (Invitrogen/Life Technologies; Carlsbad, CA #V04450) that contains the 
coding sequence of the humanized Renilla green fluorescent protein (hrGFP) from 
phrGFP-C (Stratagene) driven by a CMV promoter.  
 
LINE-1 Expression Constructs 
 
pJM101/L1.3: has been described previously (Dombroski et al., 1993; Sassaman et al., 
1997) and consists of the pCEP4 backbone (Invitrogen/Life Technologies; Carlsbad, CA 
#V04450) containing a full-length copy of the L1.3 element (Sassaman et al., 1997) with 
the mneoI retrotransposition indicator cassette in the 3’UTR (Freeman et al., 1994; 
Moran et al., 1996). 
 
pJM105/L1.3: has been described previously (Wei et al., 2001). It consists of the 
pCEP4 backbone (Invitrogen/Life Technologies; Carlsbad, CA #V04450) containing a 
full-length copy of the L1.3 element with the mneoI indicator cassette in the 3’UTR. The 
L1.3 contains a missense mutation (D702A) in the RT domain of the ORF2 protein 
resulting in its inefficiency to retrotranspose.  
 
pJJ101/L1.3: This plasmid was described previously (Kopera et al., 2011). It contains a 
full-length retrotransposition-competent L1 element, L1.3 (Sassaman et al., 1997), 
tagged with a mblastI retrotransposition indicator cassette in the 3’UTR and was 
subcloned in pCEP4 (Invitrogen). 
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pJJD205A/L1.3: This plasmid was described previously (Kopera et al., 2011). This 
construct is similar to pJJ101/L1.3 but contains a D205A mutation in the ORF2p EN 
domain.  
 
pJCC9/JM105/L1.3: has been described previously (Beck et al., 2010). This construct 
is similarly to pJM105/L1.3 except that it is a pBluescript (Stratagene) vector. 
 
pCEP4/LRE3-mEGFPI: has been described previously (Garcia-Perez et al., 2010). It 
consists of the pCEP4 backbone (Invitrogen/Life Technologies; Carlsbad, CA #V04450) 
containing a full-length RC-L1 (LRE3)(Brouha et al., 2002) and the mEGFPI indicator 
cassette (Ostertag et al., 2000) driven by a CMV promoter subcloned into the 3’UTR of 
LRE3. LRE3 is driven by its native 5’UTR. The pCEP4 hygromycin selectable marker is 
replaced by a puromycin selectable marker.  
 
pCEP4/JM111/LRE3-mEGFPI: is identical to pCEP4/LRE3-mEGFPI except that it 
contains two missense mutations in ORF1 (RR261-262AA), resulting in a 
retrotransposition incompetent LRE3 (Moran et al., 1996). Dr. William Giblin (University 
of Michigan Medical School) constructed the plasmid (Zhang et al., 2014). 
 
pKUB102/L1.3-sv+: has been described previously (Wissing et al., 2012). It consists of 
a modified backbone version of pBSKS-II (Stratagene) that contains a human ubiquitin 
C promoter (nucleotides 125398319-125399530 of human chromosome 12) upstream 
of an L1.3 element (Sassaman et al., 1997). The L1.3 element contains the mneoI 
indicator cassette (Freeman et al., 1994) and the SV40 late polyadenylation signal 3’ of 
the engineered L1. 
 
pCEP99/UB-LRE3-mEGFPI: has been described previously (Coufal et al., 2009). This 
construct comprises a pCEP4 backbone (Invitrogen/Life Technologies; Carlsbad, CA 
#V04450) containing a full-length RC-L1, LRE3 (Brouha et al., 2002), driven by an 
ubiquitin C promoter (a 1.2-kb fragment of the human UBC gene nucleotides 
125398319-125399530 of human chromosome 12) and the mEGFPI indicator cassette 
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(Ostertag et al., 2000) driven by CMV followed by a SV40 late polyadenylation signal 3’ 
of the engineered L1. The hygromycin marker in pCEP4 is replaced by a puromycin 
marker.  
 
pCEP99/JM111/UB-LRE3-mEGFPI: is a derivative of pCEP99/UB-LRE3-mEFFPI that 
has been described previously (Coufal et al., 2009). It contains a full-length 
retrotransposition defective L1 (Kimberland et al., 1999) that contains two engineered 
missense mutations in L1-ORF1p (RR261-262AA) that abolishes retrotransposition 
activity (Moran et al., 1996; Ostertag et al., 2000). The LRE3 is tagged with the mEGFPI 
retrotransposition indicator cassette (Ostertag et al., 2000), and is cloned in the same 
modified pCEP4 vector as pCEP99/UB-LRE3-mEGFPI. 
 
Cell Culture 
All cell lines were grown at 37˚C in the presence of 7% CO2 and 100% humidity. 
 
HeLa-JVM Cells  
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine calf serum (FBS) (Invitrogen) and 1X 
penicillin/streptomycin/glutamine (Invitrogen) to create DMEM-complete medium as 
described previously (Moran et al., 1996).  
 
PA-1 Cells  
Cells were cultured in Minimum Essential Media (MEM) (Invitrogen) supplemented with 
10% heat-inactivated Fetal Bovine Serum (FBS) (Invitrogen), 1X 
penicillin/streptomycin/glutamine (Invitrogen) and 0.1mM non-essential amino acids 
(Invitrogen). 
 
H9 hESC Cells 
All reagents were purchased from Invitrogen’s GIBCO-Life Technologies unless 
otherwise indicated. Human Foreskin Fibroblasts (HFFs, passage 3-10, from ATCC) 
were used to prepare HFF-conditioned media (HFF-CM) as described (Macia et al., 
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2011). HFFs were grown following the provider’s instructions in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 25 mM HEPES, 2mM L-glutamine and 
10% heat-inactivated fetal bovine serum (FBS).  
 
Human embryonic stem cells (hESCs) were grown as previously described using HFF-
CM (Garcia-Perez et al., 2007; Macia et al., 2011). WA09/H9-hESCs were obtained 
from Wicell and maintained in HFF-conditioned media (HFF-CM) using matrigel coated 
plates. To prepare HFF-CM, HFFs were mitotically inactivated by γ-irradiation with 
3000-3200 rads, seeded at 3x106 cells in T-225 flask and cultured with hESC media 
(DMEM KnockOut supplemented with 4 ng/ml β-FGF, 20% KnockOut serum 
replacement, 1mM L-Glutamine, 0.1 mM b-mercaptoethanol and 0.1mM non-essential 
amino acids) for 24 h. HFF-CM was collected 24h later and frozen at -80°C until used. 
We collected HFF-CMs during four consecutive days. Mycoplasma spp. was confirmed 
at least once a month using a PCR-based assay (Minerva). STR-genotyping (at least 
once a year) was used to control the identity of cell lines used in this study (LorGen, 
Granada, Spain). 
 
H9 hESC-derived NPC Cells 
 The differentiation of neuronal progenitor cells (NPCs) from hESCs was carried out 
using a previously established methodology (Coufal et al., 2009; Muotri et al., 2010). 
Briefly, H9 hESCs that were grown on Matrigel for at least 5 passages were cultured 
during 2 days in N2 media (DMEM/F12 + N2 supplement) containing 1µm of 
Dorsomorphin (Calbiochem) and 10µm of SB-431542 (Yirmiya et al.). Undifferentiated 
hESCs were detached using a cell-scraper and transferred to low-attachment plates to 
allow for Embryo Body (EB) formation using the same culture media. Once EBs formed 
(4-6 days), these were then plated in a 60mm matrigel-coated plate, and cultured for 5-7 
days using NB medium (0.5x N2, 0.5x B-27, 20ng/ml of FGF-2 (Miltenyi Biotec) and 1% 
P/S), changing the media every other day. Rosettes were collected, dissociated and 
plated on poly-L-ornithine (Yirmiya et al.)/Laminin (Invitrogen) plates using NPC medium 
(KnockOut DMEM/F-12 with Stem Pro Neural Supplement, 1mM L-Glutamine and 
Penicillin-Streptomycin (10,000 U/mL)). NPCs were expanded, when confluent, using 
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StemPro Accutase Cell Dissociation Reagent (Invitrogen) and were not used for more 
than 15 passages. NPC culture medium is: KnockOut™ DMEM/F-12 media 
supplemented with 1x StemPro Neural Supplement, 10 ng/mL EGF (R&D), 1x Glutamax 
and 20 ng/mL FGF-2 (R&D). To induce neural differentiation from confluent NPCs, 1mM 
all-trans Retinoic Acid (Yirmiya et al.) was added to the NPC culture media. 
Mycoplasma spp. was confirmed at least once a month using a PCR-based assay 
(Minerva). STR-genotyping (at least once a year) was used to control the identity of cell 
lines used in this study (LorGen, Granada, Spain). 
 
PC39  
As previously described (Garcia-Perez et al., 2010) PC39 is a PA-1 clonal cell line that 
contains 2 previously characterized L1 insertions (pc-39-A and pc-39-B).  This cell line 
was grown in the same conditions as those described for PA-1.  Genomic DNA isolated 
from these cells was used as a positive control in LINE-1 retrotransposition capture 
PCR reactions.  
 
LINE-1 Retrotransposition Assays 
HeLa 
Retrotransposition assays in HeLa-JVM cells were carried out as previously described 
(Moran et al., 1996; Wei et al., 2000). Cells were plated 85-90% confluency in T-175 
flasks (BD Biosciences) or 150mm x 25mm dishes (Corning; Corning, New York) to 
obtain quantifiable colonies for the retroelement expression construct used (either 
pJM101/L1.3 or pCEP4/LRE3-mEGFPI). Additionally, simultaneously a 6-well dish was 
plated with HeLa cells to be transfected 18 hours after plating: 2 wells were co-
transfected with pJM101/L1.3 and pCEP4/GFP, 2 wells were transfected with 
pCEP4/GFP only, and the last 2 wells remained untransfected. An additional 2 wells in 
a 6-well dish were transfected with pJM1015/L1.3 as a retrotransposition control.   
 
Eighteen hours after plating, transfections were carried out using the FuGene 6 
transfection reagent (Roche; Penzberg, Germany) and Opti-MEM (Invitrogen), 
according to manufacturer’s protocol (3 µl FuGENE 6 and 97 µl Opti-MEM per µg of 
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DNA transfected in 6-well and 19µg of DNA with 58µl FuGENE 6 in T-175 flask). Cell 
culture media was replaced the following day. Cells were subjected to selection with 
400 µg/ml G418 (Invitrogen) 72 hours post-transfection. Additionally, 72 hours post 
transfection cells in the 6-well dish were collected and subject to flow cytometry to 
determine transfection efficiency. The transfection efficiency of each sample was 
determined by the percent of green fluorescent protein (EGFP) expressing cells. On 
average, transfection efficiency was ~75% for HeLa cells. For the remaining T-175 
flasks or 150mm x 25mm dishes, selection was carried out until 14 days after 
transfection, replacing the selection media every other day. To visualize the number of 
cells with successful retrotransposition events, a flask was fixed and stained. Media was 
aspirated from the flask and cells were washed with 10mL of 1x PBS. The PBS was 
aspirated and then 5.0mLs of Fix Solution (1X PBS, 2% Formaldehyde and 0.2% 
Glutaraldehyde) coated the flask and was left to sit at 4˚C for 30 minutes. The fixed cells 
were than flushed with water, and then stained with 0.1% crystal violet at room 
temperature for 5 minutes. Cells were then rinsed again with water and left to dry.  
 
PA-1 
The retrotransposition assay in PA-1 cells were carried out as previously described 
(Garcia-Perez et al., 2010).  Cells were plated at 90-95% confluency in T-175 flasks (BD 
Biosciences), 150mm x 25mm dishes (Corning; Corning, New York), or T-75 flasks (BD 
Biosciences) to obtain quantifiable colonies for the pCEP4/LRE3-mEGFPI construct 
used. In addition, a 6-well dish was plated with PA-1 cells for control transfection 
experiments.  
 
Eighteen hours after plating the 6-well dish (Corning; Corning, New York), 2-wells were 
co-transfected with equal amounts of a reporter plasmid human enhanced green 
fluorescent protein pCEP4/GFP and pCEP4/LRE3-mEGFPI. Another 2-wells in the 6-
well dish contained PA-1 cells transfected only with pCEP4/GFP, and the last 2-wells 
contained untransfected PA-1 cells. Additionally, as a retrotransposition control, 2 wells 
of a 6-well dish were transfected with pCEP4/JM111/LRE3-mEGFI. For transfections, 
FuGENE HD transfection reagent (Roche Biochemical) at 8ul per 2.0 ug of plasmid 
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DNA per 6 well was used. T-175 flasks (BD Biosciences) or 150mm x 25mm dishes 
(Corning; Corning, New York) were transfected with 32.0µg of plasmid DNA and 128ul 
FuGENE HD transfection reagent (Roche Biochemical). Forty-eight hours post 
transfection cells were selected for transfection with media containing 2µg/mL of 
puromycin and selection continued until five days post transfection. Seventy-two hours 
post-transfection, the cells in the 6-well tissue culture dish were washed with 1X PBS, 
trypsinized, collected, and subjected to flow cytometry. The transfection efficiency of 
each sample was determined by the percent of green fluorescent protein (EGFP) 
expressing cells. On average, transfection efficiency was ~20% for PA-1 cells. The 
remaining flasks were fed daily with the puromycin selection media until five days post 
transfection. At five days post transfection cells were fed with media containing no drugs. 
Seven days post-transfection, cells were chemically treated for 14-16 hours with 0.5µM 
Trichostatin A (TSA, Sigma) or 18-24 hours with 2uM anisomycin. Flow cytometry 
measured percentage of EGFP-positive cells in both the untreated and drug-treated 
samples. Eight days post-transfection, cells from a set of T-175 flasks that were not 
drug-treated were collected for isolation of gDNA. A second set of T-175 flasks were 
drug-treated and subsequently flow-sorted selecting for GFP positive cells (~1x106 total 
cells). Those collected GFP positive cells were then plated into a small T-25 flask and 
once confluent, moved to a T-175 flask. Once confluency was reached in the T-175 
flask, cells were collected for gDNA isolation.  
 
H9 hESC  
We used a previously described protocol, with minor modifications (Garcia-Perez et al., 
2007). Specifically, H9 hESCs were transfected with the indicated plasmid DNA using 
the Amaxa Human Stem Cell Nucleofector Kit 2 (Lonza VPH-5022) and using the 
program A-23. Plasmid DNAs were purified using a Midi-kit (Qiagen) and filtered 
through a 0.22µm filter (Milipore). As described (Watanabe et al., 2007), and to prevent 
cell death during nucleofection, cells were cultured with HFF-CM containing 10µM iRock 
(Y-27632, Sigma) for 1 hour prior to harvesting hESCs. Next, cultured H9-hESCs were 
detached from matrigel-coated plates using TryPle-Select (Thermofisher) following 
manufacturer´s instructions. Collected H9-hESCs were washed twice with pre-warmed 
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HFF-CM containing 4ng/ml β-FGF and 10µM iRock. Finally, H9-hESCs were filtered 
through a strainer (70µ m Nylon, Corning). An aliquot of harvested H9-hESCs was used 
to calculate the number of cells/ml using 0.05% Trypsin. We routinely used 2-4x106 H9-
hESCs and 4µg of each plasmid DNA per transfection. As a control, we always 
transfected an aliquot of hESCs with pCEP4/GFP and determined the percentage of 
transfected cells using FACS-sorting 48h after nucleofection. After nucleofection, 
transfected hESCs were slowly recovered from the nucleofection cuvette and seeded 
on a 10cm matrigel-coated plate. Media was replaced 6-8 hours post-transfection. In 
non-selection experiments, transfected hESCs were simply grown during 7 days using 
HFF-CM supplemented with fresh β-FGF (20 ng/ml) and 1µM iRock and the media was 
changed daily. In experiments where L1 retrotransposition events were selected with 
G418, transfected hESCs were first cultured during four days using HFF-CM 
supplemented with fresh β-FGF (20 ng/ml) and 1µM iRock and culture media was 
changed daily. After four days, H9-hESCs were selected with 50µg/ml G418 during 7 
days and with 100µg/ml of G418 for an additional 7 days using HFF-CM supplemented 
with fresh β-FGF (20 ng/ml) and 1µM iRock. 
 
H9 hESC-derived NPC Cells 
We used a previously described protocol (Coufal et al., 2009). NPCs were transfected 
with the Rat Neuronal Stem Cell Nucleofection kit (Lonza VPG-1004) using the program 
A-33. Plasmid DNAs were purified using a Midi-kit (Qiagen) and filtered through a 
0.22µm filter (Milipore). Confluent cultures of NPCs (with passage number 3-15) were 
used in nucleofection experiments. Briefly, cells were detached using StemPro 
Accutase Cell Dissociation Reagent (Thermofisher). Next, NPCs were washed twice 
using pre-warm NPC media (KnockOut™ DMEM/F-12 media supplemented with 1x 
StemPro Neural Supplement, 10 ng/mL EGF (R&D), 1x Glutamax and 20 ng/mL FGF-2 
(R&D)) and NPCs were filtered through a cell strainer (70µ m Nylon, Corning). An 
aliquot of NPCs was used to calculate the number of cells/ml using 0.05% Trypsin. We 
routinely used 1x106 H9-hESC-deirved NPCs and 8µg of each plasmid DNA per 
transfection. After nucleofection, transfected NPCs were slowly recovered from the 
nucleofection cuvette and seeded on 3 wells of a poly-L-ornithine/Laminine coated 6-
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well plate. Media was replaced 6-8 hours post-transfection. Next, transfected NPCs 
were cultured during 7 days changing the media every day. When indicated, we added 
1mg/ml puromycin (Yirmiya et al.) 48h post-transfection to the NPC media to select 
transfected cells. In experiments conducted with differentiating NPCs, we transfected 
NPCs using the same method but added 1mM all-trans Retinoic Acid (Yirmiya et al.) to 
the NPC media (starting with the first change of media 6-8h post-transfection). 
 
As above, we transfected an aliquot of NPCs with a plasmid expressing GFP 
(pCEP4/GFP) to determine the efficiency of transfection using FACS-sorting 48h after 
nucleofection. Also, we used NPCs transfected with plasmid pCEP99/UB-JM111/LRE3-
mEGFI to determine the background level of autofluorescence in FACS-sorting 
analyses.  
 
The retrotransposition efficiency was determined using FACS (BD FACS Aria device); 
however, to avoid silencing of engineered insertions, as described (Coufal et al., 2009; 
Garcia-Perez et al., 2010), 500nM Trichostatin A (TSA) was added to transfected NPCs 
7 days post-transfection and cells cultured for 18h prior to FACS analyses. 
 
PD20F  
PD20F and PD20FD2 (PD20F cells complemented with a retroviral vector containing 
the human FANCD2 CDNA via the previously described protocol Puslipher et al. 1998) 
cells were transfected using Fugene6 (Roche/Promega) using manufacturer instructions. 
Briefly, 8x104 cells were plated per 100mm culture plates and transfected 16h later 
using 10µl of Fugene6 and 4µg of each plasmid DNA using OptiMEM (Invitrogen) 
following the manufacturer instructions. 24h later, fresh media was added and cells 
were cultured for the next 4 days, changing the media every other day. Five days after 
transfection cells were selected with 2µg/ml Blasticidin-S (Invitrogen) for the following 7 
days, changing the media every other day. After the selection process, blast-resistant 
foci were harvested by trypsinization and genomic DNA extracted. Transfection 
efficiency controls were included, co-transfecting cells in parallel with a GFP expression 
	 118	
vector (pCEP4/GFP) and determining the percentage of GFP-expressing cells 48h post-
transfection by FACS.  
 
Genomic DNA Isolation  
hESC, NPC, PD20F Retrotransposition Assay gDNA Isolation 
Once retrotransposition assays were completed, a cell-scrapper was used to harvest 
hESC and NPC cells. Cells were then washed twice with 1xPBS and gDNA was 
extracted and purified using phenol-chloroform extraction or using a DNeasy Blood & 
Tissue Mini Kit (Qiagen) following the manufacturer’s instructions. Genomic DNA 
concentration was measured with a Nanodrop (Thermofisher). 
 
HeLa and PA-1 Retrotransposition Assay gDNA Isolation 
Once retrotransposition assays were completed, HeLa and PA-1 cells were trypsinized 
and harvested from flasks. Cells were then washed twice with 1xPBS and gDNA was 
extracted and purified using the Blood and Cell Culture DNA Midi Kit (Qiagen # 13343). 
Concentrations were determined using a nanospectrometer. Genomic DNA, 1µg, was 
run on a 0.75% agarose gel to check quality of isolations.  
 
Retrotransposition Cassette PCR 
A preliminary test to check if genomic DNA contained retrotransposition events involved 
PCR with primers flanking the intron of the reporter cassette. Amplification of genomic 
DNA resulted in two distinct bands, a larger band (Neo: 1,396bp band, EGFP: 1,245bp) 
indicative of unspliced DNA with the intron intact, and a smaller band (Neo: 493bp band, 
EGFP: 343bp) indicating removal of the intron from the reporter cassette and thus the 
presence of a successful retrotransposition event (Figure 2.9) (Moran et al., 1996; 
Ostertag et al., 2000). 
 
LINE-1 Retrotransposition Capture 
Primer sequences: All oligonucleotides used in this study were synthesized by 
Integrated DNA Technologies (IDT; Coralville, Iowa). 
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PCR Library Preparation 
Top strand adapter with T overhang; purified by high-performance liquid 
chromatography (HPLC):  
5’-GGAAGCTTGACATTCTGGATCGATCGCTGCAGGGTATAGGCGAGGACAACT-3’  
 
Bottom strand adapter with 5’ phosphorylation and 3’ amino modifier; purified by high-
performance liquid chromatography (HPLC): 5’-/5Phos/GTTGTCCT/3AmMO/-3’ 
 
10µM final concentrations of annealed adapters were made by incubation of both the 
top and bottom strand adapters at 95˚C for 5 minutes in H2O and 1x NEB T4 DNA 
ligase Buffer (NEW England BioLabs), followed by allowing the tube to naturally come 
to room temperature.  
 
Genomic DNA (15µg) was randomly sheared to 3kb fragments following protocols for 
the Covaris S220/E220 operating systems. Sheared gDNA was purified following QIA-
quick PCR Purification Kit (Qiagen). Purified sheared gDNA was end repaired following 
NEBNext End Repair Module (New England BioLabs). End repaired gDNA was purified 
following QIA-quick PCR Purification Kit (Qiagen). A non-templated dAMP was then 
incorporated on the 3’ end of the purified end repaired gDNA as outlined by NEBNext 
dA-Tailing Module (New England BioLabs). Following this reaction dA-tailed gDNA was 
subsequently purified with the MinElute PCR Purification Kit (Qiagen). Annealed 
adapters were ligated onto the final purified DNA molecules in the following conditions: 
1µg DNA to 90µM of annealed adapter (Final Adapter concentration of 4.5µM) in a 20µl 
total volume reaction with 1µl (200U) of T4 DNA ligase (NEW England BioLabs). 
Ligation reactions were incubated overnight at 16˚C and heat inactivated at 65˚C for 20 
minutes. Samples were purified of excess linkers with QIAquick PCR purification kits 
(Qiagen) and eluted in 50µl EB Buffer.  
 
Uni-linear Biotinylated Amplification 
Biotinylated LEAP; purified by high-performance liquid chromatography (HPLC); 5’ Dual 
Biotin; 18bp internal spacer; 5’-/52-Bio//iSp18/GTTCGAAATCGATAAGCTTGGATCC-3’ 
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Linear extension reactions were performed with Roche Expand Long Range dNTP Pack 
PCR system. Reactions contained 500ng of template gDNA, the Manufacturer’s Expand 
Long Range Buffer including 12.5mM MgCl2, 0.25µM biotinylated LEAP primer, 500µM 
PCR Nucleotide mix (dATP, dCTP, dGTP, dTTP at 10µM each), 3% DMSO and 3.5U of 
Expand Long Range Enzyme.  Cycling conditions used are as follows: 94˚C for 5 
minutes, followed by 30 cycles of 94˚C, 15s; 65˚C, 30s; 68˚C for 3 min., and a seven-
minute extension at 68˚C.   
 
The Uni-linear extension products were subsequently column purified with QIA-quick 
PCR Purification Kit (Qiagen). Purified products were biotin captured following 
Dynabeads kilobaseBINDER Kit (Invitrogen) for 3 hours at room temperature while 
rotating the tube.  After capture, beads were placed on a magnet and washed twice with 
the Wash Buffer, and washed a final time with ddH2O. Final biotin captured products 
were eluted to 30µl with ddH2O.  
 
Nested PCR 
Adapter primer: 5’-ATCGATCGCTGCAGGGTATAGG-3’ 
SV40-polyA-start site: 5’-GCAATAAACAAGTTAACAACAAAAAAAAA-3’ 
 
Each 30µl biotinylated captured product was divided amongst 3 separate PCR reactions, 
where 10µl is used as the starting template per PCR reaction. PCR reactions were 
performed with Roche Expand Long Range dNTP Pack PCR system. PCR reactions 
contained the Manufacturer’s Expand Long Range Buffer including 12.5mM MgCl2, 
0.25µM Adapter primer and 0.25µM SV40-polyA-start site primer, 500µM PCR 
Nucleotide mix (dATP, dCTP, dGTP, dTTP at 10µM each), 3% DMSO and 3.5U of 
Expand Long Rang Enzyme. Cycling conditions are as follows: 94˚C for 3 minutes, 
followed by 35 cycles of 94˚C, 10s; 57˚C, 30s; 68˚C for 2 min., and a seven-minute 
extension at 68˚C.  
 
Final PCR products were column purified with QIA-quick PCR Purification kit (Qiagen) 
and eluted to a final volume of 50µl with elution buffer. Samples were checked for gDNA 
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concentration with Invitrogen’s Qubit Fluorometer and then sent to the University of 
Michigan’s Sequencing Core for PacBio Single Molecule Real Time (SMRT) circular 
consensus sequencing. 
 
PCR Product Characterization 
 PCR products were column purified using the QIAquick PCR Purification Kit (Qiagen). 
Products were cloned into TA Cloning Kit Dual Promoter (pCR II) cloning vector 
(Invitrogen), transformed, and plasmid DNA recovered by mini-prep (Promega SV Mini-
Prep kit; Promega, Fitchburg, Wisconsin). Individual clones were then sequenced with 
M13 Forward and M13 Reverse primers. Resulting Sanger sequences were then blatted 
to the UCSC GRCh37/hg19 Human Genome Browser ( http://genome.ucsc.edu/)(Kent, 
2002).  
 
PC39 a positive control 
As previously described, (Garcia-Perez et al., 2010) PC39 is a clonal cell-line of PA-1, a 
human embryonic derived carcinoma cell-line, that was transfected with pCEP4/LRE3-
mEGFI. PC39 contains two previously characterized EGFP silenced insertions, 
identified as pc-39-A and pc-39-B. Pc-39-A is a 5’ truncated insertion within the EGFP 
cassette, with a 101bp poly(A) tail located on chromosome 5 at base pair position 
16173755 (hg19 reference) within the intron of the gene MARCH11 (Figure 2.10A).  Pc-
39-B is an inverted/deleted insertion with a 105 bp poly(A) tail inserted on chromosome 
1 at base pair position 158239404 (GRCh37/hg19 reference coordinates) (Figure 
2.10A). The PC39 clonal cell-line served as a source of gDNA that was used as a 
positive control in our LINE-1 capture method. Since the insertion locations were 
characterized previously, instead of randomly shearing gDNA from PC39, we digested 
the genomic DNA with restriction enzyme PacI and NdeI, both of which are downstream 
of the 3’ genomic sequence surrounding insertion pc-39-A and pc-39-B respectively. 
After performing the biotinylated L1 linear amplification, capturing the biotinylated 
products, and performing nested PCR, this amplified digested PC39 gDNA resulted in 
two distinct bands ~580bp (pc-39-A) and ~330bp (pc-39-B) on a 0.75% agarose gel 
(Figure 2.1D).  
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Additionally, a third distinct band was apparent at ~1.2kb. After further analysis, this 
third band resulted in the discovery of a third previously unidentified insertion in this 
PC39 clonal cell-line. Sanger sequencing this distinct band identified a poly(A) tail of 
33bp and 1,111bp of flanking gDNA on chromosome 19. This genomic DNA is flanked 
by an NdeI restriction site (Figure 2.10). After performing a number of PCRs, walking 3’ 
to 5’ with primer sequences along the engineered LINE-1 sequence, we were finally 
able to fully characterize this third insertion, following the previous nomenclature we 
labeled this insertion as pc-39-C. This insertion is 5’ truncated, containing the last 100bp 
of the ORF2p sequence. It is flanked by an 18bp target site duplication, a poly(A) tail of 
33bp and has a cleavage site of 5’-TTCTT/GG on chromosome 19 at base pair position 
13627881 (GRCh37/hg19 reference coordinates) on the minus strand (Figure 2.10). 
 
Independent Validation PCRs of Identified LINE-1 Insertions 
For 4 insertions that were identified by independent CCS reads, validation PCRs were 
performed by the following technique: Primers were designed flanking the site of the 
insertion (Table 2.13). The primer 5’ of the insertion site was named the “empty site” 
primer designed to amplify gDNA absent of the insertion. Two primers were designed 3’ 
of the insertion site. The primer furthest from the insertion site was called the “outer” 
primer and the primer closest to the 3’ end of the insertion was named “inner.”  Nested 
PCR was performed on the initially purified pooled gDNA. A combination of PCR 
reactions were performed, the first PCR set included the “outer” primer along with one 
of the following e primers: a biotinylated primer specific to the cassette CMV promoter, 
the LEAP sequence (LEAPv1.1), or the “empty” primer. The second PCR, then included 
the same CMV, LEAP, or “empty” primer with the “inner” primer sequence. Amplified 
bands were verified by being cloned into Invitrogen’s Dual TA promoter cloning vector 
and Sanger sequenced. PCR reactions were performed with Invitrogen’s Platinum Taq. 
PCR reactions contained the Manufacturer’s PCR Buffer including 12.5mM MgCl2, 
0.25µM of each primer, 500µM PCR Nucleotide mix (dATP, dCTP, dGTP, dTTP at 
10µM each), and 3.5U of Platinum Taq. Cycling conditions were as follows: The first 
PCR : 96˚C for 12 minutes, followed by 35 cycles of 96˚C, 30s; 60˚C, 45s; 72˚C, 2 min., 
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and a four-minute extension at 72˚C. Second PCR: 96˚C for 3 minutes, followed by 25 
cycles of 96˚C, 30s; 60˚C, 30s; 72˚C, 1.5 min., and a three-minute extension at 72˚C.  
 
Mapping CCS reads to the human genome 
PacBio single molecule real time circular consensus sequencing reads were first 
aligned to the adapter primer and SV40pA primer sequences with Bowtie2 (Langmead 
and Salzberg, 2012). Reads that aligned to each primer sequences were then hard-
clipped of the primer sequences and orientated so that the most 5’-end of the sequence 
read contained a poly(A) tract if present. An in-house utility called homopolymer was 
then used to determine the presence of a poly(A) tail within the 5’-end of the sequence. 
Briefly, homopolymer performs a Hidden Markov model with 5 states (no homopolymer, 
or homopolymer of each of the 4 possible nucleotides) to find homopolymer segments 
in a sequence. We set the ZERO_PROB setting of homopolymer to 10% or 0.1. Reads 
that contained at least a 15bp poly(A) tract were aligned to the human genome 
reference GRCh37/hg19 with Bowtie2 allowing for up to 100 possible mapped locations 
in the output for each single CCS read. We also aligned reads to the GRCh38/hg38 
reference with Bowtie2. The best mapped read location was then determined for each 
read as the alignment that starts within the first 1% of the length of the read near the 
poly(A) tract and aligns up to the last 2.5% of the read. If multiple alignments fit this 
criteria then a best mapped read location was chosen if the alignment score was at 
least greater than 20 as compared to the alignment score of the next best mapped read 
location (Figure 2.7A). Because all four cell types (HeLa, PA-1, NPC, hESC) were 
female, we did not keep any insertions in which the best mapped read was to the Y 
chromosome. If the next best mapped read location and the highest aligning mapped 
read had an alignment score difference of greater than 20, then the read and insertion 
was termed ‘unmappable’ to the human genome.  
 
We found that occasionally alignment of the CCS read sequence to the genome would 
be disrupted due to the presence of the poly(A) stretch 5’ of the sequence. Disruption of 
alignment resulted in gapped alignments of the sequence to the genome as Bowtie2 
attempted to align the entire sequence read as opposed to the largest stretch of 
	 124	
consecutive nucleotides of the sequence read to the genome. In order to account for 
this mapping disparity we utilized the Smith-Waterman algorithm to further refine 
alignment to the genome to base-pair resolution. When running the Smith-Waterman 
algorithm we aligned the sequence read to the best mapped location given by the 
Bowtie2 results with an additional 50 to 100bp upstream and downstream of the given 
genomic location. All poly(A)s present in the sequence read that were also present in 
the human genome sequence at the point of integration were assigned to the genomic 
point of insertion as opposed to the poly(A) tail length count  (Figure 2.7A). Additionally, 
when mapping insertions to base-pair resolution, if the genomic sequence contained a 
poly(A) stretch we called the point of insertion as the most 5’ A found in the genome 
sequence. In so doing, this means that the base-pair 5’ of the integration site will never 
be an A, and since the EN consensus cleavage site is the reverse complement of this 
sequence that means a T will never be in the 6th position of the 7bp endonuclease 
cleavage sequence.  
 
Once the final base-pair position of alignment to the genome was determined, the 
poly(A) tail size was then re-calculated to verify that at least a 15bp poly(A) tail was 
present in the read that could not be attributed to the genomic location of integration. 
Insertion call sets that came from the same biological replicate were then examined for 
the presence of insertions that may be within 10bp of each other and in which one site 
only had one CCS read associated with the call. The insertion site with just one read 
was then assigned to the other insertion site within 10bp which contained more CCS 
reads. Situations of this nature most likely represent the same insertion site but due to 
either PacBio polymerase amplification slipping or polymerase amplification slipping 
during capture techniques, part of the flanking sequence was lost. Insertion sites that 
may be at the same integration site in the genome, but come from different biological 
samples were called as two independent insertions. Finally, certain highly repetitive 
sequences in the genome such as centromeric or telomeric regions were found to 
contain large clusters of insertions. These regions of the genome contain large 
repetitive tandem repeats as identified by the Tandem repeats finder (Benson, 1999), 
making it difficult to determine if one integration site actually occurred and reads for the 
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same insertion were mapped to the incorrect reference genome or several insertions 
actually occurred in these locations of the genome. And we thus, filtered out any 
insertions called within these regions of the genome as well. 
 
Bowtie2 command line settings to align to adapter and primer sequences: 
bowtie2 -N1 -L3 --ma 3 -a -q --local -x ADAPTERS -U fastq.files –S 
sample_Adapters.SAM 
 
Bowtie2 command line settings to align to human genome: bowtie2 --no-hd --local -k 
100 --un $UNALIGNED_FILE -x $BT2_IDX -U -) 
 
We also aligned reads to the human genome with the following setting since we found 
that Bowtie2 was not aligning longer reads through the local method: bowtie2 --no-hd -k 
100 –un $UNALIGNED_FILE –x $BT2_IDX –U - 
 
Smith Waterman scoring used: no trimming of the reads, matched point of 1, mismatch 
penalty of -1.5, gap open penalty of -2.5, gap extension penalty of -1  
 
Logo Plots 
Logo plots of the L1 EN consensus cleavage site were created with Bioconductor’s 
SeqLogo R package. Corrected logo plots were calculated by determining the 
proportion of each nucleotide at each observed base pair position of the 7bp EN 
consensus cleavage site and correcting (dividing by) the observed proportion of 
nucleotides observed at that location in the human genome. (Bembom O 
(2017). seqLogo: Sequence logos for DNA sequence alignments. R package version 
1.42.0.). 
 
Modeling L1 integration 
We created a weighted random dataset based upon the L1 EN degenerate consensus 
cleavage site. The consensus cleavage site was determined for the total 65,079 
insertions from all four different cell samples. The frequency of occurrence of each of 
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the possible variations of the 7bp consensus cleavage site (5’-TTTTT/AA) observed 
within our four samples was determined. Due to our sliding of mapped insertions, 
favoring any poly-T stretch to the genomic location, we will never observe EN sites with 
a thymidine in the 6th position, which means we can only observe 12,288 EN sites (e.g. 
5’-NNNNN/VN; N represents A, C, G, or T and V represents A, C, or G). Next we 
removed insertions from our dataset that mapped within clusters found in highly 
repetitive sequences in the genome such as centromeric or telomeric regions. These 
regions were deemed ‘unmappable’ due to their large repetitive tandem repeats as 
identified by the Tandem repeats finder (Benson, 1999). Likewise, removing these 
regions from the genome as well as gaps and unambiguous ‘N’ sequences, this 
dropped our genomic size to 5,669,914,180bp to pick from in the genome.  
 
We determined the EN site for each of these positions in the genome. We applied the 
same ‘T-sliding’ approach in our genomic analysis as our mapping of insertion reads. 
Thus, some positions in the genome will never be picked, and instead their neighboring 
position will be picked twice or more (Figure 2.7A). We found that regardless of cell type, 
all insertions displayed a similar distribution of observed EN sites (Figure 2.2A).  This 
similarity across cell types allowed us to create one model for all insertions. For every 
EN site position observed we calculated the insertion frequency as the number of 
insertions observed for an EN site of interest over the total number of observed 
insertions. Of the possible 12,2888 EN site variants, 11,545 EN sites had less than 3 
observed integration sites at that sequence. The majority (97.14%) of insertions contain 
EN sequences in which there are 3 or more insertions which display the given EN site 
(Figure 2.2D). Thus, when picking sites in the human genome to model our insertion 
dataset we are only using our predicted model calculations for 3% of the total insertion 
dataset.  
 
We created a 1-4-2 model in which we treated motif position 1 as independent from 
motif positions 2-5 which were grouped as one 4bp unit, which is also independent from 
motif positions 6-7 which were also grouped as one 2bp unit. We then calculated the 
position frequency for every A, C, G, or T base observed in motif position 1. For motif 
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positions 2-5 we calculated the frequency of every 256 possible 4-mer observed. And 
for positions 6-7 we calculated the frequency of the 12 possible 2-mers (T cannot ever 
be assigned to position 6). The modeled insertion frequency for an EN site in which we 
observed less than 3 insertions becomes the products of the position probability matrix 
(Figure 2.2E). 
 
We weighted all EN sites by the most observed EN site, 5’-TTTTT/AA-3’ (weights were 
the insertion frequency of EN site of interest divided by the 5’-TTTTT/AA-3’ insertion 
frequency) (Table 2.5). These weights were then applied when randomly picking sites 
from the genome so as to mimic the same number of occurrences of EN sites observed 
in our actual insertion data.  
 
These weighted probabilities were applied to every base pair in the human genome 
reference (GRCh37/hg19) based upon the nucleotide’s corresponding degenerate 
consensus cleavage site if an L1 insertion were to occur at that precise nucleotide. We 
then executed a weighted randomization with R, including all sites in the human 
genome in which a consensus cleavage site could be determined (gap areas and 
consensus cleavage sites including an ambiguous “N” nucleotide were not included). 
We then repeated picking sites in the genome based upon this model for 10,000 
iterations. 
 
A ‘corrected’ weighted random model was also created in which observed insertion 
frequencies were ‘corrected’ or divided by the observed frequency of the 7mer in the 
genome. This model accounts for the frequency of the EN site found in the genome, 
thus ‘correcting’ for EN cleavage sites that are found more often than others in the 
genome. This model was also used in data analysis comparisons.  
 
Total RNA isolation 
Total RNA was extracted from confluent H9 hESC and H9 hESC derived NPCs using 
Trizol (Invitrogen) and following the manufacturer’s instructions. Total RNA was 
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extracted from confluent HeLa and PA-1s using an RNeasy Mini kit (Qiagen) following 
the manufacturer’s instructions. 
 
RNA-seq Analysis 
Two biological replicates of total RNA was isolated from H9 hESC, NPCs, HeLa and 
PA-1s each. RNA-sequencing libraries were created at the University of Michigan 
Sequencing Core. Total RNA samples were first filtered with an Illumina Ribo-Zero 
rRNA removal kit (#MRZH116). Immediately samples underwent the Illumina TruSeq 
Stranded mRNA Library Prep Kit (#RS-122-2101) following the Low Sample Protocol 
and beginning prep at the elute-prime-fragment step. A 1-minute fragmentation was 
performed to generate a 190bp target insert size and 12 cycles of PCR were performed 
instead of 15. One biological replicate for each of the four cell types was performed with 
a 100bp paired-end HiSeq sequencing run at the University of Michigan Sequencing 
Core. A second biological replicate was performed with 125bp paired-end sequencing, 
as the 100bp paired-end sequencing kit was no longer available for the second 
biological replicate run. For each sequencing run, all four samples were multiplexed and 
run on a single Illumina HiSeq Sequencing cell. Details of sequencing results and read 
counts from runs can be found in Table 2.8. 
 
RNA-sequencing reads were aligned to the GRCh37/hg19 (GENCODE genome version 
19) with Tophat version 2.1.1 and ENSEMBL GRCh37/hg19 transcripts (Aken et al., 
2017; Trapnell et al., 2009). The Cufflinks Suite version 2.2.1 was utilized to run 
Cufflinks with ENSEMBL GRCh37/hg19 transcripts to get assembled transcripts and 
isoforms (Roberts et al., 2011; Trapnell et al., 2010). Cuffmerge was then performed to 
get the final transcriptome (ENSEMBL) assembly. Cuffquant was used to quantify gene 
and transcript expression, and then cuffnorm was used to merge biological replicates 
and normalize all samples to the same scale for comparison.  
 
Tophat settings: ./tophat --library-type fr- firststrand –GTF 
chr_hg19_ENSEMBL_genes.gtf --num-threads 4  
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Cufflinks settings: ./cufflinks -b GRCh37.p13.genome.fa -u --library-type fr-firststrand --
max-bundle-frags 10000 --GTF-guide chr_hg19_ENSEMBL_genes.gtf --label PA1 --
num-threads 4 accepted_hits.bam 
 
Cuffmerge settings: ./cuffmerge -g chr_hg19_ENSEMBL_genes.gtf -s hg19.fa -p 4 
assembly_GTF_list.txt 
 
Cuffquant settings: ./Cuffquant -p 4 -b hg19.fa -u merged.gtf accepted_hits.bam  
 
Cuffnorm settings: ./cuffnorm -L PA1 -p 4 --library-type fr-firststrand --library-norm-
method geometric --output-format cuffdiff merged.gtf abundances.cxb 
 
With the cuff norm data output we first divided the genome into those regions of the 
genome expressed (FPKM > 0.3) vs. not expressed. Significance was determined using 
the χ2 test and comparing sample counts versus the median of the weighted random 
dataset.  
 
We also divided expressed regions of the genome into 30 (roughly same number of 
base pairs of the genome) bins and compared the counts of insertions in each bin 
(Table 2.10) as compared to the weighted random dataset simulations containing the 
same number of insertions as found in expressed regions of the genome (Sample: 
number of insertions in expressed regions; HeLa: 6,614; PA-1: 6,125; NPC: 3,379; 
hESC:1,660). Significance was determined using the χ2 test. For each simulation we 
compared the observed amount of insertions in our sample within a given expressed bin, 
versus the simulated counts of insertions and performed the χ2 test. Of the 10,000 
iterations we then determined the proportion of iterations where the χ2 test p-value was 
below a given threshold. 
 
Transcriptional Analysis 
Bru-seq experiments and initial transcription FPKM expressions were performed as 
previously published (Paulsen et al., 2014). The Bru-Seq generated bed files of 1kb 
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segments were analyzed to determine transcribed regions of the genome in both PA-1 
and HeLa cells. We utilized the web base interface, MIBrowser to help determine RPKM 
threshold of transcription. The RPKM threshold was determined by identifying regions of 
the genome in which there are clear defined differences in expression between 
intragenic and intergenic regions of the genome. For PA-1, regions of the genome in 
which the combined RPKM expression of both the top and bottom strand was above 
0.024 were classified as actively transcribed. For HeLa analysis a combined top and 
bottom strand RPKM expression threshold above 0.022 was used to define transcribed 
regions of the genome. About 35.3% of the PA-1 genome is transcribed, while 34.1% of 
the HeLa genome is transcribed. We compared the count of insertions within 
transcribed regions vs. non-transcribed regions of the genome of the PA-1 and HeLa 
samples to 10,000 iterations of weighted random datasets that contained the same 
amount of randomly picked sites as in their respectively compared sample insertion 
dataset (Figure 2.4B). Significance was determined using the χ2 test and comparing 
sample counts versus the median of the weighted random dataset.  
 
We also divided the transcribed regions of the genome into 30 roughly equally sized 
bins, where each bin represents a different range of RPKM transcription expression 
(Table 2.9). In PA-1 cells we identified 5,391 insertions in transcribed regions of the 
genome. We then performed 10,000 iterations of selecting 5,391 sites within transcribed 
regions of the genome under the weighted random dataset probabilities. These sites, 
and the corresponding counts of sites within the 30 different transcriptionally expressed 
bins were compared to the observed PA-1 insertion counts within these bins and 
significance was determined by χ2 test (Figure 2.16A). Sample insertion bin counts were 
determined to be significant if at least 95% of the 10,000 iterations resulted in a χ2 test 
p-value of less than 0.05, 99% of the 10,000 iterations for a χ2 test p-value less than 
0.01 etc.  Likewise, the above analysis was performed for the HeLa transcriptional 
dataset, except 6,617 sites were randomly selected based on the weighted random 
dataset, representing the same amount of HeLa insertions found within transcribed 
regions of the genome.  
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We also divided the transcribed regions of the genome based upon transcriptional bias.  
The transcriptional bias was calculated as the absolute value of the ratio of the 
difference in RPKM expression between the top and bottom strand of a site in the 
genome over the total RPKM expression of both strands of that site in the genome 
(Figure 2.16B). Transcriptional bias ratio values were sorted into respective perl integer 
expression functions resulting in 11 bins from 0.0 to 1.0. For every transcriptional bias 
bin we counted the total number of insertions that fell within the respective bin, and then 
the fraction of insertions that inserted into the template strand.  We plotted counts of the 
sample insertions versus the weighted random dataset (Figure 2.4D). To determine 
significance we tested each simulation count versus the observed insertion count and 
performed χ2 test. If 99% of the 10,000 iterations showed a χ2 test p-value less than 0.01 
then the χ2 test p-value was determined to be < 0.01.  We performed this comparison all 
the way to a p-value <0.00001. 
 
Okazaki Sequencing Analysis 
Previously published Edu labeled HeLa and GM06990 Okazaki sequencing (OK-seq) 
data was downloaded from the NCBI Sequence Read Archive under accession number: 
SRP065949 (Petryk et al., 2016).  Two independent Okazaki-sequencing (OK-seq) 
datasets were published for HeLa (Spearman’s rho of 0.962 between the two sets) and 
two independent datasets for GM06990 lymphoblastoid cell line (Spearman’s rho of 
0.954 between the two sets). The two independent cell types, HeLa versus GM06990 
lymphoblastoid cell line, when compared to each other show a Spearman’s rho of 0.61.   
We applied additional smoothing parameters on the data to determine replication fork 
direction (RFD) and RFD slope values. All insertion datasets were compared to both 
replicates for the HeLa and GM06990 OK-seq data, and the trends observed were the 
same in all comparisons analysis made.  Figures are shown for one of each of the 
replicates.  
 
Like transcription data, we plotted both cumulative distribution function (CDF) plots with 
the data.  We also plotted boxplots involving the simulated uncorrected weighted model 
and our observed insertion dataset with the genome divided into 11 bins based upon 
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|RFD| values from zero to one. Significance in boxplots was determine using the χ2 test 
and testing each of the 10,000 iterations of the weighted random model versus the 
actual observed insertion data value. We then determined the proportion of iterations in 
which a significant χ2 test p-value was observed, to determine the significance of the 
reported p-value. 
 
Kolmogorov-Smirnov Boostrap test 
The Kolmogorov-Smirnov Bootstrap test [ks.boot R function; 10,001 boot iterations] was 
performed to determine if the observed insertion dataset differed significantly from the 
corrected model as compared to the simulated insertion dataset difference from the 
corrected model. This test was performed for all datasets involving a cumulative 
distribution function (CDF) plot.  
 
Chromatin States Enrichment Analysis 
Mnemonics chromatin state bed files (15-state and 18-state) published by the Roadmap 
Epigenomics Consortium were downloaded 
(http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmMode
ls/coreMarks/jointModel/final) (Roadmap Epigenomics et al., 2015).  Specifically, for the 
15-state model we downloaded the mnemonics bed file for E008 – H9 hESC cells, E009 
– H9 hESC derived neuronal progenitor cultured cells, E010 – H9 hESC derived neuron 
cultured cells, E065 - Aorta, E066 - Liver, E117 – HeLa-S3 cervical carcinoma, E118 – 
HepG2 hepatocellular carcinoma, and E123 K562 leukemia.  
For the 18-state model, we downloaded the mnemonics bed file 
(http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmMode
ls/core_K27ac/jointModel/final/) for E003 – H1 hESC cells, E007 – H1 hESC derived 
neuronal progenitor cultured cells, E008 – H9 hESC cells, E065 - Aorta, E066 - Liver, 
E117 – HeLa-S3 cervical carcinoma, E118 – HepG2 hepatocellular carcinoma, E123 
K562 leukemia.  The E065 and E066 files were downloaded as negative controls. Since 
there is no 18-state model for female H9 hESC-derived NPCs we used male H1 hESC 
derived NPCs as a supplement.  
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As a positive control of strong enrichment and depletion we downloaded the MLV 
integration events in HepG2 and K562 from LaFave et al. 2014 (LaFave et al., 2014).  
 
The Genome Structure Correction tool was utilized to determine enrichment or depletion 
of insertions in the respective chromatin states 
(https://github.com/ParkerLab/encodegsc) (Bickel et al., 2010). The following settings 
were used after identifying the r and s value that resulted in the least over dispersion: 
/block_bootstrap.py -1 Sample_insertion.bed -2 Chromatin_State_mnemonic.bed –d 
Ungapped_reference.bed –r 0.20 –s 0.15 –n 10000 –t rm –B –v.  Enrichment was then 
calculated for insertions in each individual state and a heatmap was created using the 
ggplot R function.  States that covered a very small proportion of the genome and result 
in observance of less than 30 expected insertions, were masked as grey boxes in the 
heat plot as these states contain too small of a sample set to determine a true 
enrichment or depletion. 	
 
Chromosomal Ideogram 
Chromosomal ideograms (Figure 2.3B and Figure 2.14) were created using PhenoGram 




We used DAVID Bioinformatics Resource 6.8 (Huang da et al., 2009a, b) to determine if 
NPC insertions were enriched in genes associated with neurons. We uploaded the list 
of genes using the human genome as the default background with the highest 
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Figure 2.1: Generation and identification of de novo engineered L1 
retrotransposition events.  
A) General schematic of engineered L1 plasmid constructs to generate L1 
retrotransposition events: All four cell types were transfected with episomal plasmids 
containing an engineered L1 with retrotransposition indicator cassette located within the 
3’UTR (represented by green rectangle labeled ‘REP’, short for ‘Reporter’). Reporter 
cassettes are driven by an upstream promoter (small black arrow). The coding 
sequence of the reporter cassette is in the opposite orientation of the respective L1 
sequence, disrupted by an intron (indicated by black lines in ‘v’ shape), and followed by 
a polyadenylation signal (black lollipop). The intron is in the same orientation of the L1 
sequence (SD: splice donor site; SA: splice acceptor site). The ‘LEAP’ (orange) 
sequence is downstream of the reporter cassette, which is present in these engineered 
L1 constructs, but is not present in the sequence of endogenous L1 sequences. If the 
engineered L1 construct is transcribed and the intron is spliced from the reporter 
cassette, expression of the respective reporter cassette occurs only after successful 
reverse transcription and integration of the engineered L1 into a new genomic location.  
B) Selection or screening of engineered L1 retrotransposition events: (Top) T-175 flask 
of HeLa L1 retrotransposition events. Proportion of EGFP expressing cells, indicative of 
de novo engineered L1 retrotransposition events, from representative retrotransposition 
assay in PA-1 cells (Untransfected: Untransfected PA-1 cells, ORF1p Mutant: LRE3 
ORF1p mutant pCEP4/JM111/LRE3-mEGFPI transfected PA-1 cells, Wild-type L1: 
wildtype LRE3 pCEP4/LRE3-mEGFPI transfected PA-1 cells).  
C) Capture of engineered L1 retrotransposition events: Partially double-stranded 
adapters (red rectangles) are ligated onto end-repaired, dA-tailed sheared genomic 
DNA collected from cells following completion of the retrotransposition assay. The 
adapters contain a 3’ ammine (indicated by the red asterisk) on the shorter strand to 
prevent the amplification of spurious genomic DNA by the presence of excess single-
stranded adapters. Adapter ligated genomic DNA is subjected to a linear amplification 
utilizing a dual-biotinylated LEAP primer, a sequence specific to our engineered L1 
construct (orange arrow with circle on 5’ end indicating biotin). Biotinylated products are 
streptavidin bead captured (grey circle) and subjected to nested PCR utilizing a primer 
specific to the SV40pA primer sequence (black arrow) and a primer specific to the 
adapter sequence (red arrow). Following successful amplification, PacBio CCS 
SMRTbell adapters (navy dumbbells) are ligated onto products and subjected to PacBio 
CCS sequencing. 
D) Amplified 3’ L1 and flanking gDNA: PCR amplified products were run on a 1.0% 
agarose gel. + Control: PC39, a clonal PA-1 cell line with three known engineered L1 
integration events, genomic DNA is used as a positive control. The three distinct bands 
represents 3 known engineered L1 integration sites in PC39 (pc-39-C ~1150bp; pc-39-B 
~580bp; pc-39-A ~330bp). 1 H2O Control: Uni-linear PCR H2O template control. 2-1 
H2O Control: PCR2 using uni-linear amplified H2O control as template. 2 H2O Control: 
Nested PCR with H2O as template. PA-1: amplified library of gDNA from PA-1 cells 
transfected with pCEP4/LRE3-mEGFPI and subjected to capture techniques. The 
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shmear represents hundreds of successfully amplified retrotransposition events and 
their flanking 3’ gDNA.  Ladder: 1kb Plus DNA Ladder (ThermoFisher Scientific). 
E) Identification of de novo L1 insertions: Independent biological replicates (2nd row) of 
retrotransposition assays were performed and subjected to the above capture, 
amplification, and PacBio CCS sequencing. The total number of CCS read counts are 
provided for each sample (3rd row), and the number of unique L1 insertions identified in 
each sample (4th row) are shown after filtration. 
F) Independent PacBio CCS reads support PA-1 Insertions: The proportion of total PA-1 
insertions (y-axis) that are represented by a number of independent CCS reads (x-axis).  
G) Engineered insertions display long poly(A) tails: The frequency of PA-1 insertions (y-
axis) with the corresponding poly(A) tail length shown in base pairs (x-axis).  
H) Engineered insertions are found within AT-rich regions of the genome: Different 
lengths of genomic sequence upstream and downstream of L1 insertion sites were 
examined for GC content. A window size of 24bp indicates that 12bp upstream and 
downstream of the L1 integration site was examined. The blue dotted line represents 
the average human GC content of 40.94%. Engineered insertions from all four cell types 
show this same trend as shown here for the PA-1 engineered insertions (Figure 2.7F). 
I) Engineered insertions display the degenerate endonuclease consensus cleavage site: 
A logo plot depicting the 7bp degenerate EN consensus cleavage site of PA-1 insertions.  
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Figure 2.2: A weighted random model based upon L1 EN degenerate consensus 
cleavage site.  
A) All four cell-types show similar degenerate EN consensus sequence distributions: 
Observed frequency (y-axis) of the 12,288 possible 7bp degenerate EN consensus 
cleavage sites (x-axis) among the four different cell types. The distribution of observed 
7mer variants for the top 80% of the insertions in each sample set is plotted for  each 
cell type individually (respective colors) and the total set of insertions combined (black).  
B) Some base pair positions of the L1 EN consensus cleavage site are dependent upon 
each other: After observing all EN cleavage sequences of insertions in which the 5th 
nucleotide did not contain a T (top left logo plot), we observed a stronger preference for 
T in nucleotide positions 2 through 4, but no change in position 1 or positions 6 and 7. 
Likewise when we select all EN sequences that contain a C in the 5th nucleotide position 
(top right logo plot) or when we condition for the presence of a T or C in the 3rd position 
(bottom two logo plots) we observe the same trend. Thus, conditions made upon 
nucleotides 2-5 do not change the preference of position 1 or of positions 6 and 7.  
These logo plots indicated to us the need for a 3 group independent model of 1-4-2 
where position 1 is a 1bp unit independent from positions 2-5, a 4bp unit, which is 
independent from positions 6-7, a 2bp unit.   
C) Positions 2-5 of L1 EN consensus cleavage site are dependent upon each other: The 
total percentage of insertions from all four cell-types (column 2) that contained a T or C 
nucleotide within positions 2 through 5 of the L1 EN consensus cleavage site. N 
represents any nucleotide of A, T, C, or G.  V represents any nucleotide except T. Since 
we “slide” insertions to determine base-pair resolution, we never observe a T in the 6th 
position. 
D) Predicted weights from model are less than weights from observed frequencies for 
EN sites with insertion counts less than 3: Each point represents one of the 12,288 
possible EN consensus cleavage sites. Plot of log10 weights for an EN site when 
calculated from the position probability matrix (x-axis) vs. log10 weights for an EN site 
calculated when using the actual observed insertion frequencies (y-axis). Light grey line 
represents 1 to 1 weights in which EN sites that are given the exact same weight by 
both approaches. Points to the left of the grey line indicate EN sites that are weighted 
less by the model than by using actual observed frequencies.  Points to the right of the 
grey line indicate EN sites that are weighted more by the model than by using the actual 
observed frequencies. Red points represent EN sites supported by less than 3 
insertions (red) and blue points EN sites observed by 3 or more insertions. Thus, a 
threshold of 3 or more insertions at an EN site was created. With this 3 insertion 
threshold we use the model for 11,454 EN 7mer sites, 93.2% of total 7mers, and model 
1,860 insertions, only 2.86% of the total insertions. [Note, in order to distinguish points 
we used the R jitter() function with a factor value of 1 for y-axis values; for weights 
which had a value of 0 we assigned a value of 1x10-10]. 
E) Weighted random model schematic: We created a weighted random model based 
upon the observed 7pb L1 EN consensus cleavage site. All 7bp iterations of the EN 
sequence site were determined, with the exception that we will never observe a T in the 
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6th position because we always favor a T to the human genome reference. Thus, this 
leaves 12,288 possible 7mer combinations. For each EN site observed we calculated 
the insertion frequency of that site (IF7mer,obs) as the number of insertions at that site 
(Nins,7mer) over the total number of insertions (Nins). Insertion counts from all four cell- 
types determined the insertion site calculations. For EN sites in which we observed less 
than 3 insertions we determined the insertion site frequency as the probability of the 
expected frequency from the position probability matrix determined from observed EN 
sites. We then weighted the EN sites based on the EN site that had the most insertion 
counts. These weights were then applied to each respective position in the genome 
based on the corresponding 7mer and sites in the human genome were then randomly 
picked based on these weights. We repeated picks for 10,000 iterations. 
F) Weighted random model sites display L1 EN degenerate consensus cleavage site: 
As proof of principle we collected sequence surrounding sites chosen by our weighted 
random model algorithm and created a logo plot. The logo plot displays that our model 
is selecting degenerate L1 EN consensus cleavage sites in the human genome, 
mimicking our insertion dataset. 
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Figure 2.2: A weighted random model based upon L1 EN degenerate consensus 
cleavage site.  
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Figure 2.3: LINE-1 is dispersed throughout the human genome.  
A) Chromosome insertion counts are correlated with chromosome size: Plots display 
the shortest chromosome to the largest chromosome from left to right along the x-axis, 
and the corresponding counts of PA-1 insertions (red circles) per chromosome on the y-
axis. Boxplots represent the range of insertion counts observed for the 10,000 iterations 
of the weighted random model. In PA-1s (red circles), the X chromosome contains more 
insertions than expected (Outlier test, Bonferroni correction p-value: 0.0046).  
B) Engineered insertions are dispersed throughout the human genome: Chromosomal 
ideogram (from PhenoGram from the Ritchie Lab at PennState) depicting all PA-1 
insertions with respect to their mapped location on the corresponding chromosome. 
Each red horizontal line is a single engineered PA-1 insertion site.  
C) L1 integrates into exons: Boxplot of the range of  observations from the 10,000 
iterations of the weighted random dataset for each corresponding sample within exons. 
Exons (including 5’UTR, coding exon, and 3’UTR) are defined by the UCSC genome 
browser’s definition. Most samples contain the expected amount of insertions in exons, 
with PA-1s showing a depletion of insertions within exons (χ2 test p-value: 5.782 x 10-8). 
D) L1 integration within introns of genes: Boxplot of the range of observations from 
10,000 simulations of the weighted random iterations found within introns for each 
sample. Intron boundaries are defined by the UCSC genome browser’s definition. HeLa, 
PA-1, and NPC insertions all show a depletion of insertions in introns (χ2 test p-value: 
1.48 x 10-9, <2.2 x 10-16, <2.2 x 10-16 respectively). 
E) A schematic of L1 integration into genes: A diagram showing an L1 insertion 
antisense and sense with respect to the expressed gene (green arrow). The ‘top’ strand 
is the coding sequence of the gene. An antisense insertion preference shows a bias of 
the EN consensus site on the coding strand in the genome. 
F) The L1 degenerate EN consensus cleavage site drives insertions towards antisense 
insertion bias within genes: Utilizing the UCSC Genome Browser annotation of exon 
(including 5’UTR, coding exon, and 3’UTR) and intron, we considered insertions within 
an exon or an intron to be within a gene. We calculated the proportion of antisense to 
sense genic insertions as the number of genic insertions that are in the opposite 
(antisense) orientation with respect to the expressed gene, over the number of 
insertions that are in the same (sense) orientation with respect to the expression of the 
gene. The boxplots show the range of expectations from the 10,000 iterations of the 
weighted random dataset, showing a median preference of antisense: sense ratio of 
greater than one. All insertions, except hESC insertions, which show a stronger 
antisense preference (χ2 test p-value: 0.00272), are within the expected range of 




Figure 2.3: LINE-1 is dispersed throughout the human genome.  
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Figure 2.4: LINE-1 does not target transcribed regions of the genome.  
A) Schematic of L1 preferentially targeting the coding strand during transcription: (Top) 
Schematic of the hypothesize preferential cleavage of L1 EN ORF2p (blue circle) 
activity at an EN consensus cleavage site of the accessible coding strand during 
transcription, while RNA polymerase (depicted by green oval) occupies the noncoding 
strand. (Melander et al.) Bru-seq involves labeling of nascent transcripts in cells with 
bromouridine (BrU), capture of bromouridine transcripts, and sequencing of transcripts 
by Illumina sequencing. A visual of PA-1 Bru-seq data in the MIBrowser is shown below 
for an identified PA-1 insertion antisense of the transcribed RAVER2 gene [green 
rectangle depicting 5’ to 3’ expression on top strand with positive RPKM expression 
values (blue line)]. JAK1 (red rectangle), is a gene transcribed and expressed from the 
bottom strand and thus has negative RPKM expression levels (blue line). 
B) Transcription deters L1 integration: Boxplot for the range of observations from the 
10,000 iterations of the weighted random dataset observed in transcribed vs. non-
transcribed regions of the genome. The blue squares in the top plot represent the 
observed HeLa insertion counts in transcribed vs. non-transcribed regions of the 
genome, while the red squares in the bottom plot depict the observed PA-1 insertions. 
In both samples, we observe significantly more insertions in non-transcribed regions of 
the genome and significantly less insertions in transcribed regions (χ2 Test: HeLa p-
value: 6.795 x 10-6; PA-1 p-value: < 2.2 x 10-16).  
C) L1 EN preferentially cleaves regions of low transcription levels in the genome: 
Cumulative distribution functions are plotted for position weighted modeled corrected 
(red), 10,000 simulated uncorrected weighted model iterations (gray) and actual 
insertion (blue) datasets, with increasing transcription levels on the x-axis. Both HeLa 
and PA-1 insertions differ significantly from the corrected model as compared to the 
simulated insertions when tested against the corrected model (Kolmogorov-Smirnov 
bootstrap test p-value < 1 x 10-6 for both PA-1 and HeLa plots). HeLa and PA-1 
insertions display a faster accumulation of insertions in less transcribed regions of the 
genome. 
D) L1 EN can cleave coding strand during transcription: Transcription bias was 
calculated as the rate of transcription for the top strand of a region in the genome minus 
the bottom strand of the same region in the genome over the combined (total 
expression) of the top and bottom strands (Figure 2.16B). The absolute value of this 
expression was plotted, and rates were divided into 11 bins from 0 to 1 in 0.1 
increments. A transcriptional bias of 0 indicates equal transcription expression from both 
strands in the genome, while a bias of 1 means only one strand in the genome is 
actively transcribed. Since Bru-seq measures a population of cells, most regions in the 
genome have a transcription bias ranging from 0 to 0.8. Box plots represent range of 
observations observed from each transcriptional bias condition from weighted random 
iterations. Blue squares represent HeLa insertion observed values and red squares are 
PA-1 insertion values. In HeLa cells at transcription bias of 0.9 there is significantly 




Figure 2.4: LINE-1 does not target transcribed regions of the genome.  
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Figure 2.5: L1 does not target a specific chromatin state in the human genome.  
A) Schematic of L1 integrating throughout the genome: The Roadmap Epigenomics 
Consortium Hidden Markov Modeled 15 Chromatin State Set separates the genome 
into 15 different chromatin states, which can roughly be divided into four states: 
enhancer, promoter, transcription-related, or heterochromatic regions of the genome. 
We want to test if L1 integration is enriched in any one of these states. 
B) L1 integrates throughout the genome, independent of chromatin state: Insertion 
sample sets were compared to the Roadmap Epigenomics Consortium Hidden Markov 
Modeled 15 Chromatin State Set. Each box represents fold enrichment of the insertion 
set across the other cell types. The most relevant cell line to compare to the given 
insertion dataset is on the leftmost end. Insertions were compared to every cell type 
tested, as well as the control datasets, E065_Aorta and E066_Liver. Gray boxes are 
those states in which there are too few insertions (less < 30 insertions) to be able to test 
for statistically significant enrichment or depletion. As a comparison of extreme 
enrichment and depletion we included the MLV integration dataset capture from the 
leukemia K562 cell line (LaFave et al., 2014).  
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Figure 2.5: L1 does not target a specific chromatin state in the human genome.  
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Figure 2.6: Replication influences L1 integration in the human genome.  
A) Examining the influence of replication on L1 EN cleavage and integration in genome: 
Depicted is a representation of a replication fork in the genome, where L1 EN has 
cleaved the lagging strand template (grey). We hypothesize that the lagging strand 
template is more accessible during replication, thus providing an opportunity for L1 EN 
cleavage and subsequent L1 integration. Shown below is a MIBrowser screen shot of 
representative HeLa OK-seq data from chr5 in which a sense L1 insertion was 
discovered in a region of the genome in which the replication fork was moving towards 
the left. This is a representative example in which the L1 EN cleaved the lagging strand 
template for integration to occur in the genome. 
B) L1 endonuclease cleavage shows slight bias towards cleavage of lagging strand 
template during replication: Plots display the absolute value of the Replication Fork 
Direction (RFD) on the x-axis. Regions of the genome were binned into 11 bins with 
respect to the replication fork direction measurement of the region of the genome based 
upon the data published by Petryk et al. (2016). An RFD of 0 indicates replication 
occurring from the right and left, while an RFD of 1 indicates regions of the genome that 
are only replicated from one direction. Insertions that land within each region of the 
genome were plotted based upon the fraction of the insertions in each bin in which the 
L1 EN had to cleave the lagging strand template of replication for integration to have 
occurred. All datasets were compared to the lymphoblastoid replication fork direction 
data from Petryk et al. (2016), except HeLa, which was compared to the HeLa 
replication fork direction data. All comparisons were made with all datasets, and all 
showed the same trends observed here favoring cleavage on the lagging template 
strand. Box plots represent the distribution of the 10,000 weighted random model for the 
sample. There is a significant enrichment of HeLa insertions cleaved on the lagging 
strand template in bin 0.7 (χ2 p-value: < 0.05). There exists a significant excess of PA-1 
insertions in replication fork direction bins 0.3 through 0.8 (χ2 p-value for bins 0.3 to 0.5: 
< 0.05; χ2 p-value for bin 0.6: < 1x10-4; χ2 p-value for bins 0.7 and 0.8: < 1x10-6).  
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Figure 2.6: Replication influences L1 integration in the human genome.  
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Figure 2.7: Generation and identification of de novo engineered L1 
retrotransposition events (Supporting Figure 2.1).  
A) Filtering of de novo L1 insertions: Amplified products are sequenced by Pacific 
Bioscience’s (PacBio) single-molecule real time (SMRT) circular consensus sequencing 
and reads are filtered for de novo L1 integration events. Gray box represents SV40pA 
primer sequence, black box with As represents a poly(A) tail, black wavy line represent 
3’ flanking gDNA, and red rectangle the adapter primer sequence. Reads that contain 
both expected primer sequences, as well as presence of a poly(A) tail of at least 15bp 
(top blue oval) are first clipped of their primer sequences and then mapped to the 
human genome (GRCh37/hg19 and GRCh38/hg38 via Bowtie2). Reads that are 
missing a poly(A) tail (orange circle) or lacking both expected primer sequences (yellow 
circle) are not mapped to the genome. The best mapped read location is chosen (blue 
oval) as the alignment that covers 96.5% of the total read, and the alignment with the 
highest alignment score difference (ASDIF) that is at least 20 points higher than the 
next best alignment. Bottom image: When mapping circular consensus sequences 
(CCS) to the genome we always favor any poly(A) stretch that may be present in the 
genome to the insertion call site as opposed to attributing the poly(A) stretch to the 
poly(A) tail. We classify the most 5’ A in the poly(A) stretch the called/annotated 
insertion site (as shown by the ‘A’ marked in blue with the asterisk above). The cleaved 
EN consensus sequence is the sequence on the opposite strand, and EN cleavage 
occurs between the T and A marked in red, also indicated by the black triangle. 
B) Proportion of CCS reads filtered: The initial number of total collected CCS reads are 
shown in parenthesis. These CCS reads are filtered for the presence of both primer 
sequences and presence of a poly(A) tail (blue). The proportion of CCS reads that 
contain both primer sequences, but lack a poly(A) tail, are shown in orange. Reads that 
do not contain both primers are shown in yellow. 
C) Filtered CCS reads mapped to hg19 and hg38 reference: Pie charts detailing 
mapping states per Bowtie2 for CCS reads. The proportion of reads mapped uniquely to 
one genomic location are in blue, while multi-mapped reads with one unique location 
(defined from selecting mapped location with the highest alignment score difference 
(ASDIF > 20)) are in light blue. In yellow is the proportion of mapped CCS reads that 
cannot be called to one unique location, and the fraction of reads that did not map at all 
to the genome is shown in orange.  
D) PacBio CCS read lengths: Frequency of insertions (y-axis) at observed CCS read 
lengths (x-axis). On average, we obtained ~600bp CCS reads.  
E) Number of Insertions supported by Independent CCS Reads: Proportion of total 
insertions (y-axis) and the number of independent CCS reads that support insertions (x-
axis). In order for two sequences to be considered independent CCS reads for the same 
insertion site, the 3’ end of the sequence reads ligated to the adapter sequence must 
have different end sequences, but both reads must uniquely map to the same poly(A) 
tract/3’ genomic sequence junction site in the genome. 
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F) Engineered L1 insertions display long poly(A) tails: Frequency of insertions (y-axis) 
with a given poly(A) tail length in base pairs (x-axis). We observe insertions with longer 
poly(A) tail lengths due to the strong SV40 polyadenylation signal in our engineered L1 
constructs. 
G) Degenerate EN consensus logo plots: Logo plots generated from the sequence 
directly surrounding identified L1 insertions. Insertions from all the examined cell types 




Figure 2.7: Generation and identification of de novo engineered L1 
retrotransposition events. (Supporting Figure 2.1).  
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Figure 2.8: Engineered L1 plasmid constructs (Supporting Figure 2.1A).  
Schematics of the labeled constructs used in engineered L1 retrotransposition assays. 
All constructs have a pCEP4 backbone, except pKUB102/L1.3-sv+, which consists of a 
pBSKS-11 backbone.  In pJM101/L1.3 the L1.3 sequence is driven by a CMV promoter 
and contains a mneoI retrotransposition cassette driven by an SV40 promoter (black 
arrow labeled P’). In pCEP4/LRE3-mEGFPI, LRE3 is driven by it’s native promoter in 
the 5’UTR and has an mEGFPI retrotransposition cassette driven by a CMV promoter. 
All constructs with LRE3 contain puromycin resistance. The pCEP99/UB-LRE3-mEGFPI 
construct contains LRE3 driven by an ubiquitin C promoter (pUBC) and the same 
mEGFPI construct described in pCEP4/LRE3-mEGFPI. In pKUB102/L1.3-sv+ the 
5’UTR of L1.3 has been replaced with pUBC, and contains the same mneoI cassette 































Figure 2.9: Reporter cassette PCR verifying L1 retrotransposition (Supporting 
Figure 2.1B).  
A) Schematic of the retrotransposition reporter cassette PCR:  This PCR setup has 
been described previously in Moran et al. (1996) and Ostertag et al. (2000). Primers 
(magenta arrows) flanking the respective reporter cassette amplify both unspliced and 
spliced reporter cassette products.  
B) Genomic DNA collected after retrotransposition assays show presence of spliced 
reporter cassettes: 493bp product found in HeLa cells transfected with pJM101/L1.3 
and selected with G418 for retrotransposition events is observed (lanes labeled HeLa).  
PA-1 cells transfected with pCEP4/LRE3-mEGFPI were either selected for plasmid 
(PuroR) or screened for GFP expressing cells (GFP).  Spliced GFP shows a band at 
























Figure 2.9: Reporter cassette PCR verifying L1 retrotransposition (Supporting 






Figure 2.10: pc-39-C characterization (Supporting Figure 2.1D).  
A) Details of three PC39 insertions: PC39 is utilized as a positive control during library 
preparation techniques. Instead of randomly shearing gDNA from PC39 we double 
digest gDNA with NdeI and PacI.  Pc-39-C and pc-39-B insertions contain a 3’ flanking 
NdeI restriction site while pc-39-A contains a 3’ flanking PacI site. We then prepare this 
digested DNA for adapter ligation and subject the library prep to the same capture and 
amplification techniques we used to discover our de novo L1 insertions. Shown here is 
the known poly(A) tail length, expected flanking gDNA length, and location of the 
restriction sites. The GRCh37/hg19 coordinates indicate the integration site of the 
insertion in the genome. 
B) Three independent engineered L1 insertions in PC39: Following library capture and 
amplification techniques we observe three bands on a 0.75% agarose gel that represent 
distinct L1 integration events (pc-39-C ~ 1150bp; pc-39-B ~580bp; pc-39-A ~330bp). 
Pc-39-A and pc-39-B were previously characterized in Garcia-Perez et al. (2010).   
C) Characterization of pc-39-C insertion: With our capture technique we identified a 
third, previously uncharacterized insertion, pc-39-C. Pc-39-C is located on chr19: 
13627881 (GRCh37/hg19) on the reverse strand. The L1 is truncated at the 5’ end and 
includes the last 100bp of ORF2p, and is flanked by 18bp TSD, with a 33bp poly(A) tail. 
The pre-integration site sequence is shown as well as the sequence surrounding the L1 
integration. Red nucleotides and red triangle represent where initial EN cleavage 
occurred. Black triangle represents location of second-strand cleavage. 
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Figure 2.11: L1 insertions are located within AT-rich regions of the genome 
(Supporting Figure 2.1H).  
A) Engineered L1 insertions are found in AT-rich regions of the genome: Plots 
displaying different spanning base-pair window sizes of examined sequence 
surrounding insertion sites (x-axis) versus the percentage of GC sequence found in the 
sequence (y-axis). All engineered L1 insertions display the same trend regardless of 
cell-type. 
B) Insertions are located in T-rich sequence in the genome: Similar to Figure 2.8A, we 
examined the sequence surrounding insertion sites. For 100bp upstream and 
downstream of the L1 EN consensus cleavage site we examined the nucleotide ratio for 
each base-pair. In general the sequence surrounding insertions is T-rich. The proportion 
of T-rich sequence preference transitions to a steep increase at about 25bp upstream of 
the insertion site, which may be due to our requirement of insertions containing at least 
a 15bp poly(A) stretch.  We are observing the complement sequence in this figure, 




Figure 2.11: L1 insertions are located within AT-rich regions of the genome 
(Supporting Figure 2.1H).  
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Figure 2.12: L1 EN cleavage site is degenerate (Supporting Figure 2.2).  
A) L1 EN site is influenced primarily by a 7mer sequence: Capturing 25bp upstream and 
25bp downstream of insertion sites for a logo plot reveals that a 7mer sequence (5’-
TTTTT/AA) primarily influences the EN logo. We thus examined 7mer sequences in the 
genome when creating our weighted random model. 
B) Description of the term ‘Hamming Distance’: Hamming Distance refers to the number 
of nucleotide mismatches of a sequence as compared to some standard sequence. In 
this instance the sequence we want to match is the perfect L1 EN consensus cleavage 
site of 5’-TTTTT/AA. Thus, the ‘Hamming Distance’ of this sequence is 0. Any 7mer 
variant that has one mismatch in any position has a ‘Hamming Distance’ of 1, a 7mer 
with two mismatches has a ‘Hamming Distance’ of 2, etc..  
C) Majority of L1 insertions occur at L1 EN consensus cleavage site with at least one or 
more mismatches: This plot shows increasing ‘Hamming Distance’ on the x-axis with 
the proportion of total insertions (y-axis) per sample.. Regardless of cell type, all 
datasets follow the same trend showing that about 10% of total insertions directly match 
the perfect EN consensus cleavage site, while more than half of the insertions contain 1 
or 2 mismatches in this sequence.  
D) EN site drives towards AT-rich sequences in genome: When randomly picking 
10,000 sites in the human genome (left plot) regardless of the window span of 
sequence surrounding the site, the GC content stays relatively constant near 40%. For 
our weighted random model (right plot), when examining picked sites from one iteration 
of our model, we observe the same trend we see with our engineered L1 insertion 
datasets. This suggests that the variants of the EN consensus cleavage site are found 
within AT-rich regions of the genome and the EN consensus cleavage site is what 
drives L1 towards AT-rich regions of the genome. 
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Figure 2.12: L1 EN cleavage site is degenerate (Supporting Figure 2.2).  
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Figure 2.13: LINE-1 is dispersed throughout the genome (Supporting Figure 2.3).   
A) Insertion counts correlated with chromosome size: Chromosomes are plotted by the 
smallest chromosome to the largest from left to right along the x-axis. Insertion counts 
mapped to each chromosome are shown on the y-axis.  Boxplots show the distribution 
observed from 10,000 iterations of the weighted random dataset. Colored points show 
the actual observed counts from the corresponding sample. Spearman’s rho correlation 
for chromosome size and insertion counts for each sample: HeLa: 0.948, p-value: 2.859 
x 10-6; NPC: 0.927, p-value: 3.231 x 10-6; hESC: 0.932, p-value: 3.165 x 10-6. The X 
chromosome is a significant outlier for NPC and hESC insertions, while chromosome 5 
is a significant outlier in HeLa (Bonferonni corrected p-value from linear model outlier 
test – HeLa: 0.0049; NPC: 0.0028; hESC: 0.0063).  
B) L1 insertions are more prevalent in non-expressed regions of the genome:  RNA-seq 
data from each cell type measured expressed regions of the genome. There are less 
insertions (colored squares) found within expressed regions (> 0.3 FPKM) of the 
genome than expected from the weighted random dataset (boxplots). We observe a 
significant depletion of insertions in expressed regions of the genome as compared to 
the weighted random datasets for HeLa, PA-1, and NPC insertions datasets (χ2 p-
values: 1.776 x 10-12, < 2.2 x 10-16, < 2.2 x 1016 respectively).  
C) L1 insertions are not preferentially located within highly expressed regions of the 
genome: Expressed regions of the genome ( > 0.3 FPKM) were divided into 30 different 
bins based upon expression levels of lowest to highest (Table 2.10 and Table 2.11). For 
each bin, we determined the number of observed L1 retrotransposition events as 
compared to the weighted random dataset of 10,000 iterations (box plots). We observe 
as many L1 insertions as expected by the weighted random dataset in HeLa and hESCs. 
In NPCs we observe more insertions than expected at low expression in bin 2 (χ2 p-
value < 0.05). We observe more L1 insertions in PA-1s at lower expressed regions of 
the genome (bin 1 χ2 p-value: < 0.05; bin2 χ2 p-value: < 0.0001; bin 4 χ2 p-value: < 1 x 
10-6). We also observe significantly less PA-1 L1 insertions in more highly expressed 











Figure 2.13: LINE-1 is dispersed throughout the genome (Supporting Figure 2.3).   
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Figure 2.14: Engineered insertions are dispersed throughout the human genome 
(Supporting Figure 2.3B).  
A) Engineered HeLa insertions are dispersed throughout the human genome: Horizontal 
blue lines represent locations of mapped HeLa insertions throughout the human 
genome. 
 B) Engineered NPC insertions are dispersed throughout the human genome: Horizontal 
green lines represent locations of mapped engineered NPC insertions. 
 C) Engineered hESC insertions are dispersed throughout the human genome: 





Figure 2.14: Engineered insertions are dispersed throughout the human genome 
(Supporting Figure 2.3B).  
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Figure 2.15: Endogenous LINE-1s in the human genome.  
A) Young L1 insertions are within AT-rich regions of the genome: For every LINE-1  and 
L1Hs sequence identified by RepeatMasker in the GRCh37/hg19 human genome 
reference, we examined different windows sizes upstream and downstream of the 
annotated integration site. In general, younger, L1Hs sequences are in AT-rich regions 
as compared to older L1s.  
B) Counts of L1 events in the genome are correlated with chromosome size: 
Endogenous LINE-1 insertions found in the human genome were plotted based on 
insertion count (y-axis) and chromosome size (x-axis).  Chromosomes were plotted left 
to right by size. In general more insertions are found on larger chromosomes. As 








Figure 2.16: LINE-1 does not target transcribed regions of the genome 
(Supporting Figure 2.4).  
A) Higher rate of transcription negatively influences integration sites: Transcribed 
regions of the genome were divided into 30 roughly equally sized bins (Table 2.9). 
Boxplots represent the range of observations from the 10,000 iterations of the weighted 
random datasets. In the left graph, blue squares represent the observed HeLa insertion 
counts in each transcriptional bin. From left to right, the rate of transcription increases in 
each bin. In the graph on the right, red squares represent the observed PA-1 insertion 
counts in each bin. Asterisks mark statistically significant differences observed between 
the sample insertion counts and the weighted random dataset (HeLa: bin 2 χ2 p-value: < 
0.05; PA-1: bin 1 χ2 p-value < 0.01; bin 2 χ2 p-value < 0.0001; bin 3 χ2 p-value < 1 x 10-
6; bin 4 χ2 p-value < 1 x 10-5; bin 26 χ2 p-value < 0.01; bin 28 χ2 p-value < 0.01; bin 29 χ2 
p-value < 1 x 10-6; bin 30 χ2 p-value < 1 x 10-5). 
B) Calculating transcription bias throughout the genome: Depicted is a screenshot of the 
MIBrowser depicting Bru-seq data for HeLa cells on chr1. Bias is calculated as the 
RPKM expression of the top strand minus the bottom strand of a region in the genome 
over the sum total expression of both strands. The gene CCNL2 (leftmost red rectangle) 
is expressed from the bottom strand and since there is no other gene present 
expressed from the top strand, the genome transcription Bias is -1.  For the region of 
the genome containing RP3-758J18 (leftmost green rectangle) expressed on the top 
strand and MRPL20 and RN7SL657P, both expressed from the bottom strand, the Bias 
is -0.62 as there is more transcription from the bottom strand in the genome.  Finally, 
since there is only transcription from the top strand where RP4-758J18.13 is located, 
the bias is 1. 
C) Interpreting CDF plots of transcription bias: Drawn here are hypothetical cumulative 
distribution function (CDF) plots for transcription bias data when looking at L1 insertions 
in which EN cleavage occurred on the top (top plot) or bottom strands (bottom plot) in 
the genome. Gray lines represent expectations from the uncorrected weighted model 
simulated data expectations, and the red line represents the corrected model 
distribution. If the L1 EN strictly prefers cleavage on the coding strand, we expect to 
observe an exaggerated trend in the data as shown by the dotted navy line, but if the 
EN strongly favors cleaving the noncoding strand then we expect to observe the dotted 
light blue line distribution. 
D) L1 EN shows a slight preference for cleavage of coding strand during transcription: 
L1 insertions were first subdivided into two groups; insertions in which EN cleavage 
occurred on the top strand of the genome, or insertions in which EN cleavage occurred 
on the bottom strand of the genome. For each group we plotted the cumulative 
distribution function (CDF) for insertions based on Transcription Bias values (x-axis). 
HeLa insertions show a significant (Kolmogorov-Smirnov bootstrap test p-value < 0.05) 
trend towards favoring EN cleavage on the coding strand. Only PA-1 insertions in which 
EN cleavage occurred on the top strand show a significant preference (Kolmogorov-
Smirnov boot strap test p-value < 0.01) for EN cleavage on the coding strand.  
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Figure 2.16: LINE-1 does not target transcribed regions of the genome 
(Supporting Figure 2.4).  
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Figure 2.17: MLV integration preference in the human genome (Supporting 
Information for Figure 2.5).  
A) MLV integration sites show enrichment in promoter and transcribed regions of the 
genome:  We randomly selected 27,777, MLV integration events in K562 from LaFave 
et al. (2014), a count equal to the number of observed PA-1 L1 insertion events. This 
analysis shows that given a sample size equivalent to that of our PA-1 integration 
events for a dataset with chromatin state enrichment, we should be able to detect such 
trends. 
 B) Distinct MLV ‘hotspots’ in the human genome: Using the same dataset in 2.16A, the 
downgraded MLV integration dataset containing the same number of events as in our 
PA-1 L1 integration dataset, plotting MLV integration spots (black horizontal lines) on 
the chromosomal ideogram shows distinct clustering of deep black, indicating ‘hotspot’ 




Figure 2.17: MLV integration preference in the human genome (Supporting 
Information for Figure 2.5).  
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Figure 2.18: L1 is not enriched in any specific chromatin state (Supporting Figure 
2.5).  
We compared our insertions datasets to the Roadmap Epigenomic Consortiums’ 
Hidden Markov Modeled 18 chromatin states.  The most comparable cell type is shown 
in the leftmost column for each heat map. Each box shows enrichment for the insertion 
dataset across the different cell types. For visual comparison of strong enrichment we 
included the MLV integration events in K562 cells (LaFave et al., 2014). In general, 










Figure 2.19: Replication influences L1 integration in the human genome 
(Supplemental Information for Figure 2.6).  
A) EN cleavage preference for lagging strand template cleavage: For all four cell types, 
insertions were subdivided into two different groups, insertions in which the EN cleaved 
the bottom strand and insertions in which the EN cleaved the top strand. Plots for 
bottom strand cleaved insertions that are shifted towards the left show preference for 
cleavage on the lagging strand template. Plots for top strand cleavage which are shifted 
towards the right, show a preference for cleavage of the lagging strand template. All 
plots except hESC insertions cleaved on the top strand show a significant shift towards 
L1 EN cleavage favoring the lagging strand template. While these plots show significant 
difference from the corrected model, insertion sets are not showing an overly 
exaggerated bias towards lagging strand template cleavage (Kolmogorov-Smirnov boot 
strap test P-values: HeLa Bottom: < 1x10-6; HeLa Top: < 0.05; PA-1 Bottom and Top: < 
1x10-6; NPC Bottom and Top: < 0.001; hESC Bottom: < 0.05). 
B) L1 EN shows slight preference for cleavage at replication fork initiation sites in HeLa 
and hESC:. Cumulative distribution function plots are shown for insertions based on 
replication fork direction (RFD) slope.  A negative slope value indicates a preference for 
replication fork termination in the genome, while a positive slope indicates a preference 
for replication fork initiation. While all insertion datasets significantly differ from the 
corrected model distribution, the trend observed display a preference for areas of the 
genome between initiation and termination of forks in both PA-1s and NPCs. HeLa and 
hESCs insertions display less or near similar amounts of insertions near termination of 
forks, and then less insertions in the ‘between’ phase, and more insertions climbing 
towards replication fork initiation sites than the corrected model. Kolmogorov-Smirnov 




Figure 2.19: Replication influences L1 integration in the human genome 
(Supplemental Information for Figure 2.6).  
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Figure 2.20: Verifying calling algorithm.  
To determine the accuracy of our calling algorithm for defining reads at base pair 
resolution, we randomly selected 100,000 ungapped, locations in the genome. The 
length of the sequence followed the distribution of CCS read lengths we observed with 
our actual sequenced data (Figure 2.7D). We then attached a 5’ poly(A) tract to these 
reads that mimicked the length of poly(A) tails observed in our L1 insertion dataset 
(Figures 2.1G and 2.7F). These random sequences were mapped to the GRCh37/hg19 
genome reference with Bowtie2 under the same conditions of our insertion data (Figure 
2.7A) and then we determined the best mapped read location if possible. Further 
refinement of the site to base pair resolution was completed using the Smith Waterman 
algorithm. We accurately called 97,748 of these 100,000 reads, but were unable to 
identify the best mapping location for 2,136 of the reads, and we incorrectly called 116 












Figure 2.21: Generation, alignment, and filtering scheme for RNA-seq data.  
For each cell type we collected two biological replicates of total RNA. A Ribo-Zero rRNA 
Removal Kit was performed to remove cytoplasmic ribosomal RNA. Samples were then 
library prepped with the Illumina TruSeq Stranded RNA-seq Kit. One set of biological 
replicates was sequenced with the Illumina HiSeq at 100bp paired-end reads, while the 
other biological set was Illumina HiSeq sequenced at 125bp paired-end reads.  
Following sequencing, reads were aligned to the GRCh37/hg19 genome reference with 
Tophat. Reads were then assembled with Cufflinks to get transcripts and isoforms. 
Then Cuffmerge was used to create the final transcription assembly using the 
ENSEMBL assembly as a guide. Cuffquant then quantified gene and transcript 
expression in terms of FPKM. We then merged biological replicates and normalized all 










Figure 2.22: Slight enrichment in enhancers is not associated with low GC 
content.   
HeLa insertions appear to be somewhat enriched in enhancer states and bivalent 
enhancers, while hESC insertions also appear enriched in enhancer states in the 
Encode’s 15 chromatin state (Figure 2.5). We were curious to explore if these states are 
correlated with being AT-rich.  In general this enhancer and bivalent enhancer states 
are not the most AT-rich.  Similarly, in Encode’s 18 chromatin state analysis HeLa 
insertions appear enriched in enhancer states (EnhA1, EnhA2, EnhWk) as well, while 
hESC insertions appear enriched in some enhancer states (EnhA2, EnhWk) and 
repeats.  These states are near the genome average GC content, suggesting that any 




Figure 2.22: Slight enrichment in enhancers is not associated with low GC 










Figure 2.24 Slight enrichment in enhancers is not associated with low GC content. 
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Figure 2.23: Super enhancers and typical enhancers are not highly enriched for 
L1 insertions.   
A) HeLa and hESC insertions are not enriched in super and typical enhancers: Gray 
boxes represent less than 30 insertions found within a given condition, and which may 
result in false enrichment or depletion measurements. There was no H9 hESC dataset 
of super and typical enhancers available so we compared our hESC insertions to the H1 
hESC dataset of super and typical enhancers and find that our hESC insertions are 2.48 
times enriched in typical enhancers. This enrichment is minimal when compared to 
enrichment levels observed with MLV integration events. Furthermore, we observe little 
enrichment of HeLa insertions in super and typical enhancers.  Thus, hESC and HeLa 
insertion are not preferentially integrating within super and typical enhancers. 
B) Super and Typical Enhancers are as GC-rich as average genomic levels: We 
examined the average GC-content of super and typical enhancers to determine if these 
regions of the genome are in overly AT-rich regions of the genome. Super and typical 
enhancers of H1 hESC and HeLa cells are slightly above average genomic GC content 


















Figure 2.23: Super enhancers and typical enhancers are not highly enriched for 






Table 2.1: Independent HeLa samples and contribution to final dataset.   
Seven independent retrotransposition assays were performed and after completion of 
the assay gDNA was collected from all. Independent sample names are found in 
column 1, date/s in which the sample was submitted for PacBio sequencing is marked 
in column 2, selection or screening performed on the sample is listed in column 3 and 
the proportion of total insertions of the final dataset that this sample comprised is found 
in column 4. All samples except HGFP4 were transfected with pJM101/L1.3 and 
retrotransposition events were selected in the presence of Neomycin.  HGFP4 was 
















H1014 7.15.13 Neo 12.76% 
H1015 7.15.13 Neo 2.13% 
H1017 7.15.13 Neo 15.58% 
H1019 11.13.13 Neo 46.96% 
HJM101 7.15.13 Neo 2.50% 
HGFP4 (LRE3) 11.26.13 GFP  0.93% 
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Table 2.2: Independent PA-1 samples and contribution to final dataset.   
Independent sample names are found in column 1, date/s in which the sample was 
submitted for PacBio sequencing is marked in column 2, selection or screening 
performed on the sample is listed in column 3 and the proportion of total insertions of 
the final dataset that this sample comprised is found in column 4. All PA-1 samples 
were transfected with pCEP4/LRE3-mEGFPI. Samples PL5, PL6, PL7, and PL8 were 
selected for transfected cells in the presence of puromycin as the pCEP4/LRE3-
mEGFPI contains a puromycin resistance. The rest of the PA-1 samples were screened 
for GFP positive cells that represent de novo L1 retrotransposition events.   
  











PL5 7.17.13 Puro 0.03% 
PL6 7.17.13 Puro 0.51% 
PL7 7.17.13 Puro 0.06% 
PL8 7.17.13 Puro 1.35% 
PGFP 7.30.13 GFP 27.78% 
PGFP2 7.30.13 GFP 2.21% 
PGFP3 8.2.13; 7.30.13 GFP 1.90% 
PGFP4 11.13.13 GFP 5.70% 
PGFP6 11.13.13 GFP 25.54% 
PGFP7 11.13.13 GFP 9.87% 
PGFP8 11.26.13 GFP 20.06% 
PGFP9 11.26.13 GFP 4.99% 
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Table 2.3: Independent NPC samples and contribution to final dataset.  
Independent sample names are found in column 1, date/s in which the sample was 
submitted for PacBio sequencing is marked in column 2, selection or screening 
performed on the sample is listed in column 3 and the proportion of total insertions of 
the final dataset that this sample comprised is found in column 4. NPCs were 
transfected with pCEP99/UB-LRE3-mEGFPI and transfected cells were selected in the 
presence of puromycin. NPC-RA and NPC-RA2 are NPC samples that were transfected 






















NPC 2.20.14 Puro 1.87% 
NPC1 5.7.14 Puro 3.16% 
NPC-RA 11.18.13 Differentiated 4.10% 
NPC-RA2 2.20.14 Differentiated 0.70% 
NPC5 10.2.14 Puro 0.72% 
NPC74 10.2.14 Puro 0.43% 
NPC125 5.27.15 Puro 26.81% 
NPC172 5.14.15 Puro 43.14% 
NPC183 5.14.15 Puro 19.07% 
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Table 2.4: Independent hESC samples and contribution to final dataset.  
Independent sample names are found in column 1, date/s in which the sample was 
submitted for PacBio sequencing is marked in column 2, selection or screening 
performed on the sample is listed in column 3 and the proportion of total insertions of 
the final dataset that this sample comprised is found in column 4. All hESC samples 
were transfected with pKUB102/L1.3-sv+ and selected for retrotransposition events in 
the presence of neomycin. 
  












hESC1 5.27.14 Neo 13.86% 
hESC2 5.27.14 Neo 6.75% 
hESC4 12.6.13 Neo 4.18% 
hESC5 12.9.13 Neo 3.36% 
hESC96 10.2.14 Neo 28.42% 
hESC03 1.14.16 Neo 2.96% 
hESC06 12.17.15 Neo 8.79% 
hESC09 1.22.16 Neo 3.57% 
hESC10 1.14.16 Neo 2.87% 
hESC15 10.3.14 Neo 25.24% 
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Table 2.5: Top 20 weighted 7mers for uncorrected and corrected models.   
In the corrected model (right) observed 7mer frequencies are corrected for the 
frequency of the 7mer in the human genome. This correction is not made in the 
uncorrected model (left). The final top 20 model weights of the uncorrected and top 21 
model weights of corrected model are shown. In the uncorrected model the perfect EN 
cleavage is given the highest weight of 1, while in the corrected model a variant of the 
sequence, 5’-TTTTCAA is given the highest weight of 1. Since 5’-TTTTT/AA is the most 
prevalent 7mer in the human genome, when ‘correcting’ 7mer frequencies with the 
frequency of the 7mer in the genome, the perfect EN consensus cleavage site becomes 
the 21st highest weighted 7mer.  
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Table 2.6: L1 insertions in conserved regions of the human genome.  
We identified endogenous LINE-1s and endogenous L1Hs sequences in the human 
genome with RepeatMasker and determined how many of these insertions are found 
within ultra-conserved (Bejerano et al., 2004), ultra-conserved noncoding (McCole et al., 
2014), and transposon free regions (Simons et al., 2006) of the genome (columns).  
Additionally we examined whether we identified any engineered L1 insertions within 
these areas of the genome (rows). Engineered L1 insertions were identified in all three 
examined regions of the genome while endogenous L1s are absent or barely identified 
within these regions of the genome. Indeed this indicates that these regions of the 




















Endogenous L1s in Human Genome 
L1s 0 1 500 951,780 
L1Hs 0 0 0 1,544 
Engineered L1 Insertions 
HeLa 4 11 453 21,497 
PA-1 4 13 496 27,777 
NPC 2 3 199 12,223 
hESC 1 2 134 3,582 
Engineered L1 Insertions in FANCD2 Deficient Cells 
PD20FD2 + L1.3 0 2 76 4,372 
L1.3 0 7 339 18,124 
L1.3/D205A 0 1 21 1,514 
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Table 2.7: Majority of L1 insertions are not within DNase I hypersensitive sites in 
the genome.  
We explored both broad and narrow peak (column 2) DNase I hypersensitive site 
datasets from ENCODE (column 1) and determined the genomic coverage of the 
DNase I sites in the genome (column 3) and the proportion (column 4) and number of 
insertions (column 5) we identified in each dataset as compared to the weighted random 
dataset min (column 6), median (column 7) and observed max (column 8). While there 
are certainly more HeLa and hESC insertions within DNase I hypersensitive sites than 
expected based upon the presence of the EN consensus cleavage site, a small portion 
of the total insertions are located within these sites. Thus, DNase I hypersensitive sites 
are not primarily targeted L1 integration sites in the human genome. This observation 























Min Median Max 
hESC 
ENCFF495NIW Broad 1.27% 3.38% 121 7 23 42 
ENCFF552URI Narrow 0.61% 2.04% 73 1 10 23 
HeLa 
ENCFF792CTF Broad 2.11% 3.62% 779 260 327 402 




Table 2.8: Details of two biological replicate RNA-seq runs.  
The number of Illumina HiSeq reads (column 2) obtained for each cell type (column 1), 
and the percentage of those reads that contained perfect index reads (column 3), as 
well as the percentage of reads that contained a quality score above 30 (column 4) and 
the mean quality score of all the reads (column 5) is shown in the tables. Each table 









Biological Replicate 1; 190bp target insert size, 100PE 





 91,023,978 98.82 89.6 35.43 
PA-1 56,386,346 98.44 89.3 35.36 
H9 94,446,704 98.86 89.32 35.37 
NPC 107,465,106 98.45 90.65 35.78 
Biological Replicate 2; 190bp target insert size, 125PE 





86,945,121 98.68 84.9 34.48 
PA-1 68,422,258 97.71 85.29 34.57 
H9 70,103,961 98.01 85.94 34.69 
NPC 84,313,027 98.26 85.15 34.66 
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Table 2.9: Transcription bin thresholds (Supporting Figure 2.16A). 
The left table provides the range of RPKM thresholds of Bru-seq data for the HeLa 
(hela0h1) sample.  The right table provides the range of RPKM threshold of Bru-seq 
data for the PA-1 (PA10h1) sample. The first column indicates the bin number as on the 
corresponding graph in Figure 2.16A. The second column indicates the maximum 
RPKM threshold of the bin. The minimum threshold would be above the previous bin’s 
threshold.  The third column indicates the number of base pairs in the genome that lie 





Value of Bin 
Genomic bps 
Coverage in bin 
1 0.024781606 34080481 
2 0.02818962 34086000 
3 0.03241205 34111130 
4 0.03848944 34067000 
5 0.047122262 34087723 
6 0.079979682 34081777 
7 0.107857 34008729 
8 0.129406256 34095000 
9 0.15020497 33883000 
10 0.1752554 33999000 
11 0.21069716 34123000 
12 0.253964101 34094158 
13 0.38129427 34065512 
14 0.45586647 34069000 
15 0.522449 34097000 
16 0.574950644 34095000 
17 0.637818 34183000 
18 0.696108 34107727 
19 0.7608266 34087000 
20 0.831118902 34078000 
21 0.91805 34091000 
22 1.184538924 34158000 
23 1.319869 34087000 
24 1.467176754 34133000 
25 1.642058919 34102000 
26 1.8294586 34091000 
27 2.124498636 34091000 
28 2.52164266 34090000 
29 3.58425 34117000 
30 2768.753 34213000 






Value of Bin 
Genomic bps 
in bin 
1 0.0285259 35176137 
2 0.0323187 35166174 
3 0.037394081 35187892 
4 0.044066909 35215468 
5 0.0580608 35209000 
6 0.09536488 35197951 
7 0.120273362 35174000 
8 0.140583099 35198935 
9 0.162625292 35171126 
10 0.185052869 35193000 
11 0.2166588 35152000 
12 0.3094766 35189000 
13 0.382980925 35172000 
14 0.43955916 35220960 
15 0.503519 35172000 
16 0.564641 35251000 
17 0.61669445 35190000 
18 0.677942 35191000 
19 0.734481888 35213000 
20 0.803848065 35214000 
21 0.899497099 35194000 
22 1.210994053 35184000 
23 1.3515564 35174000 
24 1.501154 35149000 
25 1.67440847 35150000 
26 1.869549112 35195000 
27 2.13061279 35252000 
28 2.478356 35185000 
29 3.14265245 35184000 
30 3539.517 35162000 
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Table 2.10: RNA-seq bin thresholds (Supporting Figure 2.13C). 
The minimum FPKM threshold is 0.3. The left table provides the range of FPKM 
thresholds of RNA-seq data for HeLa cells, and the right table provides the FPKM 
thresholds for PA-1 cells. The first column indicates the bin number as on the 
corresponding graph in Figure 2.13C. The second column indicates the maximum 
FPKM threshold for the given bin. The third column shows the number of genomic base 






Value of Bin 
Genomic bps 
in bin 
1 0.499896 33094138 
2 0.759631 33099809 
3 1.279752415 33062286 
4 1.712661 33075321 
5 2.356952596 33181107 
6 2.966676343 33209054 
7 3.788838638 32945089 
8 4.622322347 33160888 
9 5.589120453 33120856 
10 6.487361619 33103467 
11 7.489477415 33056034 
12 8.505062 33136218 
13 9.641971238 33115496 
14 11.05339728 33123585 
15 12.65272247 33102850 
16 13.87764743 33005912 
17 15.33025967 33135676 
18 17.18377703 33105114 
19 19.38723312 33119129 
20 21.70851967 33186671 
21 24.62518039 33118869 
22 28.7845 33097011 
23 32.50899315 33100540 
24 37.74997663 33121347 
25 45.59394941 33166090 
26 56.49152152 33127500 
27 73.60984483 33065727 
28 105.5027538 33116965 
29 220.9436737 33099818 
30 1036720 32873081 
Bin 




1 0.45842034 35934011 
2 0.746659396 35642246 
3 1.101606055 36149574 
4 1.607600998 36153537 
5 2.079394 35956776 
6 2.673266718 35998435 
7 3.235764195 36018154 
8 4.016335018 35919118 
9 4.728476001 35976914 
10 5.633175866 35992354 
11 6.653097026 35937464 
12 7.676101892 35908051 
13 8.688693047 35949061 
14 9.95716434 35944878 
15 11.19146983 35784585 
16 12.41333181 36085877 
17 13.68018476 36384758 
18 14.998743 36001246 
19 16.95349403 35964887 
20 19.3292167 35931436 
21 21.62713492 35984487 
22 24.45868869 35856917 
23 28.27377022 35743233 
24 32.3982754 35950149 
25 38.3289205 35898208 
26 48.14190217 35911705 
27 61.89892384 35933491 
28 84.4693149 35956411 
29 175.4542595 35914709 




Table 2.11: RNA-seq bin thresholds (Supporting Figure 2.13C). 
The min FPKM threshold is 0.3. The left table provides the range of FPKM thresholds of 
RNA-seq data for NPC cells, and the right table provides the FPKM thresholds for hESC 
cells. The first column indicates the bin number as on the corresponding graph in Figure 
2.13C. The second column indicates the max FPKM threshold for the given bin. The 
third column shows the number of genomic base pairs that lie within the range of that 





FPKM Max Value 
of Bin 
Genomic 
bps in bin 
1 0.459709 38102677 
2 0.664583 38115969 
3 1.014338781 38131130 
4 1.458215479 37959868 
5 2.02636 38097369 
6 2.782311842 38098060 
7 3.61710834 38148378 
8 4.525517692 38121636 
9 5.41829 37860522 
10 6.375903015 38146209 
11 7.420902807 38029917 
12 8.41578093 38102873 
13 9.5762255 38224419 
14 10.7959509 38131137 
15 12.06247006 38047218 
16 13.5318039 38195782 
17 15.14749386 37980459 
18 16.81769472 38173138 
19 18.62876403 38194791 
20 21.01211626 37967876 
21 23.46602993 37735702 
22 26.39131809 38146580 
23 30.1539223 38121118 
24 33.87719404 38062299 
25 40.6624096 38074312 
26 51.22123669 37923409 
27 64.99839231 38213587 
28 93.5016082 38034312 
29 216.4132872 38429031 
30 1145440 38880418 
Bin 




1 0.431395542 43997452 
2 0.630456722 43967342 
3 0.870761 43947446 
4 1.164081041 43886877 
5 1.547452239 43930214 
6 1.993006924 44128554 
7 2.536438385 44085027 
8 3.1386812 43916130 
9 3.748654263 44040110 
10 4.411615 44127543 
11 5.18653511 43969049 
12 6.088857721 43976535 
13 7.01823 43968868 
14 7.96448552 44118426 
15 9.228033328 43996549 
16 10.2992229 44048143 
17 11.54539791 44053523 
18 12.97345806 44020200 
19 14.66226967 43986962 
20 16.36990668 44001391 
21 18.49413867 43909177 
22 20.72052294 43927822 
23 23.56412733 44073132 
24 27.108519 43969626 
25 31.8956 43938978 
26 39.5475551 43983553 
27 50.61908632 44035490 
28 72.74626068 44077849 
29 155.329 43975599 




Table 2.12: LINE-1 insertions validated by independent PCRs.  
Sanger Sequence read show results of independent validation PCRs. The L1 sequence 
(5’ to 3’) is shown in black, including the poly(A) tail, and the flanking 3’ gDNA is shown 
in blue. The listed PacBio CCS read IDs that support this insertion are shown and the 

















CCS read IDs: 
200442:1012058-200442:1013625-200442:1069288-205247:1009755-
205247:1061356-205247:1140523
*CCS reads predicted 27, 28, 33bp poly-A tail














*CCS poly A call 33bp 
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Table 2.12: LINE-1 insertions validated by independent PCRs (continued). 
 



















*CCS poly-A tail call 71bp


















*CCS call poly A-tail call 71,76,77,78
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Table 2.13: Independent validation PCR primer sequences. 
Column one indicates the primer name used in independent validation PCRs and 
column 2 lists the primer sequence 5’ to 3’. 
  



















Table 2.14: Engineered L1 insertions in repetitive sequences in the human 
genome.  
Column 1 indicates the repetitive sequences in the human genome that were tested for 
integration either, SINES or LINES. Coordinates for repetitive sequences are those 
provided by RepeatMasker. For each sample, we then counted the number and 
proportion of total insertions (provided in parentheses) found within known SINE and 




































Table 2.15: NPC DAVID results against the human genome (highest stringency). 
Listed are the DAVID Results when testing all genic NPC insertions (UTRs, exonic, or 
intronic) as compared to the human genome. Column 1 lists the Annotation Clusters. 
Column 2 shows the enrichment score for a cluster as well as the key words.  Column 3 
indicates the number of insertions within each group. Column 4 shows the p-value of a 
modified Fisher’s exact test (EASE score), and the multiple testing corrected Benjamini 




Table 2.15: NPC DAVID results against the human genome (highest stringency). 
 
 
Annotation Cluster 1 Enrichment Score: 13.16 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Fibronectin type-III 3 39 2.4E-15 4.7E-12
UP_SEQ_FEATURE domain: Fibronectin type-III 1 49 3.6E-14 5.2E-11
UP_SEQ_FEATURE domain: Fibronectin type-III 2 48 1.2E-13 1.1E-10
SMART FN3 54 2.2E-12 9.9E-10
Annotation Cluster 2 Enrichment Score 12.73 Count P_Value Bejamini
UP_KEYWORDS ATP-binding 246 5.8E-15 3.8E-13
UP_KEYWORDS Nucleotide-binding 294 1.3E-13 7.4E-12
GOTERM_MF_DIRECTATP binding 257 8.7E-12 1.3E-08
Annotation Cluster 3 Enrichment Score 8.27 Count P_Value Bejamini
UP_KEYWORDS Transmembrane 747 1.1E-10 4.9E-09
UP_KEYWORDS Transembrane helix 744 1.5E-10 5.6E-09
UP_SEQ_FEATURE transmembrane region 668 3.0E-08 1.5E-05
GOTERM_CC_DIRECTintegral component of membrane 678 1.7E-06 1.6E-04
Annotation Cluster 4 Enrichment Score: 7.29 Count P_Value Bejamini
INTERPRO Protein kinase, catalytic domain 102 7.8E-10 2.7E-07
UP_KEYWORDS Serine/threonine-protein kinase 84 2.3E-09 6.0E-08
UP_SEQ_FEATURE domain: Protein kinase 97 4.5E-09 2.9E-06
INTERPRO Protein kinase-like domain 106 5.6E-09 1.5E-06
INTERPRO Protein kinase, ATP binding site 80 5.5E-08 1.4E-05
UP_SEQ_FEATURE binding site: ATP 105 6.2E-08 2.1E-05
GOTERM_MF_DIRECTprotein serine/threonine kinase activity 80 6.5E-08 3.3E-05
INTERPRO
Serine/threonine-protein kinase, active 
site 66 6.8E-07 1.3E-04
SMART S TKc 79 2.7E-06 2.1E-04
UP_SEQ_FEATURE active site: Proton acceptor 113 6.2E-06 1.1E-03
Annotation Cluster 5 Enrichment Score: 5.93 Count P_Value Bejamini
UP_SEQ_FEATURE domain: AGC-kinase C-terminal 23 4.3E-08 2.1E-05
INTERPRO AGC-kinase, C-terminal 22 3.1E-07 6.3E-05
SMART S_TK_X 18 1.2E-04 5.0E-03
Annotation Cluster 6 Enrichment Score 5.68 Count P_Value Bejamini
UP_SEQ_FEATURE domain: PH 56 2.3E-07 7.2E-05
INTERPRO Pleckstrin homology domain 59 1.1E-06 1.8E-04
SMART PH 59 3.7E-05 1.9E-03
Annotation Cluster 7 Enrichment Score 5.66 Count P_Value Bejamini
UP_KEYWORDS SH3 domain 51 1.6E-07 2.9E-06
INTERPRO Src homology-3 domain 50 1.7E-06 2.6E-04
UP_SEQ_FEATURE domain:SH3 42 2.4E-06 5.3E-04
SMART SH3 49 3.6E-05 2.0E-03
Annotation Cluster 8 Enrichment Score 5.65 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Ig-like C2-type 3 35 8.5E-07 2.2E-04
UP_SEQ_FEATURE domain: Ig-like C2-type 1 46 3.4E-06 7.2E-04
UP_SEQ_FEATURE domain: Ig-like C2-type 2 46 3.9E-06 8.0E-04
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Annotation Cluster 9 Enrichment Score 5.59 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Fibronectin type-III 6 17 5.2E-08 2.0E-05
UP_SEQ_FEATURE domain: Fibronectin type-III 8 13 4.3E-06 8.5E-04
UP_SEQ_FEATURE domain: Fibronectin type-III 7 13 4.3E-06 8.5E-04
UP_SEQ_FEATURE domain: Fibronectin type-III 9 10 4.7E-05 6.9E-03
Annotation Cluster 10 Enrichment Score: 5.19 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Laminin G-like 4 11 4.9E-07 1.4E-04
UP_SEQ_FEATURE domain: Laminin G-like 3 12 2.0E-06 4.5E-04
UP_SEQ_FEATURE domain: Laminin G-like 1 13 4.2E-05 6.5E-03
UP_SEQ_FEATURE domain: Laminin G-like 2 13 4.2E-05 6.5E-03
Annotation Cluster 11 Enrichment Score: 5.09 Count P_Value Bejamini
GOTERM_MF_DIRECTionotropic glutamate receptor activity 11 6.9E-07 2.6E-04
INTERPRO Ionotropic glutamate receptor 11 6.1E-06 7.6E-04
INTERPRO
Glutamate receptor, L-
glutamate/glycine-binding 11 6.1E-06 7.6E-04
INTERPRO NMDA receptor 11 6.1E-06 7.6E-04
GOTERM_MF_DIRECT
extracellular-glutamate-gated ion 
channel activity 11 7.2E-06 1.8E-03
SMART PBPe 11 2.3E-05 1.5E-03
SMART SM00918 11 2.3E-05 1.5E-03
GOTERM_BP_DIRECT
ionotropic glutamate receptor signaling 
pathway 12 3.1E-05 1.6E-02
Annotation Cluster 12 Enrichment Score: 4.65 Count P_Value Bejamini
INTERPRO P-type ATPase, cytoplasmic domain N 15 1.8E-05 1.8E-03
INTERPRO Cation-transporting P-type ATPase 15 1.8E-05 1.8E-03
INTERPRO P-type ATPase, phosphorylation site 15 1.8E-05 1.8E-03
INTERPRO P-type ATPase, A domain 15 1.8E-05 1.8E-03
UP_SEQ_FEATURE
active site:4-aspartylphosphate 




Table 2.15 (continued) 
 
Annotation Cluster 13 Enrichment Score: 4.46 Count P_Value Bejamini
INTERPRO
Dynein heavy chain, P-loop conaining 
D4 domain 10 7.8E-06 9.1E-04
INTERPRO Dynein heavy chain, colied coil stalk 10 1.6E-05 1.7E-03
INTERPRO Dynein heavy chain, domain-2 10 1.6E-05 1.7E-03
INTERPRO Dynein heavy chain domain 10 1.6E-05 1.7E-03
INTERPRO Dynein heavy chain 10 1.6E-05 1.7E-03
UP_SEQ_FEATURE region of interest: AAA 6 9 1.7E-05 2.9E-03
UP_SEQ_FEATURE region of interest: AAA 5 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: AAA 4 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: Stalk 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: AAA 1 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: AAA 3 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: AAA 2 9 3.6E-05 5.9E-03
UP_SEQ_FEATURE region of interest: Stem 8 3.4E-04 3.6E-02
UP_KEYWORDS Dynein 12 5.0E-04 5.0E-03
Annotation Cluster 14 Enrichment Score: 3.86 Count P_Value Bejamini
UP_SEQ_FEATURE domain: FERM 17 4.6E-05 6.8E-03
INTERPRO Band 4.1 domain 17 9.9E-05 8.7E-03
INTERPRO FERM central domain 17 9.9E-05 8.7E-03
INTERPRO FERM domain 17 9.9E-05 8.7E-03
INTERPRO
FERM/acyl-coA-binding protein, 3-
helical bundle 16 2.8E-04 2.0E-02
SMART B41 17 5.3E-04 1.9E-02
Annotation Cluster 15 Enrichment Score: 3.83 Count P_Value Bejamini
INTERPRO PDZ domain 36 4.4E-05 4.1E-03
UP_SEQ_FEATURE domain:PDZ 27 2.2E-04 2.5E-02
SMART PDZ 36 3.3E-04 1.3E-02
Annotation Cluster 16 Enrichment Score: 3.51 Count P_Value Bejamini
UP_SEQ_FEATURE domain: EGF-like 7 12 1.1E-04 1.4E-02
UP_SEQ_FEATURE domain: EGF-like 6 15 1.8E-04 2.2E-02
UP_SEQ_FEATURE domain: EGF-like 5 13 1.5E-03 1.2E-01
Annotation Cluster 17 Enrichment Score: 3.45 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Collagen-like 1 9 2.2E-04 2.4E-02
UP_SEQ_FEATURE domain: Collagen-like 2 9 2.2E-04 2.4E-02
UP_SEQ_FEATURE domain: Collagen-like 3 7 9.4E-04 8.3E-02
Annotation Cluster 18 Enrichment Score: 3.36 Count P_Value Bejamini
UP_SEQ_FEATURE domain: Fibronectin type-III 12 7 2.6E-04 2.8E-02
UP_SEQ_FEATURE domain: Fibronectin type-III 11 7 5.2E-05 5.1E-02
UP_SEQ_FEATURE domain: Fibronectin type-III 10 7 5.2E-04 5.1E-02
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     Chapter 3 
The Influence of the ATR and FANCD2 DNA Repair Proteins  
on L1 Integration Preferences in the Human Genome 
Dr. Huira Kopera, in the laboratory of Dr. John V. Moran, performed the ATR 
knockdown, GFP knockdown, and L1 retrotransposition experiments. Mr. Cesar Lopez-
Ruiz, in the laboratory of Dr. José L. García-Perez, performed FANCD2-deficient L1 
retrotransposition assays. I characterized the resultant L1 retrotransposition events and 
conducted the data analysis on all the samples presented in this Chapter. 
Overview 
Previous studies have demonstrated that human LINE-1s lacking endonuclease 
(L1 EN) activity can retrotranspose by an endonuclease-independent mechanism (L1 
ENi) in cultured cells that contain mutations in genes that render the non-homologous 
end joining (NHEJ) pathway of DNA repair and p53 inactive. As a result, L1 ENi 
retrotransposition events are hypothesized to integrate at endogenous DNA lesions, 
which include dysfunctional telomeres. Here, we explore whether the disruption of DNA 
repair pathways other than NHEJ influence L1 integration in the human genome. First, 
we knocked down the Ataxia telangiectasia mutated and Rad3-Related (ATR) protein in 
HeLa cells, and then tested whether ATR knockdown affects the integration preference 
of engineered L1s. Second, we explored whether the Fanconi anemia (FA) complex 
influences L1 integration. Defects in the FA pathway lead to the accumulation of inter-
strand DNA crosslinks (ICLs) that can interfere with DNA replication. If left unrepaired, 
the resultant DNA lesions can be processed into double-strand DNA breaks, which may 
provide a pathway for enhanced ENi L1 retrotransposition. Third, we also examined 
whether missense mutations in a proliferating cell nuclear antigen (PCNA) interacting 
domain (PIP) affect L1 integration preferences. Our findings suggest that different DNA 
repair factors influence L1 integration in the retrotransposition process. FA proteins can 
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influence initial integration, while ATR and possibly interaction with PCNA appears to 
influence the later stages of reverse transcription and integration of the L1.  
Introduction 
A Brief Background about ATR 
Below I provide a brief background about ATR biology and the DNA repair 
response. Notably, the DNA repair response has been thoroughly reviewed by Shiotani 
and Zou (Shiotani and Zou, 2009), and later by Awasthi, Foiani, and Kumar (Awasthi et 
al., 2015).  
The Ataxia telangiectasia mutated and Rad3-related protein (ATR) is a guardian 
of the genome and responds to a broad spectrum of DNA damage, including single-
strand endonucleotyic nicks, double-strand DNA breaks, and DNA damage that 
interferes with DNA replication (Zou, 2007). ATR primarily operates during the S and G2 
phases of the cell cycle (Jazayeri et al., 2006) and plays a critical role in stabilizing the 
genome during DNA replication (Brown and Baltimore, 2003). Additionally, ATR plays a 
key role in the intra-S and G2/M cellular DNA checkpoint pathways (Abraham, 2001). 
ATR is an essential protein and ATR-deficiency leads to cell autonomous lethality within 
a few cell divisions (Brown and Baltimore, 2000).  
ATR recognizes structures that arise as a result of DNA damage or the inhibition 
of DNA replication [e.g., single-strand DNA (ssDNA) and double-stranded DNA 
(dsDNA)/single strand DNA junctions (Shiotani and Zou, 2009)]. For example an 
accumulation of ssDNA can occur at replication forks when DNA polymerase and DNA 
helicase activities become discordant (Byun et al., 2005; Walter and Newport, 2000). 
Additionally, it is believed that common fragile sites represent unreplicated ssDNA 
regions of DNA that are caused by stalled or collapsed replication forks that are a 
consequence of DNA replication inhibition (Casper et al., 2002). Several DNA repair 
mechanisms (e.g., nucleotide excision repair, mismatch repair, and long-patch base 
excision repair) can also induce ssDNA gaps (Friedberg, 2003; Lopes et al., 2006), as 
can the resection of double strand DNA breaks by exonucleases and/or endonucelases 
(Lee et al., 1998).  
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The replication protein A (RPA) complex initially recognizes ssDNA that arises 
during DNA damage (Figure 3.1). The ATR-interacting protein (ATRIP), which interacts 
with ATR, then binds to RPA-coated ssDNA substrates, allowing the localization of the 
ATR-ATRIP complex to sites of DNA damage (Ball et al., 2005; Namiki and Zou, 2006; 
Zou and Elledge, 2003). The full activation of the ATR-ATRIP DNA checkpoint response 
then requires additional ATR regulators, including RAD9, RAD1, and HUS1 (which are 
components of the 9-1-1 complex), and RAD17. RAD17 recruits the 9-1-1 complexes to 
5’ dsDNA/ssDNA junctions that arise upon the resection of double-stranded DNA 
breaks that can arise as a consequence of stalled DNA replication forks (Ellison and 
Stillman, 2003; Majka et al., 2006; Zou and Elledge, 2003). The recruitment of the ATR-
ATRIP and 9-1-1 complexes then stimulates ATR kinase activity at DNA damage sites 
(Kumagai et al., 2006). 
In contrast to the situation by which ATR responds to DNA damage arising during 
DNA replication, the activation of ATR at double-stranded DNA breaks depends on 
another kinase, the Ataxia telangiectasia mutated protein (ATM) (Jazayeri et al., 2006; 
Myers and Cortez, 2006). The MRN complex, which consists of meiotic recombination 
protein 11 (MRE11), RAD50, and Nijmegen breakage syndrome protein 1 (NBS1) is 
one of the first lines of cellular defense that recognizes double-strand DNA breaks. The 
MRN complex then recruits and stimulates ATM kinase activity at double-stranded DNA 
breaks at all phases in the cell cycle (Berkovich et al., 2007; Falck et al., 2005; 
Kitagawa et al., 2004; Lee and Paull, 2005; You et al., 2005). ATM activation then leads 
to the activation of exonuclease and endonuclease activities that function in double-
strand break resection, resulting in the formation of long regions of single-strand DNAs 
at the initial double strand break site in genomic DNA (Jazayeri et al., 2006). The 
resultant single-strand DNA then serves as a substrate for ATR recruitment and its 
subsequent activation (Shiotani and Zou, 2009). 
ATR is a kinase and phosphorylates a number of proteins that play critical roles 
in the ATR DNA damage checkpoint response (e.g., RPA, ATRIP, RAD17, members of 
the 9-1-1 complex, and claspin). The ATR DNA damage checkpoint response  
ultimately leads to cell cycle arrest to ensure that the damaged DNA can undergo DNA 
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repair (Shiotani and Zou, 2009). ATR can also phosphorylate claspin, a protein thought 
to interact with DNA replication forks, in response to DNA damage. Claspin 
phosphorylation initiates a signal transduction cascade, where ATR phosphorylates the 
S-phase checkpoint 1 kinase (CHk1), allowing its dissociation from chromatin (Kumagai 
et al., 2004). The phosphorylated form of the Chk1 kinase can then phosphorylate 
downstream effector proteins that play critical roles in the G1/S and G2/M cell cycle 
transitions (Shiotani and Zou, 2009) 
Previous work in the Moran lab by Dr. Huira Kopera, using retrotransposition 
assays in HeLa cells, demonstrated that ATR knockdown results in 3.5- to 10-fold 
increase in retrotransposition of an engineered wildtype L1 when compared to control 
HeLa cells. Examination of several integration events suggests that ATR knockdown 
results in longer (e.g., increased length) L1 insertions. Furthermore, ATR knockdown 
does not lead to increased L1 ENi retrotransposition. These data suggest that ATR 
knockdown does not lead to substrates that could be utilized as a primer for reverse 
transcription by L1 RT during ENi retrotransposition. 
In collaboration with Dr. Kopera, we tested whether ATR knockdown affects the 
integration preferences of engineered human L1s. We hypothesized that ATR 
knockdown compromises DNA damage sensing within a cell, which may alter the L1 
integration profiles in the genome. Alternatively, ATR may not affect initial integration, 
but instead may respond to retrotransposition intermediates generated during TPRT, 
thereby leading to altered structures of integrated L1s when compared to ATR-proficient 
cells. To discriminate between these possibilities, we sought to identify whether there 
were differences in de novo engineered L1 integration preferences in ATR-proficient vs. 
ATR-deficient cells. More specifically, we sought to determine if the DNA damage 
resulting from the absence of ATR could specifically influence L1 integration. We further 
hypothesized that the knockdown of ATR may render fragile sites, regions associated 
with stalled replication forks, or replication origins ‘hot spots’ for L1 integration. In this 
chapter, I address L1 integration in the human genome when ATR is knocked down, 
and the potential genomic instability that L1 utilizes for integration.  
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A Brief Background on Fanconi Anemia 
Another DNA damage repair pathway involves the Fanconi Anemia (FA) family of 
proteins. Twenty-two FA complementation groups have been identified thus far 
(subtypes A, B, C, D1, D2, E, F, G, I, J, L, M, N, O, P, Q, R, S, T, U, V, and W) (Bogliolo 
et al., 2013; Bogliolo and Surralles, 2015; de Winter et al., 2000a; de Winter et al., 
2000b; de Winter et al., 1998; Deans and West, 2011; Dorsman et al., 2007; Foe et al., 
1996; Howlett et al., 2002; Huang et al., 2006; Knies et al., 2017; Levitus et al., 2005; 
Levran et al., 2005; Litman et al., 2005; Meetei et al., 2004; Meetei et al., 2005; 
Mosedale et al., 2005; Pickering et al., 2013; Reid et al., 2007; Sims et al., 2007; 
Smogorzewska et al., 2007; Strathdee et al., 1992; Timmers et al., 2001; Xia et al., 
2007). Mutations in genes comprising the Fanconi anemia (FA) pathway can result in 
both autosomal recessive and X-linked recessive forms of the disease (Sasaki, 1975). 
Clinically, FA patients exhibit specific developmental abnormalities, 
hematological defects, and have increased susceptibilities to cancers (Moldovan and 
D'Andrea, 2009). A hallmark of FA is hypersensitivity to a class of DNA damaging 
agents [e.g., mitomycin C (MMC), diepoxybutane, and cisplatin (D'Andrea and Grompe, 
2003)] that create inter-strand DNA crosslinks (ICLs) that, if unrepaired, can lead to the 
accumulation of stalled DNA replication forks that effectively block both DNA replication 
and RNA transcription (Scharer, 2005). These toxic ICLs are removed primarily during 
DNA replication (Akkari et al., 2000).  
The FA pathway acts to remove ICLs by coordinating the actions of several 
different DNA repair pathways (e.g., nucleotide excision repair, translesion synthesis, 
and homologous recombination (Niedzwiedz et al., 2004). Moreover, clastogenic agents 
[e.g., ultraviolet (UV) and ionizing radiation (IR)], chemical treatments that block DNA 
replication (e.g., hydroxyurea), and ICLs that spontaneously arise during the process of 
DNA replication can activate the FA pathway (Dunn et al., 2006; Garcia-Higuera et al., 
2001; Howlett et al., 2002; Taniguchi et al., 2002). Most of the resultant DNA lesions 
arising during replication can be repaired using conventional DNA repair pathways; 
however, ICL repair relies upon the FA pathway.  
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When DNA replication becomes blocked at an ICL, a double-strand break is 
generated by endonucleases (De Silva et al., 2000; Hanada et al., 2006). The resultant 
double-strand DNA break leads to the uncoupling of one sister chromatid from the other. 
Incisions occur in the phosphodiester backbone on both sides of the ICL (Niedernhofer 
et al., 2004), the remaining cross-linked base undergoes processing, and specialized 
DNA polymerases can then continue replication by bypassing the resultant lesion 
(Niedzwiedz et al., 2004). The replication fork can then be re-established, which likely 
involves sister-chromatid mediated homologous recombination.  
The mono-ubiquitination of FANCD2 is a key event in FA activation. Following 
exposure to DNA lesions that arise during DNA replication, FANCM and FAAP24 recruit 
the FA core complex (which consists of the FA proteins A, B, C, E, F, G, and L) to DNA 
lesions (Garcia-Higuera et al., 1999; Medhurst et al., 2001; Meetei et al., 2004; Meetei 
et al., 2003). Recruitment of the FA core complex leads to the mono-ubiquitination of 
the downstream effector proteins FANCD2 and FANCI. Mono-ubiquinated FANCD2 and 
FANCI then localize with FANCD1 at stalled replication forks with other DNA repair 
proteins, which include RAD51, BRCA1, and the proliferating cell nuclear antigen DNA 
polymerase processivity factor, PCNA (Garcia-Higuera et al., 2001; Howlett et al., 2005; 
Hussain et al., 2004; Smogorzewska et al., 2007; Taniguchi et al., 2002). Once DNA 
repair is completed, the FANCD2 protein undergoes de-ubiquitination and the cell cycle 
resumes (D'Andrea and Pellman, 1998). 
Interestingly, ATR is the main upstream regulator of the FA pathway (Friedel et 
al., 2009). Following the inhibition of DNA synthesis or replication (also known as 
replication stress), ATR phosphorylates FANCD2, which leads to FANCD2 mono-
ubiquitination (Andreassen et al., 2004; Ho et al., 2006; Howlett et al., 2005; Pichierri 
and Rosselli, 2004). Furthermore, since mutations in the FANCD2 PCNA protein 
interacting (PIP)-box disrupt FANCD2 mono-ubiquitination, PCNA also may play a role 
in FANCD2 mono-ubiquitination (Howlett et al., 2009). 
An immortalized fibroblast cell line, called PD20F (Coriell Institute GM16633, 
NA16633), was generated from a 7 year-old male FA patient (Whitney et al., 1995).  
This patient harbors a maternally inherited FANCD2 allele containing an S126G amino 
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acid, which promotes mis-splicing, leading, to the inclusion of 13bp from intron 5 into the 
FANCD2 mRNA (Timmers et al., 2001). This 13bp insertion generates a frameshift 
mutation that is predicted to result in a severely truncated FANCD2 protein of 180 
amino acids. The paternally inherited FANCD2 allele contains a missense change, 
R1236H. These inherited changes result in markedly diminished FANCD2 protein levels 
(Timmers et al., 2001). 
Utilizing this PD20F immortalized fibroblast cell line, Mr. Cesar Lopez-Ruiz in Dr. 
José García-Perez lab, performed L1 retrotransposition assays in PDF20F and 
complemented PD20F cells using three different engineered L1s: wild-type L1.3, an 
L1.3/D205A EN mutant, and an L1.3/PIP6 mutant. I then performed our L1 capture 
techniques to determine where the de novo engineered L1 integration events occur in 
these cells. Given the role of FANCD2 in DNA repair and the prevention of stalled 
replication forks, we hypothesized that the resultant engineered L1 insertions may be 
driven towards stalled replication forks. Thus, we were eager to explore if there were 
any potential differences in L1 insertion site profiles in the FANCD2-deficient PD20F 
versus the complemented FANCD2-proficient cell lines. 
While endonuclease independent (ENi) retrotransposition rarely occurs in most 
tissue culture cell types, cell types with inactivated NHEJ and p53 functions exhibit 
abundant ENi retrotransposition (Coufal et al., 2011; Morrish et al., 2007; Morrish et al., 
2002). Curiously the L1.3/D205A EN mutant retrotransposes at 23% of wild-type L1.3 
levels in PD20F, but does not exhibit appreciable retrotransposition in complemented 
PD20F cells. These data suggest that PD20F cells may contain unrepaired DNA lesions 
that facilitate L1 ENi retrotransposition. As such, we also wanted to explore if there were 
any differences in insertion site profiles in the FANCD2-deficient PD20F between the 
wildtype and EN-deficient engineered L1s.  
PCNA and its Role During LINE-1 Retrotransposition 
 PCNA is a DNA sliding clamp that is an essential co-factor for DNA polymerases 
during replication (O'Donnell et al., 2013; Siddiqui et al., 2013). PCNA tethers 
polymerases to DNA and dramatically increases their processivity (Choe and Moldovan, 
	 220	
2017). PCNA lacks enzymatic activity and participates in several DNA repair processes 
by recruiting various enzymes to DNA. Most proteins interact with PCNA through a 
canonical PCNA-interacting protein (PIP) box. L1 contains a PIP box at residues 407-
415 in the ORF2p (Taylor et al., 2013). There are several hypotheses about how PCNA 
interaction with L1 may be involved in L1 retrotransposition. One hypothesis is that 
PCNA may support L1 retrotransposition by recruiting L1 ORF2p onto genomic DNA 
until a preferred L1 EN target site is recognized to initiate TPRT. Another possibility is 
that PCNA may act as a processivity factor for L1 RT. Finally, it is possible that ORF2p 
recruits PCNA to help repair nicks and gaps at junctions between L1 and the host DNA 
that arise during TPRT. We sought to determine if the loss of PCNA binding affects L1 
EN consensus cleavage site recognition and L1 integration preferences. 
An L1.3 PIP mutant was created, L1.3/PIP6, which contains a YY414,415 AA 
mutation located within a PIP-box, which is located between the ORF2p EN and RT 
domains at amino acids 407-415 (Taylor et al., 2013). Curiously, this L1.3/PIP6 is 
severely compromised for retrotransposition in HeLa cells, as well as the NHEJ-
deficient Chinese Hamster Ovary cell line XR-1, but readily retrotransposes in the 
FANCD2-deficient cell line PD20F, and the FANCA deficient Chinese Hamster cell line 
VH4 (unpublished data from Dr. José García-Perez). Intriguingly, a previous study 
observed decreased ORF2p/PCNA co-purification in HEK293T cells, and a decrease in 
the retrotransposition efficiency of a L1.3/PIP6 double mutant when expressed from a 
synthetic L1 in HeLa and HEK293T cells (Taylor et al., 2013). Additionally, PCNA has 
been implicated in recruiting RNase H2 to RNA/DNA hybrids in genomic DNA (Bubeck 
et al., 2011). This ability of PCNA is curious, as L1 does not encode a recognizable 
RNase H activity, even though RNase H activity might be required to degrade the 
original L1 RNA template strand from the L1 RNA/cDNA duplex that occurs during first-
strand L1 cDNA synthesis (Richardson et al., 2014) Indeed, such an RNase H activity 
could potentially facilitate L1 second-strand L1 cDNA synthesis. Indeed, PCNA may 
recruit an RNase H activity that functions in L1 integration. Thus, we were interested to 
test whether the lack of interaction with PCNA affected the integration preferences of 
the L1.3/PIP6 mutant in PD20F cells. 
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Since both ATR and FANCD2 are involved in DNA repair pathways, data from 
these retrotransposition conditions are presented together in this chapter. Curiously, 
since ATR is a regulator of the FA pathway, we were interested to compare L1 
insertions between ATR and FANCD2-deficient conditions to test whether these 
proteins play different roles in L1 integration. In Chapter 2, we observed that wildtype 
L1s intersperse throughout the genome regardless of cell type used in our studies. In 
this chapter we investigate whether we observe a shift in L1 insertion preference when 
DNA repair processes are perturbed in the cell.  
Results 
Previous Work: Generation of L1 Insertions 
Dr. Huira Kopera performed L1 retrotransposition assays to determine whether 
ATR knockdown influences L1 integration preferences in the human genome. The 
retrotransposition indicator cassette mblastI, was used to tag the 3’ untranslated region 
(UTR) of a human L1 (pJJ101/L1.3) (Kopera et al., 2011). The resultant construct 
contains an engineered retrotransposition competent L1 (L1.3) (Dombroski et al., 1994; 
Sassaman et al., 1997) sequence with a blasticidin deaminase indicator cassette in its 
3’UTR (Morrish et al., 2002). Only cells that harbor a de novo L1 retrotransposition 
event will become resistant to blasticidin drug selection. An advantage to the blasticidin 
retrotransposition cassette is that blasticidin kills cells quickly allowing us to capture 
ATR knockdown and L1 retrotransposition simultaneously. 
HeLa cells were co-transfected with a pJJ101/L1.3 expression constructs and 
small interfering RNAs that target either ATR (siATR) or GFP (siGFP), which should not 
affect HeLa cell viability of L1 retrotransposition (Figure 3.2). As a negative control for 
retrotransposition, an L1 RT mutant (D702A; pJJ105/L1.3) was transfected in parallel. 
Cells were selected for de novo engineered L1 retrotransposition events in the presence 
of blasticidin three days post-transfection. At completion of the retrotransposition assay, 
cells were fixed, and were counted to determine the relative L1 retrotransposition 
efficiency. We observed wildtype L1 retrotransposition events under both ATR and GFP 
knockdown conditions. Genomic DNA was collected from cells ten days post-
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transfection and sequencing libraries were created specifically capturing amplified de 
novo engineered L1 events.  
 Mr. Cesar Lopez-Ruiz, in Dr. José García-Perez’s laboratory, performed the 
wildtype and mutant L1 retrotransposition assays in the immortalized fibroblast PD20F 
cell line. Briefly, a wildtype L1 construct, pJJ101/L1.3, and mutant derivatives 
(pJJD205A/L1.3 and pJJ101/L1.3-YY414,415AA) were transfected into PD20F cells and 
retrotransposition assays were performed as noted above. All of the constructs contain 
the retrotransposition-competent L1.3 tagged with the mblastI retrotransposition 
indicator cassette in the L1 3’UTR. An L1 EN mutant (pJJD205A/L1.3), an L1 PIP 
mutant (pJJ101/L1.3-YY414, 415AA), and an L1 RT mutant (pJJ105/L1.3) were also 
assayed for retrotransposition in FANCD2-deficient PD20F cells and FANCD2 
complemented PD20F cells, which contain a full-length FANCD2 cDNA that was 
delivered into cells by a retroviral expression vector (Pulsipher et al., 1998). Wildtype L1 
retrotransposition occurs in both FANCD2 complemented and FANCD2-deficient 
PD20F cells. The L1 EN and PIP mutant retrotransposition events are only observed in 
FANCD2-deficient PD20F cells. 
FANCD2-deficient and FANCD2-proficient cells were transfected with the 
wildtype and mutant L1 constructs noted above. Five days post transfection cells were 
selected in the presence of blasticidin. A week after selection, cells were isolated, gDNA 
was collected, and sequencing libraries were assembled specifically capturing de novo 
engineered L1 events.  
 Capture of L1 insertions in ATR-deficient and FANCD2-deficient Cell Lines 
Engineered L1 integration capture procedures were performed as described in 
Chapter 2. Briefly, genomic DNAs were randomly sheared to 3kb and adapter 
sequences described were ligated onto the end-repaired, dA-tailed genomic DNA. The 
dual-biotinylated LEAP primer was used to linearly amplify the 3’ end of de novo L1 
retrotransposition events and their associated 3’ flanking sequence. Following biotin 
capture on streptavidin bead, nested PCR was performed with oligonucleotide primers 
complementary to the SV40pA signal primer sequence and 3’ adapter sequence. 
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Captured products were characterized using Pacific Bio Science (PacBio) single 
molecule real-time (SMRT) circular consensus sequence (CCS) sequencing and 
subjected to the same filtering and analysis schemes described in Chapter 2 (Figure 
2.7A). The average CCS read length obtained for insertions was ~600bp (Figure 3.3B).  
We identified 3,815 de novo engineered L1 insertions in siATR knockdown 
experiments and 474 de novo engineered L1 insertions in siGFP knockdown 
experiments. In PD20F FANCD2-deficient retrotransposition assays, we identified 
18,124 wildtype L1.3, 1,514 L1.3/D205A EN-mutant, and 13,162 L1.3/PIP6 mutant 
integration events. We also identified an additional 4,372 wildtype L1.3 insertions from 
the FANCD2-complemented PD20F cell line.  
The presence of more than one independent CCS for a single insertion site 
indicates that at least two independent molecules for the same insertion were identified 
by PacBio sequencing, which gives us greater confidence that we are observing a bona 
fide de novo engineered L1 integration site as opposed to a PCR artifact. At least two or 
more independent L1 insertion CCS reads were identified in the siATR knockdown 
experiments (14.78% of the total insertions) and siGFP knockdown experiments 
(38.82% of the total insertions) (Figure 3.3C). Moreover, at least two or more 
independent CCS reads containing L1 insertions were identified in the following cell 
lines: PD20F FANCD2-deficient cells [wildtype L1.3 (14.61% of the total insertions); 
L1.3/D205A (51.65% of the total insertions); and L1.3/PIP6 (27.12% of the total 
insertions)] and FANCD2 complemented cells [wildtype L1 (20.8% of the total 
insertions)]. Notably, as in Chapter 2, the L1 insertions contained long poly(A) tails 
(Figure 3.3A), occurred within AT-rich regions of the genome (Figure 3.4) (Gasior et al., 
2007; Lander et al., 2001), and integrated at an L1 EN consensus cleavage site (Figure 
3.5). Importantly, the L1 consensus target site sequence from L1 EN mutants differs 
from those of the other L1 constructs (Figure 3.5C) (see below for more discussion). 




Engineered Insertions are Located Throughout the Genome  
As in Chapter 2, we compared our L1 insertion dataset to 10,000 simulations of 
the weighted random dataset model that uses the L1 EN degenerate consensus 
cleavage site to randomly select L1 integration site in the human genome. The wildtype 
L1 insertions from ATR and GFP knockdown experiments are distributed throughout the 
genome (Figure 3.6) and, in general, positively correlate with chromosome size 
(Spearman’s rho in the siATR and siGFP experiments is 0.93 and 0.91, respectively). 
As in Chapter 2, we once again observed a significant increase in the numbers of L1 
insertion sites on chromosomes 1 and 5 in the siATR knockdown experiments, likely 
because there are more than two copies of these chromosomes in HeLa cells. A slight 
increase, although still within expected boundaries of the weighted random dataset, of 
insertions on chromosomes 1 and 5 is also seen in the siGFP dataset; however, the 
smaller difference likely reflects the smaller number of L1 integrations characterized in 
this experiment (3815 siATR knockdown vs. 474 siGFP knockdown L1 insertions, 
respectively).  
 The L1 insertions in the FANCD2-deficient cell line are also distributed 
throughout the genome (Figure 3.6) and positively correlate with chromosome size 
(Spearman’s rho ranges between 0.89 and 0.90). Curiously, all four retrotransposition 
conditions in PD20F cells show an increase of insertions on chromosomes 8, 11, and 
20 when compared to the weighted random dataset. However, none of these large 
chromosomal insertion counts are significant when testing for outliers using a linear 
regression model with respect to chromosome size and insertion counts. To our 
knowledge, PD20F cells do not exhibit chromosome abnormalities, although many FA-
deficient cells have an increased proportion of cells with 4N DNA content (Kaiser et al., 
1982; Kubbies et al., 1985). However, there is no reason to believe that this would result 
in an increase in insertions only on these three specific chromosomes. This observed 
phenomenon appears to be PD20F cell type specific and is observed in both FANCD2-
deficient and FANCD2-proficient cellular conditions. Finally, we plotted L1 insertions on 
a chromosomal ideogram, where each horizontal line represents the genomic location 
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of an integration event (Figure 3.7). The L1 insertions are clearly distributed across 
chromosomes and do not show specific ‘hot spot’ regions of integration preference.  
 L1 Integration into L1 EN Consensus Cleavage Site Dependent Upon L1 EN Activity 
We next analyzed the L1 integration sites in greater detail to determine whether 
ATR knockdown alters L1 integration preference. In ATR and GFP knockdown cells, the 
wildtype L1 retrotransposition events integrate into the 7bp L1 EN consensus cleavage 
site (5’-TTTTT/AA-3’) (Figure 3.5A). Correcting the L1 EN consensus cleavage sites for 
the proportion of 7mers found in the human genome still displays the distinct 
degenerate L1 EN consensus cleavage site (Figure 3.5B). In FANCD2-proficient and 
FANCD2-deficient cells, wildtype L1 retrotransposition events integrate into a 
degenerate L1 EN consensus cleavage site (Figure 3.5C). In FANCD2-deficient cells, 
L1 PIP mutant retrotransposition events also integrate into a degenerate L1 EN 
consensus cleavage site (Figure 3.5C). Thus, deficiencies in ATR and FANCD2 do not 
appear to alter wildtype or PIP mutant L1 integration preferences (Figure 3.5B). 
In contrast to the above data, L1 ENi retrotransposition events in FANCD2-
deficient cells display a shift in integration within L1 target site sequence variants. We 
observed a decreased preference for a T in the 2nd and 5th position of the 7bp L1 EN 
consensus sequence, and an even greater decreased preference for an A in the 6th and 
7th position (Figure 2.7B). This shift in target site preference is consistent with the 
hypothesis that ENi is occurring at endogenous lesions in genomic DNA. 
Genes are not Preferential L1 Integration Sites 
We next addressed whether the knockdown of ATR or the absence of FANCD2 
alters the ability of engineered L1s to retrotranspose into genes identified in UCSC build 
GRCh37/hg19 of the human genome. Consistent with the data reported in Chapter 2, 
we did not identify significant depletions or enrichments of any of our L1 insertion 
datasets within exons when compared to our random weighted model (Figure 3.8A). 
The L1 retrotransposition events from ATR knockdown and GFP knockdown cells also 
show no significant depletion or enrichment of insertions within introns of genes when 
compared to the weighted random dataset (Figure 3.8B).  
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Of the PD20F sample insertion datasets, the L1.3/PIP6 insertions show a 
significant depletion of insertions in introns (Pearson’s χ2 test, p-value 1.792 x 10-5). The 
wildtype L1 retrotransposition events in FANCD2 complemented PD20F also show a 
significant depletion of intronic insertions (Pearson’s χ2 test, p-value 0.04724). Notably, 
these datasets contain the greatest number of L1 insertions examined in the chapter, 
suggesting that large insertion datasets are needed to observe a depletion of insertions 
in introns. Additionally, we did not observe a significant excess of L1 insertions in the 
antisense orientation of genes for any of the analyzed datasets. However, as reported in 
Chapter 2, there is a slight preference for antisense integration into genes, which likely 
reflects the increased prevalence of the L1 EN consensus cleavage site in the sense 
strand of genes (Figure 3.8C).  
L1 Integration in ATR-deficient Cells is Independent of Gene Transcription and 
Expression 
We next explored whether ATR knockdown influences L1 integration towards 
expressed regions of the genome. During transcription, the DNA coding strand 
becomes untethered from its complementary strand, potentially becoming an accessible 
target for L1 EN cleavage. We found that transcription status does not have a significant 
effect on the distribution of L1 insertions in ATR knockdown HeLa cells (Figures 3.9A).  
We next examined L1 retrotransposition events from ATR and GFP knockdown 
with HeLa cell Bru-seq transcription data (Paulsen et al., 2014; Paulsen et al., 2013) 
and RNA-seq expression data. Consistent with the data reported in Chapter 2, we did 
not observe an enrichment or depletion of L1 insertions in transcribed regions of the 
genome when compared to the weighted random model (Figures 3.9A, 3.9B, 3.10A, 
and 3.10B). Moreover, the rate of transcription does not significantly alter L1 integration 
preferences (Figure 3.9C). However, as observed in Chapter 2 (Figure 2.4D), there 
appears to be a slight underlying preference towards EN cleavage on the coding strand 
in the genome (Figure 3.9D). Notably, our approach may have pitfalls if ATR knockdown 
significantly alters the HeLa cell transcription profile and results in global changes in the 
assignments of expressed and non-expressed genes. That being stated, ATR 
knockdown does not appear to significantly alter L1 integration profiles. 
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L1 Integration in ATR Knockdown Cells is Independent of Replication 
When DNA polymerase activity and DNA helicase activity become discordant, 
increased amounts of ssDNA, an ATR substrate, can be generated at stalled DNA 
replication forks. Thus, we next determined whether ATR knockdown altered L1 
integration preferences into lagging or leading strand DNA replication templates. We did 
not observe statistically significant changes in the numbers of L1 insertions favoring the 
lagging strand template when comparing our wildtype L1 insertion dataset with Okazaki 
sequencing data from HeLa cells (Petryk et al., 2016) (Figure 3.11A and 3.11B). 
Similarly, we did not observe an L1 integration bias towards replication fork initiation or 
termination sites (Figure 3.11C). Once again, our approach may have pitfalls if ATR 
knockdown affects replication fork initiation, directionality, or termination in a significant 
portion of the genome. That being stated, the preliminary data presented here suggests 
that ATR knockdown does not lead to replication biased changes in L1 integration 
preferences. 
ENi Integration Events Display Replication Bias Favoring Okazaki Fragments as ENi 
Substrates 
 We next compared the insertion profiles of wildtype L1 retrotransposition events 
generated in FANCD2-deficient cells with the Okazaki sequencing data from 
lymphoblastoid cells and HeLa cells. Comparisons with both cell types showed the 
same trends, but in this chapter we only show results from comparisons with 
lymphoblastoid cell OK-seq data. Consistent with data obtained from wildtype L1 
retrotransposition events reported in Chapter 2 (Figure 2.6B), wildtype L1s show a slight 
preference for L1 EN cleaving the lagging strand template in FANCD2-deficient cells 
(Figures 3.11A and 3.11B; bottom strand cleavage Ks.bootstrap p-value < 1 x 10-6; top 
strand cleavage Ks.bootstrap p-value < 0.001). A similar trend also was observed for 
wildtype L1 insertions in FANCD2-proficient cell lines (Figures 3.11A and 3.11B). 
As opposed to wildtype L1s, endonuclease-deficient L1s likely exploit 
endogenous DNA lesions to mediate their insertion (Morrish et al., 2007; Morrish et al., 
2002). Indeed, Okazaki fragments present at DNA replication forks during lagging 
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strand DNA synthesis contain a 3’-OH group, which may provide a suitable substrate for 
the L1 RT to initiate TPRT in the absence of L1 EN activity. Thus, we next compared 
the insertion profiles of ENi L1 retrotransposition events generated in FANCD2-deficient 
cells with the Okazaki sequencing data.  As opposed to the trends observed for wildtype 
L1s (Figures 2.6B, 3.11A and 3.11B), the ENi retrotransposition integration events show 
an opposite integration preference (Figures 3.11A and 3.11B; Kolmogorov-Smirnov boot 
strap test bottom and top strand analysis p-values < 0.01). Together, the above data 
suggest that wildtype L1s may show a slight preference for insertion into the lagging 
strand template.  
PCNA is Not Required for L1 Integration into Replication Forks 
Since PCNA is an essential co-factor for DNA replication, PCNA may be involved 
in guiding L1 to replication forks to direct integration. Thus, we hypothesized that the 
L1.3/PIP6 PIP-box mutant may block interactions with PCNA and alter L1 integration 
preferences within the genome. To test this hypothesis, we compared the L1 insertion 
datasets in FANCD2-deficient cells to lymphoblastoid Okazaki sequencing data. We 
observed a slight preference for L1 EN cleavage on the lagging strand template for the 
L1.3/PIP6 PIP-box mutant  (cleavage on top strand Ks.bootstrap test p-value < 0.01; 
cleavage on bottom strand Ks.bootstrap test p-value < 0.05)  (Figures 3.11A and 3.11B). 
Notably, this trend is the same as that observed for wildtype L1s in FANCD2-deficient 
cells, as well as the L1 insertions reported in Chapter 2. This data suggests that PCNA 
is not involved in guiding L1 EN cleavage to a specific strand in replication forks. 
Finally, we wanted to test whether the L1.3/PIP6 mutant preferentially integrates 
into replication fork origins or replication fork termination sites. While PD20F L1.3/PIP6 
insertions significantly differ from the weighted random dataset (Ks.bootstrap test p-
value <0.01), most insertions are found within regions of the genome that are replicated 
by overlapping extending forks, and not overwhelmingly in replication origins or sites of 
termination (Figure 3.11C). Intriguingly, wildtype L1 insertions in FANCD2-deficient cells 
are depleted in replication termination sites, while L1.3/PIP6 PIP-box mutant insertions 
are depleted in both replication origins and replication termination sites. Thus,  
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comparisons of these data suggest that PCNA may possibly play a role in guiding 
wildtype L1s to replication fork origins.   
ATR Knockdown does not Drive L1 Integration to Known Fragile Sites in the Human 
Genome 
Common chromosomal fragile sites are unstable genomic regions that break 
under replication stress. Aphidicolin, an inhibitor of DNA replication, induces common 
fragile sites . Fungtammasan et al. (2012) published a set of defined aphidicolin-induced 
common fragile sites, as well as a set of non-fragile sites. Since it is believed that fragile 
sites represent unreplicated ssDNA regions that are caused by stalled or collapsed DNA 
replication forks, and ssDNA regions are substrates for ATR activation, we 
hypothesized we might observe an increase of L1 integration into stalled replication 
forks in the absence of ATR. Thus, we next asked whether L1 insertions in ATR 
knockdown cells are enriched within common fragile sites when compared to simulated 
L1 insertions generated using our weighted random dataset (Table 3.1). In general, we 
observed that ATR knockdown neither significantly increases L1 integration into fragile 
site regions, nor does ATR knockdown significantly decrease L1 integration into non-
fragile sites of the genome. Notably, these comparisons are limited in their ability to 
determine if fragile sites induced specifically by ATR knockdown are L1 integration 
preferences, as these data sets represent common fragile sites induced by aphidicolon. 
Furthermore, these data sets will not allow us to determine if preferential integration 
occurs at random fragile sites induced by ATR knockdown. 
FANCD2-deficient Cells do not Harbor More L1 Integration Sites in Common Fragile 
Sites 
Since FANCD2 is involved in the repair of ICLs, which typically arise during DNA 
replication, we next hypothesized that FANCD2-deficient cells may lead to an increase 
in stalled replication forks that arise at common fragile sites (Casper et al., 2002). Thus, 
we tested whether L1 insertions in FANCD2-deficient cells are enriched within common 
fragile sites when compared to simulated L1 insertions generated using our weighted 
random dataset. In general, though we did observe a slight over-representation of 
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wildtype L1 insertions into non-fragile sites in FANCD2-proficient cells as compared to 
our simulated L1 integration sites generated from our weighted random model (Table 
3.1). We did not observe an enrichment of wildtype, EN mutant, or L1.3/PIP6 insertions 
into common fragile sites in FANCD2-deficient cells (Table 3.1). However, the L1.3/PIP6 
insertions exhibit an increase in non-fragile sites as well.  Thus, we did not observe an 
increase of L1 integration sites into common fragile sites, but these results cannot rule 
out L1 integration preference in fragile sites induced by stalled replication forks in 
FANCD2-deficient cells. Aphidicolin induced common fragile sites may differ in location 
from FANCD2-deficient fragile sites.  
Discussion 
ATR Affects L1 Integration Post-EN Cleavage 
Our data suggests that ATR knockdown does not significantly affect L1 
integration preference. Intriguingly, data generated by Dr. Huira Kopera indicated that 
ATR knockdown leads to increased L1 retrotransposition in HeLa cells. Moreover, the 
resultant integration events tend to be ‘longer’ in length, are often flanked by long target 
site duplications, and have a higher incidence of genomic deletions at the L1 integration 
site. How these structural alterations arise requires further study.  
The activation of ATR at double-strand DNA breaks is reliant upon ATM 
(Jazayeri et al., 2006; Myers and Cortez, 2006). Interestingly, ATM-deficient mice and 
NPCs also exhibit slightly elevated levels of L1 retrotransposition (Coufal et al., 2011). 
Moreover, L1 retrotransposition events in ATM-deficient NPCs appear to be longer in 
length when compared to ATM-proficient controls (Coufal et al., 2011). Thus, both ATM 
and ATR may play a role in combating L1 retrotransposition.  
Given the above data, we hypothesize that ATR and ATM may recognize DNA 
structures that arise during TPRT to inhibit L1 retrotransposition. Potential substrates 
include: (1) single-strand L1 cDNAs; (2) single-strand L1 cDNA/dsDNA junctions; or (3) 
single nicks or single-strand DNA substrates that arise on the ‘top’ DNA strand during 
TPRT. The activation of ATR and/or ATM at these structures may then lead to the 
recruitment of DNA repair proteins that recognize TPRT as DNA damage intermediates, 
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thereby inhibiting retrotransposition. Consistent with the idea that TPRT intermediates 
may be recognized as sites of DNA damage, it is notable that the overexpression of 
components of the nucleotide excision repair pathway strongly inhibits engineered L1 
retrotransposition in cultured human cells (Servant et al., 2017). 
The L1 PIP-box is Not Required for Directing ORF2p to L1 EN Target Site  
FANCD2-deficient L1.3/PIP6 insertions display a long poly(A) tail (Figure 3.3A), 
are found in AT-rich regions of the genome (Figure 3.4), and contain the L1 EN 
consensus cleavage site (Figure 3.5C). This data suggests that interaction with PCNA is 
not required for L1s to integrate into L1 EN consensus cleavage sites throughout the 
genome. This further implies that L1 ORF2p/PCNA interactions would likely be 
important for L1 retrotransposition after the initiation of L1 EN cleavage of genome DNA 
during TPRT.  
Since PCNA plays an important role in DNA replication, we hypothesized that the 
interaction of L1 ORF2p with PCNA may be involved in guiding L1 to replication forks. 
Our data does not suggest any profound discrepancies in L1 integration preference at 
replication forks. We observe the same trend in data among wildtype L1s and PIP6—
they both show a slight preference at cleaving the lagging strand template of DNA 
replication forks to mediate L1 integration (Figures 3.11A and 3.11B). Similar trends 
were also observed for wildtype L1 insertions in FANCD2-deficient cells (Figure 3.11A 
and 3.11B), as well as in other cell types examined in Chapter 2 (Figures 2.6 and 2.7).   
We observed suggestive evidence that PCNA may be involved in directing L1 
integration towards DNA replication origins (Figure 3.11C). This data is by no means 
conclusive, but certainly is worthy of follow up experimentation. Indeed, comparing the 
L1 PIP mutant insertion profiles with OK-seq data generated from the PD20F FA-
deficient cell line, could yield a definitive conclusion as to whether PCNA guides L1 to 
replication fork origins. Given this suggestive evidence that PCNA may guide L1 to 
replication fork origins, it will also be interesting to test whether PCNA guides 
endonuclease-deficient L1s to stalled replication forks. Indeed, the examination of the 
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L1 insertion profiles of PIP-box/EN- double mutants could critically test if PCNA plays a 
role in ENi L1 retrotransposition. 
Finally, it is possible that PCNA plays an important role during TPRT. For 
example ORF2p/PCNA interactions could potentially increase the processivity of the L1 
RT activity or could recruit other proteins [e.g., RNase H2 (Bubeck et al., 2011) or DNA 
ligase] to sites of TPRT, thereby facilitating the completion of L1 integration. Indeed, 
examining the structures of L1 PIP-box retrotransposition events may provide insight 
about the roles of PCNA during L1 integration. 
FANCD2-deficiency Does Not Influence Wildtype L1 Integration Preference  
The wildtype L1 integration events in FANCD2-deficient cells show the same 
general integration preferences as the wildtype insertion datasets analyzed in Chapter 2. 
These data are consistent with previous studies from our lab (Morrish et al., 2007; 
Morrish et al., 2002) and suggest that wildtype L1s integrate via canonical TPRT even 
under cellular conditions that promote ENi L1 retrotransposition. An additional means to 
test this hypothesis would be to characterize wildtype L1 integration sites in FANCD2-
deficient cells to determine if the resultant L1 integration events exhibit structural 
hallmarks indicative of canonical TPRT or ENi retrotransposition (e.g. 5’ and 3’ 
truncations, lack TSDs, deletions at integration site).    
Finally, since FANCD2 is primarily involved in repairing ICLs that arise 
throughout the genome during DNA replication, the data presented here cannot directly 
assess whether wildtype L1s preferentially target unrepaired ICLs as integration 
substrates. Thus, while we did not observe a significant skewing of wildtype or 
L1.3/PIP6 integration events in FANCD2-deficient cells, we cannot rule out the 
possibility that L1 integration preferences in these cells may be influenced by 




Endonuclease-independent Retrotransposition Can Utilize Replication Forks for 
Integration  
Our observations in FANCD2-deficient cells strongly suggest that stalled 
replication forks or structures arising during the repair of stalled replication forks may 
provide integration substrates for ENi L1 retrotransposition. The resultant ENi L1 
retrotransposition integration events also differ, subtly but significantly, from other 
integration data sets with respect to their target integration site sequence (Figure 3.5C). 
The ENi L1 integration sites are still enriched for the first five T residues, but show a 
distinct decrease in the last two A residues in the 7bp target site sequence. Moreover, 
examination of the nucleotides surrounding the EN mutant L1 integration target site 
show a distinct peak in T rich sequence up to 25bp upstream of the integration site as 
compared to other insertion datasets (Figure 3.4A). These data suggest that 
interactions between the L1 poly(A) tail and single-strand, T-rich 3’ overhangs are 
important structures to initiate ENi L1 retrotransposition (Kulpa et al., 2006). The 
decrease in the preference of the last two A residues, which are critical for L1 EN target 
site (Figure 3.5C), provide additional support that ENi L1 retrotransposition events are 
using endogenous lesions as DNA repair substrates. 
Future studies are needed to determine the nature of the integration substrates 
used to accommodate ENi L1 retrotransposition in FANCD2-deficient [and for that 
matter XRCC4-deficient cells (Morrish et al., 2002)]. Stalled replication forks may be 
processed to double-strand break repair intermediates that are favorable substrates of 
ENi L1 retrotransposition. Alternatively, and consistent with the data presented in 
Figures 3.11A and 3.11B, it is possible that the 3’OH groups present at Okazaki 
fragments could be used as primers to initiate ENi L1 retrotransposition. Indeed, in 
certain respects, the structures at DNA replication forks and/or at double-strand breaks 
that arise from collapsed DNA replication forks may be similar to those at dysfunctional 
telomeres, which can serve as substrates for ENi L1 retrotransposition (Morrish et al., 
2007; Morrish et al., 2002). Thus, our data suggest a new mechanism by which L1s 
lacking endonuclease activity utilize properties of the replication cycle to integrate within 
the genome. 
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Materials and Methods 
Plasmids were purified using a Qiagen Plasmid Midi kit (#12143).  
Plasmids 
pJJ101/L1.3 : This plasmid was described previously (Kopera et al., 2011). It contains a 
full-length retrotransposition-competent L1 element, L1.3 (Sassaman et al., 1997), 
tagged with a mblastI retrotransposition indicator cassette in the 3’UTR  and subcloned 
in pCEP4 (Invitrogen). 
pJJD205A/L1.3 : This plasmid was described previously (Kopera et al., 2011). This 
construct is similar to pJJ101/L1.3 but contains a D205A mutation in the ORF2p EN 
domain.  
pJJ101/L1.3-YY414,415AA : is a derivative of JJ101/L1.3 that contains a double 
missense mutations in the PIP domain of L1-ORF2p (YY at position 414 and 415 
mutated to A). 
pJJ105/L1.3 : This plasmid was described previously (Kopera et al., 2011). This 
construct is identical to pJJ101/L1.3 but contains a missense mutation (D702A) in the 
ORF2p RT domain. 
pCEP/GFP: has been described previously (Alisch et al., 2006). It consists of a pCEP4 
backbone (Invitrogen/Life Technologies; Carlsbad, CA #V04450) that contains the 
coding sequence of the humanized Renilla green fluorescent protein (hrGFP) from 
phrGFP-C (Stratagene) driven by a CMV promoter. 
Cells culture and transfection of ATR and GFP knockdown HeLa cells 
 HeLa cells were grown in a humidified incubator at 37°C and 7% CO2. HeLa cells were 
grown in DMEM (Life Technologies #11960051) with 10% FBS, 1× Pen Strep Glutamine 
(100 U/mL penicillin, 100 µg/mL streptomycin, and 292 µg/mL glutamine; PSG), and 
1mM NaPyruvate. All DNA transfections were performed with FuGene6 (Promega 
#E2692) according to manufacturer’s directions. Briefly, 1x106 HeLa cells were plated in 
a 10 cm tissue culture dish. The following day, 18 µg of pJJ101/L1.3 LINE-1 plasmid 
DNA was incubated with 90 µL of 10 µM GFP or ATR siRNA (Dharmacon, #P-002048-
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01-20 and #M-003202-05-0005, respectively) and 60 µl of DuoFect (Dharmacon, #T-
2010-03) in 1 ml of OptiMem for 20 minutes at room temperature before adding the 
transfection mix to the cells. After 16-18 hours, transfections were stopped by changing 
the media (day 1 post-transfection). Three days post-transfection, retrotransposition 
events were selected under 10 mg/ml blasticidin. Media was changed again 6 days 
post-transfection. Ten days post-transfection, cells were harvested for genomic DNA 
purification. Genomic DNA was isolated and purified using the Qiagen Blood and Cell 
Culture DNA Midi kit (Qiagen #13343). 
PD20F Cell culture 
All reagents were purchased from GIBCO-Life Technologies unless otherwise indicated. 
PD20F (FANCD2 mutant cells) and complemented PD20FD2 cells (FANCD2 mutant 
cells complemented with a retroviral vector containing the human FANCD2 cDNA) were 
grown using Dulbecco's Modified Eagle Medium (DMEM) high glucose, GlutaMAX, 
supplemented with 10% fetal bovine serum (FBS), and Penicillin-Streptomycin (10,000 
U/mL). Cells were passaged by standard trypsinization (using a 0.05% stock). The 
absence of Mycoplasma spp. in cultured cells was confirmed at least once a month by a 
PCR-based assay (Minerva) and STR-genotyping confirmed the identity of the cell lines 
(LorGen, Granada, Spain). 
Transfection of PD20F cells and Retrotransposition assays 
All retrotransposition assays performed in PD20F and FANCD2 complemented PD20F 
were performed in 4 biological replicate reactions. PD20F and PD20FD2 cells were 
transfected using Fugene6 (Promega #E2692) using manufacturer instructions. Briefly, 
8x104 cells were plated per 100mm culture plates and transfected 16h later using 10µl 
of Fugene6 and 4µg of each plasmid DNA using OptiMEM (Invitrogen #31985062) 
following the manufacturer instructions. 24h later, fresh media was added and cells 
were cultured for the next 4 days, changing the media every other day. Five days after 
transfection cells were selected with 2µg/ml Blasticidin-S (Invitrogen) for the following 7 
days, changing the media every other day. After the selection process, blast-resistant 
foci were harvested by trypsinization and genomic DNA extracted. Transfection 
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efficiency controls were included, co-transfecting cells in parallel with a GFP expression 
vector and determining the percentage of GFP-expressing cells 48h post-transfection by 
FACS.  
Genomic DNA isolation  
Genomic DNAs from PD20F retrotransposition assays were purified using a DNeasy 
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Figure 3.1 Recognition of DNA damage by ATR 
This figure was adapted and modified from Shiotani and Zou et al. 2009. DNA damage 
that results in single-strand DNA (ssDNA) either from stalled replication forks, or 
resection of DNA becomes a target for replication protein A (RPA).  Ataxia 
telangiectasia mutated and Rad3-Related (ATR) and ATR-interacting protein (ATRIP) 
are then recruited to the RPA-ssDNA complex. Independently, RAD17 is also recruited 
to the RPA-ssDNA complex. Then the 9-1-1 complex, consisting of Rad9, Rad1, and 
HUS1, is recruited to the site of damage along with TopBP1.  At this point ATR 
becomes activated to stabilize the genome during this DNA damage.  
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Figure 3.2 Schematic of siRNA knockdown retrotransposition assay in HeLa cells 
On Day -1, 1x106 HeLa cells are plated in a 10cm tissue culture dish. Twenty-four hours 
later on Day 0, the HeLa cells are co-transfected with pJJ101/L1.3 and siRNA, either 
siGFP or siATR. Twenty-four hours post-transfection media is changed.  Three days 
after transfection selection with blasticidin begins for the next 48 hours. On day 6 the 
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Figure 3.3 Engineered insertions display known LINE-1 insertion characteristics 
A) Engineered insertions display long poly(A) tails: Histograms of poly(A) tail lengths in 
base pairs (x-axis) for PD20F insertions complemented with FANCD2 and transfected 
with pJJ101/L1.3 (labeled ‘PD20F : PD20FD2 + L1.3’), PD20F cells transfected with 
pJJ101/L1.3 (labeled ‘PD20F : L1.3’), PD20F cells transfected with L1.3 EN mutant 
pJJD205A/L1.3 (labeled ‘PD20F : L1.3/D205A’), and PD20F cells transfected with L1.3 
PIP-box mutant pJJ101/L1.3-YY414,415AA (labeled ‘PD20F : L1.3/PIP6’). Histogram of 
poly(A) tail lengths for HeLa retrotransposition assays involving wild type L1.3 
transfected with pJJ101/L1.3 and siATR knockdown (labeled ‘siATR’; right top plot ) or 
siGFP knockdown (labeled ‘siGFP’; right bottom plot). These insertions had the 
representative longer poly(A) tail length due to the SV40 polyadenylation signal present 
in the engineered L1 constructs.  
B) PacBio Sequencing of Insertions results in long CCS Reads: Histogram of PacBio 
CCS read lengths in base pairs (x-axis) acquired for insertions from the respective 
labeled transfection conditions.  
C) Independent PacBio CCS reads support insertions: A plot of the proportion of 
insertions that are supported by 1 or more independent PacBio CCS reads. Number of 
independent CCS reads supporting a single insertion is show on the x-axis, while 
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Figure 3.4 L1 insertions are located within A-T rich regions of the human genome.   
A) Insertions are located in T-rich sequencings in the genome: Plotting nucleotide 
frequency of 100bp upstream and downstream of insertions from the corresponding 7bp 
EN consensus cleavage site reveals the sequence directly surrounding integration sites 
are primarily T-rich. Green represents Adenine, blue represents Cytosine, orange 
represents Guanine and red represents Thymine nucleotides.  
B) Engineered L1 insertions are found in AT-rich regions of the genome: Different 
lengths (x-axis) of genomic sequence upstream and downstream of L1 insertion sites 
were examined for GC content (y-axis). Boxplots represent the range of distributions of 
GC content observed for each respective window size. The box represents the middle 
50% of the data, while the line in the middle of the box represents the median observed 
observation. Whiskers represent the ranges for the bottom 25% and top 25% of the data 






Figure 3.4 L1 insertions are located within A-T rich regions of the human genome.    
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Figure 3.5 Engineered L1 insertions display endonuclease consensus cleavage 
site 
A) L1 EN site is influenced primarily by a 7mer sequence: We analyzed twenty-five base 
pairs upstream and downstream of the 7bp EN consensus cleavage site for insertions 
from siATR and siGFP retrotransposition assays and created a logo plot.  These 
insertions display the expected 7bp EN degenerate consensus cleavage site.  
B) L1 EN consensus cleavage site observed in ATR knockdown experiments: Logo 
plots of the specific 7bp EN consensus sequence was further examined in siATR and 
siGFP samples. Whether nucleotides were corrected for genomic frequency of EN sites 
in the genome (labeled ‘Corrected’) or uncorrected (labeled ‘Uncorrected’), the strong 
5’-TTTTT/AA EN cleavage is observed.  
C) L1 EN consensus cleavage site observed at FANCD2-deficient integration events: 








Figure 3.6 L1 insertions are located throughout the genome 
We compared insertion counts (y-axis) on chromosomes (x-axis) in respective PD20F 
insertion assay conditions (top plots) and siATR (bottom left plot) or siGFP (bottom right 
plot) knockdown retrotransposition assays. Boxplots represent the range of 
observations observed from the 10,000 iterations of the weighted random dataset. Each 
colored point represents the observed counts of insertions on each respective 

























Figure 3.7 L1 insertions are interspersed across chromosomes 
Depicted are chromosomal ideograms for all the insertions of the given sample listed 
above.  Each horizontal line represents a single insertion site on the corresponding 
location on the given chromosome.  Insertions are dispersed across chromosomes.  
PD20F is a male cell line so insertions are found on chromosome Y, while siATR and 
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Figure 3.8 L1 inserts into genes 
A) L1 insertions are located within exons: We explored the amount of insertions that are 
located within the UCSC genome browser’s annotation of exons of genes. Both 
insertion datasets (colored dot) fall within the expected range of exonic insertions as 
compared to the weighted random dataset (boxplots).  
B) L1 integration can occur at introns: We plotted the expected weighted random 
distribution of insertions within UCSC defined introns (boxplots) vs. the observed 
insertion counts (colored dots). PD20F complemented FANCD2, L1.3 insertions and 
L1.3/PIP6 insertions show significantly less intronic insertions (proportion test p-values 
0.047, 1.792e-05 respectively).  
C) Antisense genic insertion preference driven by L1 EN consensus cleavage site: We 
plotted the ratio of antisense to sense insertions found within exons and introns as 
defined by the UCSC genome browser annotation. In general, both sets of insertions 
(colored dots) fall within the expected range as compared to the weighted random 





Figure 3.8 L1 inserts into genes 
 
	 256	
Figure 3.9 Transcribed regions of genome are not preferential L1 integration sites 
A) Transcription is not preferentially targeted by L1 EN: Utilizing Bru-seq data performed 
on HeLa cells we defined the genome into transcribed regions (RPKM > 0.025) vs. not 
transcribed regions. We then plotted the counts of insertions (colored squares) that fell 
within each category  as compared to the weighted random datasets (box plots).  
B) Transcription does not influence L1 integration preference: Cumulative Distribution 
Function (CDF) plots of siATR and siGFP insertions with respect to transcription levels 
(x-axis) as determined either by HeLa segments Bru-seq data (top plots) or HeLa 1kb 
binned Bru-seq data (bottom plots). Red line represents the corrected weighted random 
model, blue line indicates the actual observed insertion dataset, and grey lines 
represent the weighted random model simulations. 
 C) Rate of transcription has no influence on L1 integration: Of transcribed regions in the 
HeLa genome we divided these regions into 30 distinct bins, from lowest transcription 
(left most of x-axis) to highest transcription (right most of x-axis). Regardless of 
transcription rate (x-axis) we observed the expected number of insertions (y-axis) as 
based on the weighted random model (box plot). Observed insertion counts from 
datasets are shown by connected colored squares. 
D) L1 EN shows no inherit preference for cleavage of coding or noncoding strand during 
transcription: Transcription Bias for each region in the genome is calculated as the 
absolute value of the rate of transcription on the top strand minus the bottom strand 
over the cumulative (top and bottom strand) transcription level in the region. We then 
distinguished transcription bias into 11 distinct bins from 0 to 1, where 0 indicates no 
strand transcription preference, and 1 indicates that one strand in the genome (top or 
bottom) is always biased towards being transcribed. For each bin we then counted the 
proportion of insertions in which EN cleavage occurred on the coding strand.  Boxplots 
represent the distribution observed from the weighted random dataset and colored 














Figure 3.10 Gene expression determined from RNA-seq does not influence L1 
integration 
A) RNA-seq expression does not influence L1 integration preference: Using RNA-seq 
data we divided the genome into two distinct bins, those regions of the genome 
expressed (FPKM > 0.3) and those regions not expressed. Weighted random dataset 
distributions is shown by the box plots and observed insertion counts are shown by the 
colored squares. RNA-seq expression from HeLa cells shows that insertions in ATR (left 
plot) and GFP (right plot) knockdown experiments are within expected ranges of 
expressed regions of the genome as compared to the weighted random model.  
B) Rate of expression does not influence integration: Expressed regions of the genome 
(FPKM > 0.3) were divided into 30 distinct bins from lowest expression rates (left most 
of x-axis on plot) to the highest expressed rate (right most of x-axis). Box plots 
represent the distribution observed from the weighted random dataset and colored 













Figure 3.11 Replication has no influence on L1 integration 
A) L1 EN shows slight preference for cleavage of lagging strand template during 
replication: We used the previously published HeLa and lymphoblastoid OK-seq data 
from Petryk et al. 2016 to determine if L1 EN preferentially cleaves the lagging strand 
template. HeLa OK-seq data was used for siATR and siGFP L1.3 insertion datasets and 
L1.3/PIP6 insertions in FANCD2-deficient cells was compared to the lymphoblastoid 
OK-seq data.  Replication Fork Direction was previously described and it’s value can be 
used to determine the leading or lagging strand template during DNA replication. We 
took the absolute value of this measurement and divided the genome into 11 bins (x-
axis). For each bin we then determined the proportion of insertions found in each bin in 
which the EN cleavage occurred on the lagging strand template during replication (y-
axis).  Boxplots represent the observed weighted random dataset distributions and 
colored connected squares represent the actual observed insertion data. 
B) L1 EN shows slight preference for cleavage of lagging strand template during 
replication (an alternative plot): We divided insertion datasets based upon whether L1 
EN cleaved the top strand (+) or bottom strand (-) in the genome.  We then plotted 
these insertions with respect to replication fork direction (RFD) bias. For insertions in 
which the EN cleaved the bottom (-) strand for integration into the genome a negative 
RFD bias value indicates lagging strand template cleavage is preferred whereas a 
positive RFD bias value indicated leading strand template cleavage preference. Red 
line represents the corrected weighted random model, blue line indicates the actual 
observed insertion dataset, and grey lines represent the weighted random model 
simulations. CDF plots of insertions in which EN cleaved the bottom (top plots) or top 
strand (bottom plots) during replication. FANCD2-deficient PIP6 mutant insertions 
significantly differ from the weighted random model when insertions are cleaved on the 
top strand (Kolmogorov-Smirnov bootstrap test p-value < 0.05) as well as when 
insertions are cleaved on the bottom strand in the genome (Kolmogorov-Smirnov 
bootstrap test p-value < 0.01). Both wildtype L1.3 insertions datasets in PD20F, 
including complemented with PD20FD2, show a trend favoring EN cleavage on the 
leading template strand. The D205A EN mutant in PD20F shows the opposite trend.  
Since the L1.3/D205A lacks EN activity this data suggest that the Okazaki fragments 
are utilized for priming during reverse transcription (Kolmogorov-Smirnov boot strap test 
P-values: PD20F L1.3 Bottom: < 1x10-6; PD20F L1.3 Top: < 0.001; PD20F L1.3/D205A 
Bottom and Top: < 0.01). 
C) L1 EN shows no strong preference for replication initiation or termination sites in the 
genome: Replication fork direction slope was plotted with respect to the cumulative 
fraction of insertions with that value.  A negative RFD slope value indicates fork 
termination while a positive RFD slope value indicates fork initiation. Red line 
represents the corrected weighted random model, blue line indicates the actual 
observed insertion dataset, and grey lines represent the weighted random model 
simulations. FANCD2-deficient L1.3/PIP6 mutant insertions significantly differ from the 
corrected weighted random model (Kolmogorov-Smirnov bootstrap test p-value < 0.01). 
FANCD2-deficient L1.3 insertion dataset differs significantly from the corrected 
weighted random model (Kolmogorov-Smirnov bootstrap test p-value < 0.05).   
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Figure 3.11 Replication has no influence on L1 integration 
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Figure 3.11 Replication has no influence on L1 integration 
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Figure 3.12 The L1 endonuclease domain influences cleavage and L1 integration 
preference in replication forks. 
In this figure we plotted all the engineered insertion samples (including those from 
Chapter 2) with respect to the proportion of insertions cleaved on the lagging strand 
template (y-axis) versus the replication fork direction (x-axis). Each color represents a 
different sample (see legend on top left of plot). All insertion datasets generated from an 
engineered L1 with wildtype endonuclease activity show a preference for cleavage on 
the lagging strand template during replication, as more than 50% of the total insertions 
show this preference (table to right of plot).  The L1.3/DD205A EN- mutant insertions 
only cleave the lagging strand template for 42.39% of the total insertions. This strong 
difference in trend between the two L1s, wildtype EN and mutant EN, suggest a 











Figure 3.13 FANCD2-deficient cells, PD20F, support wildtype and ENi 
retrotransposition. 
FANCD2 deficient (bottom row) or FANCD2 complemented (top row) were transfected 
with a wildtype L1 (left column) or L1 EN- mutant (right column) and following 
completion of the retrotransposition assay colonies were fixed and stained.  
Endonuclease mutant L1 is capable of ‘jumping’ in FANCD2 deficient cells to levels 
23% of wildtype levels.   
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Table 3.1 Insertions in fragile and non-fragile sites 
 Column 1 indicates the published dataset and their respective genomic locations of 
fragile and non-fragile sites.  There are two different fragile sites datasets, the second 
published dataset is from Mrasket et al.  2010 as indicated, and the first Fragile Sites 
dataset as well as last Non-Fragile Sites dataset is from Fungtammasan et al. 2012. 
Column 2 indicates the number of insertions (percentage of total insertions given in 
parenthesis) for the given sample in the listed published data set. Columns 3-5 give the 
min, median, and max of expected insertions of the weighted random dataset within the 
corresponding listed dataset. In general we observe the expected amount of insertions 
in fragile sites.  We do not observe an increase of insertions in fragile sites, nor a 
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(38.53%) 1390 1521 1630 
Sample Weighted Random 








(38.82%) 144 189 224 
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(42.63%) 1623 1745 1845 
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(41.00%) 6974 7229 7476 
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(39.96%) 528 603 677 
Sample Weighted Random 








(41.93%) 5031 5248 5474 
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My dissertation research has focused on identifying LINE-1 insertion preferences 
in the human genome. In chapter two, I examined tens of thousands of engineered 
LINE-1 insertions from four different cell lines that are proxies for in vivo cell types 
known to accommodate endogenous de novo L1 retrotransposition events. I discovered 
that the L1 EN is the principal factor dictating retrotransposition events into degenerate 
L1 EN consensus cleavage sites in AT-rich regions of the genome. Notably, the L1 EN 
consensus sequence is enriched on the sense strand of genes. I further demonstrate 
that gene expression, DNA replication status, and epigenetic features only exert 
minimal effects on L1 integration preferences. Thus, L1 EN is the principal determinant 
driving L1 integration throughout the human genome.  
In Chapter 3, I explored the effects of various DNA repair processes on L1 
integration preference. Specifically, I examined whether two DNA repair proteins, ATR 
and FANCD2, influence L1 integration. My data, in collaboration with Dr. Huira Kopera, 
strongly suggest that ATR senses TPRT intermediates; knocking down ATR expression 
does not significantly affect L1 integration preferences. By comparison, FANCD2-
deficient cells accommodate high levels of ENi L1 retrotransposition. The integration 
preference of wildtype L1s is not significantly affected in FANCD2-deficient cells; 
however, the available data suggest that L1 endonuclease-deficient mutants can target 
replication intermediates, perhaps using the 3’OH group present at Okazaki fragments 
or resultant double-strand DNA breaks present at collapsed DNA replication forks to 
initiate ENi retrotransposition. Interestingly, it is proposed that other endonuclease-
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deficient non-LTR retrotransposons (e.g., some mobile group II introns), can 
retrotranspose by a similar mechanism. 
In Chapter 3, I further explored whether mutations that disrupt the L1 PCNA-
interacting protein (PIP) domain hinder the ability of ORF2p to interact with PCNA, 
influence L1 integration. Interestingly, PIP mutants display similar integration 
preferences as wildtype L1s.  
Finally, in collaboration with Dr. Thomas Widmann, Mr. Alejandro Roldán, Mrs. 
Sarah Emery, and Dr. Weichen Zhou I have demonstrated that the capture technique 
used to characterize engineered L1 insertions in Chapters 2 and 3 can be easily 
modified to capture de novo engineered zebrafish L2 integration sites (Appendix A), as 
well as endogenous L1Hs integration sites in the human genome (Appendix B). Below, I 
discuss the significance of the data presented in this dissertation and suggest possible 
future directions for subsequent research.  
LINE-1 Endonuclease Drives LINE-1 Integration Preference 
Identification of Authentic Engineered L1 Integration Events 
In Chapter 2, I generated a large data set of 65,079 engineered L1 
retrotransposition events in various human tissue culture cell lines. Our first concern 
was to verify that our capture based technique and bioinformatics pipeline led to the 
identification of bona fide L1 integration events. We verified that our insertions end in a 
poly(A) tail (Figures 2.1G and 2.7F), integrate into a previously identified degenerate L1 
EN consensus cleavage site (Figures 2.1I and 2.7G), and occurred within sequences in 
the genome with a high local AT-content (Figures 2.1H and 2.7F). Since our insertions 
displayed these known L1 structural hallmarks, we were confident that our dataset 
contained authentic de novo L1 retrotransposition events (Gilbert et al., 2002; Lander et 
al., 2001; Morrish et al., 2002; Symer et al., 2002; Szak et al., 2002). Moreover, the 
presence of poly(A) tails reassured us that PacBio CCS sequencing technology allows 
us to sequence through poly(A) rich sequences, which often present a technical 
challenge for experiments using Illumina-based sequencing technology. Finally, many of 
our insertions are supported by more than one independent CCS read, which ranged 
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from 4.7% of HeLa cells insertions to ~60% of hESC insertions (Figures 2.1H and 2.7E). 
As expected, the number of duplicate reads reflects the number of independent 
retrotransposition events examined in our experiments. Thus, I generated a robust 
dataset of authentic, de novo L1 engineered integration events. 
A Closer Examination of the LINE-1 Endonuclease 
We hypothesized the L1 EN must be a determinant in L1 integration, as previous 
studies indicated that the vast majority of engineered L1 insertions occur at an L1 EN 
degenerate consensus cleavage site (5’-TTTT/A-3’) (Gilbert et al., 2002; Jurka et al., 
1997; Morrish et al., 2002; Symer et al., 2002; Szak et al., 2002). While the L1 EN 
cleavage site is typically described as a 5bp sequence, we found that that the L1 EN 
consensus cleavage is actually contributed by 7bp located at the integration site  (5’-
TTTTT/AA-3’) (Figures 2.1I and 2.7G). We discovered that each nucleotide within the 
7mer sequence is not independent (Figure 2.2B). The first position of the EN cleavage 
site is independent from the next four base pairs which is considered as one unit, which 
are then independent from the last two base pairs considered as another unit of the 
cleavage site (This creates a 1-4-2 model). We conclude that the L1 EN does not cut 
DNA in a random manner, further confirming that a simple random model, which treats 
all possible sites in the genome equally, cannot mimic L1 integration sites.   
In depth examination of the L1 EN consensus cleavage site revealed that a large 
majority (44.92%) of our L1 insertions often contain a cytosine residue instead of a 
thymidine residue in the T-rich sequence (e.g., 5’-TTCTT/AA-3’) (Figure 2.2C). It 
remains possible that L1 EN, which is classified as, and displays sequence similarities 
to, apurinic/apyrimidinic-like endonucleases (APEs), recognizes cytidine residues within 
the T-rich sequence to cleave at the target site. Indeed, previous work suggests that the 
human L1 EN crystal structure is most closely related to human apurinic/apyrimidinic 
endonuclease 1 (APE1), which cleaves DNA at apurinic and apyrimidinic sites of DNA 
damage (Mol et al., 2000; Weichenrieder et al., 2004). The dispersed cytosines found 
throughout the L1 EN cleavage site may be recognized by the L1 EN enzymatically and 
initiate the cleavage reaction, as in similar respects to other APEs.   
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I also studied the possible influence of the spatial configuration of nucleotides at 
the L1 EN cleavage. Specifically, as a consequence of local sequence-dependent 
unwinding of the helix and structural flexibility, the 5’-TnAn-3’ junction normally results in 
a wider minor groove structure (Cost and Boeke, 1998), where base stacking is minimal 
(Mack et al., 2001; Stefl et al., 2004). It is thought that the TpA junction in the minor 
grove of DNA is sensed, contacted, and widened by the insertion of a hairpin loop 
protruding from the L1-EN protein surface. Thus, target recognition may involve the 
accommodation of the 3’ adenine residue in an extra-helical conformation in a pocket of 
L1 EN (Weichenrieder et al., 2004). Another study also suggested that the L1 EN 
recognizes structural features present at the DNA target sequence, such as the 
structural flexibility of the DNA at the 5’-poly(T)/A-3’ junction, rather than specific 
nucleotides in the target sequence (Repanas et al., 2007). We hoped our model would 
be able to capture this aspect of L1 EN cleavage specificity.  
We created a weighted random model that accounted for the fact that L1 EN 
drives L1 integration into degenerate L1 EN consensus cleavage sequences. Since the 
L1 EN cleavage site is degenerate (e.g., 5’-TTTT/A-3’ and variants of that sequence, 
such as 5’-TTTA/A-3’, 5’-TTCT/A-3’, etc.) we used our empirical data to construct a 
model that captures this variability. As such, we used all possible 7mer sequence 
variants (12,288) in our modeling; 97% of our total insertions are found within 6% of 
these variants (Figure 2.2D). For L1 EN cleavage sites observed by three or more 
insertions, we used our observed frequencies of the corresponding EN cleavage site. 
For L1 EN cleavage sites observed by fewer than three insertions, we used our 1-4-2 
model to generate a position probability matrix and calculate frequencies for the 
integration sites (Figure 2.2E). These frequencies were then weighted by the most 
commonly observed EN consensus cleavage site which happened to be 5’-TTTTT/AA-
3’. Our weighted random model picked as many positions in the genome as total 
insertions in our dataset. To capture the variability of L1 EN integration sites, we 
repeated the L1 EN weighted integration picking process 10,000 times.  
To confirm the validity of our model, we asked if the simulated L1 EN sites 
display the same variability in the L1 EN consensus cleavage site observed in our 
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actual data (Figure 2.2F). The sequences surrounding the simulated sites are located in 
local AT-rich sequences of the genome (Figure 2.12D), just as we observed with our 
actual data set (Figures 2.1H and 2.11), which is consistent with the idea that L1 EN 
drives L1 integration sites into AT-rich regions of the genome. Notably, as opposed to 
previous studies, our model accounts for known L1 insertion preferences. Previous 
studies only analyzed a limited number of retrotransposition events and tend to use old 
L1 and/or young L1Hs sequences within the genome as benchmarks for comparisons to 
their empirical data (Baillie et al., 2011; Ovchinnikov et al., 2001). Making comparisons 
of this nature does not account for selective forces that have influence the distribution of 
L1s over evolutionary time, thereby skewing the genomic L1 distribution.  
LINE-1 Integrates Throughout the Genome 
Now that we had generated a model that assumes that L1 EN is the principal 
factor in directing L1 integration at a degenerate consensus cleavage site, we were 
ready to examine whether other genomic features might influence L1 integration. In 
essence our model controls for the known L1 EN univariate, and we now wanted to 
explore other variables, such as specific genomic features, which may also influence L1 
integration, resulting in a possible multivariable model for L1 integration. As observed 
previously, we saw a significant increase of engineered L1 insertions on the X 
chromosome in PA-1, NPCs, hESC, but not HeLa cells (Figures 2.3A, 2.3B, 2.14A, and 
2.15). There are longstanding debates in the field as to whether L1s prefer to insert on 
the X-chromosome, or whether the X-chromosome simply accumulates greater 
numbers of L1 insertions over evolutionary time, since unique portions of the X-
chromosome cannot undergo meiotic recombination in males (Langley et al., 1988; 
Wichman et al., 1992). Indeed, some have suggested that the increase of L1 insertions 
on the X chromosome plays a functional role in X-inactivation (Bailey et al., 2000; 
Gartler and Riggs, 1983; Lyon, 1998; Riggs, 1990). All of our cell types examined are 
female. Thus, I speculate the observed increase of engineered L1 insertions on the X-
chromosome may be due to specific, but not yet studied, epigenetic modifications that 
influence L1 integration. The hypothesis follows that the X-chromosomes in HeLa cells 
would lack such features.  
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We did not find a preference for L1 integration within the exons or introns of 
genes (Figures 2.3C and 2.3D). We did observe a slight antisense preference for L1 
insertions within genes in HeLa, PA-1, and hESC-derived NPCs; however, careful 
analyses revealed that this is due to an increase in the presence of L1 EN cleavage 
sites on the sense strand of genes (Figure 2.3F). Importantly, these data differ from 
observations of genomic L1s, which show a profound accumulation in the antisense 
orientation of genes (Smit, 1999). Thus, Darwinian selective forces likely influence the 
accumulation of genomic L1s over evolutionary time, perhaps because alleles 
containing L1s in the sense orientation are detrimental and selectively removed from the 
population.  
Intriguingly, L1 insertions in hESCs show a significant antisense insertion bias 
into genes. We speculate that this observed enrichment could occur if L1 into the sense 
orientation are more detrimental in hESCs than in other cell types. For example, this 
scenario could result if sense strand L1 insertions promote hESC differentiation. These 
somewhat paradoxical findings warrant further examination. 
Several reports have claimed that L1 preferentially targets expressed genes, 
especially in neurons (Upton et al., 2015). By comparison, we did not observe any 
preference for L1 integration within expressed or transcribed regions of the genome by 
comparing L1 insertion profiles to both Bru-seq and RNA-seq datasets generated from 
representative cell lines used in our study (Figures 2.4B, 2.4C, 2.13B, and 2.13C). It is 
formally possible that L1 insertion preferences within neurons differ from those in 
cultured cells. However, it is more likely that the single cell WGA amplification used to 
detect de novo L1 integration events in neurons are plagued by high false positive rates 
(e.g., due to a high rate of chimeric sequencing artifacts) and only a handful of 
insertions were verified by orthogonal validation experiments (Evrony et al., 2016). If so, 
the L1 insertion datasets in neurons may not be appropriate for assessing L1 integration 
preferences. Given the extensive validation of our datasets, we believe the L1 insertion 
preferences in neurons warrants re-examination. 
We observed that engineered L1s readily insert into ‘transposon-free’ regions of 
the genome (Table 2.6) (Bejerano et al., 2004; Simons et al., 2006), as well as into 
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protein codon exons. These results differ significantly from genomic L1s, where 
endogenous L1s are either absent or severely depleted from these regions. Thus, we 
conclude that  ‘transposon-free’ regions of the genome and protein codon exons are 
accessible L1 integration sites. It stands to reason that alleles containing these 
detrimental insertions would be subject to strong negative selective pressures and 
would be removed from the population. Indeed, these data are consistent with the idea 
that many disease-producing L1 insertions represent evolutionary dead ends. For 
example, individuals presenting with Duchenne muscular dystrophy due to an L1-
mediated retrotransposition event will sadly seldom father children. Our data also clearly 
demonstrate the ability of the cultured cell L1 retrotransposition assay to ‘capture’ 
mutagenic insertions and underscores our assertion that our data set represents a 
relatively unbiased set of L1 integration events in the human genome. 
Since we observed a depletion of L1 integration sites in expressed and 
transcribed regions of the genome, we asked whether L1 preferentially integrates within 
heterochromatic regions of the genome. We compared our L1 integration data set to the 
15 and 18 chromatin state data generated by the NIH roadmap epigenomics mapping 
consortium (Roadmap Epigenomics et al., 2015). Notably, we did not observe a 
significant enrichment of engineered L1 integration sites within any of the modeled 
chromatin states (Figures 2.5 and 2.19), though we did observe a depletion of L1 
insertions into certain regions, such as genes (Figure 2.3C and 2.3D).  
As a control for our analyses, we reanalyzed a previously published MLV 
retrovirus integration data set and confirmed that MLV exhibits preference for integrating 
into transcriptional start sites, enhancers, and active promoters (LaFave et al., 2014). 
Indeed, downsizing the MLV integration site datasets to reflect the numbers of L1 
integration events examined in our study still revealed an appreciable enrichment of 
MLV integration sites in transcriptional start sites, enhancers, and active promoters, 
(Figure 2.17). These findings support the assertion that our sample sizes could have 
detected a correlation between the 15 to 18 chromatin states examined by the NIH 
roadmap epigenomics mapping consortium and L1 integration preferences. Finally, the 
above findings are consistent with previous studies from our laboratory and support the 
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hypothesis that the epigenetic silencing of engineered L1 retrotransposition events in 
PA-1 cells either during or immediately after their insertion is due to an active 
mechanism and cannot simply be explained by the insertion of L1 into heterochromatic 
regions of the genome (Garcia-Perez et al., 2010).  
We compared our insertion data set to previously published Okazaki fragment 
sequencing (Petryk et al., 2016), and found that wildtype L1s do not exhibit a strong 
integration preference into DNA replication initiation sites, DNA replication termination 
sites, or template or lagging strand DNA templates. Okazaki fragment DNA sequencing 
(OK-seq), involves capture of Okazaki fragments during DNA replication and 
characterization by high-throughput DNA sequencing. We downloaded the previously  
published OK-seq data performed on HeLas and a lymphoblastoid cell line (Petryk et al., 
2016). OK-seq involves capture of Okazaki fragments during DNA replication and 
characterization by high-throughput DNA sequencing. We did find a slight L1 integration 
preference into the lagging strand template in each of our cell types (Figures 2.6B and 
2.19A). Importantly, and in agreement with previous studies, these data further suggest 
that a proportion of engineered L1 retrotransposition events likely occur during the S-
phase of the cell cycle (Kubo et al., 2006; Morrish et al., 2002) (also see below). 
We readily admit that it would be ideal to perform OK-seq on a representative 
group of cell lines used in our studies; however, such an analysis is expensive, time-
consuming, and labor intensive. Moreover, unlike RNA expression data, previous 
studies suggest that DNA replication timing is reasonably correlated between different 
cell types (Petryk et al., 2016), thereby justifying our approach. That being stated, we 
acknowledge that cell type specific peculiarities in replication timing will be missed in 
our analyses. 
There are other caveats and potential limitations to our study. First, we cannot 
rule out the possibility that genomic features other than the presence of a degenerate 
L1 EN cleavage site influence L1 integration preferences to some extent. Although the 
size of our dataset has provided an unprecedented opportunity to examine L1 insertion 
preferences in a statistically robust manner, the dataset size also allows us to observe 
statistically significant deviations from our weighted random model that have a small 
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effect size on L1 integration preference. Second, it remains possible that the use of 
engineered L1s containing selectable (i.e., neomycin) or screenable (i.e., green 
fluorescence protein) retrotransposition indicator cassettes lead to an ascertainment 
bias in our data set. If so, we would expect to see an enrichment of L1 integration 
events in open chromatin and/or expressed genes; however, we did not observe such 
enrichments. Notwithstanding these caveats, we conclude that L1 EN is the principal 
factor that drives L1 integration preferences in the genome. 
FANCD2-deficient Cells Display ENi and PCNA-independent Retrotransposition 
ENi Retrotransposition in FANCD2-deficient Cells 
 In collaboration with Dr. José L. Garcia-Perez, we characterized a smaller subset 
of engineered wildtype L1 retrotransposition events in both FANCD2-deficient and 
FANCD2-proficient cells. As in Chapter 2, we did not observe significant deviations in 
L1 integration preferences from those generated in simulations using our weighted 
random model with respect to the L1 chromosomal distribution or L1 insertions into 
genes. Similar results also were obtained using an L1 containing a missense mutant 
that blocks the ability of L1 ORF2p to interact with PCNA. Once again, these data again 
support the hypothesis that L1 EN is the driving force for L1 integration in these cell 
lines. 
 Previous data from our laboratory demonstrated that L1s could bypass the 
requirement of L1 EN and undergo endonuclease-independent retrotransposition in 
Chinese Hamster Ovary cells and human cell lines that are compromised for the non-
homologous end joining (NHEJ) pathway of DNA repair and lack p53 activity (Coufal et 
al., 2011; Morrish et al., 2007; Morrish et al., 2002). Indeed, dysfunctional telomeres 
could be used as ENi integration substrates in DNA protein kinase catalytic subunit-
deficient CHO cells (Morrish et al., 2007). Thus, through either diffusion or by 
associating with host factors, endonuclease-deficient L1s are able to localize to 
genomic sites of disrepair to initiate ENi retrotransposition. 
Intriguingly, ENi L1 retrotransposition also occurs in a subset of Fanconi anemia-
deficient cells. The examination of a cohort of ENi L1 retrotransposition events in 
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FANCD2-deficient cells suggests that endonuclease-deficient L1s can target replication 
intermediates, perhaps by using a 3’OH group present at Okazaki fragments or at 
double-strand DNA breaks present at collapsed DNA replication forks, to initiate ENi 
retrotransposition (Figures 3.11A and 3.11B and 4.1). These findings are curiously 
similar to previous studies with an endonuclease-deficient group II intron, which 
suggested that it preferentially integrates into lagging strand templates, most likely 
utilizing Okazaki fragments to prime cDNA synthesis (Ichiyanagi et al., 2003; Ichiyanagi 
et al., 2002).  
How some EN-deficient L1 integration events target DNA replication forks for 
integration requires elucidation. Indeed, it will be interesting to examine whether L1 
ORF2p EN-/PIP domain double mutants exhibit similar or different integration 
preferences when compared to EN-deficient L1 mutants. Moreover, the nature of the 
lesion(s) used to initiate ENi in FANCD2-deficient cells require elucidation. A thorough 
characterization of the structural hallmarks associated with ENi retrotransposition 
events (e.g., the presence or absence of TSDs and genomic alterations) may provide 
valuable insight into this process. Preliminary data from Dr. Garcia-Perez indicates that 
wildtype and ENi retrotransposition events isolated from FANCD2 cells generally 
contain poly(A) tails; thus, it seems likely that our capture method allows the 
characterization of a representative cohort of ENi retrotransposition events. 
Does ENi Retrotransposition in FANCD2-deficient Cells Recognize Replication Forks for 
Integration? 
The FA pathway is involved in the replication-dependent removal of ICLs; the 
failure to repair ICLs can lead to stalled replication forks (Scharer, 2005). Thus, 
FANCD2-deficient cells may harbor more substrates for ENi retrotransposition than 
FANCD2-proficient cells. Consistent with this idea, previous studies demonstrated that 
treating FANCD2-deficient cells with low doses of aphidicolin, which inhibits DNA 
polymerase α and δ and increases the appearance of common fragile sites (Glover et 
al., 1984), led to an increase in chromosomal gaps and breaks in metaphase 
chromosomes (Howlett et al., 2005). Common fragile sites are late-replicating regions of 
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the genome particularly susceptible to replication fork stalling or collapse, which if 
unrepaired leads to genomic instability (Howlett et al., 2005).  
We did not observe an increase of ENi L1 retrotransposition events at common 
fragile sites in FANCD2-deficient cells (Table 3.1). However, if endonuclease-deficient 
L1s use stalled replication forks as integration substrates, it is possible that aphidicolin 
treatment may lead to an increase of ENi L1 retrotransposition at common fragile sites. 
That being stated, such experiments may be technically difficult because treating an 
asynchronous population of cells with aphidicolin is a blunt tool—only a small portion of 
cells in the population may have the lesion required for ENi L1 retrotransposition. Thus, 
negative results will be difficult to interpret. Moreover, it also is possible that stalled 
replication forks are not the actual substrates used for ENi L1 retrotransposition. Instead, 
ENi might occur at double-strand DNA breaks that occur as a consequence of stalled 
replication forks. Indeed, such double-strand DNA breaks may also serve as ENi 
retrotransposition integration substrates in XRCC4- and a subset of DNA-PKcs-deficient 
Chinese Hamster Ovary cells (Morrish et al., 2007). 
 Does ENi Retrotransposition Represent an Ancestral Mechanism of L1 
Retrotransposition?  
In sum, our results suggest that ENi L1 retrotransposition may represent an 
ancestral mechanism used by L1-like retrotransposons prior to the acquisition of an 
endonuclease domain. Under this scenario, L1-like elements were reliant on genomic 
features (e.g., site of genomic DNA damage, replication forks, and, less frequently, 
dysfunctional telomeres) as sites to initiate TPRT in the absence of an endonuclease. 
The acquisition of an endonuclease domain then allowed L1 to exert its will on the 
genome, creating site-specific endonucleolytic breaks to liberate 3’-OH groups, which, 
in essence, allowed it to autonomously insert throughout the genome (Figure 4.2). 
Notably, this scenario differs to that of other retrotransposons discussed in the 
introductory chapter, where the acquisition of a site-specific endonuclease or 
interactions between an element-encoded integrase-type activity and other proteins 
allowed transposable elements to target genomic ‘safe havens’ to minimize TE damage 
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to the host. Indeed, we posit that the acquisition of an endonuclease, as originally 
implied by its name, allowed L1 to become an interspersed retrotransposon. 
Does PCNA Interact with L1 post-EN Cleavage?  
PCNA is an important co-factor for DNA polymerase during replication (O'Donnell 
et al., 2013; Siddiqui et al., 2013) and also participates in several DNA repair processes. 
Previous studies suggest that an L1 containing a missense mutation in the PIP domain  
exhibits a decrease in L1 retrotransposition efficiency (Taylor et al., 2013). Drs. Jose  L. 
Garcia-Perez and Tomoichiro Miyoshi observed similar results—an L1 PIP mutant, PIP6, 
exhibited < 5% of wild-type L1 retrotransposition levels in HeLa cells. Moreover, the L1 
PIP6 mutant does not phenocopy L1 EN-deficient mutants because it does not jump in 
the NHEJ-deficient Chinese Hamster Ovary cell line XR-1.  
In Chapter 3, I found that the L1 PIP6 mutant does not affect L1 integration 
preferences, as the resultant insertions integrate into a degenerate L1 EN consensus 
cleavage site (Figures 3.4B and 3.5C) and are located throughout the genome (Figures 
3.6 and 3.7). Thus, L1 EN activity is not disrupted in the PIP6 mutant, suggesting that 
PCNA may interact with L1 after the initiation of TPRT, perhaps by recruiting additional 
host factors required for the completion of L1 integration. Precedence for such 
interactions exist. For example, PCNA is implicated in recruiting RNase H2 to RNA/DNA 
hybrids in genomic DNA (Bubeck et al., 2011). It is tempting to speculate that such 
recruitment may play a role in TPRT (Figure 4.3). 
Since PCNA also is involved in several DNA repair pathways, including long 
patch DNA repair synthesis, it also is possible that PCNA may aid in the completion of 
L1 integration. For example, LIG1 is a human DNA ligase that interacts with PCNA 
(Prasad et al., 1996; Srivastava et al., 1998) and is involved in the ligation of single-
stranded DNA breaks during long patch repair (Caldecott, 2008). One could easily 
imagine that the recruitment of LIG1 plays a role in ligating the L1 cDNA to genomic 
DNA (Figure 4.3). Clearly, the characterization of L1 PIP6 insertions from FANCD2-
deficient cells represents a first step toward addressing the above possibilities.  
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Does PCNA Guide L1 to Replication Forks? 
We compared our L1 PIP6 mutant insertion data set in FANCD2-deficient cells 
with OK-seq replication data (Petryk et al., 2016) to determine if loss of PCNA binding 
effects integration preference in initiating or terminating replication forks. Examination of 
our L1 PIP6 mutant insertions shows a significant depletion of insertions at both 
initiating and terminating replication forks (Figure 3.11C). When we adjust for the 
observed depletion of wildtype L1 insertions in FANCD2-deficient cells at terminating 
replication forks, this suggests PCNA may guide L1 to initiating replication forks. These 
are very preliminary results and need further validation. Additional analysis with Okazaki 
sequencing directly from FANCD2-deficient cell line could help tease these results out.  
Although OK-seq in FANCD2-deficient cells may prove to be difficult to perform, as well 
as interpret, if these cells harbor stalled replication forks.  
Since PCNA is a co-factor involved in DNA replication and L1 retrotransposition 
is believed to occur during S-phase (Kubo et al., 2006; Morrish et al., 2002), PCNA may 
guide L1 to replication forks.  If PCNA guides L1 to replication forks, PCNA-deficient 
retrotransposition in FANCD2-deficient cells may occur because cells harbor an 
abundance of stalled replication forks, and moreover it would suggest that L1 can find 
such forks in abundance on its own. 
Additional retrotransposition assays of a double L1 EN- and PIP-box mutant in 
FANCD2-deficient cells could elucidate whether the L1 EN- mutant is dependent upon 
PCNA to guide L1 integration. We may expect decreased retrotransposition efficiency in 
this double mutant if PCNA is directly involved in guiding the L1 EN mutant to its priming 
substrate. We believe that L1 EN mutants utilize the Okazaki fragments or downstream 
double-stranded substrates as primers for reverse transcription, but if the L1 can no 
longer be led to replication forks, what does the L1 RT use as a primer to initiate cDNA 
synthesis? Would this double mutant kill L1 retrotransposition entirely in FANCD2-
deficient cells? If this double mutant leads to observable levels of retrotransposition, 
characterization of integration events and integration sites could help determine if PCNA 
may play a role in ENi L1 retrotransposition. 
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ATR Affects L1 Integration Post-EN Cleavage 
Recognition and signaling of DNA damage is mediated by the ataxia 
telangiectasia mutated (ATM) and ATM Rad3-related (ATR) proteins, which bind to 
broken DNA ends (Christmann et al., 2003). Previous reports show that ATM-deficient 
NPCs exhibit increased wild-type L1 retrotransposition levels when compared to ATM-
proficient NPCs (Coufal et al., 2011). The characterization of L1 retrotransposition 
events from ATM-deficient NPCs have typical L1 structural hallmarks, suggesting they 
integrated via canonical TPRT. However, there appear to be longer, or perhaps more L1 
retrotransposition events in ATM-deficient NPCs compared to those in ATM-proficient 
NPCs. Thus, ATM may act to inhibit L1 retrotransposition in NPCs. 
Importantly, Dr. Huira Kopera observed that L1 retrotransposition increases in 
HeLa cells upon ATR knockdown. Since a complete knockout of ATR leads to cell death, 
it is hypothesized that ATR may recognize single-strand DNA breaks or other 
intermediates generated during TPRT. Indeed, consistent with this model, ATR 
knockdown neither enhances ENi retrotransposition nor does it affect L1 integration 
preferences in the genome (see Chapter 3). Moreover, L1 integration events 
characterized from ATR-deficient cells are often longer than those characterized from 
ATR-proficient cells, and contain an increased frequency of intra-L1 rearrangements 
and/or genomic deletions at the L1 integration site. Thus, like ATM, ATR may act to 
inhibit L1 retrotransposition in cultured cells. 
Does ATR Act at Second-Strand Cleavage? 
ATR also has the potential to recognize single-strand DNA nicks generated 
during TPRT second strand cleavage. I speculate that second-strand cleavage could 
lead to an exposed single strand DNA gap that is bound by replication protein A (RPA), 
which subsequently recruits ATR, the ATR-interacting protein (ATRIP), and the RAD17 
complex to participate in DNA repair (Figure 3.1 and Figure 4.4). In the absence of ATR, 
this substrate would not be subject to repair; as such, one may observe longer 
retrotransposition events. Similarly, if the second strand endonucleolytic nick occurs 
upstream (leading to a 5’ overhang) of the initial EN cleavage site, or is resected, failure 
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to repair the resultant single strand DNA gap could lead to the genomic deletions 
accompanying L1 retrotransposition events in ATR-deficient cells. 
Concluding Remarks 
My thesis has examined L1 integration preferences in the human genome and 
ultimately concludes that the L1 EN is the principal determinant for L1 integration 
preference. Our data suggests that the degenerate L1 EN consensus cleavage site is 
responsible for previously observed L1 integration characteristics, such as integration 
events into AT-rich regions of the genome.  
We generated a weighted random model that mimics L1 integration sites in 
degenerate L1 EN consensus cleavage sites distributed throughout the human genome. 
We utilized this model to determine if certain cellular conditions, cellular host factors, or 
alternative retrotransposition pathways may influence L1 integration preference. We 
suggest a new mechanism for EN-independent L1 integration utilizing Okazaki 
fragments or resultant double strand DNA breaks present at collapsed DNA replication 
forks to initiate EN-independent retrotransposition. Analysis of additional integration 
sites from DNA repair protein knockdown or deficiency experiments suggests evidence 
for cellular factors preventing L1 mobilization pre-EN cleavage (FA pathway) or post-EN 
cleavage (ATR). Lastly, we examined integration sites of a PCNA-interacting protein-
box L1 mutant and find evidence to suggest that PCNA aids L1 integration post-EN 
cleavage. As demonstrated in this thesis, we have generated an invaluable toolset for 
the transposable element biology field to gain mechanistic insights about how additional 
cellular conditions, cellular host factors, or retrotransposition pathways might influence 







Figure 4.1 A Mechanism for wildtype L1 and L1 EN mutant integration into 
replication forks.  
A) Replication Fork Structure: As depicted here the green arrows represent Okazaki 
fragments or the replication intermediates complementary to the lagging strand template.  
These intermediates may be replicated DNA primed off the Okazaki fragments but not 
yet ligated to form one singular strand.  The orange arrow represents the leading strand 
in a replication fork. 
 
B) Proposed integration of wildtype L1 during replication: L1 EN may preferentially 
cleave the lagging strand template during replication, as the strand may be more 
accessible than the leading strand template, which is being passed by the DNA 
polymerase for replication.  
 
C) Proposed integration of L1 EN mutant during replication: We propose, and our 
data in Chapter 2 suggests, that the L1 EN mutant (blue circle with star) utilizes Okazaki 
fragments or replication intermediates containing a free 3’-hydroxl to prime and allow for 
reverse transcriptase of L1 RNA. In this model second strand cleavage would need to 
occur by other cellular host factors to ensure integration into the genome. An alternative 
possibility is that stalled replication forks lead to double strand breaks which can then be 




Figure 4.1 A mechanism for wildtype L1 and L1 EN mutant integration into 

































Figure 4.2 Acquisition of the L1 endonuclease has allowed L1 to integrate 
throughout the human genome.  
The L1.3/D205A EN mutant is similar to an ancestral state of L1, which lacks 
endonuclease activity. This ancestral state, lacking EN activity must rely upon DNA 
double strand breaks created throughout the genome in order to ensure integration. 
DNA break opportunities can be presented during stalled replication forks, DNA repair 
intermediates, or at the end of chromosomes near telomeres. The integration sites of 
the ancestral L1 are heavily influenced and reliant upon these genomic features.  
Acquisition of the EN activity allowed L1 to mobilize throughout the genome, no longer 
























Figure 4.3 PCNA, a recruiter for cellular host RNase H or ligase to aid in L1 
retrotransposition. 
During TPRT the L1 EN activity of the ORF2p (shown by blue circle) cleaves at a 
double stranded DNA substrate. If PCNA is bound to ORF2p during TPRT it may be 
used to recruit Exo1 or similar proteins that contain RNase H activity. This RNase H 
activity would act after reverse transcriptase of the L1 RNA to cDNA, removing the L1 
RNA from the RNA/DNA hybrid so that second strand synthesis can occur. Another 
proposed mechanism of PCNA is that it recruits ligase to ligate the remaining ssDNA 
breaks that flank the L1 integration site. PCNA may sit on the 3’ end of the cleavage, 
become modified (light blue hexagon) and thus act as a signal for LIG1 to come to the 



































Figure 4.4 Proposed model of ATR acting at second strand cleavage during TPRT. 
During TPRT, it is unclear how or when second strand cleavage occurs, but it must 
happen for integration to occur. At the site of second strand cleavage a ssDNA complex 
is formed which is the ideal substrate for ATR induced DNA damage repair. This ssDNA 
may become bound by RPA, which then signals ATR, ATRIP, and RAD17 binding to 
begin repair. ATR could be seen as a cellular host factor trying to prevent L1 integration. 
Knockdown of ATR may force the second strand to undergo additional repair 
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     Appendix A 
Identification of de novo LINE-2 Insertions in Early Development of Zebrafish 
Work in this appendix was done in collaboration with Dr. Thomas Widmann and 
Mr. Alejandro Roldán while in the laboratory of Dr. José L. Garcâ-Perez. Dr. Thomas 
Widmann performed retotransposition experiments in the zebrafish and isolated gDNA. I 
performed LINE-2 capture techniques on the retrotransposed zebrafish gDNA. Mr. 
Alejandro Roldán performed bioinformatics analyses to identify LINE-2 insertions. 
Introduction  
In collaboration with Dr. Thomas Widmann and Dr. José L. García-Perez, 
currently at the University of Edinburgh, we sought to capture, amplify, and sequence 
de novo engineered LINE-2 insertions from early embryonic zebrafish Danio rerio. The 
aim was to determine the location of de novo LINE-2 events during early 
embryogenesis and determine if LINE-2 preferentially integrates within the D. rerio 
genome.  
Two retrotransposition-competent LINEs, ZfL2-1 and Zfl2-2, were identified in the 
zebrafish genome (Kapitonov and Jurka, 2003; Sugano et al., 2006). Both ZfL2-1 and 
ZfL2-2 are members of the L2 clade (Sugano et al., 2006). They are classified as 
stringent type LINEs as their encoded enzymatic machinery specifically recognizes its 
own RNA 3’ tail during retrotransposition (Sugano et al., 2006). This RNA 3’ tail is 
predicted to form a stem-loop structure, which may aid in recognition by the reverse 
transcriptase (Kajikawa et al., 2005). Upon integration these elements do not generate 
target site duplications and their 3’ tails are composed of microsatellites; of which 
specific microsatellite sequences can be used to identify distinct element families 
(Kapitonov and Jurka, 2003). These microsatellites are not sequence targets for these
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LINE-2 elements, but rather are inserted into the genome together with the element 
sequence (Kapitonov and Jurka, 2003). It is believed that generation of these 3’ end 
microsatellites is a result of non-templated additions by the LINE-2 reverse transcriptase 
(Kapitonov and Jurka, 2003). 
ZfL2-1 is approximately 5kb long and encodes two open reading frames (ORFs).  
ZfL2-1 ORF1 encodes a protein composed of a putative coiled-coil (CC) motif and an 
esterase (ES) domain, while ORF2 is composed of an endonuclease (EN) domain and 
reverse transcriptase (RT) domain (Figure A.1). Each ORF is required for efficient 
retrotransposition (Sugano et al., 2006). While the functional significance of the 
esterase domain, a catalytic triad composed of serine, histidine and aspartic acid 
residues is unknown, point mutations within the domain result in reduced 
retrotransposition efficiency, suggesting that this ES domain has an enhancing function 
during retrotransposition (Ho et al., 1997; Sugano et al., 2006). It has been 
hypothesized that the ES domain is important for interaction with cellular membranes, 
aiding in penetration of host cells (Kapitonov and Jurka, 2003; Nakamura, et al., 2012). 
The 3’ termini of ZfL2-1 elements are composed of (ATTGA)n which follows 5’-GCTTGA 
and the polyadenylation signal (Kapitonov and Jurka, 2003). 
ZfL2-2 on the other hand is approximately 4.2kb long and contains a repeated 
sequence in the 5’ untranslated region (UTR). The element encodes only one open 
reading frame with EN and RT domains. The 3’ termini of ZfL2-2 contain (AAATGT)n 
and they do not have any polyadenylation signal (Figure A.1).  
Here we examined engineered ZfL2-1 and Zfl2-2 integration events from 
zebrafish embryos. We modified the capture and amplification techniques described in 
Chapter 2, and resulting amplicon products were sequenced by Pacific Biosciences 
single molecule real time (SMRT) circular consensus sequence (CCS) sequencing 
technology. This appendix describes the specific modifications performed to capture de 





Generating LINE-2 Insertions in Zebrafish 
Dr. Thomas Widmann generated ZfL2-1 and ZfL2-2 DNA containing a T7 
promoter upstream to generate ZfL2-1 and ZfL2-2 mRNA transcripts to be injected into 
zebrafish eggs. Three or eight days post injection, zebrafish embryos were collected 
and genomic DNA (gDNA) was isolated by Proteinase-K and phenol extraction 
protocols. Transfected zebrafish gDNA was then sent to the University of Michigan 
where I performed capture methods and PacBio Sequencing.  
Capture of de novo LINE-2 Insertions 
Utilizing the same general format for capture of de novo insertion events in 
Chapter 2, methods were slightly modified to allow for LINE-2 capture. Transfected 
zebrafish gDNA was randomly sheared to 3kb fragments with the Covaris S220/E220 
series and following the same format as in Chapter 2, libraries were created with the 
same adapter sequences. Libraries were subjected to a linear amplification utilizing a 
biotinylated primer specific to both the ZfL2-1 and ZfL2-2 sequence (Figure A.2). 
Following biotinylation amplification, biotinylated products were streptavidin bead 
captured and subjected to a nested PCR with an adapter specific primer as well as 
primers specifically designed for each the ZfL2-1 and ZfL2-2 sequences. Successfully 
amplified products were column purified. A portion of amplified products was ligated into 
a cloning vector and Sanger sequenced to verify the capture of de novo LINE-2 
insertion events in the zebrafish genome. The remaining products were sent for PacBio 
SMRT CCS sequencing at the University of Michigan Sequence Core and sequences 
were sent to Dr. José García-Perez’s lab for further analysis and characterization by Mr. 
Alejandro Roldán. 
Materials and Methods 
Primer sequences: All oligonucleotides used in this study were synthesized by 
Integrated DNA Technologies (IDT; Coralville, Iowa). 
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PCR Library Preparation 
 
Top strand adapter with T overhang; purified by high-performance liquid 
chromatography (HPLC):  
5’-GGAAGCTTGACATTCTGGATCGATCGCTGCAGGGTATAGGCGAGGACAACT-3’  
 
Bottom strand adapter with 5’ phosphorylation and 3’ amino modifier; purified by high-
performance liquid chromatography (HPLC):  
5’-/5Phos/GTTGTCCT/3AmMO/-3’ 
 
10µM final concentrations of annealed adapters were made by incubation of both the 
top and bottom strand adapters at 95˚C for 5 minutes, followed by allowing the tube to 
naturally come to room temperature.  
 
15µg of isolated gDNA was sheared to 3kb random fragments following protocols for the 
Covaris S220/E220 operating systems. Sheared gDNA was purified following QIA-quick 
PCR Purification Kit (Qiagen #28104). Purified sheared gDNA was end repaired 
following NEBNext End Repair Module (NEB #E6050). End repaired gDNA was purified 
following QIA-quick PCR Purification Kit (Qiagen #28104). A non-templated dAMP was 
then incorporated on the 3’ end of the purified end repaired gDNA as outlined by 
NEBNext dA-Tailing Module (NEB #E6053). Following this reaction dA-tailed gDNA was 
subsequently purified with the MinElute PCR Purification Kit (Qiagen #28004). Annealed 
adapters were ligated onto the final purified DNA molecules in the following conditions: 
1µg DNA to 90µM of annealed adapter (Final Adapter concentration of 4.5µM) in a 20µl 
total volume reaction with 1µl (200U) of T4 DNA ligase (NEB #M0202). Ligation 
reactions were incubated overnight at 16˚C and heat inactivated at 65˚C for 20 minutes. 
Samples were purified of excess linkers with QIAquick PCR purification kits (Qiagen 




Uni-linear Biotinylated amplification 
Biotinylated Zebrafish; purified by high-performance liquid chromatography (HPLC); 5’ 
Dual Biotin; 18bp internal spacer;  
5’-/52-Bio//iSp18/ATTTACCGTAAGTTATGTAACGCGG-3’ 
Linear extension reactions were performed with Roche Expand Long Range dNTP Pack 
PCR system. Reactions contained 500ng of template gDNA, the Manufacturer’s Expand 
Long Range Buffer including 12.5mM MgCl2, 0.25µM Biotinylated Zebrafish primer, 
500µM PCR Nucleotide mix (dATP, dCTP, dGTP, dTTP at 10µM each), 3% DMSO and 
3.5U of Expand Long Range Enzyme.  Cycling conditions used are as follows: 94˚C for 
3.5 minutes, followed by 30 cycles of 94˚C, 15s; 65˚C, 30s; 68˚C, 3 min., and a seven-
minute extension at 68˚C.   
Biotin Capture 
The Uni-linear extension products were subsequently column purified with QIA-quick 
PCR Purification Kit (Qiagen #28104). Purified products were biotin captured following 
Dynabeads kilobaseBINDER Kit (Invitrogen #60101) for 3 hours at room temperature 
while rotating the tube. After capture, beads were placed on a magnet and washed 
twice with the Wash Buffer, and washed a final time with ddH2O. Final biotin captured 
products were eluted to 30µl with ddH2O.  
 Nested PCR 
ZfL2-1 Insertion Primers 
Adapter primer ZfL2-1: 5’-ATCGATCGCTGCAGGGTATAGG 
Zebra primer 3 with ZfL2-1: 5’-ATATGGGCTATGAACTAATG 
ZfL2-2 Insertion Primers 
Adapter primer Zfl2-2: 5’-GCTTGACATTCTGGATCGATCGC 
Zebra primer 5 with ZfL2-2: 5’-ATTAAATTCCTGCAGGTTTGGG 
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Each 30µl biotinylated captured product was divided amongst 3 separate PCR 
reactions, where 10µl is used as the starting template per PCR reaction.  PCR reactions 
were performed with Invitrogen Taq DNA Polymerase (Invitrogen #18038042). PCR 
reactions were brought to 50 uL total volume with ddH2O and contained final 
concentrations of 1X of the manufacturer’s provided PCR buffer minus Mg, 1.5 mM 
MgCl2, 0.4µM Adapter primer and 0.4µM zebra primer, 800µM Deoxynucleotide (dNTP) 
Solution Mix (NEB) (Mix initially contains dATP, dCTP, dGTP, dTTP at 10mM each), 
and 1U of Taq DNA Polymerase. Cycling conditions are as follows: 94˚C for 2 minutes, 
followed by 35 cycles of 94˚C, 45s; 57˚C, 30s; 68˚C, 3 min and 15s., and a seven-
minute extension at 68˚C.  
Final PCR products were column purified with QIA-quick PCR Purification kit (Qiagen 
#28104) and eluted to a final volume of 50µl with elution buffer. Samples were 
measured for gDNA concentration with Invitrogen’s Qubit fluorometer and then sent to 
the University of Michigan’s Sequencing Core for PacBio Single Molecule Real Time 
(SMRT) circular consensus sequencing. 
PCR Product Characterization 
Additionally, products were cloned into TA Cloning Kit Dual Promoter (pCR II) cloning 
vector (Invitrogen #K207020), transformed, and plasmid DNA recovered by Wizard Plus 
SV minipreps DNA purification system (Promega #A1460). Individual clones were then 
sequenced with M13 Forward and M13 Reverse primers. Resulting Sanger sequences 
were then blatted to the UCSC Zv9/danRer7 Zebrafish Genome Browser 
(http://genome.ucsc.edu/) (Kent, 2002) to determine successful capture and 
amplification of de novo L2 events and flanking 3’ gDNA.  
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Figure A.1 Schematics of the ZfL2-1 and ZfL2-2 elements. ZfL2-1 is approximately 
5kb long and encodes two open reading frame  (ORF) proteins. ORF1p contains a 
coiled-coil (CC) domain as well as an esterase (ES) domain. ORF2p contains an 
endonuclease (EN) and reverse transcriptase (RT) domain. The element ends in a 
3’UTR and typically insertions contain the (ATTGA)n microsatellite sequence. ZfL2-2 is 
approximately 4.2 kb long and contains one ORF with an EN and RT domain. The 

























Figure A.2 ZfL2-1 sequence showing primer sequences. ZebrafishL2-1 sequence 
depicting the presence of the biotinylated zebrafish primer sequence (orange) and the 
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Identifying Somatic Endogenous LINE-1 Insertions 
The work presented here is in collaboration with the Michigan Brain Somatic 
Moscaicism Network. Mrs. Sarah Emery in Dr. Jeffrey Kidd’s laboratory performed 
tissue culture, genomic DNA extractions, and single cell whole genome amplification 
experiments. Dr. Weichen Zhou in Dr. Ryan Mill’s laboratory is performing analysis of 
the MiSeq sequencing results generated from this Appendix.  
Introduction 
As described in Chapter 1, L1 is actively mobilizing within our genomes today, 
and a number of studies have created methods to capture polymorphic or somatic L1Hs 
insertions. L1Hs is the currently active L1 sequence within the human genome to date 
(Beck et al., 2011; Brouha et al., 2003; Moran et al., 1996; Sassaman et al., 1997). A 
number of studies have identified somatic L1Hs events in the human brain (Baillie et al., 
2011; Erwin et al., 2016; Evrony et al., 2012; Evrony et al., 2015; Upton et al., 2015).  
As part of a National Institute of Mental Health (NIMH) initiative to define the frequency 
and pattern of somatic mutations in neurotypical individuals and in schizophrenia 
populations, we devised a set of methods to specifically capture 3’ L1Hs sequences and 
their 3’ flanking gDNA (McConnell et al., 2017). We want to address how somatic L1Hs 
insertions may contribute to neuronal diversity within the neurotypical spectrum as well 
as in diseased brains.  
Neurons are among the longest-lived cells in the body, arising from neural stem 
cells and progenitor cells that must undergo tens of billions of cell divisions before birth 
and during the first years of life in order to generate the ~80 billion neurons in the fully 
developed human brain (Lui et al., 2011; McConnell et al., 2017). Thus, adult neurons 
have the potential to accumulate several somatic mutations throughout their lifetime. 
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Background on Schizophrenia 
Schizophrenia is a devastating chronic psychotic illness affecting 0.5-1.0% of the 
population worldwide. The neurodevelopmental hypothesis of schizophrenia states that 
abnormalities during critical early periods of brain development may trigger the later 
appearance of clinical symptoms (Bloom, 1993; Murray et al., 1992; Weinberger, 1987).  
Schizophrenia has an inherited genetic risk estimated at 64% (Lichtenstein et al., 2009). 
Numerous GWAS studies have led to the idenfication of one-hundred and eight genetic 
loci containing common alleles with minor risk associated with schizophrenia (odds ratio 
< 1.2) (Schizophrenia Working Group of the Psychiatric Genomics, 2014). Since 
somatic brain DNA variations have been found to contribute to the incidence of other 
neuronal diseases such as early-onset Alzheimer’s disease (Beck et al., 2004), brain 
malformations (Evrony et al., 2012), and Sturge-Weber syndrome (Nakashima et al., 
2014; Shirley et al., 2013), several studies have begun to investigate the role of L1 as a 
source of DNA variation in schizophrenia.  
Role of L1 in Progression of Schizophrenia 
In 2014 Bundo et al. reported significant increase of L1 DNA content, via 
quantitative real-time PCR, in prefrontal cortex neurons of patients with schizophrenia 
as compared to healthy controls. Likewise, increased L1 copy number was observed in 
iPS cell-derived neurons of patients with schizophrenia containing a 22q11 deletion. 
The 22q11 deletion is a well-defined high-risk genetic factor for schizophrenia, affecting 
about 1%-2% of schizophrenia patients (Karayiorgou et al., 2010). Because the 22q11 
deletion results in the deletion of several genes related to schizophrenia, the L1 
increase in schizophrenia patients with the 22q11 deletion is likely to modulate 
phenotypes of schizophrenia rather than be a direct cause. Examination of affected 
genes by brain-specific L1 insertions revealed overrepresentation of neuronal function-
related terms such as synapse and protein phosphorylation in schizophrenia compared 
to controls.  
Doyle et al. 2017 performed L1-seq (Ewing and Kazazian, 2010) on gDNA also 
obtained from postmortem dorsolateral prefrontal cortex neurons of schizophrenic 
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patients and healthy controls. An increase of intragenic novel L1 insertions was 
observed in schizophrenic patients as compared to cases studied. The Bundo et al. and 
Doyle et al. studies present evidence that schizophrenic patients may harbor L1 
insertions, some of which are located in genes implicated in the pathophysiology of 
schizophrenia.   
What remains to be determined is the functional significance of L1 insertions 
within genes related to schizophrenia. Furthermore, the population allele frequencies of 
most detected L1 insertions remain unknown making it difficult to firmly establish 
association of each with schizophrenia. Whether novel L1 insertions are the cause or 
the result of putative alterations in brain development in schizophrenia remains to be 
determined.  
Here we present a set of methods which were created and used to capture L1Hs 
insertions from two female members of the CEPH pedigree 1463: NA12878 and 
NA12890. β-Lymphocyte cells of each individual were obtained and gDNA was isolated. 
After completion of the initial testing of these two different presented methods on 
NA12878, we will perform the more robust method on pooled gDNA from a neurotypical 
brain chunk, and then move on to several neurotypical and schizophrenia brain samples. 
Results/Discussion 
Mrs. Sarah Emery kept NA12878 and NA12890 lymphoblastoid cell lines in 
tissue culture and when confluent, isolated pooled gDNA and single-cell gDNA from 
each. Mrs. Emery also performed whole genome amplification (WGA) on single-cell 
gDNA isolations and I performed L1Hs capture techniques on resulting samples. 
Depending upon the protocol followed, either 5µg or 20µg of gDNA was randomly 
sheared to 1kb or 2kb fragments with the Covaris M220 series. Following shearing, 
gDNA was end-repaired and dA-tailed so that our designed adapters with a T overhang 




Revised Iskow et al. 2010 method 
Final prepped libraries were subjected to two amplification cycling conditions.  In 
the revised Iskow et al. 2010 method, the first PCR performed involves an L1Hs specific 
sequence containing the ‘ACA’ tri-nucleotide specific to L1Hs elements in the 3’UTR, as 
well as an ‘outside’ primer specific to the ligated adapter sequence (Figure B.1). After 
completion of initial amplification these first PCR products are used as a template in 
subsequent PCR amplification conditions. This 2nd PCR involves a downstream L1Hs 
primer sequence, upstream of the L1Hs poly-A signal, and an ‘internal’ adapter primer 
sequence.  The Resultant products are run on a 1.2% agarose gel and fragments, 
~600bp in size, are gel extracted and purified.   
Biotinylated Capture Method 
Biotinylated capture techniques involve a uni-linear amplification with a dual-
biotinylated L1Hs specific primer. This primer is the same sequence in the revised 
Iskow et al. 2010 method but contains dual biotins and an internal 18bp spacer on the 5’ 
end of the primer. After this uni-linear amplification, products are streptavidin bead 
captured and subjected to several washes. The washed captured products are PCR 
amplified, with the same 2nd PCR conditions as in the revised Iskow et al. 2010 method. 
Amplified products are run on a 1.2% agarose gel, size selected to ~600bp fragments, 
and gel extracted. 
Illumina MiSeq Primer Modifications 
Amplified products to be run on the Illumina MiSeq sequencing machine, should 
contain p5i502/03 and p7i702/03 primers in the 2nd and final PCR amplification step. 
These primers add the required sequence needed to complement the MiSeq 
sequencing platform. When running the Ilumina MiSeq sequencer, the i7 primer, Rd1 
SeqPrimer (Adapter) and Rd2 SeqPrimer (L1Hs) need to be added to the appropriate 
wells of the MiSeq sequencing cartridge. Read 1 from the MiSeq sequencer results 
should contain the adapter sequence and subsequent 3’ flanking gDNA of the L1 
insertions, while read 2 should contain the 3’ end of L1Hs sequence, including a poly-A 
tail, and possibly 3’ flanking gDNA of the insertion site. 
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Materials and Methods 
 
Adapter Design 
Primer sequences: All oligonucleotides used in this study were synthesized by 
Integrated DNA Technologies (IDT; Coralville, Iowa). 
 
Top strand adapter with T overhang; purified by high-performance liquid 
chromatography (HPLC):  
5’-GGAAGCTTGACATTCTGGATCGATCGCTGCAGGGTATAGGCGAGGACAACT-3’  
 
Bottom strand adapter with 5’ phosphorylation and 3’ amino modifier; purified by high-
performance liquid chromatography (HPLC): 5’-/5Phos/GTTGTCCT/3AmMO/-3’ 
 
10µM final concentrations of annealed adapters were made by incubation of 10µl of 
100µM top and 10µl of 100µM bottom strand adapters with 10µl 10X T4 DNA Ligase 
Reaction Buffer (NEB #M0202) and 70µl of ddH2O bringing the total volume to 100µl at 
95˚C for 5 minutes, followed by allowing the tube to naturally come to room temperature.  
 
Pooled gDNA Library Preparation 
Isolated gDNA, max of 20µg DNA, was sheared to 2kb in Covaris’ clear miniTUBE 
(Covaris PN 520064) with the Covaris M220 series following the appropriate setting and 
protocols found at: http://covarisinc.com/resources/protocols/. Following shearing, 
gDNA is end repaired using NEBNext End Repair Module (NEB #E6050).  End repaired 
fragments are then column purified with the QIAquick PCR purification kit (Qiagen 
#28104). Next, purified products are dA-tailed with NEBNext dA-tailing Module Protocol 
(NEB #E6053). Finally, products are purified once more with the QIAquick PCR 
purification kit (Qiagen #28104) and eluted to a max volume of 50µl. 
 
Whole Genome Amplified Single-cell Library Preparation 
Isolated gDNA, max of 5µg, is sheared to a target bp peak of ~1kb with the Covaris 
microTUBE-50 (Covaris PN 520166) on the Covaris M220 series. Settings for shearing 
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were modified as follows: Peak Incident Power (W) of 50, Duty Factor of 20%, Cycles 
per Burst of 200, Treatment time of 20s, Temperature at 20˚C. Following shearing, 
sheared gDNA is end repaired and dA-tailed in one single reaction following NEBNext 
Ultra End Repair/dA-Tailing Module (NEB #E7442). Following completion of this 
reaction, products are column purified with Qiagen’s MinElute PCR column purification 
(Qiagen #28004) and eluted to a final volume of 10µl. 
 
Annealing Adapters 
Annealed adapters were ligated onto the final purified DNA molecules in the following 
conditions: Up to 1µg DNA to 90µM of annealed adapter (Final Adapter concentration of 
4.5µM) in a 20µl total volume reaction with 1µl (200U) of T4 DNA ligase (NEB #M0202). 
Ligation reactions were incubated overnight at 16˚C and heat inactivated at 65˚C for 20 
minutes. Samples were purified of excess linkers with the QIAquick PCR purification kit 
(Qiagen #28104) and eluted in 50µl EB Buffer. NOTE: For WGA single-cell samples, 
final purification is performed with Qiagen’s MinElute PCR column purification (Qiagen 
#28004) and eluted to a final volume of 12µl.  
 
PCR Primers 
L1Hs TA Iskow: 5’- ATA CCT AAT GCT AGA TGA CAC A 
L1Hs TA Biotin: 5’- /52-Bio//iSp18/ATA CCT AAT GCT AGA TGA CAC A  
L1Hs Nested: 5’- CAT GGC ACA TGT ATA CAT ATG TAA CTA ACC TGC ACA ATG 
TG 
Adapter Outside: 5’- GCT TGA CAT TCT GGA TCG ATC GC 
Adapter Shifted: 5’- ATC GAT CGC TGC AGG GTA TAG G 
 
Illumina Primers 
p5i502 Adapter: 5’- AAT GAT ACG GCG ACC ACC GAG ATC TAC ACA TGT CAC 
ATG ATC GAT CGC TGC AGG GTA TAG G 
 Index for Illumina MiSeq: 5’- ATGTCACATG 
p5i503 Adapter: 5’- AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT TTC CGT TAT 
ATC GAT CGC TGC AGG GTA TAG G 
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 Index for Illumina MiSeq: 5’- TTTCCGTTAT 
p7i702 L1Hs: 5’- CAA GCA GAA GAC GGC ATA CGA GAT AGA CGA CCG AGC ACA 
TGT ATA CAT ATG TAA CTA ACC TGC ACA ATG TG 
 Index for Illumina MiSeq: 5’- TCGGTCGTCT  
p7i703 L1Hs: 5’- CAA GCA GAA GAC GGC ATA CGA GAT TCG AAC CAG GGC ACA 
TGT ATA CAT ATG TAA CTA ACC TGC ACA ATG TG 
 Index for Illumina MiSeq: 5’- CCTGGTTCGA 
 
Illumina Sequencing Primers 
i7Primer (L1Hs): 5’- GGT ACA TGT GCA CAT TGT GCA GGT TAG TTA CAT ATG TAT 
ACA TGT GC 
Rd1 SeqPrimer (Adapter): 5’- ATC GAT CGC TGC AGG GTA TAG GCG AGG ACA 
ACT 
Rd2 SeqPrimer (L1Hs): 5’- GCA CAT GTA TAC ATA TGT AAC TAA CCT GCA CAA 
TGT GCA CAT GTA CCC 
Rd1 SeqPrimer should be added to Pos12 and Rd2 SeqPrimer should be added to 
Pos14 of Illumina MiSeq wells for sequencing. 
 
Modified Iskow et al. 2010 PCR Capture and Amplification 
1st PCR Conditions: 
Starting library template of 40-100ng is amplified with Invitrogen Platinum Taq DNA 
Polymerase (Invitrogen #10966018). In 50µl total volume reactions 1X manufactured 
PCR Buffer, -Mg, 1.5mM MgCl2, 0.2mM each dNTP, 0.4µM each primer (L1Hs TA 
Iskow and Adapter Outside), and 2U of Platinum Taq DNA Polymerase were mixed. 
The first PCR reaction conditions were as follows: Initial denaturation at 96˚C for 2 
minutes; 12 cycles: denature at 96˚C for 30s; 60˚C annealing for 1 min 30s; extension at 
72˚C for 1 min 30s; followed by a final extension at 72˚C for 3 min.  
 
2nd PCR Conditions: 
Utilizing the same Invitrogen Platinum Taq DNA polymerase as in the 1st Iskow PCR, 
after completion of the 1st PCR, 5µl of the first PCR products are used as a template for 
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the 2nd PCR. L1Hs TA Nested and Adapter Shifted primers should be used, but if next 
step is sequencing on Illumina MiSeq sequencing platform then p5i502 Adapter and 
p7i702 L1Hs primers should be used in PCR reactions. In 50µl total volume reactions 
1X manufactured PCR Buffer, -Mg, 1.5mM MgCl2, 0.2mM each dNTP, 0.4µM each 
primer (L1 TA Nested and Adapter Shifted), and 2U of Platinum Taq DNA Polymerase 
were mixed. The 2nd PCR reaction conditions were as follows: Initial denaturation at 
96˚C for 2 minutes; 20 cycles: denature at 96˚C for 30s; 60˚C annealing for 30s; 
extension at 72˚C for 1 min 30s; followed by a final extension at 72˚C for 5 min.  
 
Biotin L1Hs Capture and Amplification 
1st PCR conditions and Biotin Capture: 
Starting library template of 40-100ng is linearly extended with Invitrogen Platinum Taq 
DNA Polymerase (Invitrogen #10966018). In 50µl total volume reactions 1X 
manufactured PCR Buffer, -Mg, 1.5mM MgCl2, 0.2mM each dNTP, 0.4µM L1Hs TA 
Biotin Primer, and 2U of Platinum Taq DNA Polymerase were mixed. The first PCR 
reaction conditions were as follows: Initial denaturation at 96˚C for 3 minutes; 35 cycles: 
denature at 96˚C for 30s; 60˚C annealing for 1 min 30s; extension at 72˚C for 2 min; 
followed by a final extension at 72˚C for 3 min.  
 
Biotinylated products were then biotin captured with Invitrogen’s Dynabeads 
kilobaseBINDER Kit (Invitrogen #60101) for 3 hours at room temperature while rotating 
the tube [Note: Invitrogen’s Dynabeads kilobaseBINDER kit is the only streptavidin bead 
kit that works successfully with this protocol].  After capture, beads were placed on a 
magnet and washed twice with the provided Wash Buffer, and washed a final time with 
ddH2O. Final biotin captured products are brought to 30µl volume with ddH2O. 
 
2nd PCR Conditions: 
Template for the 2nd PCR is 5µl of the biotin bead captured products. The same 
Invitrogen Platinum Taq DNA polymerase as in the 1st PCR is used again. L1Hs TA 
Nested and Adapter Shifted primers should be used, but if next step is sequencing on 
Illumina MiSeq sequencing platform then p5i502 Adapter and p7i702 L1Hs primers 
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should be used in PCR reactions (or p5i503 Adapter and p7i703 L1Hs can be used). In 
50µl total volume reactions 1X manufactured PCR Buffer, -Mg, 1.5mM MgCl2, 0.2mM 
each dNTP, 0.4µM each primer (L1 TA Nested and Adapter Shifted), and 2U of 
Platinum Taq DNA Polymerase were mixed. The 2nd PCR reaction conditions were as 
follows: Initial denaturation at 96˚C for 3 minutes; 20 cycles: denature at 96˚C for 30s; 
60˚C annealing for 30s; extension at 72˚C for 2 min; followed by a final extension at 
72˚C for 5 min. 
 
Final Purification and Illumina MiSeq Sequencing: 
Final PCR products were loaded and run on a 1.2% UltraPure low melting point agarose 
gel (Invitrogen # 16520050). Products ~500bp in size were gel extracted and purified 
with QIAquick Gel Extraction Kit (Qiagen #28704).  Final gDNA concentrations are 
determined with Invitrogen’s Qubit Flourometer. Sarah Emery then performed real-time 
PCR to determine more accurate sample concentrations before running samples on 





Mrs. Sarah Emery in Dr. Jeffrey Kidd’s lab was a tremendous help on this project. She 
was also invaluable in helping run samples on the MiSeq machine in the Moran 
Laboratory. Dr. Weichen Zhou in Dr. Ryan Mill’s laboratory analyzed the paired-end 












Figure B.1 The L1Hs specific primer sequences to amplify L1Hs integration 
events and flanking 3’ gDNA. 
The 3’ end of the L1Hs sequence is shown. Displayed in orange is the L1Hs TA primer 
specific to the ‘ACA’ tri-nucleotide found in L1Hs specific sequences.  The L1Hs nested 
primer sequence created for the 2nd nested PCR amplification is displayed in navy. The 
red ‘g’ represents a SNP expected if successful amplification of L1Hs has occurred. A 
polymorphic or somatic insertion, if present, should follow this sequence with a poly-A 
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